

# Structure of the SARS-CoV-2 spike receptor-binding do

Nature

581, 215-220

DOI: [10.1038/s41586-020-2180-5](https://doi.org/10.1038/s41586-020-2180-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Predicting susceptibility to SARS-CoV-2 infection based on structural differences in ACE2 across species. <i>FASEB Journal</i> , 2020, 34, 15946-15960.	0.2	44
2	Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution. <i>Frontiers in Microbiology</i> , 2020, 11, 2112.	1.5	35
3	Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 226.	1.6	12
4	Angiotensin-Converting Enzyme 2 as a Possible Correlation between COVID-19 and Periodontal Disease. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6224.	1.3	21
5	COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. <i>Pharmaceutics</i> , 2020, 12, 945.	2.0	14
6	The prophylaxis and treatment potential of supplements for COVID-19. <i>European Journal of Pharmacology</i> , 2020, 887, 173530.	1.7	40
7	Could aquaporin modulators be employed as prospective drugs for COVID-19 related pulmonary comorbidity?. <i>Medical Hypotheses</i> , 2020, 143, 110201.	0.8	8
8	SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors. <i>Virus Research</i> , 2020, 289, 198154.	1.1	14
9	Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain. <i>Informatics in Medicine Unlocked</i> , 2020, 21, 100451.	1.9	17
10	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. <i>Journal of Clinical Virology</i> , 2020, 131, 104611.	1.6	61
11	The Architecture of Inactivated SARS-CoV-2 with Postfusion Spikes Revealed by Cryo-EM and Cryo-ET. <i>Structure</i> , 2020, 28, 1218-1224.e4.	1.6	140
12	Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2. <i>Toxicology Reports</i> , 2020, 7, 1366-1372.	1.6	9
13	Comprehensive Analysis of the Glycan Complement of SARS-CoV-2 Spike Proteins Using Signature Ions-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation (ETHcD) Mass Spectrometry. <i>Analytical Chemistry</i> , 2020, 92, 14730-14739.	3.2	53
14	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. <i>Nature</i> , 2020, 586, 560-566.	13.7	527
15	Greener liquid-phase synthesis and the ACE inhibitory structure-activity relationship of an anti-SARS octapeptide. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 8433-8442.	1.5	10
16	Syncytia formation by SARS-CoV-2-infected cells. <i>EMBO Journal</i> , 2020, 39, e106267.	3.5	361
17	Bibliometric and Visualization Analysis of Human Coronaviruses: Prospects and Implications for COVID-19 Research. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 581404.	1.8	33
18	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Nervous System: Implications of COVID-19 in Neurodegeneration. <i>Frontiers in Neurology</i> , 2020, 11, 583459.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. <i>Virologica Sinica</i> , 2020, 35, 857-860.	1.2	39
20	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. <i>Biochemical Pharmacology</i> , 2020, 182, 114225.	2.0	83
21	High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models. <i>Cell</i> , 2020, 183, 429-441.e16.	13.5	100
22	Preventing the Interaction between Coronaviruses Spike Protein and Angiotensin I Converting Enzyme 2: An In Silico Mechanistic Case Study on Emodin as a Potential Model Compound. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6358.	1.3	4
23	ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110678.	2.5	184
24	The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2438-2444.	1.9	32
25	Druggable targets from coronaviruses for designing new antiviral drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115745.	1.4	20
26	Cardiac inflammation in COVID-19: Lessons from heart failure. <i>Life Sciences</i> , 2020, 260, 118482.	2.0	72
27	The influence of ABO blood groups on COVID-19 susceptibility and severity: A molecular hypothesis based on carbohydrate-carbohydrate interactions. <i>Medical Hypotheses</i> , 2020, 144, 110155.	0.8	42
28	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. <i>Science</i> , 2020, 370, .	6.0	511
29	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. <i>Frontiers in Pharmacology</i> , 2020, 11, 1224.	1.6	30
30	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. <i>Cell</i> , 2020, 183, 1024-1042.e21.	13.5	1,195
31	Identification of twenty-five mutations in surface glycoprotein (Spike) of SARS-CoV-2 among Indian isolates and their impact on protein dynamics. <i>Gene Reports</i> , 2020, 21, 100891.	0.4	20
32	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. <i>Life Sciences</i> , 2020, 262, 118496.	2.0	8
33	Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2020, 11, 585647.	2.2	89
34	Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Proteinâ€“Drug and Proteinâ€“Protein Structures: An Analysis of Kinetically Active Residues. <i>Biomolecules</i> , 2020, 10, 1346.	1.8	13
35	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. <i>Viruses</i> , 2020, 12, 1104.	1.5	29
36	Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. <i>Cell Host and Microbe</i> , 2020, 28, 586-601.e6.	5.1	334

#	ARTICLE	IF	CITATIONS
37	Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106177.	1.1	21
38	In-silico design of a potential inhibitor of SARS-CoV-2 S protein. <i>PLoS ONE</i> , 2020, 15, e0240004.	1.1	36
39	The Potential Intermediate Hosts for SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2020, 11, 580137.	1.5	105
40	Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation. <i>Biophysical Chemistry</i> , 2020, 267, 106472.	1.5	12
41	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020, 183, 1058-1069.e19.	13.5	305
42	Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19. <i>Journal of Chemical Neuroanatomy</i> , 2020, 110, 101874.	1.0	16
43	Thermodynamics of the Interaction between the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus-2 and the Receptor of Human Angiotensin-Converting Enzyme 2. Effects of Possible Ligands. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 9272-9281.	2.1	39
44	Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. <i>Cardiovascular Research</i> , 2020, 116, 2197-2206.	1.8	205
45	Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions. <i>AIMS Microbiology</i> , 2020, 6, 350-360.	1.0	61
46	2020 update on human coronaviruses: One health, one world. <i>Medicine in Novel Technology and Devices</i> , 2020, 8, 100043.	0.9	21
47	Rabies virus-based COVID-19 vaccine CORAVAX <sup>®</sup> induces high levels of neutralizing antibodies against SARS-CoV-2. <i>Npj Vaccines</i> , 2020, 5, 98.	2.9	26
48	Identifying Pathways and Networks Associated With the SARS-CoV-2 Cell Receptor ACE2 Based on Gene Expression Profiles in Normal and SARS-CoV-2-Infected Human Tissues. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 568954.	1.6	18
49	Superimposition of Viral Protein Structures: A Means to Decipher the Phylogenies of Viruses. <i>Viruses</i> , 2020, 12, 1146.	1.5	8
50	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	2.9	59
51	Engineered ACE2 receptor traps potentially neutralize SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28046-28055.	3.3	219
52	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. <i>Cell Reports</i> , 2020, 33, 108274.	2.9	152
53	Metallo drug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. <i>Nature Microbiology</i> , 2020, 5, 1439-1448.	5.9	140
54	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. <i>Bioorganic Chemistry</i> , 2020, 104, 104326.	2.0	18

#	ARTICLE	IF	CITATIONS
55	Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. <i>International Journal of Infectious Diseases</i> , 2020, 101, 220-225.	1.5	55
56	Autoimmunity to ACE2 as a possible cause of tissue inflammation in Covid-19. <i>Medical Hypotheses</i> , 2020, 144, 110043.	0.8	13
57	Analysis of Continuous Mutation and Evolution on Circulating SARS-CoV-2. <i>Evolutionary Bioinformatics</i> , 2020, 16, 117693432095487.	0.6	1
58	Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. <i>Annals of Hematology</i> , 2020, 99, 1953-1965.	0.8	54
59	Cerebellar infarction requiring surgical decompression in patient with COVID 19 pathological analysis and brief review. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2020, 22, 100850.	0.2	10
60	Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions. <i>Trends in Immunology</i> , 2020, 41, 1006-1022.	2.9	79
61	Involvement of the nervous system in COVID-19: The bell should toll in the brain. <i>Life Sciences</i> , 2020, 262, 118568.	2.0	41
62	Reducing False Negatives in COVID-19 Testing by Using Microneedle-Based Oropharyngeal Swabs. <i>Matter</i> , 2020, 3, 1589-1600.	5.0	39
63	Is a COVID-19 vaccine developed by nature already at work?. <i>Medical Hypotheses</i> , 2020, 145, 110335.	0.8	6
64	New Frontiers for Selective Biosensing with Biomembrane-Based Organic Transistors. <i>ACS Nano</i> , 2020, 14, 12271-12280.	7.3	25
65	Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. <i>Science Advances</i> , 2020, 6, .	4.7	57
66	Host Receptors of Influenza Viruses and Coronavirusesâ€™ Molecular Mechanisms of Recognition. <i>Vaccines</i> , 2020, 8, 587.	2.1	13
67	Convalescent Blood Products in COVID-19: A Narrative Review. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096064.	1.1	3
68	Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against SARS-CoV-2 Key Proteins in Silico. <i>Toxins</i> , 2020, 12, 602.	1.5	5
69	Molecular biology of coronaviruses: current knowledge. <i>Heliyon</i> , 2020, 6, e04743.	1.4	75
70	Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays. <i>Journal of Immunological Methods</i> , 2020, 486, 112837.	0.6	16
71	New insights on possible vaccine development against SARS-CoV-2. <i>Life Sciences</i> , 2020, 260, 118421.	2.0	8
72	A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104507.	1.0	31

#	ARTICLE	IF	CITATIONS
73	Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines. <i>Microbial Pathogenesis</i> , 2020, 149, 104553.	1.3	55
74	Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. <i>Virus Research</i> , 2020, 288, 198141.	1.1	116
75	Molecular Simulations and Network Modeling Reveal an Allosteric Signaling in the SARS-CoV-2 Spike Proteins. <i>Journal of Proteome Research</i> , 2020, 19, 4587-4608.	1.8	72
76	Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. <i>Cell Discovery</i> , 2020, 6, 68.	3.1	132
77	In silico exploration of small-molecule $\alpha$ -helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 1546-1557.	2.0	7
78	Distinct conformational states of SARS-CoV-2 spike protein. <i>Science</i> , 2020, 369, 1586-1592.	6.0	995
79	Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. <i>SLAS Discovery</i> , 2020, 25, 1097-1107.	1.4	5
80	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 384.	1.3	13
81	Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. <i>Nature</i> , 2020, 583, 834-838.	13.7	1,185
82	Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artemimol for COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6184-6194.	2.0	57
83	SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. <i>Nature Communications</i> , 2020, 11, 3581.	5.8	251
84	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature Medicine</i> , 2020, 26, 1428-1434.	15.2	400
85	The molecular virology of coronaviruses. <i>Journal of Biological Chemistry</i> , 2020, 295, 12910-12934.	1.6	365
86	Structural basis of a shared antibody response to SARS-CoV-2. <i>Science</i> , 2020, 369, 1119-1123.	6.0	536
87	Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. <i>Journal of Virology</i> , 2020, 94, .	1.5	139
88	Minireview of progress in the structural study of SARS-CoV-2 proteins. <i>Current Research in Microbial Sciences</i> , 2020, 1, 53-61.	1.4	43
89	COVID-19 vaccine development and a potential nanomaterial path forward. <i>Nature Nanotechnology</i> , 2020, 15, 646-655.	15.6	501
90	Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment. <i>Biosafety and Health</i> , 2020, 2, 210-216.	1.2	23

#	ARTICLE	IF	CITATIONS
91	The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions. <i>Life Sciences</i> , 2020, 257, 118075.	2.0	87
92	Making waves: Wastewater surveillance of SARS-CoV-2 for population-based health management. <i>Water Research</i> , 2020, 184, 116181.	5.3	138
93	Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. <i>Molecular Neurobiology</i> , 2020, 57, 4106-4116.	1.9	38
94	SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. <i>Diabetes</i> , 2020, 69, 1875-1886.	0.3	61
95	A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. <i>International Journal of Medical Sciences</i> , 2020, 17, 1522-1531.	1.1	92
96	EMMPRIN/BASIGIN as a biological modulator of oral cancer and COVID-19 interaction: Novel propositions. <i>Medical Hypotheses</i> , 2020, 143, 110089.	0.8	15
97	The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor. <i>Analytical Chemistry</i> , 2020, 92, 10930-10934.	3.2	45
98	AGTR2, one possible novel key gene for the entry of SARS-CoV-2 into human cells. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2020, 18, 1-1.	1.9	42
99	The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. <i>Clinica Chimica Acta</i> , 2020, 510, 186-190.	0.5	35
101	Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. <i>Nature Communications</i> , 2020, 11, 3618.	5.8	166
102	Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. <i>European Respiratory Journal</i> , 2020, 56, 2002378.	3.1	67
103	Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 846-854.	3.6	434
104	Current Status of COVID-19 (Pre)Clinical Vaccine Development. <i>Angewandte Chemie</i> , 2020, 132, 19045-19057.	1.6	4
105	Current Status of COVID-19 (Pre)Clinical Vaccine Development. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 18885-18897.	7.2	61
106	The renin-angiotensin-aldosterone system: Role in pathogenesis and potential therapeutic target in COVID-19. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00623.	1.1	13
107	Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1103-1108.	0.3	15
108	Current and Future Direct-Acting Antivirals Against COVID-19. <i>Frontiers in Microbiology</i> , 2020, 11, 587944.	1.5	16
109	Structural Characterization of N-Linked Glycans in the Receptor Binding Domain of the SARS-CoV-2 Spike Protein and their Interactions with Human Lectins. <i>Angewandte Chemie</i> , 2020, 132, 23971-23979.	1.6	9



#	ARTICLE	IF	CITATIONS
110	Profile of SARS-CoV-2. Wiener Klinische Wochenschrift, 2020, 132, 635-644.	1.0	4
111	Computational Design of 25-mer Peptide Binders of SARS-CoV-2. Journal of Physical Chemistry B, 2020, 124, 10930-10942.	1.2	37
112	Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19. Frontiers in Cardiovascular Medicine, 2020, 7, 593061.	1.1	3
113	Toward COVID-19 Therapeutics: A Viewpoint from the Nonprotein Amino Acid Based Synthetic Peptide Design Approach. ACS Chemical Neuroscience, 2020, 11, 3701-3703.	1.7	3
114	Global SNP analysis of 11,183 SARS-CoV-2 strains reveals high genetic diversity. Transboundary and Emerging Diseases, 2021, 68, 3288-3304.	1.3	50
115	SSSCPreds: Deep Neural Network-Based Software for the Prediction of Conformational Variability and Application to SARS-CoV-2. ACS Omega, 2020, 5, 30556-30567.	1.6	6
116	Natural Products Database Screening for the Discovery of Naturally Occurring SARS-CoV-2 Spike Glycoprotein Blockers. ChemistrySelect, 2020, 5, 13309-13317.	0.7	24
117	Detection and Characterization of Bat Sarbecovirus Phylogenetically Related to SARS-CoV-2, Japan. Emerging Infectious Diseases, 2020, 26, 3025-3029.	2.0	117
118	Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. Frontiers in Medicine, 2020, 7, 608259.	1.2	34
119	Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study. RSC Advances, 2020, 10, 37707-37720.	1.7	57
120	COVID-19 Infection Detection and Prevention by SARS-CoV-2 Active Antigens: A Synthetic Vaccine Approach. Vaccines, 2020, 8, 692.	2.1	3
121	Plasma-activated water: An alternative disinfectant for S protein inactivation to prevent SARS-CoV-2 infection. Chemical Engineering Journal, 2021, 421, 127742.	6.6	109
122	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host and Microbe, 2020, 28, 867-879.e5.	5.1	316
123	Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. Cell Stem Cell, 2020, 27, 876-889.e12.	5.2	167
124	Systems Biology Approaches for Therapeutics Development Against COVID-19. Frontiers in Cellular and Infection Microbiology, 2020, 10, 560240.	1.8	13
125	SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in Cellular and Infection Microbiology, 2020, 10, 587269.	1.8	552
126	SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nature Communications, 2020, 11, 6013.	5.8	828
127	An Original ELISA-Based Multiplex Method for the Simultaneous Detection of 5 SARS-CoV-2 IgG Antibodies Directed against Different Antigens. Journal of Clinical Medicine, 2020, 9, 3752.	1.0	30



#	ARTICLE	IF	CITATIONS
128	A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5392.	1.7	26
129	Airborne Transmission of COVID-19: Aerosol Dispersion, Lung Deposition, and Virus-Receptor Interactions. <i>ACS Nano</i> , 2020, 14, 16502-16524.	7.3	109
130	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. <i>Immunity</i> , 2020, 53, 1272-1280.e5.	6.6	185
131	A safety consideration of mesenchymal stem cell therapy on COVID-19. <i>Stem Cell Research</i> , 2020, 49, 102066.	0.3	22
132	Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions. <i>Communications Biology</i> , 2020, 3, 715.	2.0	37
133	Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 605236.	1.6	159
134	Advances toward COVID-19 Therapies Special Issue Call for Papers. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15073-15074.	2.9	1
135	In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2020, 10, 20584.	1.6	53
136	Investigation of the Effect of Temperature on the Structure of SARS-CoV-2 Spike Protein by Molecular Dynamics Simulations. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 583523.	1.6	55
137	Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. <i>Nature</i> , 2020, 588, 327-330.	13.7	684
138	Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target. <i>Emerging Microbes and Infections</i> , 2020, 9, 2663-2672.	3.0	46
139	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <i>Cell Host and Microbe</i> , 2020, 28, 880-891.e8.	5.1	153
140	Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2716-2746.	2.9	149
141	Identifying the Zoonotic Origin of SARS-CoV-2 by Modeling the Binding Affinity between the Spike Receptor-Binding Domain and Host ACE2. <i>Journal of Proteome Research</i> , 2020, 19, 4844-4856.	1.8	27
142	Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein. <i>Molecules</i> , 2020, 25, 5605.	1.7	14
143	Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. <i>Nature Communications</i> , 2020, 11, 6122.	5.8	304
144	SARS-CoV2 infectivity is potentially modulated by host redox status. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3705-3711.	1.9	25
145	Molecular Dynamics Reveals Complex Compensatory Effects of Ionic Strength on the Severe Acute Respiratory Syndrome Coronavirus 2 Spike/ Human Angiotensin-Converting Enzyme 2 Interaction. <i>Journal of Physical Chemistry Letters</i> , 2020, 11, 10446-10453.	2.1	20

#	ARTICLE	IF	CITATIONS
146	On the Challenges for the Diagnosis of SARS-CoV-2 Based on a Review of Current Methodologies. ACS Sensors, 2020, 5, 3655-3677.	4.0	80
147	The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor. Biomaterials Science, 2020, 8, 6603-6610.	2.6	23
148	Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An In Silico Analysis. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	29
149	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. Molecules, 2020, 25, 5535.	1.7	21
150	Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein Journal, 2020, 39, 644-656.	0.7	213
151	Computational Insights into the Conformational Accessibility and Binding Strength of SARS-CoV-2 Spike Protein to Human Angiotensin-Converting Enzyme 2. Journal of Physical Chemistry Letters, 2020, 11, 10482-10488.	2.1	42
152	CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduction and Targeted Therapy, 2020, 5, 283.	7.1	806
153	ACE2 partially dictates the host range and tropism of SARS-CoV-2. Computational and Structural Biotechnology Journal, 2020, 18, 4040-4047.	1.9	31
154	Methods for making multiple alignment of genomic sequences for severe acute respiratory syndrome coronavirus 2. Meta Gene, 2020, 26, 100785.	0.3	0
155	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). Journal of Cardiac Critical Care TSS, 2020, 4, 121-131.	0.0	0
156	The Intersection between COVID-19, the Gene Family of ACE2 and Alzheimer's Disease. Neuroscience Insights, 2020, 15, 263310552097574.	0.9	8
157	SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic Î²-Cells and in the Human Pancreas Microvasculature. Frontiers in Endocrinology, 2020, 11, 596898.	1.5	144
158	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery, 2020, 6, 80.	3.1	172
159	SARS-CoV-2 and interferon blockade. Molecular Medicine, 2020, 26, 103.	1.9	3
160	Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity. Journal of Agricultural and Food Chemistry, 2020, 68, 13982-13989.	2.4	66
161	A Hydrophobic Interaction-Based Mechanism Triggers Docking between the SARS-CoV-2 Spike and Angiotensin-Converting Enzyme 2. Global Challenges, 2020, 4, 2000067.	1.8	18
162	New putative animal reservoirs of SARS-CoV-2 in Italian fauna: A bioinformatic approach. Heliyon, 2020, 6, e05430.	1.4	9
163	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. Methods in Pharmacology and Toxicology, 2020, , 329-431.	0.1	4

#	ARTICLE	IF	CITATIONS
164	SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in $\beta^2$ Cells. <i>Cell Metabolism</i> , 2020, 32, 1028-1040.e4.	7.2	148
165	Spike Glycoprotein-Mediated Entry of SARS Coronaviruses. <i>Viruses</i> , 2020, 12, 1289.	1.5	35
166	Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2. In <i>Silico Pharmacology</i> , 2020, 8, 3.	1.8	20
167	Peptide and peptide-based inhibitors of SARS-CoV-2 entry. <i>Advanced Drug Delivery Reviews</i> , 2020, 167, 47-65.	6.6	132
168	Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3518-3527.	1.9	75
169	Triterpenoid-Mediated Inhibition of Virus-Host Interaction: Is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15371-15388.	2.9	19
170	Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. <i>Clinical Cardiology</i> , 2020, , .	0.7	58
171	Identification of polyphenols from <i>Broussonetia papyrifera</i> as SARS CoV-2 main protease inhibitors using <i>in silico</i> docking and molecular dynamics simulation approaches. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6747-6760.	2.0	54
172	Effect of mutation on structure, function and dynamics of receptor binding domain of human SARS-CoV-2 with host cell receptor ACE2: a molecular dynamics simulations study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 7231-7245.	2.0	56
173	The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. <i>AAPS PharmSciTech</i> , 2020, 21, 225.	1.5	240
174	Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. <i>Immunity</i> , 2020, 53, 864-877.e5.	6.6	450
175	SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. <i>Journal of Infectious Diseases</i> , 2020, 222, 1452-1461.	1.9	116
176	&lt;p&gt;Molecular Basis for Pathogenicity of Human Coronaviruses&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2385-2405.	1.1	8
177	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. <i>Kidney International</i> , 2020, 98, 1296-1307.	2.6	173
178	Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 942-949.	3.6	153
179	Clinical features and risk factors for ICU admission in COVID-19 patients with cardiovascular diseases. , 2020, 11, 763.		18
180	&lt;p&gt;Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review&lt;/p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2657-2665.	1.1	70
181	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24

#	ARTICLE	IF	CITATIONS
182	Interdiction of Protein Folding for Therapeutic Drug Development in SARS CoV-2. Journal of Physical Chemistry B, 2020, 124, 8201-8208.	1.2	13
183	Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. Medicinal Chemistry Research, 2020, 29, 1777-1791.	1.1	34
184	Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level. Journal of Proteome Research, 2020, 19, 4417-4427.	1.8	155
185	Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19. Pharmacological Reports, 2020, 72, 1509-1516.	1.5	73
186	Mutations Strengthened SARS-CoV-2 Infectivity. Journal of Molecular Biology, 2020, 432, 5212-5226.	2.0	386
187	Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 105182.	0.7	24
188	Potential Role of Peptide-Based Antiviral Therapy Against SARS-CoV-2 Infection. ACS Pharmacology and Translational Science, 2020, 3, 783-785.	2.5	29
189	Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. Journal of Molecular Graphics and Modelling, 2020, 100, 107697.	1.3	52
190	Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders. Annals of the National Academy of Medical Sciences (India), 2020, 56, 112-115.	0.2	1
191	Evaluation of Current Therapies for COVID-19 Treatment. Microorganisms, 2020, 8, 1097.	1.6	11
192	Using surgical wrapping material for the fabrication of respirator masks. PLoS ONE, 2020, 15, e0236239.	1.1	8
193	Targeting SARS-CoV-2 RBD Interface: a Supervised Computational Data-Driven Approach to Identify Potential Modulators. ChemMedChem, 2020, 15, 1921-1931.	1.6	7
194	A Thermostable mRNA Vaccine against COVID-19. Cell, 2020, 182, 1271-1283.e16.	13.5	485
195	Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science, 2020, 369, 1505-1509.	6.0	358
196	Medium Term Follow-Up of 337 Patients With Coronavirus Disease 2019 (COVID-19) in a Fangcang Shelter Hospital in Wuhan, China. Frontiers in Medicine, 2020, 7, 373.	1.2	16
197	Therapeutic Strategies Against COVID-19 and Structural Characterization of SARS-CoV-2: A Review. Frontiers in Microbiology, 2020, 11, 1723.	1.5	69
198	A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0. International Journal of Molecular Sciences, 2020, 21, 5152.	1.8	34
199	Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature, 2020, 584, 115-119.	13.7	1,524

#	ARTICLE	IF	CITATIONS
200	A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. <i>Nature</i> , 2020, 584, 120-124.	13.7	1,237
201	COVID-19 and the Kidneys: An Update. <i>Frontiers in Medicine</i> , 2020, 7, 423.	1.2	79
202	Discovering genomic patterns in SARS-CoV-2 variants. <i>International Journal of Intelligent Systems</i> , 2020, 35, 1680-1698.	3.3	16
203	Increased Serum Aminotransferase Activity and Clinical Outcomes in Coronavirus Disease 2019. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 533-539.	0.4	14
204	Infection of dogs with SARS-CoV-2. <i>Nature</i> , 2020, 586, 776-778.	13.7	580
205	Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May Explain Higher Mortality in COVID-19 Patients With Obesity. <i>Frontiers in Endocrinology</i> , 2020, 11, 530.	1.5	78
206	Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2117-2131.	1.9	27
207	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , 2020, 89, 102068.	3.4	60
208	Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 815-829.	4.0	108
209	Antiviral potential of some novel structural analogs of standard drugs repurposed for the treatment of COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6676-6688.	2.0	20
210	COVID-19: a wreak havoc across the globe. <i>Archives of Physiology and Biochemistry</i> , 2020, , 1-13.	1.0	6
211	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. <i>Function</i> , 2020, 1, .	1.1	12
212	Hypernatremia—A Manifestation of COVID-19: A Case Series. <i>A&amp;A Practice</i> , 2020, 14, e01295.	0.2	41
214	ACE2, Metformin, and COVID-19. <i>iScience</i> , 2020, 23, 101425.	1.9	45
215	Computational Prediction of Mutational Effects on SARS-CoV-2 Binding by Relative Free Energy Calculations. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5794-5802.	2.5	62
216	Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. <i>ACS Nano</i> , 2020, 14, 10616-10623.	7.3	89
217	Single Virus Targeting Multiple Organs: What We Know and Where We Are Heading?. <i>Frontiers in Medicine</i> , 2020, 7, 370.	1.2	31
218	In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy. <i>Chinese Journal of Integrative Medicine</i> , 2020, 26, 663-669.	0.7	45

#	ARTICLE	IF	CITATIONS
219	Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1141-1149.	2.8	1,611
220	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 950-958.	3.6	268
221	In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. <i>Scientific Reports</i> , 2020, 10, 13093.	1.6	311
222	Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 7246-7262.	2.0	54
223	Studying the Effects of ACE2 Mutations on the Stability, Dynamics, and Dissociation Process of SARS-CoV-2 S1/hACE2 Complexes. <i>Journal of Proteome Research</i> , 2020, 19, 4609-4623.	1.8	22
224	Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 444.	1.2	119
225	Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. <i>Cell</i> , 2020, 182, 1295-1310.e20.	13.5	1,726
226	Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. <i>American Journal of Pathology</i> , 2020, 190, 2290-2303.	1.9	197
227	Proteomics in Non-model Organisms: A New Analytical Frontier. <i>Journal of Proteome Research</i> , 2020, 19, 3595-3606.	1.8	40
228	Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: <i>in silico</i> studies. <i>RSC Advances</i> , 2020, 10, 29873-29884.	1.7	23
229	SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5707.	1.8	58
230	Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?. <i>Viruses</i> , 2020, 12, 861.	1.5	43
231	Advanced Analysis of Biosensor Data for SARS-CoV-2 RBD and ACE2 Interactions. <i>Analytical Chemistry</i> , 2020, 92, 11520-11524.	3.2	34
232	Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 313-329.	1.0	81
233	Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. <i>Annals of Medicine and Surgery</i> , 2020, 57, 236-243.	0.5	36
234	Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449.	13.7	956
235	The Pursuit of COVID-19 Biomarkers: Putting the Spotlight on ACE2 and TMPRSS2 Regulatory Sequences. <i>Frontiers in Medicine</i> , 2020, 7, 582793.	1.2	16
236	SARS-CoV-2 Identification and IgA antibodies in saliva: One sample two tests approach for diagnosis. <i>Clinica Chimica Acta</i> , 2020, 510, 717-722.	0.5	59



#	ARTICLE	IF	CITATIONS
237	Antiviral Polymers: Past Approaches and Future Possibilities. <i>Macromolecules</i> , 2020, 53, 9158-9186.	2.2	90
238	Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	40
239	Potential neuroinvasive and neurotrophic properties of SARS-CoV-2 in pediatric patients: comparison of SARS-CoV-2 with non-segmented RNA viruses. <i>Journal of NeuroVirology</i> , 2020, 26, 929-940.	1.0	2
240	The Perfect Storm: COVID-19 Health Disparities in US Blacks. <i>Journal of Racial and Ethnic Health Disparities</i> , 2021, 8, 1153-1160.	1.8	48
241	COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 256.	7.1	152
242	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 575404.	1.8	4
243	Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 579250.	2.2	72
244	Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients. <i>Journal of Proteome Research</i> , 2020, 19, 4455-4469.	1.8	189
245	ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 588618.	1.6	77
246	The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	21
247	SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	675
248	New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve Regions of Intrinsic Disorder Important for Virus Replication and Release. <i>Evolutionary Bioinformatics</i> , 2020, 16, 117693432096514.	0.6	39
249	Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses. <i>Small</i> , 2020, 16, e2004237.	5.2	13
250	Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology. <i>Advances in Experimental Medicine and Biology</i> , 2020, 21, 13-127.	0.8	29
251	In silico analysis of ACE2 orthologues to predict animal host range with high susceptibility to SARS-CoV-2. <i>3 Biotech</i> , 2020, 10, 483.	1.1	11
252	A graph-based approach identifies dynamic H-bond communication networks in spike protein S of SARS-CoV-2. <i>Journal of Structural Biology</i> , 2020, 212, 107617.	1.3	26
253	Critical Sequence Hotspots for Binding of Novel Coronavirus to Angiotensin Converter Enzyme as Evaluated by Molecular Simulations. <i>Journal of Physical Chemistry B</i> , 2020, 124, 10034-10047.	1.2	54
254	The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. <i>Cells</i> , 2020, 9, 2343.	1.8	73



#	ARTICLE	IF	CITATIONS
255	How ADA methodology informs SARS-CoV-2 assay development. <i>Bioanalysis</i> , 2020, 12, 1275-1277.	0.6	0
256	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. <i>Journal of Proteome Research</i> , 2020, 19, 4291-4315.	1.8	68
257	<i>Uncaria tomentosa</i> (cat's claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2227-2243.	2.0	29
258	Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2 / COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3023-3033.	1.4	8
259	Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines. <i>Frontiers in Immunology</i> , 2020, 11, 586984.	2.2	82
260	Identification of SARS-CoV-2 entry inhibitors among already approved drugs. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1347-1353.	2.8	66
261	High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity. <i>Journal of Biological Chemistry</i> , 2020, 295, 18579-18588.	1.6	82
262	<i>In silico</i> analysis of the interactions of certain flavonoids with the receptor-binding domain of 2019 novel coronavirus and cellular proteases and their pharmacokinetic properties. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2460-2474.	2.0	22
263	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. <i>Frontiers in Immunology</i> , 2020, 11, 576622.	2.2	317
264	COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Barrier Relevance. <i>Cells</i> , 2020, 9, 2360.	1.8	125
265	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. <i>Cell</i> , 2020, 183, 1367-1382.e17.	13.5	420
267	Quantifying the adhesive strength between the SARS-CoV-2 S-proteins and human receptor and its effect in therapeutics. <i>Scientific Reports</i> , 2020, 10, 17538.	1.6	10
268	Comparative ACE2 variation and primate COVID-19 risk. <i>Communications Biology</i> , 2020, 3, 641.	2.0	121
269	Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects. <i>International Journal of Biological Macromolecules</i> , 2020, 165, 1626-1633.	3.6	18
270	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. <i>Journal of NeuroVirology</i> , 2020, 26, 631-641.	1.0	38
271	Cobrotoxin could be an effective therapeutic for COVID-19. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1258-1260.	2.8	13
272	SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	57
273	Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. <i>Blood</i> , 2020, 136, 2080-2089.	0.6	283

#	ARTICLE	IF	CITATIONS
274	Host genetic factors and susceptibility to SARS-CoV-2 infection. American Journal of Human Biology, 2020, 32, e23497.	0.8	7
275	Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America. Journal of Translational Medicine, 2020, 18, 338.	1.8	86
276	Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo, 2020, 34, 3023-3026.	0.6	98
277	The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury. International Journal of Molecular Sciences, 2020, 21, 6204.	1.8	64
278	Kinetics of Viral Clearance and Antibody Production Across Age Groups in Children with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Pediatrics, 2020, 227, 31-37.e1.	0.9	34
279	SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of Hematology and Oncology, 2020, 13, 120.	6.9	505
280	Coordinating the research response to COVID-19: Mali's approach. Health Research Policy and Systems, 2020, 18, 105.	1.1	11
281	Quinazoline-Schiff base conjugates: <i>in silico</i> study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins. RSC Advances, 2020, 10, 34033-34045.	1.7	37
282	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science, 2020, 370, 950-957.	6.0	504
283	Molecular Architecture of the SARS-CoV-2 Virus. Cell, 2020, 183, 730-738.e13.	13.5	793
284	Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell, 2020, 183, 1013-1023.e13.	13.5	227
285	Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opinion on Therapeutic Targets, 2021, 25, 415-421.	1.5	52
286	Sex differences in severity and mortality from COVID-19: are males more vulnerable?. Biology of Sex Differences, 2020, 11, 53.	1.8	197
287	Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms. Scientific Reports, 2020, 10, 14214.	1.6	211
288	Insights into the structural and dynamical changes of spike glycoprotein mutations associated with SARS-CoV-2 host receptor binding. Journal of Biomolecular Structure and Dynamics, 2022, 40, 263-275.	2.0	29
289	SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig. Journal of Virology, 2020, 94, .	1.5	100
290	ACE2 Protein Landscape in the Head and Neck Region: The Conundrum of SARS-CoV-2 Infection. Biology, 2020, 9, 235.	1.3	40
291	Can a gluten-free diet be partly protective for COVID-19 infection?. Apmis, 2020, 128, 558-559.	0.9	4

#	ARTICLE	IF	CITATIONS
292	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. <i>Hypertension</i> , 2020, 76, 1339-1349.	1.3	147
293	EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA). <i>Diagnostics</i> , 2020, 10, 593.	1.3	19
294	Particulate Alum via Pickering Emulsion for an Enhanced COVID-19 Vaccine Adjuvant. <i>Advanced Materials</i> , 2020, 32, e2004210.	11.1	65
295	Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. <i>Journal of Biological Chemistry</i> , 2020, 295, 15174-15182.	1.6	34
296	Naltrexone a potential therapeutic candidate for COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 963-970.	2.0	19
297	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2921-2931.	1.4	85
298	Genetic variants of the human host influencing the coronavirus-associated phenotypes (SARS, MERS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	74
299	Control Measures for SARS-CoV-2: A Review on Light-Based Inactivation of Single-Stranded RNA Viruses. <i>Pathogens</i> , 2020, 9, 737.	1.2	71
300	Structural models of human ACE2 variants with SARS-CoV-2 Spike protein for structure-based drug design. <i>Scientific Data</i> , 2020, 7, 309.	2.4	26
301	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <i>Shock</i> , 2020, 54, 416-437.	1.0	41
302	Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain. <i>Frontiers in Chemistry</i> , 2020, 8, 572885.	1.8	76
303	<i>In silico</i> investigation of spice molecules as potent inhibitor of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 860-874.	2.0	35
304	Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 941-962.	2.0	43
305	Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective. <i>Frontiers in Immunology</i> , 2020, 11, 570018.	2.2	43
306	In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins. <i>Journal of Proteome Research</i> , 2020, 19, 4637-4648.	1.8	50
307	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <i>Science</i> , 2020, 370, 426-431.	6.0	464
308	No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19. <i>Nanomedicine</i> , 2020, 15, 2411-2427.	1.7	19
309	Structural Characterization of N-Linked Glycans in the Receptor Binding Domain of the SARS-CoV-2 Spike Protein and their Interactions with Human Lectins. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 23763-23771.	7.2	81

#	ARTICLE	IF	CITATIONS
310	Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. <i>Nature Communications</i> , 2020, 11, 4541.	5.8	485
311	Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein. <i>Npj Vaccines</i> , 2020, 5, 81.	2.9	23
312	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 812-816.	0.6	14
313	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. <i>Molecular Neurobiology</i> , 2020, 57, 4856-4877.	1.9	26
314	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 1258.	1.6	91
315	Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1017-1019.	2.5	36
316	Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. <i>Scientific Reports</i> , 2020, 10, 14031.	1.6	173
317	Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states. <i>Journal of Chemical Physics</i> , 2020, 153, 075101.	1.2	111
318	Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22311-22322.	3.3	517
319	COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. <i>PLoS Pathogens</i> , 2020, 16, e1008762.	2.1	194
320	Comparing the binding properties of peptides mimicking the Envelope protein of SARS-CoV and SARS-CoV-2 to the PDZ domain of the tight junction-associated PALS1 protein. <i>Protein Science</i> , 2020, 29, 2038-2042.	3.1	48
321	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. <i>Microorganisms</i> , 2020, 8, 1259.	1.6	14
322	Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. <i>ACS Nano</i> , 2020, 14, 11821-11830.	7.3	72
323	Screening of Natural Products Targeting SARS-CoV-2 ACE2 Receptor Interface – A MixMD Based HTVS Pipeline. <i>Frontiers in Chemistry</i> , 2020, 8, 589769.	1.8	14
324	Comparative molecular dynamics study of the receptor-binding domains in SARS-CoV-2 and SARS-CoV and the effects of mutations on the binding affinity. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 4662-4681.	2.0	26
325	Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9167.	1.8	6
326	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2020, 11, 610688.	2.2	190
327	A Potential Peptide From Soy Cheese Produced Using <i>Lactobacillus delbrueckii</i> WS4 for Effective Inhibition of SARS-CoV-2 Main Protease and S1 Glycoprotein. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 601753.	1.6	39

#	ARTICLE	IF	CITATIONS
328	Impact of COVID-19 Pandemic on Pediatrics and Pediatric Transplantation Programs. <i>Frontiers in Pediatrics</i> , 2020, 8, 612627.	0.9	6
329	Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection <i>In Vitro</i> . <i>MBio</i> , 2020, 11, .	1.8	52
330	In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform. <i>BMC Bioinformatics</i> , 2020, 21, 527.	1.2	40
331	Computational Studies of Hydroxychloroquine and Chloroquine Metabolites as Possible Candidates for Coronavirus (COVID-19) Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 569665.	1.6	3
332	A New Crystal Form of the SARS-CoV-2 Receptor Binding Domain: CR3022 Complex—An Ideal Target for In-Crystal Fragment Screening of the ACE2 Binding Site Surface. <i>Frontiers in Pharmacology</i> , 2020, 11, 615211.	1.6	7
333	An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2. <i>Cell Reports</i> , 2020, 33, 108528.	2.9	77
334	Multitarget in silico studies of <i>Ocimum menthiifolium</i> , family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-11.	2.0	16
335	Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3989.	1.0	35
336	Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features. <i>Molecules</i> , 2020, 25, 5906.	1.7	33
337	A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters. <i>Frontiers in Immunology</i> , 2020, 11, 614256.	2.2	32
338	Evaluating ELISA, Immunofluorescence, and Lateral Flow Assay for SARS-CoV-2 Serologic Assays. <i>Frontiers in Microbiology</i> , 2020, 11, 597529.	1.5	37
339	The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 33, 108488.	2.9	76
340	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104510.	1.0	9
341	Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. <i>Cell Reports Medicine</i> , 2020, 1, 100142.	3.3	142
342	Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. <i>Heliyon</i> , 2020, 6, e05684.	1.4	132
343	Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 5832-5852.	2.5	134
344	Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in <i>Pichia pastoris</i> and mammalian cells. <i>Scientific Reports</i> , 2020, 10, 21779.	1.6	89
345	Tracing the driving forces responsible for the remarkable infectivity of 2019-nCoV: 1. Receptor binding domain in its bound and unbound states. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 28277-28285.	1.3	3

#	ARTICLE	IF	CITATIONS
346	Understanding the biological role of PqqB in <i>Pseudomonas stutzeri</i> using molecular dynamics simulation approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 4237-4249.	2.0	10
347	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. <i>Trials</i> , 2020, 21, 1005.	0.7	16
348	Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 591873.	1.6	83
349	Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. <i>Cells</i> , 2020, 9, 2638.	1.8	138
350	Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. <i>Pharmaceuticals</i> , 2020, 13, 447.	1.7	24
351	Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8268.	1.8	37
352	Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-14.	0.5	30
353	Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1430-1433.	2.5	18
354	Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2917-2933.	2.0	26
355	Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. <i>Microorganisms</i> , 2020, 8, 1704.	1.6	37
356	Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. <i>Nature Communications</i> , 2020, 11, 5588.	5.8	132
357	Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection: in silico approaches. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-12.	2.0	5
358	Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2701-2714.	2.0	9
359	Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2715-2732.	2.0	11
360	De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. <i>Science</i> , 2020, 370, 1208-1214.	6.0	172
361	An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. <i>Science</i> , 2020, 370, 1473-1479.	6.0	336
362	Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation. <i>Molecules</i> , 2020, 25, 5091.	1.7	35
363	Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus. <i>Genomics</i> , 2020, 112, 5331-5342.	1.3	32



#	ARTICLE	IF	CITATIONS
364	Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Proteinâ€‘Human ACE2 Receptor Interface. <i>Molecules</i> , 2020, 25, 4645.	1.7	6
365	Integrate structural analysis, isoform diversity, and interferon-inductive propensity of ACE2 to predict SARS-CoV2 susceptibility in vertebrates. <i>Heliyon</i> , 2020, 6, e04818.	1.4	13
366	Targeting the initiation and termination codons of SARS-CoV-2 spike protein as possible therapy against COVID-19: the role of novel harpagide 5-O-Î²-D-glucopyranoside from <i>Clerodendrum volubile</i> P Beauv. (Labiatae). <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 2475-2488.	2.0	7
367	Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal. <i>Emerging Microbes and Infections</i> , 2020, 9, 2488-2496.	3.0	20
368	Advanced Pulmonary and Cardiac Support of COVID-19 Patients. <i>Circulation: Heart Failure</i> , 2020, 13, e007175.	1.6	39
369	Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. <i>Immunity</i> , 2020, 52, 971-977.e3.	6.6	979
370	The Novel Coronavirus â€‘ Latest Findings. <i>Microbial Biotechnology</i> , 2020, 13, 819-828.	2.0	5
371	Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1076-1078.	1.3	27
372	Counter-regulatory â€‘Renin-Angiotensinâ€™ System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients. <i>Infectious Disorders - Drug Targets</i> , 2020, 20, 407-408.	0.4	49
373	Highly Conserved Homotrimer Cavity Formed by the SARS-CoV-2 Spike Glycoprotein: A Novel Binding Site. <i>Journal of Clinical Medicine</i> , 2020, 9, 1473.	1.0	73
374	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. <i>GeroScience</i> , 2020, 42, 1021-1049.	2.1	115
375	COVIDâ€™19 Clinical trials: Quality matters more than quantity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2542-2547.	2.7	20
376	The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor. <i>Viruses</i> , 2020, 12, 497.	1.5	145
377	Structural basis of receptor recognition by SARS-CoV-2. <i>Nature</i> , 2020, 581, 221-224.	13.7	3,197
378	In silico studies on the comparative characterization of the interactions of SARSâ€™CoVâ€™2 spike glycoprotein with ACEâ€™2 receptor homologs and human TLRs. <i>Journal of Medical Virology</i> , 2020, 92, 2105-2113.	2.5	354
379	Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. <i>Vascular Pharmacology</i> , 2020, 130, 106680.	1.0	44
380	SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective. <i>Infection, Genetics and Evolution</i> , 2020, 84, 104384.	1.0	115
381	COVID-19 cytokine storm: The anger of inflammation. <i>Cytokine</i> , 2020, 133, 155151.	1.4	357



#	ARTICLE	IF	CITATIONS
382	Current Perspective of Antiviral Strategies against COVID-19. ACS Infectious Diseases, 2020, 6, 1624-1634.	1.8	51
383	Structural variations and expression profiles of the SARS-CoV-2 host invasion genes in lung cancer. Journal of Medical Virology, 2020, 92, 2637-2647.	2.5	15
384	SARS-CoV-2, More than a Respiratory Virus: Its Potential Role in Neuropathogenesis. ACS Chemical Neuroscience, 2020, 11, 1887-1899.	1.7	41
385	The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. Science, 2020, 23, 101160.	1.9	177
386	Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts. Journal of Virology, 2020, 94, .	1.5	148
387	An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes. MSphere, 2020, 5, .	1.3	46
388	Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host and Microbe, 2020, 27, 891-898.e5.	5.1	227
389	COVID-19: CADD to the rescue. Virus Research, 2020, 285, 198022.	1.1	19
390	Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cellular and Molecular Immunology, 2020, 17, 621-630.	4.8	413
391	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell, 2020, 181, 1458-1463.	13.5	92
392	A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host and Microbe, 2020, 28, 124-133.e4.	5.1	540
393	Emergence of SARS-CoV-2 through recombination and strong purifying selection. Science Advances, 2020, 6, .	4.7	307
394	Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology, 2020, 73, 366-369.	1.0	120
395	Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control. Electrophoresis, 2020, 41, 1137-1151.	1.3	99
396	Understanding the B and T cell epitopes of spike protein of severe acute respiratory syndrome coronavirus-2: A computational way to predict the immunogens. Infection, Genetics and Evolution, 2020, 84, 104382.	1.0	36
397	Association of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. Epidemiology and Infection, 2020, 148, e106.	1.0	78
398	Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atom Simulations. Journal of Physical Chemistry Letters, 2020, 11, 4785-4790.	2.1	147
399	Universal coronavirus vaccines: the time to start is now. Npj Vaccines, 2020, 5, 43.	2.9	30

#	ARTICLE	IF	CITATIONS
400	Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15193-15199.	3.3	196
401	Association between renin-angiotensin system inhibitors and COVID-19 complications. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 426-434.	1.4	46
402	Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system. Biochemical and Biophysical Research Communications, 2020, 529, 257-262.	1.0	40
403	Fight against novel coronavirus: A perspective of medicinal chemists. European Journal of Medicinal Chemistry, 2020, 201, 112559.	2.6	58
404	Serological differentiation between COVID-19 and SARS infections. Emerging Microbes and Infections, 2020, 9, 1497-1505.	3.0	89
405	ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. Ocular Surface, 2020, 18, 537-544.	2.2	262
406	Computational investigation on <i>Andrographis paniculata</i> phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4415-4426.	2.0	73
407	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano, 2020, 14, 7760-7782.	7.3	289
408	A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020, 369, 650-655.	6.0	1,292
409	Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chemical Communications, 2020, 56, 8683-8686.	2.2	34
410	Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2. Biological Procedures Online, 2020, 22, 11.	1.4	32
411	Solid Organ Transplantation During the COVID-19 Pandemic. Frontiers in Immunology, 2020, 11, 1392.	2.2	30
412	Global Comparison of Changes in the Number of Test-Positive Cases and Deaths by Coronavirus Infection (COVID-19) in the World. Journal of Clinical Medicine, 2020, 9, 1904.	1.0	14
413	Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 2020, 583, 290-295.	13.7	1,695
414	Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13967-13974.	3.3	291
415	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	6.0	534
416	Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 2020, 369, 1010-1014.	6.0	1,140
417	Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Frontiers in Immunology, 2020, 11, 1441.	2.2	515

#	ARTICLE	IF	CITATIONS
418	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1606.	2.2	43
419	The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. <i>Protein Journal</i> , 2020, 39, 198-216.	0.7	427
420	Mining the PDB for Tractable Cases Where X-ray Crystallography Combined with Fragment Screens Can Be Used to Systematically Design Protein-Protein Inhibitors: Two Test Cases Illustrated by IL1 $\beta$ -IL1R and p38 $\beta$ -TAB1 Complexes. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7559-7568.	2.9	18
421	Cryo-EM structures of HKU2 and SARS-CoV spike glycoproteins provide insights into coronavirus evolution. <i>Nature Communications</i> , 2020, 11, 3070.	5.8	44
422	SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East. <i>Emerging Microbes and Infections</i> , 2020, 9, 1457-1466.	3.0	118
423	Distinct infection process of SARS-CoV-2 in human bronchial epithelial cell lines. <i>Journal of Medical Virology</i> , 2020, 92, 2830-2838.	2.5	37
424	COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1599-1608.	1.4	277
425	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020, 28, 445-454.e6.	5.1	298
426	Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV. <i>Journal of Physical Chemistry B</i> , 2020, 124, 5907-5912.	1.2	52
427	Overview of therapeutic drug research for COVID-19 in China. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1133-1140.	2.8	38
428	Unraveling the mystery of Covid-19 cytokine storm: From skin to organ systems. <i>Dermatologic Therapy</i> , 2020, 33, e13859.	0.8	47
429	Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome?. <i>Archives of Medical Research</i> , 2020, 51, 726-727.	1.5	9
430	Giovanni Di Guardo: Animal Models and Pathogenetic Insights to Covid-19. <i>Journal of Comparative Pathology</i> , 2020, 179, e1.	0.1	5
431	Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane. <i>Journal of Physical Chemistry B</i> , 2020, 124, 7128-7137.	1.2	240
432	Statins: Could an old friend help in the fight against COVID-19?. <i>British Journal of Pharmacology</i> , 2020, 177, 4873-4886.	2.7	101
433	Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury. <i>Journal of Cellular Physiology</i> , 2020, 235, 9884-9894.	2.0	60
434	COVID-19: Drug Targets and Potential Treatments. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12359-12386.	2.9	348
435	Human neutralizing antibodies to SARS-CoV-2: views and perspectives from Professor Linqi Zhang at Tsinghua University. <i>Antibody Therapeutics</i> , 2020, 3, 155-156.	1.2	0

#	ARTICLE	IF	CITATIONS
436	From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances. <i>Microorganisms</i> , 2020, 8, 850.	1.6	5
437	Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 476.	1.8	27
438	Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. <i>Protein and Cell</i> , 2020, 11, 707-722.	4.8	97
439	Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165878.	1.8	770
440	Rationale for targeting complement in COVID-19. <i>EMBO Molecular Medicine</i> , 2020, 12, e12642.	3.3	101
441	Pulmonary surfactant itself must be a strong defender against SARS-CoV-2. <i>Medical Hypotheses</i> , 2020, 144, 110020.	0.8	34
442	New Strategy for COVID-19: An Evolutionary Role for RGD Motif in SARS-CoV-2 and Potential Inhibitors for Virus Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 912.	1.6	36
443	Potential of Flavonoid-Inspired Phytochemicals against COVID-19. <i>Molecules</i> , 2020, 25, 2707.	1.7	127
444	Coronavirus SARS-CoV-2: filtering fact from fiction in the infodemic. <i>FEBS Letters</i> , 2020, 594, 1127-1131.	1.3	10
445	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. <i>Cell</i> , 2020, 182, 685-712.e19.	13.5	825
446	A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. <i>Cell</i> , 2020, 182, 722-733.e11.	13.5	412
447	Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor. <i>ACS Omega</i> , 2020, 5, 16292-16298.	1.6	140
448	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e4197-e4205.	2.9	337
449	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. <i>Theranostics</i> , 2020, 10, 7448-7464.	4.6	180
450	GS-5734: a potentially approved drug by FDA against SARS-Cov-2. <i>New Journal of Chemistry</i> , 2020, 44, 12417-12429.	1.4	24
451	The SARS-CoV-2 main protease as drug target. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127377.	1.0	550
452	Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. <i>Journal of Molecular Structure</i> , 2020, 1221, 128823.	1.8	125
453	Docking approaches for modeling multi-molecular assemblies. <i>Current Opinion in Structural Biology</i> , 2020, 64, 59-65.	2.6	18

#	ARTICLE	IF	CITATIONS
454	Novel treatment targets for COVID-19: Contribution from molecular psychiatry. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 572-575.	1.3	1
455	Hypoxemia in COVID-19 patients: An hypothesis. <i>Medical Hypotheses</i> , 2020, 143, 110022.	0.8	15
456	Distinct Clinical Characteristics and Risk Factors for Mortality in Female Inpatients With Coronavirus Disease 2019 (COVID-19): A Sex-stratified, Large-scale Cohort Study in Wuhan, China. <i>Clinical Infectious Diseases</i> , 2020, 71, 3188-3195.	2.9	53
457	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	36
458	Human Sialome and Coronavirus Disease-2019 (COVID-19) Pandemic: An Understated Correlation?. <i>Frontiers in Immunology</i> , 2020, 11, 1480.	2.2	52
459	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approachesâ€”Insights into Chemical Structureâ€”Biological Activity and Toxicological Screening. <i>Journal of Clinical Medicine</i> , 2020, 9, 2084.	1.0	38
460	Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1209-1220.	1.3	110
461	Analysis of ACE2 Genetic Variability among Populations Highlights a Possible Link with COVID-19-Related Neurological Complications. <i>Genes</i> , 2020, 11, 741.	1.0	54
462	Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design. <i>Vaccines</i> , 2020, 8, 355.	2.1	53
463	SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 763-767.	3.6	471
464	Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. <i>Frontiers in Microbiology</i> , 2020, 11, 1796.	1.5	115
465	Cancer Patients Have a Higher Risk Regarding COVID-19â€”and Vice Versa?. <i>Pharmaceuticals</i> , 2020, 13, 143.	1.7	14
466	Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. <i>Free Radical Biology and Medicine</i> , 2020, 156, 190-199.	1.3	117
468	Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19. <i>Theranostics</i> , 2020, 10, 7034-7052.	4.6	28
469	Elucidation of cellular targets and exploitation of the receptorâ€”binding domain of SARSâ€”CoVâ€”2 for vaccine and monoclonal antibody synthesis. <i>Journal of Medical Virology</i> , 2020, 92, 2792-2803.	2.5	16
470	Coronavirus in Continuous Flux: From SARSâ€”CoV to SARSâ€”CoVâ€”2. <i>Advanced Science</i> , 2020, 7, 2001474.	5.6	14
471	Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. <i>Redox Biology</i> , 2020, 36, 101615.	3.9	110
472	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300

#	ARTICLE	IF	CITATIONS
473	Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , 2020, 26, 1422-1427.	15.2	450
474	Molecular mechanisms of sex bias differences in COVID-19 mortality. <i>Critical Care</i> , 2020, 24, 405.	2.5	79
475	Current Findings Regarding Natural Components With Potential Anti-2019-nCoV Activity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 589.	1.8	24
476	Coronaviruses in cats and other companion animals: Where does SARS-CoV-2/COVID-19 fit?. <i>Veterinary Microbiology</i> , 2020, 247, 108777.	0.8	88
477	Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2. <i>Virus Research</i> , 2020, 288, 198082.	1.1	56
478	Door to the cell for COVID-19 opened, leading way to therapies. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 104.	7.1	7
479	Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 404-411.	0.6	13
480	Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 5706-5721.	2.0	18
481	COVID-19: Progress in diagnostics, therapy and vaccination. <i>Theranostics</i> , 2020, 10, 7821-7835.	4.6	121
482	Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction. <i>Biochemical Pharmacology</i> , 2020, 178, 114123.	2.0	61
483	Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. <i>Life Sciences</i> , 2020, 257, 118056.	2.0	175
484	Considerations around the SARS-CoV-2 Spike Protein with Particular Attention to COVID-19 Brain Infection and Neurological Symptoms. <i>ACS Chemical Neuroscience</i> , 2020, 11, 2361-2369.	1.7	75
485	Employing bioactive compounds derived from <i>Ipomoea obscura</i> (L.) to evaluate potential inhibitor for SARS-CoV-2 main protease and ACE2 protein. <i>Food Frontiers</i> , 2020, 1, 168-179.	3.7	24
486	Antiviral anticoagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 774-788.	1.0	11
487	Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal-Oral Transmission? A COVID-19 Virological and Clinical Review. <i>Gastroenterology</i> , 2020, 159, 53-61.	0.6	157
488	Antibody therapies for the treatment of COVID-19. <i>Antibody Therapeutics</i> , 2020, 3, 101-108.	1.2	10
489	Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. <i>Science</i> , 2020, 368, 1499-1504.	6.0	950
490	Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2. <i>Viruses</i> , 2020, 12, 428.	1.5	140



#	ARTICLE	IF	CITATIONS
491	Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. <i>Journal of Molecular Biology</i> , 2020, 432, 3309-3325.	2.0	406
492	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. <i>Hepatology</i> , 2020, 72, 287-304.	3.6	408
493	Renin-angiotensin-aldosterone system and COVID-19 infection. <i>Annales D'Endocrinologie</i> , 2020, 81, 63-67.	0.6	65
494	Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. <i>Modern Pathology</i> , 2020, 33, 1007-1014.	2.9	762
495	The Science Underlying COVID-19. <i>Circulation</i> , 2020, 142, 68-78.	1.6	682
496	Structural Basis of SARS-CoV-2 and SARS-CoV-2 Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 465-493.	4.2	36
497	Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. <i>Journal of Medical Virology</i> , 2021, 93, 275-299.	2.5	76
498	An update on the origin of SARS-CoV-2: Despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues. <i>Journal of Medical Virology</i> , 2021, 93, 499-505.	2.5	43
499	Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection. <i>Archives of Medical Research</i> , 2021, 52, 143-150.	1.5	5
500	Culinary spice bioactives as potential therapeutics against SARS-CoV-2: Computational investigation. <i>Computers in Biology and Medicine</i> , 2021, 128, 104102.	3.9	36
501	In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain. <i>European Journal of Pharmacology</i> , 2021, 890, 173701.	1.7	17
502	Human coronavirus spike protein-host receptor recognition. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 161, 39-53.	1.4	34
503	Inmunomodulación mediante CONVEHYA® para COVID-19: de la tormenta al anticiclón de citoquinas. <i>Revista Española De Anestesiología Y Reanimación</i> , 2021, 68, 107-112.	0.1	0
504	The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 165999.	1.8	18
505	Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19. <i>European Journal of Pharmacology</i> , 2021, 890, 173720.	1.7	19
506	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. <i>Journal of Biological Chemistry</i> , 2021, 296, 100025.	1.6	43
507	Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. <i>International Journal of Pharmaceutics</i> , 2021, 592, 120028.	2.6	69
508	Digital Screen Time During the COVID-19 Pandemic: Risk for a Further Myopia Boom?. <i>American Journal of Ophthalmology</i> , 2021, 223, 333-337.	1.7	217



#	ARTICLE	IF	CITATIONS
509	Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. <i>Infection, Genetics and Evolution</i> , 2021, 89, 104490.	1.0	79
510	ACE2 isoform diversity predicts the host susceptibility of SARS-CoV-2. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1026-1032.	1.3	13
511	Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research. <i>Briefings in Bioinformatics</i> , 2021, 22, 882-895.	3.2	28
512	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 9789-9802.	7.2	50
513	Molecular Insights into Small-Molecule Drug Discovery for SARS-CoV-2. <i>Angewandte Chemie</i> , 2021, 133, 9873-9886.	1.6	9
514	Covid-19 and the cardiovascular system: a comprehensive review. <i>Journal of Human Hypertension</i> , 2021, 35, 4-11.	1.0	238
515	The increasing importance of the novel Coronavirus. <i>Hospital Practice (1995)</i> , 2021, 49, 1-11.	0.5	8
516	DockCoV2: a drug database against SARS-CoV-2. <i>Nucleic Acids Research</i> , 2021, 49, D1152-D1159.	6.5	42
517	Predicting susceptibility for SARS-CoV-2 infection in domestic and wildlife animals using ACE2 protein sequence homology. <i>Zoo Biology</i> , 2021, 40, 79-85.	0.5	23
518	Risk of human-wildlife transmission of SARS-CoV-2. <i>Mammal Review</i> , 2021, 51, 272-292.	2.2	69
519	Autopsy findings in COVID-19-related deaths: a literature review. <i>Forensic Science, Medicine, and Pathology</i> , 2021, 17, 279-296.	0.6	153
520	Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 553-574.	1.4	33
521	Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases. <i>Annals of Hepatology</i> , 2021, 21, 100267.	0.6	34
522	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 192-203.	1.0	165
523	Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?. <i>Journal of Cellular Physiology</i> , 2021, 236, 3366-3382.	2.0	21
524	MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. <i>Briefings in Bioinformatics</i> , 2021, 22, 946-962.	3.2	21
525	Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 79-88.	1.4	45
526	Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 222-236.	5.7	112

#	ARTICLE	IF	CITATIONS
527	The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. <i>Peptides</i> , 2021, 135, 170428.	1.2	19
528	Review of COVID-19 Antibody Therapies. <i>Annual Review of Biophysics</i> , 2021, 50, 1-30.	4.5	34
529	Why Does the Novel Coronavirus Spike Protein Interact so Strongly with the Human ACE2? A Thermodynamic Answer. <i>ChemBioChem</i> , 2021, 22, 865-875.	1.3	31
530	Synthesis, spectroscopy, crystal structure, TGA/DTA study, DFT and molecular docking investigations of (E)-4-(4-methylbenzyl)-6-styrylpyridazin-3(2H)-one. <i>Journal of Molecular Structure</i> , 2021, 1228, 129435.	1.8	55
531	Repositioning microbial biotechnology against COVID-19: the case of microbial production of flavonoids. <i>Microbial Biotechnology</i> , 2021, 14, 94-110.	2.0	18
532	COVID-19 lockdown: animal life, ecosystem and atmospheric environment. <i>Environment, Development and Sustainability</i> , 2021, 23, 8161-8178.	2.7	50
533	Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1-12.	5.7	93
534	A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2). <i>Biosensors and Bioelectronics</i> , 2021, 171, 112715.	5.3	150
535	Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis. <i>Digestive and Liver Disease</i> , 2021, 53, 153-157.	0.4	61
536	An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets. <i>Chemical Physics Letters</i> , 2021, 763, 138193.	1.2	32
537	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. <i>Biochemical Pharmacology</i> , 2021, 183, 114296.	2.0	79
538	Current advances in the development of SARS-CoV-2 vaccines. <i>International Journal of Biological Sciences</i> , 2021, 17, 8-19.	2.6	114
539	N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. <i>Journal of Clinical Immunology</i> , 2021, 41, 335-344.	2.0	17
540	Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CLpro and PLpro), spike protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II receptor (ACE2). <i>European Journal of Pharmacology</i> , 2021, 891, 173759.	1.7	92
541	Assessing the consequences of environmental exposures on the expression of the human receptor and proteases involved in SARS-CoV-2 cell-entry. <i>Environmental Research</i> , 2021, 195, 110317.	3.7	11
542	SARS-CoV-2 variants evolved during the early stage of the pandemic and effects of mutations on adaptation in Wuhan populations. <i>International Journal of Biological Sciences</i> , 2021, 17, 97-106.	2.6	45
543	Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. <i>Cell Research</i> , 2021, 31, 17-24.	5.7	86
544	The flexibility of ACE2 in the context of SARS-CoV-2 infection. <i>Biophysical Journal</i> , 2021, 120, 1072-1084.	0.2	102

#	ARTICLE	IF	CITATIONS
545	Occurrence, fate and removal of SARS-CoV-2 in wastewater: Current knowledge and future perspectives. <i>Journal of Environmental Chemical Engineering</i> , 2021, 9, 104870.	3.3	59
546	The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. <i>Blood Reviews</i> , 2021, 48, 100785.	2.8	107
547	Host range projection of SARS-CoV-2: South Asia perspective. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104670.	1.0	13
548	Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein. <i>Biochimie</i> , 2021, 180, 143-148.	1.3	53
549	Transition metal complexes as potential tools against SARS-CoV-2: an <i>in silico</i> approach. <i>New Journal of Chemistry</i> , 2021, 45, 1924-1933.	1.4	32
550	Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. <i>Cell Proliferation</i> , 2021, 54, e12953.	2.4	23
551	<i>Coronapp</i> : A web application to annotate and monitor SARS-CoV-2 mutations. <i>Journal of Medical Virology</i> , 2021, 93, 3238-3245.	2.5	75
552	COVID-19 endocrinopathy with hindsight from SARS. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E139-E150.	1.8	55
553	Development of a nano-luciferase based assay to measure the binding of SARS-CoV-2 spike receptor binding domain to ACE-2. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 485-490.	1.0	9
554	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. <i>Theranostics</i> , 2021, 11, 731-753.	4.6	60
555	Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. <i>International Immunopharmacology</i> , 2021, 90, 107209.	1.7	15
556	Structural insights into SARS-CoV-2 proteins. <i>Journal of Molecular Biology</i> , 2021, 433, 166725.	2.0	241
557	The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 104-107.	1.0	85
558	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 108-115.	1.0	79
559	Comparative Analysis of Nanomechanical Features of Coronavirus Spike Proteins and Correlation with Lethality and Infection Rate. <i>Matter</i> , 2021, 4, 265-275.	5.0	20
560	Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 49-64.	10.6	126
561	Why are ACE2 binding coronavirus strains SARS-CoV-2 wild and NL63 mild?. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 389-398.	1.5	25
562	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021, 29, 44-57.e9.	5.1	937

#	ARTICLE	IF	CITATIONS
563	Lesions in the lungs of fatal corona virus disease Covid-19. <i>Annals of Anatomy</i> , 2021, 234, 151657.	1.0	10
564	Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 100-117.	6.6	63
565	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 168-189.	6.6	62
566	The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. <i>Journal of Molecular Biology</i> , 2021, 433, 166748.	2.0	12
567	Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro. <i>Life Sciences</i> , 2021, 266, 118889.	2.0	25
568	Photochemical metal-free aerobic oxidation of thiols to disulfides. <i>Green Chemistry</i> , 2021, 23, 546-551.	4.6	58
569	Novel SARS-CoV-2 encoded small RNAs in the passage to humans. <i>Bioinformatics</i> , 2021, 36, 5571-5581.	1.8	24
570	Spectrum of Cardiovascular Diseases in Children During High Peak Coronavirus Disease 2019 Period Infection in Northern Italy: Is There a Link?. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 714-721.	0.6	7
571	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
572	Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blockerâ€Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19. <i>Diabetes</i> , 2021, 70, 759-771.	0.3	18
573	The biogenesis of SARS-CoV-2 spike glycoprotein: multiple targets for host-directed antiviral therapy. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 80-87.	1.0	21
574	COVID-19: The Effect of Host Genetic Variations on Hostâ€Virus Interactions. <i>Journal of Proteome Research</i> , 2021, 20, 139-153.	1.8	14
575	Structural basis of severe acute respiratory syndrome coronavirus 2 infection. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 74-81.	1.5	7
576	Dynamic anti-spike protein antibody profiles in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 103, 540-548.	1.5	25
577	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13
578	Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. <i>Science Advances</i> , 2021, 7, .	4.7	320
579	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. <i>SLAS Discovery</i> , 2021, 26, 311-329.	1.4	4
580	<i>De Novo</i> Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein. <i>ACS Central Science</i> , 2021, 7, 156-163.	5.3	69

#	ARTICLE	IF	CITATIONS
581	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
582	Neutralizing antibodies targeting SARS-CoV-2 spike protein. <i>Stem Cell Research</i> , 2021, 50, 102125.	0.3	89
583	DNA vaccines against COVID-19: Perspectives and challenges. <i>Life Sciences</i> , 2021, 267, 118919.	2.0	172
584	Coevolutionary forces shaping the fitness of SARS-CoV-2 spike glycoprotein against human receptor ACE2. <i>Infection, Genetics and Evolution</i> , 2021, 87, 104646.	1.0	16
585	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 137-144.	1.0	12
586	The inhibitory effect of a coronavirus spike protein fragment with ACE2. <i>Biophysical Journal</i> , 2021, 120, 1001-1010.	0.2	13
587	Genetic analysis of SARS-CoV-2 isolates collected from Bangladesh: Insights into the origin, mutational spectrum and possible pathomechanism. <i>Computational Biology and Chemistry</i> , 2021, 90, 107413.	1.1	16
588	Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery. <i>Computers in Biology and Medicine</i> , 2021, 128, 104158.	3.9	14
589	Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. <i>Journal of Controlled Release</i> , 2021, 330, 529-539.	4.8	31
590	COVID-19 vaccination for people with severe mental illness: why, what, and how?. <i>Lancet Psychiatry</i> , 2021, 8, 444-450.	3.7	116
591	Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. <i>In Silico Pharmacology</i> , 2021, 9, 1.	1.8	40
592	A multiscale coarse-grained model of the SARS-CoV-2 virion. <i>Biophysical Journal</i> , 2021, 120, 1097-1104.	0.2	139
593	Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic. <i>ACS Infectious Diseases</i> , 2021, 7, 1303-1316.	1.8	1
594	Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. <i>Journal of Biological Chemistry</i> , 2021, 296, 100135.	1.6	63
595	Integrative clinical, genomics and metabolomics data analysis for mainstream precision medicine to investigate COVID-19. <i>BMJ Innovations</i> , 2021, 7, 6-10.	1.0	15
596	Biophysical analysis of SARS-CoV-2 transmission and theranostic development via N protein computational characterization. <i>Biotechnology Progress</i> , 2021, 37, e3096.	1.3	10
597	Coronavirus biology and replication: implications for SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2021, 19, 155-170.	13.6	2,062
598	Molecular diversity of coronavirus host cell entry receptors. <i>FEMS Microbiology Reviews</i> , 2021, 45, .	3.9	75

#	ARTICLE	IF	CITATIONS
599	Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 194-203.	1.0	17
600	The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. <i>JACC Basic To Translational Science</i> , 2021, 6, 1-8.	1.9	73
601	Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. <i>Nature Chemical Biology</i> , 2021, 17, 113-121.	3.9	78
602	Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein. <i>Journal of Computer-Aided Molecular Design</i> , 2021, 35, 195-207.	1.3	41
603	Structural basis of SARS-CoV-2 spike protein induced by ACE2. <i>Bioinformatics</i> , 2021, 37, 929-936.	1.8	19
604	Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. <i>Transboundary and Emerging Diseases</i> , 2021, 68, 1111-1124.	1.3	35
605	Evaluation of SARS-CoV-2 in Tears of Patients with Moderate to Severe COVID-19. <i>Ophthalmology</i> , 2021, 128, 494-503.	2.5	83
606	Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
607	<sc><i>Aframomum melegueta</i></sc> secondary metabolites exhibit polypharmacology against <sc>SARS-CoV-2</sc> drug targets: in vitro validation of furin inhibition. <i>Phytotherapy Research</i> , 2021, 35, 908-919.	2.8	30
608	Origin-independent analysis links SARS-CoV-2 local genomes with COVID-19 incidence and mortality. <i>Briefings in Bioinformatics</i> , 2021, 22, 905-913.	3.2	1
609	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2168.	3.9	28
610	Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophoblast and placenta. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 248-256.	0.9	54
611	Immune response and possible therapeutics in COVID-19. <i>RSC Advances</i> , 2021, 11, 960-977.	1.7	7
612	Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 406-409.	2.5	4
613	The Potential for Airborne Transmission of SARS-CoV-2 in Sport: A Cricket Case Study. <i>International Journal of Sports Medicine</i> , 2021, 42, 407-418.	0.8	9
615	Time Series Regression Models for COVID-19 Deaths. <i>Journal of Data Science</i> , 2021, , 269-292.	0.5	1
617	COVID-19 and the ethnicity link "is there a photochemical link?". <i>Photochemical and Photobiological Sciences</i> , 2021, 20, 183-188.	1.6	4
618	Alarmins, COVID-19 and comorbidities. <i>Annals of Medicine</i> , 2021, 53, 777-785.	1.5	17



#	ARTICLE	IF	CITATIONS
619	Positivity of SARS-CoV-2 Antibodies among Korean Healthy Healthcare Workers 1 and 2 Weeks after Second Dose of Pfizer-BioNTech Vaccination. <i>Journal of Korean Medical Science</i> , 2021, 36, e158.	1.1	11
620	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. <i>International Journal of Biological Sciences</i> , 2021, 17, 1476-1485.	2.6	23
621	Powder preparation of sugar apple ( <i>Annona squamosa</i> L.) and analyzing its potencies as anti-gout and anti-COVID-19. <i>AIP Conference Proceedings</i> , 2021, , .	0.3	2
624	Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides. <i>RSC Medicinal Chemistry</i> , 2021, 12, 197-202.	1.7	25
626	Should women with polycystic ovarian syndrome be prioritized to receive the COVID vaccine?. <i>Journal of Human Reproductive Sciences</i> , 2021, 14, 213.	0.4	0
627	Strategies for Vaccination: Conventional Vaccine Approaches Versus New-Generation Strategies in Combination with Adjuvants. <i>Pharmaceutics</i> , 2021, 13, 140.	2.0	28
628	Population Dynamics and Structural Effects at Short and Long Range Support the Hypothesis of the Selective Advantage of the G614 SARS-CoV-2 Spike Variant. <i>Molecular Biology and Evolution</i> , 2021, 38, 1966-1979.	3.5	23
629	Could repurposing existing vaccines and antibiotics help to control the COVID-19 pandemic?. , 2021, , 245-255.		0
630	Lower respiratory tract samples are reliable for severe acute respiratory syndrome coronavirus 2 nucleic acid diagnosis and animal model study. <i>Zoological Research</i> , 2021, 42, 161-169.	0.9	6
631	Demystifying COVID-19 lung pathology: A clinicopathological study of postmortem core needle biopsy. <i>Lung India</i> , 2021, 38, 343.	0.3	3
632	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 219-260.	0.8	5
634	Fast and reliable detection of SARS-CoV-2 antibodies based on surface plasmon resonance. <i>Analytical Methods</i> , 2021, 13, 3297-3306.	1.3	14
635	Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110029.	0.7	18
636	Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species. <i>Journal of Biological Chemistry</i> , 2021, 296, 100435.	1.6	30
637	Ultra-large-scale ab initio quantum chemical computation of bio-molecular systems: The case of spike protein of SARS-CoV-2 virus. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1288-1301.	1.9	21
638	Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 374-380.	1.0	52
639	Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by <i>in silico</i> affinity maturation and SPR assay. <i>RSC Advances</i> , 2021, 11, 14737-14745.	1.7	17
641	Therapeutic targets and potential agents for the treatment of COVID-19. <i>Medicinal Research Reviews</i> , 2021, 41, 1775-1797.	5.0	21



#	ARTICLE	IF	CITATIONS
643	SARS-CoV-2 Variants of Concern Have Acquired Mutations Associated With an Increased Spike Cleavage. SSRN Electronic Journal, 0, , .	0.4	0
645	The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization. Journal of Biological Chemistry, 2021, 296, 100536.	1.6	91
646	Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. Journal of Molecular Cell Biology, 2021, 13, 185-196.	1.5	44
647	In silico study of the potential interactions of 4- $\beta$ -acetamidochalcones with protein targets in SARS-CoV-2. Biochemical and Biophysical Research Communications, 2021, 537, 71-77.	1.0	15
648	SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. Journal of Basic Microbiology, 2021, 61, 180-202.	1.8	119
649	Impact of New Variants on SARS-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. SSRN Electronic Journal, 0, , .	0.4	3
650	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications, 2021, 12, 324.	5.8	79
651	A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main proteases. RSC Advances, 2021, 11, 12003-12014.	1.7	17
653	Novel Targets of SARS-CoV-2 Spike Protein in Human Fetal Brain Development Suggest Early Pregnancy Vulnerability. Frontiers in Neuroscience, 2020, 14, 614680.	1.4	15
654	Exploring G protein-coupled receptors and yeast surface display strategies for viral detection in baker's yeast: SARS-CoV-2 as a case study. FEMS Yeast Research, 2021, 21, .	1.1	3
655	Oral manifestations and dental practice recommendations during COVID-19 pandemic. Journal of Family Medicine and Primary Care, 2021, 10, 102.	0.3	6
656	Reactivity of human antisera to codon optimized SARS-CoV2 viral proteins expressed in Escherichia coli. Tzu Chi Medical Journal, 2021, 33, 146.	0.4	0
658	Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study. Nanoscale, 2021, 13, 9364-9370.	2.8	22
659	Immunonutrition effects on coping with COVID-19. Food and Function, 2021, 12, 7637-7650.	2.1	4
660	Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19. GeroScience, 2021, 43, 19-29.	2.1	24
661	High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection. MethodsX, 2021, 8, 101432.	0.7	5
662	Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes. Nature Communications, 2021, 12, 141.	5.8	17
663	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946.	3.0	11

#	ARTICLE	IF	CITATIONS
664	Understanding the Structure and Function of Viral Glycosylation by Molecular Simulations: State-of-the-Art and Recent Case Studies. , 2021, , 405-415.		1
667	COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario. Cancer Treatment and Research Communications, 2021, 28, 100425.	0.7	1
669	Elucidating Interactions Between SARS-CoV-2 Trimeric Spike Protein and ACE2 Using Homology Modeling and Molecular Dynamics Simulations. Frontiers in Chemistry, 2020, 8, 622632.	1.8	31
670	Corilagin and 1,3,6-Tri-O-galloyl- $\beta$ -D-glucose: potential inhibitors of SARS-CoV-2 variants. Physical Chemistry Chemical Physics, 2021, 23, 14873-14888.	1.3	12
672	Structure of SARS-CoV-2 Proteins. , 2021, , 91-120.		0
673	Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies. Chemical Science, 2021, 12, 6929-6948.	3.7	85
675	COVID-19 and the Kidney: Should Nephrologists Care about COVID-19 rather than Maintaining Their Focus on Renal Patients?. Contributions To Nephrology, 2021, 199, 1-15.	1.1	3
676	Comprehensive landscape of the renin-angiotensin system in Pan-cancer: a potential downstream mediated mechanism of SARS-CoV-2. International Journal of Biological Sciences, 2021, 17, 3795-3817.	2.6	7
677	Domains and Functions of Spike Protein in SARS-Cov-2 in the Context of Vaccine Design. Viruses, 2021, 13, 109.	1.5	223
678	Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein. Viruses, 2021, 13, 146.	1.5	74
679	A scoping review of the pathophysiology of COVID-19. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110480.	1.0	42
680	Bioinformatic and MD Analysis of N501Y SARS-CoV-2 (UK) Variant. IFIP Advances in Information and Communication Technology, 2021, , 1-13.	0.5	1
681	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. Computational and Structural Biotechnology Journal, 2021, 19, 3799-3809.	1.9	24
682	Binding affinity and mechanisms of SARS-CoV-2 variants. Computational and Structural Biotechnology Journal, 2021, 19, 4184-4191.	1.9	20
683	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Central Science, 2021, 7, 183-199.	5.3	134
684	Epidemiological dynamics of SARS-CoV-2 VOC Gamma in Rio de Janeiro, Brazil. Virus Evolution, 2021, 7, veab087.	2.2	23
685	Applications of bioluminescence in biotechnology and beyond. Chemical Society Reviews, 2021, 50, 5668-5705.	18.7	134
686	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167

#	ARTICLE	IF	CITATIONS
688	Singular spectrum transformation for detecting molecular motion mode change of protein systems. AIP Conference Proceedings, 2021, , .	0.3	2
689	Computational Modeling of ACE2-Mediated Cell Entry Inhibitors for the Development of Drugs Against Coronaviruses. Methods in Pharmacology and Toxicology, 2021, , 495.	0.1	1
690	Receptors   Angiotensin Receptors. , 2021, , 110-121.		0
691	Biological therapeutic modalities. , 2021, , 137-164.		7
696	Insight into the origin of SARS-CoV-2 through structural analysis of receptor recognition: a molecular simulation study. RSC Advances, 2021, 11, 8718-8729.	1.7	1
697	Insight into molecular characteristics of SARS-CoV-2 spike protein following D614G point mutation, a molecular dynamics study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 5634-5642.	2.0	24
698	ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2. Journal of Proteome Research, 2021, 20, 1296-1303.	1.8	36
699	Phenolics from the heartwood of Tecoma mollis as potential inhibitors of COVID-19 virus main protease and spike proteins: An In silico study. Pharmacognosy Magazine, 2021, 17, 278.	0.3	3
700	Antibodies to neutralising epitopes synergistically block the interaction of the receptorâ€binding domain of SARSâ€CoVâ€2 to ACE 2. Clinical and Translational Immunology, 2021, 10, e1260.	1.7	13
701	Population-Specific ACE2 Single-Nucleotide Polymorphisms Have Limited Impact on SARS-CoV-2 Infectivity In Vitro. Viruses, 2021, 13, 67.	1.5	19
702	SARS-CoV-2 and approaches for a testing and diagnostic strategy. Journal of Materials Chemistry B, 2021, 9, 8157-8173.	2.9	4
703	Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations. Informatics in Medicine Unlocked, 2021, 23, 100541.	1.9	24
704	ANTIVIRAL EFFECTS OF BACTERIOCIN AGAINST ANIMAL-TO-HUMAN TRANSMITTABLE MUTATED SARS-COV-2: A SYSTEMATIC REVIEW. Frontiers of Agricultural Science and Engineering, 2021, 8, 603.	0.9	14
705	The SARS-CoV-2 B.1.618 variant slightly alters the spike RBDâ€ACE2 binding affinity and is an antibody escaping variant: a computational structural perspective. RSC Advances, 2021, 11, 30132-30147.	1.7	57
706	Carbon nanotubes for rapid capturing of SARS-COV-2 virus: revealing a mechanistic aspect of binding based on computational studies. RSC Advances, 2021, 11, 5785-5800.	1.7	15
707	New challenges in the department of assisted reproductive technology due to the COVID-19 pandemic. Russian Journal of Human Reproduction, 2021, 27, 65.	0.1	0
708	Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. Physical Chemistry Chemical Physics, 2021, 23, 12549-12558.	1.3	6
710	Endolysosomal Ca2+ signaling in cardiovascular health and disease. International Review of Cell and Molecular Biology, 2021, 363, 203-269.	1.6	18

#	ARTICLE	IF	CITATIONS
711	Determination of intermediate state structures in the opening pathway of SARS-CoV-2 spike using cryo-electron microscopy. <i>Chemical Science</i> , 2021, 12, 9168-9175.	3.7	25
712	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. <i>Nature Communications</i> , 2021, 12, 264.	5.8	81
713	Interaction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations. <i>RSC Advances</i> , 2021, 11, 3272-3279.	1.7	20
714	Molecular recognition of SARS-CoV-2 spike glycoprotein: quantum chemical hot spot and epitope analyses. <i>Chemical Science</i> , 2021, 12, 4722-4739.	3.7	37
715	Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein. <i>FEBS Letters</i> , 2021, 595, 442-451.	1.3	9
716	Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. <i>Journal of Biological Chemistry</i> , 2021, 296, 100701.	1.6	63
717	Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. <i>MAbs</i> , 2021, 13, 1953683.	2.6	20
719	Furin cleavage sites naturally occur in coronaviruses. <i>Stem Cell Research</i> , 2021, 50, 102115.	0.3	69
720	Harnessing the Capability of CADD Methods in the Prediction of Anti-COVID Drug Likelihood. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 269-287.	0.1	0
721	Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. <i>Journal of Nanobiotechnology</i> , 2021, 19, 33.	4.2	57
722	SARS-CoV-2 leads to a small vessel endotheliitis in the heart. <i>EBioMedicine</i> , 2021, 63, 103182.	2.7	93
723	Engaging the spikes: heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 39.	7.1	39
724	Short linear motif candidates in the cell entry system used by SARS-CoV-2 and their potential therapeutic implications. <i>Science Signaling</i> , 2021, 14, .	1.6	61
725	Genetic Variation and Evolution of the 2019 Novel Coronavirus. <i>Public Health Genomics</i> , 2021, 24, 54-66.	0.6	9
726	Possible host-adaptation of SARS-CoV-2 due to improved ACE2 receptor binding in mink. <i>Virus Evolution</i> , 2021, 7, veaa094.	2.2	50
727	Can SARS-CoV-2 Virus Use Multiple Receptors to Enter Host Cells?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 992.	1.8	106
728	In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 599079.	1.6	96
729	Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies. <i>Viruses</i> , 2021, 13, 134.	1.5	56

#	ARTICLE	IF	CITATIONS
730	Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. <i>ACS Nano</i> , 2021, 15, 2738-2752.	7.3	143
731	Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 97-103.	1.0	41
732	Predicting mammalian species at risk of being infected by SARS-CoV-2 from an ACE2 perspective. <i>Scientific Reports</i> , 2021, 11, 1702.	1.6	22
733	Total phenolic and total flavonoid content of sugar cane juice and their potency as alpha-amylase inhibitor and anti COVID-19. <i>AIP Conference Proceedings</i> , 2021, , .	0.3	1
734	Alu retrotransposons and COVID-19 susceptibility and morbidity. <i>Human Genomics</i> , 2021, 15, 2.	1.4	15
735	The immunodominant and neutralization linear epitopes for SARS-CoV-2. <i>Cell Reports</i> , 2021, 34, 108666.	2.9	65
736	Recent biotechnological advances as potential intervention strategies against COVID-19. <i>3 Biotech</i> , 2021, 11, 41.	1.1	10
737	Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 459-466.	1.9	26
738	In silico study of medicinal plants with cyclodextrin inclusion complex as the potential inhibitors against SARS-CoV-2 main protease (Mpro) and spike (S) receptor. <i>Informatics in Medicine Unlocked</i> , 2021, 25, 100645.	1.9	9
739	Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1661-1671.	1.9	7
740	Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors. <i>JCI Insight</i> , 2021, 6, .	2.3	10
741	A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics. <i>Archives of Virology</i> , 2021, 166, 697-714.	0.9	21
743	Interaction of serum proteins with SARS-CoV-2 RBD. <i>Nanoscale</i> , 2021, 13, 12865-12873.	2.8	14
744	Computational and network pharmacology analysis of bioflavonoids as possible natural antiviral compounds in COVID-19. <i>Informatics in Medicine Unlocked</i> , 2021, 22, 100504.	1.9	36
745	Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 13752-13759.	1.3	5
746	Quantitative analysis of ACE2 binding to coronavirus spike proteins: SARS-CoV-2 vs. SARS-CoV and RaTG13. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 13926-13933.	1.3	11
747	Effective ACE2 peptide nanoparticle conjugation and its binding with the SARS-Cov-2 RBD quantified by dynamic light scattering. <i>Chemical Communications</i> , 2021, 57, 6979-6982.	2.2	8
749	Transcriptomic Approaches in Understanding SARS-CoV-2 Infection. , 2021, , 221-239.		0

#	ARTICLE	IF	CITATIONS
750	Disorders of sodium balance in COVID-19 patients: two Tunisian patients report. Pan African Medical Journal, 2021, 39, 199.	0.3	2
751	Accurate Evaluation on the Interactions of SARS-CoV-2 with Its Receptor ACE2 and Antibodies CR3022/CB6*. Chinese Physics Letters, 2021, 38, 018701.	1.3	38
752	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. Nature Structural and Molecular Biology, 2021, 28, 202-209.	3.6	110
753	Compounds of Citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda. Future Journal of Pharmaceutical Sciences, 2021, 7, 13.	1.1	42
754	Unraveling the molecular basis of host cell receptor usage in SARS-CoV-2 and other human pathogenic $\beta$ -CoVs. Computational and Structural Biotechnology Journal, 2021, 19, 759-766.	1.9	5
756	Design and development of plastic antibodies against SARS-CoV-2 RBD based on molecularly imprinted polymers that inhibit <i>in vitro</i> virus infection. Nanoscale, 2021, 13, 16885-16899.	2.8	26
757	Study of Specific Receptor Binding Mode Suggests a Possible Enzymatic Disinfectant for SARS-CoV-2. Langmuir, 2021, 37, 1707-1713.	1.6	2
758	Natural and Nature-Derived Products Targeting Human Coronaviruses. Molecules, 2021, 26, 448.	1.7	24
760	Lysine 164 is critical for SARS-CoV-2 Nsp1 inhibition of host gene expression. Journal of General Virology, 2021, 102, .	1.3	21
761	The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19). Theranostics, 2021, 11, 6193-6213.	4.6	16
762	<i>In silico</i> design of peptides with binding to the receptor binding domain (RBD) of the SARS-CoV-2 and their utility in bio-sensor development for SARS-CoV-2 detection. RSC Advances, 2021, 11, 3816-3826.	1.7	17
763	The dual role of the immune system in the course of COVID-19. The fatal impact of the aging immune system. Central-European Journal of Immunology, 2021, 46, 1-9.	0.4	12
764	Charged amino acids may promote coronavirus SARS-CoV-2 fusion with the host cell. AIMS Biophysics, 2021, 8, 111-121.	0.3	26
765	Structure and Function of Major SARS-CoV-2 and SARS-CoV Proteins. Bioinformatics and Biology Insights, 2021, 15, 117793222110258.	1.0	84
767	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS Journal, 2021, 23, 14.	2.2	291
768	Temperature effect on the SARS-CoV-2: A molecular dynamics study of the spike homotrimeric glycoprotein. Computational and Structural Biotechnology Journal, 2021, 19, 1848-1862.	1.9	16
769	The evolutionary history of ACE2 usage within the coronavirus subgenus <i>Sarbecovirus</i> . Virus Evolution, 2021, 7, veab007.	2.2	54
770	Weather Variability and COVID-19 Transmission: A Review of Recent Research. International Journal of Environmental Research and Public Health, 2021, 18, 396.	1.2	80



#	ARTICLE	IF	CITATIONS
771	Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 6746-6757.	1.3	30
772	Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1285.	1.7	45
774	SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 225-237.	1.3	18
775	Renin-angiotensin system inhibitors for treating COVID-19 in adults. <i>The Cochrane Library</i> , 0, , .	1.5	0
776	Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages. <i>Biomolecules</i> , 2021, 11, 297.	1.8	20
777	Kidney involvement in coronavirus-associated diseases (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 361.	0.8	3
780	Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. <i>Virology Journal</i> , 2021, 18, 46.	1.4	40
781	Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 178.	2.1	23
783	In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion. <i>Viruses</i> , 2021, 13, 365.	1.5	12
786	Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2. <i>Journal of Infection and Public Health</i> , 2021, 14, 227-237.	1.9	11
787	Tetracycline as an inhibitor to the SARS-CoV-2. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 752-759.	1.2	9
789	A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 795-803.	3.0	82
790	Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. <i>Antioxidants</i> , 2021, 10, 272.	2.2	47
791	General synthetic strategy for regioselective ultrafast formation of disulfide bonds in peptides and proteins. <i>Nature Communications</i> , 2021, 12, 870.	5.8	39
793	Single-Molecule FRET Imaging of Virus Spike-Host Interactions. <i>Viruses</i> , 2021, 13, 332.	1.5	18
794	Comprehensive in vivo secondary structure of the SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms. <i>Molecular Cell</i> , 2021, 81, 584-598.e5.	4.5	198
796	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 583914.	1.6	8
798	Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6545-6555.	2.0	40

#	ARTICLE	IF	CITATIONS
800	Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 629933.	1.1	43
801	Can ACE2 Receptor Polymorphism Predict Species Susceptibility to SARS-CoV-2?. <i>Frontiers in Public Health</i> , 2020, 8, 608765.	1.3	35
802	A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening. <i>IScience</i> , 2021, 24, 102021.	1.9	66
803	Host Diversity and Potential Transmission Pathways of SARS-CoV-2 at the Human-Animal Interface. <i>Pathogens</i> , 2021, 10, 180.	1.2	33
804	Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. <i>Cell Research</i> , 2021, 31, 395-403.	5.7	164
805	SARS-CoV-2 S protein:ACE2 interaction reveals novel allosteric targets. <i>ELife</i> , 2021, 10, .	2.8	100
806	The COVID-19 Pandemic: an Appraisal of its Impact on Human Immunodeficiency Virus Infection and Pre-Eclampsia. <i>Current Hypertension Reports</i> , 2021, 23, 9.	1.5	10
808	Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans. <i>Scientific Reports</i> , 2021, 11, 3187.	1.6	11
809	A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2. <i>Environment International</i> , 2021, 147, 106361.	4.8	10
810	Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year after Emerging. <i>Pathogens</i> , 2021, 10, 184.	1.2	29
811	Potential mechanisms of cerebrovascular diseases in COVID-19 patients. <i>Journal of NeuroVirology</i> , 2021, 27, 35-51.	1.0	24
812	Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2268.	1.8	24
813	Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. <i>Journal of Genetics</i> , 2021, 100, 1.	0.4	85
815	Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody. <i>Scientific Reports</i> , 2021, 11, 3318.	1.6	43
816	Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. <i>PLoS Pathogens</i> , 2021, 17, e1009352.	2.1	56
817	Graphene Sheets with Defined Dual Functionalities for the Strong SARS-CoV-2 Interactions. <i>Small</i> , 2021, 17, e2007091.	5.2	42
818	Potential bioactive compounds of medicinal plants against new Coronavirus (SARS-CoV-2): A review. <i>Revista Bionatura</i> , 2021, 6, 1653-1658.	0.1	9
819	Cyclic <sup>68</sup> Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1631-1637.	2.8	10

#	ARTICLE	IF	CITATIONS
821	Applications of Protein Secondary Structure Algorithms in SARS-CoV-2 Research. <i>Journal of Proteome Research</i> , 2021, 20, 1457-1463.	1.8	3
822	An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 625136.	1.5	41
823	Comparison of the binding characteristics of SARS-CoV and SARS-CoV-2 RBDs to ACE2 at different temperatures by MD simulations. <i>Briefings in Bioinformatics</i> , 2021, 22, 1122-1136.	3.2	26
824	SARS-COV-2 and Ocular Surface: From Physiology to Pathology, a Route to Understand Transmission and Disease. <i>Frontiers in Physiology</i> , 2021, 12, 612319.	1.3	20
827	A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an <i>in silico</i> investigation. <i>Briefings in Bioinformatics</i> , 2021, 22, 1476-1498.	3.2	58
829	In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1695.	1.8	72
831	Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. <i>PLoS Pathogens</i> , 2021, 17, e1009165.	2.1	40
834	Differential binding of SARS-CoV-2 Spike protein variants to its cognate receptor hACE2 using molecular modeling based binding analysis. <i>Bioinformatics</i> , 2021, 17, 337-347.	0.2	3
836	Receptor Binding Domain (RBD) Structural Susceptibility in the SARS-CoV-2 Virus Spike Protein Exposed to a Pulsed Electric Field. <i>Journal of Nuclear Physics Material Sciences Radiation and Applications</i> , 2021, 8, 177-182.	0.1	3
837	COVID-19 in Liver Transplant Recipients. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	4
838	Inflammation and Vascular Injury as the Basis of COVID-19 Skin Changes: Preliminary Analysis of 23 Patients from the Literature [Letter]. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 185-186.	0.8	3
840	2020 Clinical Update in Liver Transplantation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 1449-1457.	0.6	2
842	Mutant strains of SARS-CoV-2 are more prone to infect obese patient: a review. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 383-392.	1.0	3
843	Screening and Molecular Modeling Evaluation of Food Peptides to Inhibit Key Targets of COVID-19 Virus. <i>Biomolecules</i> , 2021, 11, 330.	1.8	6
844	DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods. <i>PeerJ</i> , 2021, 9, e10505.	0.9	9
845	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200950.	1.5	22
846	In silico analysis suggests less effective MHC-II presentation of SARS-CoV-2 RBM peptides: Implication for neutralizing antibody responses. <i>PLoS ONE</i> , 2021, 16, e0246731.	1.1	7
847	SARS CoV-2 Spike Protein in silico Interaction With ACE2 Receptors From Wild and Domestic Species. <i>Frontiers in Genetics</i> , 2021, 12, 571707.	1.1	17

#	ARTICLE	IF	CITATIONS
848	Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 1226-1243.	2.5	24
850	Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 1793-1802.	2.1	77
851	Rapid SARS-CoV-2 Spike Protein Detection by Carbon Nanotube-Based Near-Infrared Nanosensors. <i>Nano Letters</i> , 2021, 21, 2272-2280.	4.5	139
852	Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. <i>Communications Biology</i> , 2021, 4, 197.	2.0	87
853	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. <i>Science</i> , 2021, 371, 823-829.	6.0	285
854	Genomic mutations and changes in protein secondary structure and solvent accessibility of SARS-CoV-2 (COVID-19 virus). <i>Scientific Reports</i> , 2021, 11, 3487.	1.6	62
855	Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. <i>Science</i> , 2021, 371, .	6.0	304
856	Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. <i>Scientific Reports</i> , 2021, 11, 4320.	1.6	93
858	COVID-19: Immunology, Immunopathogenesis and Potential Therapies. <i>International Reviews of Immunology</i> , 2022, 41, 171-206.	1.5	30
860	Potential Applications of Conducting Polymers to Reduce Secondary Bacterial Infections among COVID-19 Patients: a Review. <i>Emergent Materials</i> , 2021, 4, 279-292.	3.2	24
861	Hematological Findings in COVID-19 and Insights to Stem Cell Therapy: From Bench to Practice. <i>Journal of Skin and Stem Cell</i> , 2021, 7, .	0.1	0
862	Renal dysfunction and prognosis of COVID-19 patients: a hospital-based retrospective cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 158.	1.3	35
864	Role of the SphK&#x2013;PIP&#x2013;IP&#x2013;IPRs pathway in invasion of the nervous system by SARS&#x2013;CoV&#x2013;2 infection. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2021, 48, 637-650.	0.9	10
865	Screening and evaluation of anti-SARS-CoV-2 components from <i>Ephedra sinica</i> by ACE2/CMC-HPLC-IT-TOF-MS approach. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 2995-3004.	1.9	34
866	Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population. <i>Scientific Reports</i> , 2021, 11, 4659.	1.6	30
867	Potential intestinal infection and faecal&#x201c;oral transmission of SARS-CoV-2. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 269-283.	8.2	223
868	Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. <i>MBio</i> , 2021, 12, .	1.8	184
869	Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1913.	1.8	11

#	ARTICLE	IF	CITATIONS
870	SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. <i>Nature Communications</i> , 2021, 12, 848.	5.8	389
872	Missense Variants in Human ACE2 May Influence its Binding Interaction with SARS-CoV-2 and Infectivity of COVID-19. <i>Journal of Physics: Conference Series</i> , 2021, 1828, 012179.	0.3	0
874	SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1626.	1.2	17
877	ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. <i>Vox Sanguinis</i> , 2021, 116, 849-861.	0.7	108
880	Scouting the receptor-binding domain of SARS-Coronavirus-2: a comprehensive immunoinformatics inquisition. <i>Future Virology</i> , 2021, 16, 117-132.	0.9	5
881	Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2. <i>Journal of Medical Virology</i> , 2021, 93, 3143-3151.	2.5	33
882	Functional alterations caused by mutations reflect evolutionary trends of SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2021, 22, 1442-1450.	3.2	32
883	An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study. <i>Scientific Reports</i> , 2021, 11, 3238.	1.6	126
884	Structural analysis of COVID-19 spike protein in recognizing the ACE2 receptor of different mammalian species and its susceptibility to viral infection. <i>3 Biotech</i> , 2021, 11, 109.	1.1	18
885	SARS-CoV-2 invasion of the central nervous: a brief review. <i>Hospital Practice (1995)</i> , 2021, 49, 157-163.	0.5	16
886	An overview of Covid-19 pandemic: immunology and pharmacology. <i>Journal of Immunoassay and Immunochemistry</i> , 2021, 42, 493-512.	0.5	1
887	An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay. <i>Immunoematology</i> , 2021, 37, 33-43.	0.2	0
888	Rôle des accélérateurs de particules dans la lutte contre le SARS-CoV-2. , 2021, , 4-9.	0.1	0
889	Mink SARS-CoV-2 infection in Poland – short communication. <i>Journal of Veterinary Research (Poland)</i> , 2021, 65, 1-5.	0.3	29
890	Ca <sup>2+</sup> -dependent mechanism of membrane insertion and destabilization by the SARS-CoV-2 fusion peptide. <i>Biophysical Journal</i> , 2021, 120, 1105-1119.	0.2	53
894	Angiotensin-Converting Enzyme Type 2 as a Molecular Mediator for Infection of Cells with SARS-CoV and SARS-CoV-2 Viruses. <i>Neuroscience and Behavioral Physiology</i> , 2021, 51, 381-389.	0.2	1
895	Genetic and epigenetic factors associated with increased severity of Covid-19. <i>Cell Biology International</i> , 2021, 45, 1158-1174.	1.4	52
896	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113157.	2.6	35

#	ARTICLE	IF	CITATIONS
897	A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion. <i>Nanomaterials</i> , 2021, 11, 807.	1.9	7
900	A study on non-synonymous mutational patterns in structural proteins of SARS-CoV-2. <i>Genome</i> , 2021, 64, 1-14.	0.9	15
901	Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. <i>European Journal of Pharmacology</i> , 2021, 894, 173836.	1.7	51
902	Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2. <i>Journal of Applied Phycology</i> , 2021, 33, 1579-1602.	1.5	29
904	Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain. <i>Journal of Virology</i> , 2021, 95, .	1.5	46
905	A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. <i>MedComm</i> , 2021, 2, 101-113.	3.1	76
906	How Does COVID-19 Affect the Neurobiology of Suicide?. <i>Current Psychiatry Reports</i> , 2021, 23, 16.	2.1	14
907	Gender-Based Disparities in Covid-19 Patient Outcomes. <i>Journal of Investigative Medicine</i> , 2021, 69, 814-818.	0.7	25
908	Concise Update on Genomics of COVID-19: Approach to Its latest Mutations, Escalated Contagiousness, and Vaccine Resistance. <i>Global Medical Genetics</i> , 2021, 08, 085-089.	0.4	10
909	Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen. <i>Frontiers in Immunology</i> , 2021, 12, 637982.	2.2	9
910	Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2. <i>Journal of Structural Biology</i> , 2021, 213, 107690.	1.3	8
911	Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 123.	7.1	89
912	Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14+ monocytes. <i>IScience</i> , 2021, 24, 102187.	1.9	102
914	Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. <i>Frontiers in Immunology</i> , 2021, 12, 635677.	2.2	19
915	Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 257-264.	2.4	19
916	All-Atom Simulations and Free-Energy Calculations of Antibodies Bound to the Spike Protein of SARS-CoV-2: The Binding Strength and Multivalent Hydrogen-Bond Interactions. <i>Advanced Theory and Simulations</i> , 2021, 4, 2100012.	1.3	2
919	Immunoinformatic analysis of structural and epitope variations in the spike and Orf8 proteins of SARS-CoV-2/B.1.1.7. <i>Journal of Medical Virology</i> , 2021, 93, 4461-4468.	2.5	10
924	Berries anthocyanins as potential SARS-CoV-2 inhibitors targeting the viral attachment and replication; molecular docking simulation. <i>Egyptian Journal of Petroleum</i> , 2021, 30, 33-43.	1.2	23



#	ARTICLE	IF	CITATIONS
925	Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutant receptor-binding domain with ACE2. <i>International Journal of Infectious Diseases</i> , 2021, 104, 491-500.	1.5	6
926	Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China. <i>Frontiers in Immunology</i> , 2021, 12, 614436.	2.2	17
927	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. <i>Science Advances</i> , 2021, 7, .	4.7	80
928	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10266-10272.	7.2	144
929	Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1386-1396.	0.9	3
930	The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. <i>Nature Communications</i> , 2021, 12, 1936.	5.8	334
931	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 463-476.e6.	5.1	1,054
934	Theaflavin-regulated Imd condensates control <i>Drosophila</i> intestinal homeostasis and aging. <i>IScience</i> , 2021, 24, 102150.	1.9	20
935	A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009328.	2.1	37
936	A mini review on the pathogenesis, diagnosis and treatment options for COVID-19. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	0
937	Binding of SARS-CoV-2/SARS-CoV spike protein with human ACE2 receptor. <i>Journal of Physics Communications</i> , 2021, 5, 035010.	0.5	6
939	A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6671-6681.	2.0	5
940	Protein N-myristoylation: functions and mechanisms in control of innate immunity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 878-888.	4.8	53
942	An in-silico approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-16.	2.0	14
943	Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution. <i>Nature Communications</i> , 2021, 12, 1607.	5.8	76
944	Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	168
945	ASSURED-SQVM diagnostics for COVID-19: addressing the why, when, where, who, what and how of testing. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 349-362.	1.5	10
947	Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis. <i>Cell Death and Disease</i> , 2021, 12, 263.	2.7	89

#	ARTICLE	IF	CITATIONS
948	Topological Analysis for Sequence Variability: Case Study on more than 2K SARS-CoV-2 sequences of COVID-19 infected 54 countries in comparison with SARS-CoV-1 and MERS-CoV. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104708.	1.0	6
949	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
950	The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing. <i>Heliyon</i> , 2021, 7, e06387.	1.4	25
951	Identifying Primate ACE2 Variants That Confer Resistance to SARS-CoV-2. <i>Molecular Biology and Evolution</i> , 2021, 38, 2715-2731.	3.5	22
952	Viruses and Endogenous Retroviruses as Roots for Neuroinflammation and Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2021, 15, 648629.	1.4	27
953	Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. <i>Angewandte Chemie</i> , 2021, 133, 10354-10360.	1.6	20
954	Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data. <i>Journal of Cellular Physiology</i> , 2021, 236, 7045-7057.	2.0	283
955	Hypovitaminosis D and the endocrine phenotype of COVID-19. <i>Endocrine</i> , 2021, 72, 1-11.	1.1	25
956	Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein. <i>Heliyon</i> , 2021, 7, e06564.	1.4	25
957	Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 350-356.	1.8	17
958	Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. <i>Journal of Traditional and Complementary Medicine</i> , 2021, 11, 144-157.	1.5	49
959	Letter from Canada: A pandemic that has humbled us?. <i>Respirology</i> , 2021, 26, 513-514.	1.3	0
963	SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2. <i>Journal of Biochemistry</i> , 2021, 170, 299-306.	0.9	13
966	An Overview of a Year with COVID-19: What We Know?. <i>Electronic Journal of General Medicine</i> , 2021, 18, em286.	0.3	2
968	Amantadine Inhibits SARS-CoV-2 In Vitro. <i>Viruses</i> , 2021, 13, 539.	1.5	38
969	A Multifunctional Peptide From Bacillus Fermented Soybean for Effective Inhibition of SARS-CoV-2 S1 Receptor Binding Domain and Modulation of Toll Like Receptor 4: A Molecular Docking Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 636647.	1.6	26
970	Mutational sensitivity of D614G in spike protein of SARS-CoV-2 in Jordan. <i>Biochemistry and Biophysics Reports</i> , 2021, 25, 100896.	0.7	6
971	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. <i>Inflammopharmacology</i> , 2021, 29, 343-366.	1.9	9

#	ARTICLE	IF	CITATIONS
972	Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction. <i>Journal of Leukocyte Biology</i> , 2021, 111, 261-267.	1.5	13
973	Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir. <i>Scientific Reports</i> , 2021, 11, 7307.	1.6	27
974	An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2. <i>Journal of Physical Chemistry B</i> , 2021, 125, 2533-2550.	1.2	24
975	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 477-488.e4.	5.1	700
976	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. <i>Cell</i> , 2021, 184, 1171-1187.e20.	13.5	541
977	Trace Minerals, Vitamins and Nutraceuticals in Prevention and Treatment of COVID-19. <i>Journal of Dietary Supplements</i> , 2021, , 1-35.	1.4	6
978	An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndromeâ€“Coronavirus. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 637550.	1.6	8
979	The characteristics of gastrointestinal symptoms in patients with severe COVID-19: a systematic review and meta-analysis. <i>Journal of Gastroenterology</i> , 2021, 56, 409-420.	2.3	28
980	Neutralizing Aptamers Block S/RBDâ€“ACE2 Interactions and Prevent Host Cell Infection. <i>Angewandte Chemie</i> , 2021, 133, 10361-10366.	1.6	15
982	Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2. <i>Machine Learning: Science and Technology</i> , 2021, 2, 025024.	2.4	16
984	Neutralizing Aptamers Block S/RBDâ€“ACE2 Interactions and Prevent Host Cell Infection. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 10273-10278.	7.2	81
985	Insight into Vaccine Development for Alphacoronaviruses Based on Structural and Immunological Analyses of Spike Proteins. <i>Journal of Virology</i> , 2021, 95, .	1.5	7
986	Genetic variation analyses indicate conserved SARSâ€“CoVâ€“2â€“host interaction and varied genetic adaptation in immune response factors in modern human evolution. <i>Development Growth and Differentiation</i> , 2021, 63, 219-227.	0.6	10
987	Emergence of novel SARS-CoV-2 variants in the Netherlands. <i>Scientific Reports</i> , 2021, 11, 6625.	1.6	22
988	COVID-19â€“A Theory of Autoimmunity Against ACE-2 Explained. <i>Frontiers in Immunology</i> , 2021, 12, 582166.	2.2	41
990	In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase. <i>Molecular Diversity</i> , 2022, 26, 279-292.	2.1	23
991	Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 635371.	2.2	46
992	Grapheneâ€“Assisted Synthesis of 2D Polyglycerols as Innovative Platforms for Multivalent Virus Interactions. <i>Advanced Functional Materials</i> , 2021, 31, 2009003.	7.8	9

#	ARTICLE	IF	CITATIONS
993	The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. <i>Pathogens</i> , 2021, 10, 379.	1.2	16
994	In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2. <i>Scientific Reports</i> , 2021, 11, 6927.	1.6	41
995	Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. <i>PLoS Pathogens</i> , 2021, 17, e1009392.	2.1	34
996	Elucidation of interactions regulating conformational stability and dynamics of SARS-CoV-2 S-protein. <i>Biophysical Journal</i> , 2021, 120, 1060-1071.	0.2	57
997	Molecular docking analysis of rutin reveals possible inhibition of SARS-CoV-2 vital proteins. <i>Journal of Traditional and Complementary Medicine</i> , 2021, 11, 173-179.	1.5	65
998	Structural and molecular perspectives of SARS-CoV-2. <i>Methods</i> , 2021, 195, 23-28.	1.9	17
999	Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence. <i>ACS Nano</i> , 2021, 15, 6929-6948.	7.3	37
1000	Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. <i>Microorganisms</i> , 2021, 9, 556.	1.6	52
1001	Genomic variation and epidemiology of SARS-CoV-2 importation and early circulation in Israel. <i>PLoS ONE</i> , 2021, 16, e0243265.	1.1	4
1002	High neutralizing potency of swine glycohumanized polyclonal antibodies against SARS-CoV-2. <i>European Journal of Immunology</i> , 2021, 51, 1412-1422.	1.6	21
1004	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. <i>Cell Research</i> , 2021, 31, 517-525.	5.7	54
1005	Severe covid-19 pneumonia: pathogenesis and clinical management. <i>BMJ, The</i> , 2021, 372, n436.	3.0	240
1006	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
1007	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
1008	Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. <i>Scientific Reports</i> , 2021, 11, 5543.	1.6	63
1010	New Acaciin-Loaded Self-Assembled Nanofibers as MPro Inhibitors Against BCV as a Surrogate Model for SARS-CoV-2. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 1789-1804.	3.3	14
1013	SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3060.	1.8	32
1015	Mutational analysis of structural proteins of SARS-CoV-2. <i>Heliyon</i> , 2021, 7, e06572.	1.4	30

#	ARTICLE	IF	CITATIONS
1016	A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors. <i>Biophysical Journal</i> , 2021, 120, 983-993.	0.2	43
1017	A Therapeutic Journey of Potential Drugs Against COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 1876-1894.	1.1	1
1019	Web resources facilitate drug discovery in treatment of COVID-19. <i>Drug Discovery Today</i> , 2021, 26, 2358-2366.	3.2	4
1020	COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7885-7898.	2.0	14
1021	Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis. <i>Chemico-Biological Interactions</i> , 2021, 338, 109420.	1.7	24
1022	Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI) Tj ETQq1 1 0.784314 rgBT /Overlock 1017	2.2	24
1023	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	109
1024	COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?. <i>Current Rheumatology Reviews</i> , 2021, 17, 7-16.	0.4	3
1025	Endothelial cell damage is the central part of COVID-19 and a mouse model induced by injection of the S1 subunit of the spike protein. <i>Annals of Diagnostic Pathology</i> , 2021, 51, 151682.	0.6	101
1031	Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 629873.	1.6	71
1032	Characterization of the SARS-CoV-2 E Protein: Sequence, Structure, Viroporin, and Inhibitors. <i>Protein Science</i> , 2021, 30, 1114-1130.	3.1	68
1033	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. <i>IScience</i> , 2021, 24, 102367.	1.9	126
1034	Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	28
1035	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 551-563.e5.	5.1	87
1036	The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. <i>Cell Research</i> , 2021, 31, 720-722.	5.7	129
1037	NeutrobodyPlex™ monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. <i>EMBO Reports</i> , 2021, 22, e52325.	2.0	43
1038	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. <i>ELife</i> , 2021, 10, .	2.8	160
1039	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347

#	ARTICLE	IF	CITATIONS
1040	InÂvivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs. <i>Cell</i> , 2021, 184, 1865-1883.e20.	13.5	153
1041	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. <i>Cell</i> , 2021, 184, 2362-2371.e9.	13.5	332
1042	RNase in the saliva can affect the detection of severe acute respiratory syndrome coronavirus 2 by real-time one-step polymerase chain reaction using saliva samples. <i>Pathology Research and Practice</i> , 2021, 220, 153381.	1.0	14
1043	Potential antiviral activity of isorhamnetin against <scp>SARSâ€CoV</scp>â€2 spike pseudotyped virus in vitro. <i>Drug Development Research</i> , 2021, 82, 1124-1130.	1.4	51
1046	Differential expression of angiotensin-converting enzyme-2 in human paranasal sinus mucosa in patients with chronic rhinosinusitis. <i>Journal of Laryngology and Otology</i> , 2021, 135, 773-778.	0.4	3
1047	Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1-15.	2.5	6
1048	Thromboembolic Complications in Covid-19: From Clinical Scenario to Laboratory Evidence. <i>Life</i> , 2021, 11, 395.	1.1	2
1049	Bacteriophages as Potential Tools for Use in Antimicrobial Therapy and Vaccine Development. <i>Pharmaceuticals</i> , 2021, 14, 331.	1.7	20
1052	Bioinformatic prediction of immunodominant regions in spike protein for early diagnosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>PeerJ</i> , 2021, 9, e11232.	0.9	5
1055	Hypertension, a Moving Target in COVID-19. <i>Circulation Research</i> , 2021, 128, 1062-1079.	2.0	61
1056	Mink, SARS-CoV-2, and the Human-Animal Interface. <i>Frontiers in Microbiology</i> , 2021, 12, 663815.	1.5	106
1058	Molecular basis for higher affinity of <scp>SARSâ€CoV</scp>â€2 spike <scp>RBD</scp> for human <scp>ACE2</scp> receptor. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1134-1144.	1.5	31
1059	Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score. <i>MSphere</i> , 2021, 6, .	1.3	23
1060	Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. <i>MBio</i> , 2021, 12, .	1.8	8
1061	Afferent and Efferent Neuro-Ophthalmic Complications of Coronavirus Disease 19. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 154-165.	0.4	28
1062	Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies. <i>Journal of Physical Chemistry B</i> , 2021, 125, 4596-4619.	1.2	60
1063	Synthetic Homogeneous Glycoforms of the SARSâ€CoVâ€2 Spike Receptorâ€Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <i>Angewandte Chemie</i> , 2021, 133, 13014-13020.	1.6	2
1064	Computational exploration of natural peptides targeting ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8018-8029.	2.0	4



#	ARTICLE	IF	CITATIONS
1066	Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. <i>Cell Discovery</i> , 2021, 7, 21.	3.1	20
1068	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009501.	2.1	97
1069	Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1158-1166.	1.5	9
1070	An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 571-596.	1.0	12
1071	Binding of the SARS-CoV-2 Spike Protein to the Asialoglycoprotein Receptor on Human Primary Hepatocytes and Immortalized Hepatocyte-Like Cells by Confocal Analysis. <i>Hepatic Medicine: Evidence and Research</i> , 2021, Volume 13, 37-44.	0.9	11
1072	Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. <i>Topics in Current Chemistry</i> , 2021, 379, 23.	3.0	6
1073	The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. <i>Archives of Virology</i> , 2021, 166, 2071-2087.	0.9	37
1074	Interplay of Opposing Effects of the WNT/ $\beta$ -Catenin Pathway and PPAR $\beta$ and Implications for SARS-CoV2 Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 666693.	2.2	33
1075	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. <i>Respiratory Medicine</i> , 2021, 180, 106355.	1.3	25
1076	The role of cell surface sialic acids for SARS-CoV-2 infection. <i>Glycobiology</i> , 2021, 31, 1245-1253.	1.3	73
1077	Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2. <i>European Journal of Pharmacology</i> , 2021, 896, 173897.	1.7	32
1078	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. <i>PLoS Pathogens</i> , 2021, 17, e1009064.	2.1	21
1079	D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect. <i>Molecules</i> , 2021, 26, 2622.	1.7	21
1080	The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses. <i>Viral Immunology</i> , 2021, 34, 165-173.	0.6	36
1082	The SARS-CoV-2 unique domain (SUD) of SARS-CoV and SARS-CoV-2 interacts with human Paip1 to enhance viral RNA translation. <i>EMBO Journal</i> , 2021, 40, e102277.	3.5	26
1083	Animal Models of COVID-19 II. Comparative Immunology. <i>ILAR Journal</i> , 2021, 62, 17-34.	1.8	20
1084	Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. <i>PLoS Biology</i> , 2021, 19, e3001237.	2.6	171
1085	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021, 184, 2183-2200.e22.	13.5	331

#	ARTICLE	IF	CITATIONS
1086	Virtual Screening and Molecular Docking Studies for Discovery of Potential RNA-Dependent RNA Polymerase Inhibitors. <i>Crystals</i> , 2021, 11, 471.	1.0	12
1088	Arthropod Ectoparasites Have Potential to Bind SARS-CoV-2 via ACE. <i>Viruses</i> , 2021, 13, 708.	1.5	7
1089	Molecular Docking of SARS-CoV-2 Nucleocapsid Protein with Angiotensin-Converting Enzyme II. <i>MikrobiolohichnyĀ-Zhurnal</i> , 2021, 83, 82-92.	0.2	10
1091	Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 636660.	1.6	12
1094	Structural insights into SARS-CoV-2 infection and therapeutics development. <i>Stem Cell Research</i> , 2021, 52, 102219.	0.3	7
1095	Discovery of Small Anti-ACE2 Peptides to Inhibit SARS-CoV-2 Infectivity. <i>Advanced Therapeutics</i> , 2021, 4, 2100087.	1.6	16
1096	Learning vector quantization as an interpretable classifier for the detection of SARS-CoV-2 types based on their RNA sequences. <i>Neural Computing and Applications</i> , 2022, 34, 67-78.	3.2	6
1097	Angiotensin Type 1 Receptor-Dependent Internalization of SARS-CoV-2 by Angiotensin-Converting Enzyme 2. <i>Hypertension</i> , 2021, 77, e42-e43.	1.3	17
1099	Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study. <i>Molecular Informatics</i> , 2021, 40, e2060080.	1.4	12
1100	The fight against COVID-19: Striking a balance in the renin-angiotensin system. <i>Drug Discovery Today</i> , 2021, 26, 2214-2220.	3.2	11
1101	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021, 11, 1336-1344.	7.7	20
1102	Variation in predicted COVID-19 risk among lemurs and lorises. <i>American Journal of Primatology</i> , 2021, 83, e23255.	0.8	7
1103	A Perspective on COVID-19 Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 1586.	1.0	8
1104	Chemodynamic features of nanoparticles: Application to understanding the dynamic life cycle of SARS-CoV-2 in aerosols and aqueous biointerfacial zones. <i>Advances in Colloid and Interface Science</i> , 2021, 290, 102400.	7.0	13
1105	Global Discrepancies between Numbers of Available SARS-CoV-2 Genomes and Human Development Indexes at Country Scales. <i>Viruses</i> , 2021, 13, 775.	1.5	7
1106	Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2. <i>Communications Biology</i> , 2021, 4, 500.	2.0	12
1107	Within-Host and Between-Host Evolution in SARS-CoV-2's New Variant's Source. <i>Viruses</i> , 2021, 13, 751.	1.5	28
1108	Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. <i>British Journal of Pharmacology</i> , 2021, 178, 2339-2350.	2.7	74

#	ARTICLE	IF	CITATIONS
1109	An Effective MM/GBSA Protocol for Absolute Binding Free Energy Calculations: A Case Study on SARS-CoV-2 Spike Protein and the Human ACE2 Receptor. <i>Molecules</i> , 2021, 26, 2383.	1.7	51
1110	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100252.	3.3	33
1112	De Novo Movement Disorders and COVID-19: Exploring the Interface. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 669-680.	0.8	27
1113	Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1453-1462.	1.4	59
1114	Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone. <i>ACS Infectious Diseases</i> , 2021, 7, 1545-1554.	1.8	64
1115	Animal Models of COVID-19. I. Comparative Virology and Disease Pathogenesis. <i>ILAR Journal</i> , 2021, 62, 35-47.	1.8	23
1117	SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. <i>Frontiers in Pharmacology</i> , 2021, 12, 638334.	1.6	14
1118	Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor. <i>Molecules</i> , 2021, 26, 2157.	1.7	24
1121	Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19. <i>Molecules</i> , 2021, 26, 2214.	1.7	0
1122	Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 330-340.	1.3	5
1124	Linking COVID-19 and Heme-Driven Pathophysiologies: A Combined Computational-Experimental Approach. <i>Biomolecules</i> , 2021, 11, 644.	1.8	16
1125	A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. <i>Frontiers in Immunology</i> , 2021, 12, 647934.	2.2	52
1126	Structure-based assortment of herbal analogues against spike protein to restrict COVID-19 entry through hACE2 receptor: An in-silico approach. <i>Acta Biologica Szegediensis</i> , 2021, 64, 159-171.	0.7	5
1128	Structural and Functional Characterization of SARS-CoV-2 RBD Domains Produced in Mammalian Cells. <i>Analytical Chemistry</i> , 2021, 93, 6839-6847.	3.2	39
1129	Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures. <i>Biosensors and Bioelectronics</i> , 2021, 177, 112969.	5.3	22
1130	Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. <i>Microbial Cell Factories</i> , 2021, 20, 88.	1.9	37
1131	The SARS-CoV-2 Spike variant D614G favors an open conformational state. <i>Science Advances</i> , 2021, 7, .	4.7	156
1132	Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2820-2826.	2.9	49

#	ARTICLE	IF	CITATIONS
1134	SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders. Cytokine and Growth Factor Reviews, 2021, 58, 1-15.	3.2	84
1135	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	1.8	47
1136	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 2021, 14, 332.	1.7	21
1138	Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Reports Medicine, 2021, 2, 100255.	3.3	402
1139	Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science, 2021, 372, 525-530.	6.0	344
1141	Differences in Interactions Within Viral Replication Complexes of SARS-CoV-2 (COVID-19) and SARS-CoV Coronaviruses Control RNA Replication Ability. Jom, 2021, 73, 1684-1695.	0.9	4
1144	ACE2 and TMPRSS2 Expression in Hepatocytes of Chronic HBV Infection Patients. Infectious Diseases & Immunity, 2021, 1, 36-42.	0.2	4
1145	Sex differences in clinical characteristics and risk factors for disease severity of hospitalized patients with COVID-19. MedComm, 2021, 2, 247-255.	3.1	6
1146	COVID-19 infection and nanomedicine applications for development of vaccines and therapeutics: An overview and future perspectives based on polymersomes. European Journal of Pharmacology, 2021, 896, 173930.	1.7	23
1147	Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS Central Science, 2021, 7, 757-767.	5.3	46
1148	The importance of genomic analysis in cracking the coronavirus pandemic. Expert Review of Molecular Diagnostics, 2021, 21, 547-562.	1.5	14
1150	Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	131
1151	ACE2 models of frequently contacted animals provide clues of their SARS-CoV-2 S protein affinity and viral susceptibility. Journal of Medical Virology, 2021, 93, 4469-4479.	2.5	11
1152	COVID-19: insights into virus-receptor interactions. Molecular Biomedicine, 2021, 2, 10.	1.7	8
1153	SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports, 2021, 35, 109017.	2.9	77
1155	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. Biochemistry, 2021, 60, 1459-1484.	1.2	62
1156	Association of smoking history with severe and critical outcomes in COVID-19 patients: A systemic review and meta-analysis. European Journal of Integrative Medicine, 2021, 43, 101313.	0.8	47
1158	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. Journal of Physical Chemistry Letters, 2021, 12, 4059-4066.	2.1	22

#	ARTICLE	IF	CITATIONS
1160	Fundamental evolution of all <i>Orthocoronavirinae</i> including three deadly lineages descendent from Chiroptera-hosted coronaviruses: SARS-CoV, MERS-CoV and SARS-CoV-2. <i>Cladistics</i> , 2021, 37, 461-488.	1.5	16
1161	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442
1162	Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> , 2021, 372, 815-821.	6.0	1,125
1163	COVID-19 and Cardiovascular Disease. <i>Circulation Research</i> , 2021, 128, 1214-1236.	2.0	232
1164	Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 12904-12910.	7.2	49
1165	Human cell receptors: potential drug targets to combat COVID-19. <i>Amino Acids</i> , 2021, 53, 813-842.	1.2	21
1166	Metabolomics and computational analysis of the role of monoamine oxidase activity in delirium and SARS-COV-2 infection. <i>Scientific Reports</i> , 2021, 11, 10629.	1.6	20
1167	The PRRA Insert at the S1/S2 Site Modulates Cellular Tropism of SARS-CoV-2 and ACE2 Usage by the Closely Related Bat RaTG13. <i>Journal of Virology</i> , 2021, 95, .	1.5	15
1168	DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsters. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009374.	1.3	18
1170	Scrutinizing Coronaviruses Using Publicly Available Bioinformatic Tools: The Viral Structural Proteins as a Case Study. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671923.	1.6	0
1171	Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8464-8493.	2.0	4
1172	ACE2-based decoy receptors for SARS coronavirus 2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1065-1078.	1.5	23
1175	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial. <i>Vaccine</i> , 2021, 39, 2746-2754.	1.7	43
1176	Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 5487-5504.	2.5	11
1177	In Vitro Models for Studying Respiratory Host-Pathogen Interactions. <i>Advanced Biology</i> , 2021, 5, e2000624.	1.4	16
1178	SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. <i>Cell</i> , 2021, 184, 2605-2617.e18.	13.5	151
1180	In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 160, 105771.	1.9	12
1181	Glycosylation is a key in SARS-CoV-2 infection. <i>Journal of Molecular Medicine</i> , 2021, 99, 1023-1031.	1.7	50

#	ARTICLE	IF	CITATIONS
1182	Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies. <i>Scientific Reports</i> , 2021, 11, 10220.	1.6	12
1183	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	6.0	309
1184	Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review. <i>Modern Pathology</i> , 2021, 34, 1614-1633.	2.9	84
1185	Inflammasome regulation in driving COVID-19 severity in humans and immune tolerance in bats. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	11
1186	The role and significance of angiotensin-converting enzyme 2 peptides in the treatment of coronavirus disease 2019. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23789.	0.9	4
1187	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. <i>Journal of General Virology</i> , 2021, 102, .	1.3	6
1188	An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods. <i>Chemical Papers</i> , 2021, 75, 1-24.	1.0	4
1189	Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. <i>Cardiovascular Diabetology</i> , 2021, 20, 99.	2.7	67
1190	SARS-CoV-2 cell entry and targeted antiviral development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3879-3888.	5.7	21
1192	Mutations and Epidemiology of SARS-CoV-2 Compared to Selected Corona Viruses during the First Six Months of the COVID-19 Pandemic: A Review. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 524-533.	0.3	1
1194	Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay. <i>Journal of Infection</i> , 2021, 82, 170-177.	1.7	27
1195	SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system. <i>Med</i> , 2021, 2, 575-590.e5.	2.2	40
1196	Antigenic Evolution on a Global Scale Reveals the Potential Natural Selection of Severe Acute Respiratory Syndrome-Coronavirus 2 by Pre-existing Cross-Reactive T-Cell Immunity. <i>Frontiers in Microbiology</i> , 2021, 12, 599562.	1.5	5
1197	Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. <i>Nature Protocols</i> , 2021, 16, 3639-3671.	5.5	29
1198	Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. <i>Frontiers in Pharmacology</i> , 2021, 12, 660710.	1.6	15
1199	Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. <i>BMC Pulmonary Medicine</i> , 2021, 21, 173.	0.8	36
1201	Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors. <i>PLoS ONE</i> , 2021, 16, e0252571.	1.1	8
1204	Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. <i>Journal of Immunology</i> , 2021, 206, 2393-2401.	0.4	19



#	ARTICLE	IF	CITATIONS
1205	Predictors of new-onset diabetic ketoacidosis in patients with moderate to severe COVID-19 receiving parenteral glucocorticoids: A prospective single-centre study among Indian type 2 diabetes patients. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 795-801.	1.8	15
1207	Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. <i>Biomolecules and Therapeutics</i> , 2021, 29, 249-262.	1.1	2
1209	Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 670815.	1.6	17
1210	The Impact of Endoplasmic Reticulum-Associated Protein Modifications, Folding and Degradation on Lung Structure and Function. <i>Frontiers in Physiology</i> , 2021, 12, 665622.	1.3	9
1211	Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. <i>Current Medicinal Chemistry</i> , 2022, 29, 635-665.	1.2	11
1212	Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. <i>Journal of Physical Chemistry B</i> , 2021, 125, 5537-5548.	1.2	41
1213	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. <i>Cell Reports</i> , 2021, 35, 109179.	2.9	63
1215	Plausible blockers of Spike RBD in SARS-CoV-2 molecular design and underlying interaction dynamics from high-level structural descriptors. <i>Journal of Molecular Modeling</i> , 2021, 27, 191.	0.8	10
1216	Effect of Positional Isomerism on Some Alcohol Based Drug towards Anti-Viral Activity against SARS-Cov-2: A Molecular Modeling Based Investigation. <i>Journal of Biomedical Research &amp; Environmental Sciences</i> , 2021, 2, 383-391.	0.1	0
1218	The human pandemic coronaviruses on the show: The spike glycoprotein as the main actor in the coronaviruses play. <i>International Journal of Biological Macromolecules</i> , 2021, 179, 1-19.	3.6	17
1219	Identification of potential inhibitors of SARS-CoV-2 S protein-ACE2 interaction by in silico drug repurposing. <i>F1000Research</i> , 2021, 10, 358.	0.8	1
1220	Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. <i>Viruses</i> , 2021, 13, 935.	1.5	22
1221	Graphene Oxide Nanosheets Interact and Interfere with SARS-CoV-2 Surface Proteins and Cell Receptors to Inhibit Infectivity. <i>Small</i> , 2021, 17, e2101483.	5.2	46
1222	The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 189.	7.1	26
1223	A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. <i>Nature Communications</i> , 2021, 12, 2623.	5.8	64
1224	Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide. <i>Biomedicines</i> , 2021, 9, 525.	1.4	28
1226	Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid. <i>Respiratory Investigation</i> , 2021, 59, 377-381.	0.9	13
1227	The UK approach to COVID-19 vaccination: why was it so different?. <i>Drugs in Context</i> , 2021, 10, 1-9.	1.0	3

#	ARTICLE	IF	CITATIONS
1231	Evaluation of SARS-CoV-2 Spike S1 Protein Response on PI3K-Mediated IL-8 Release. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 30.	1.3	2
1233	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. <i>Viruses</i> , 2021, 13, 927.	1.5	29
1234	The Spike of Concern—The Novel Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1002.	1.5	92
1235	COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. <i>Immunological Reviews</i> , 2021, 302, 228-240.	2.8	126
1237	Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists. <i>Journal of Molecular Liquids</i> , 2021, 335, 116537.	2.3	25
1238	The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic. <i>Current Medicinal Chemistry</i> , 2021, 28, 2852-2886.	1.2	20
1239	Advances of nanomaterials-based strategies for fighting against COVID-19. <i>View</i> , 2021, 2, 20200180.	2.7	16
1240	Persistently Increased Systemic ACE2 Activity Is Associated With an Increased Inflammatory Response in Smokers With COVID-19. <i>Frontiers in Physiology</i> , 2021, 12, 653045.	1.3	13
1241	Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 449-460.	0.7	41
1242	Temporal Dynamics and Evolution of SARS-CoV-2 Demonstrate the Necessity of Ongoing Viral Genome Sequencing in Ontario, Canada. <i>MSphere</i> , 2021, 6, .	1.3	7
1243	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
1245	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein—Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1519-1534.	1.8	77
1246	COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. <i>Endocrine</i> , 2021, 72, 301-316.	1.1	75
1250	Computational methods to predict the mutational landscape of the spike protein.. <i>Biophysical Journal</i> , 2021, 120, 2763-2765.	0.2	0
1252	A Strategy Based on Loop Analysis to Develop Peptide Epitopes: Application to SARS-CoV-2 Spike Protein. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 658687.	1.6	1
1253	SARS-CoV-2 first contact: Spike—ACE2 interactions in COVID-19. <i>Chemical Biology and Drug Design</i> , 2021, 98, 207-211.	1.5	6
1254	A Computer-Based Methodology to Design Non-Standard Peptides Potentially Able to Prevent HOX-PBX1-Associated Cancer Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5670.	1.8	3
1256	Is COVID-19 a Systemic Disease?. <i>Coronaviruses</i> , 2021, 2, .	0.2	7

#	ARTICLE	IF	CITATIONS
1257	Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses. <i>Emerging Infectious Diseases</i> , 2021, 27, 1380-1392.	2.0	21
1258	Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628585.	1.6	31
1261	Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV. <i>PLoS ONE</i> , 2021, 16, e0251913.	1.1	8
1262	Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?. <i>Regenerative Medicine</i> , 2021, 16, 477-494.	0.8	2
1266	The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19. <i>Annual Review of Biophysics</i> , 2021, 50, 493-523.	4.5	12
1267	SARS-CoV-2 Morphology, Transmission and Diagnosis during Pandemic, Review with Element of Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1962.	1.0	10
1268	Molecular Docking and Dynamics Simulation Study of Hyrtios Aërectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors. <i>Biology</i> , 2021, 10, 389.	1.3	34
1269	The Anti-Infectious Role of Sphingosine in Microbial Diseases. <i>Cells</i> , 2021, 10, 1105.	1.8	23
1270	Design and Numerical Analysis of a Graphene-Coated SPR Biosensor for Rapid Detection of the Novel Coronavirus. <i>Sensors</i> , 2021, 21, 3491.	2.1	82
1271	COVID-19 and the pituitary. <i>Pituitary</i> , 2021, 24, 465-481.	1.6	69
1272	Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2824-2840.	1.4	7
1273	Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies. <i>Pathogens</i> , 2021, 10, 582.	1.2	17
1274	Evolution, Ecology, and Zoonotic Transmission of Betacoronaviruses: A Review. <i>Frontiers in Veterinary Science</i> , 2021, 8, 644414.	0.9	10
1275	Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2111398.	2.8	119
1277	FunCoup 5: Functional Association Networks in All Domains of Life, Supporting Directed Links and Tissue-Specificity. <i>Journal of Molecular Biology</i> , 2021, 433, 166835.	2.0	25
1278	An Insight into Pandemic COVID-19: Structure, Epidemiology and Therapeutics. <i>Current Biotechnology</i> , 2021, 10, 13-17.	0.2	0
1279	Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain. <i>Chemical Biology and Drug Design</i> , 2021, 98, 1-18.	1.5	35
1280	FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein. <i>New Biotechnology</i> , 2021, 62, 79-85.	2.4	7

#	ARTICLE	IF	CITATIONS
1282	Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 11046.	1.6	13
1283	Emergence and outcomes of the SARS-CoV-2 "Marseille-4"™ variant. <i>International Journal of Infectious Diseases</i> , 2021, 106, 228-236.	1.5	44
1285	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	1.8	9
1286	Platycodin D, a natural component of <i>Platycodon grandiflorum</i> , prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion. <i>Experimental and Molecular Medicine</i> , 2021, 53, 956-972.	3.2	49
1287	Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients. <i>Human Genomics</i> , 2021, 15, 29.	1.4	37
1288	In Silico Analysis of Forskolin as a Potential Inhibitor of SARS-CoV-2. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 709-715.	0.3	3
1289	Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?. <i>International Journal of Biological Macromolecules</i> , 2021, 179, 33-44.	3.6	31
1290	Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. <i>PLoS Biology</i> , 2021, 19, e3001209.	2.6	31
1291	Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. <i>Molecules</i> , 2021, 26, 3213.	1.7	29
1292	Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. <i>FASEB Journal</i> , 2021, 35, e21651.	0.2	44
1293	Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys. <i>Bioconjugate Chemistry</i> , 2021, 32, 1034-1046.	1.8	23
1294	Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11. <i>Science Advances</i> , 2021, 7, .	4.7	42
1295	Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. <i>Communications Biology</i> , 2021, 4, 597.	2.0	35
1296	Aging and Options to Halt Declining Immunity to Virus Infections. <i>Frontiers in Immunology</i> , 2021, 12, 681449.	2.2	26
1297	Biosensing strategies for the electrochemical detection of viruses and viral diseases " A review. <i>Analytica Chimica Acta</i> , 2021, 1159, 338384.	2.6	73
1298	Rapid generation of potent antibodies by autonomous hypermutation in yeast. <i>Nature Chemical Biology</i> , 2021, 17, 1057-1064.	3.9	59
1299	Communication Modeling for Targeted Delivery under Bio-DoS Attack in 6G Molecular Networks. , 2021, , .		3
1304	Pharmacological management of seizures in patients with COVID-19: a systematic review. <i>AAS Open Research</i> , 0, 4, 29.	1.5	0

#	ARTICLE	IF	CITATIONS
1305	Molecular biology of the SARS-CoV-2 spike protein: A review of current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5729-5741.	2.5	37
1306	Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Different Coronavirus Spike Protein and ACE2. <i>Journal of Molecular Docking</i> , 2021, 1, 1-14.	0.0	4
1307	Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1755-1765.	2.2	54
1308	Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm. <i>Indian Journal of Clinical Biochemistry</i> , 2021, 36, 440-450.	0.9	47
1309	SARS-CoV-2 Host Receptor ACE2 Protein Expression Atlas in Human Gastrointestinal Tract. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 659809.	1.8	6
1310	Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences. <i>Frontiers in Pharmacology</i> , 2021, 12, 666600.	1.6	61
1311	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. <i>Human Gene Therapy</i> , 2021, 32, 541-562.	1.4	9
1312	Efficacy of Brazilian green propolis (EPP-AF <sup>®</sup> ) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111526.	2.5	77
1313	Exploring the effectiveness of the TSR-based protein 3-D structural comparison method for protein clustering, and structural motif identification and discovery of protein kinases, hydrolases, and SARS-CoV-2 <sup>TM</sup> s protein via the application of amino acid grouping. <i>Computational Biology and Chemistry</i> , 2021, 92, 107479.	1.1	5
1314	The key role of the level of ACE2 gene expression in SARS-CoV-2 infection. <i>Aging</i> , 2021, 13, 14552-14556.	1.4	10
1315	Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers. <i>Antibody Therapeutics</i> , 2021, 4, 109-122.	1.2	8
1316	Promising phytochemicals of traditional Himalayan medicinal plants against putative replication and transmission targets of SARS-CoV-2 by computational investigation. <i>Computers in Biology and Medicine</i> , 2021, 133, 104383.	3.9	13
1317	Engineering of Chinese Hamster Ovary Cells With NDPK-A to Enhance DNA Nuclear Delivery Combined With EBNA1 Plasmid Maintenance Gives Improved Exogenous Transient Reporter, mAb and SARS-CoV-2 Spike Protein Expression. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 679448.	2.0	5
1320	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	5.8	48
1321	Polysulfate hemmen durch elektrostatische Wechselwirkungen die SARS-CoV-2-Infektion**. <i>Angewandte Chemie</i> , 2021, 133, 16005-16014.	1.6	0
1322	Landscape of SARS-CoV-2 spike protein-interacting cells in human tissues. <i>International Immunopharmacology</i> , 2021, 95, 107567.	1.7	14
1323	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	198
1324	Neutrophil Extracellular Traps Induce the Epithelial-Mesenchymal Transition: Implications in Post-COVID-19 Fibrosis. <i>Frontiers in Immunology</i> , 2021, 12, 663303.	2.2	45

#	ARTICLE	IF	CITATIONS
1325	Attractive and repulsive residue fragments at the interface of SARS-CoV-2 and hACE2. <i>Scientific Reports</i> , 2021, 11, 12567.	1.6	5
1326	Immunogenomics guided design of immunomodulatory multi-epitope subunit vaccine against the SARS-CoV-2 new variants, and its validation through in silico cloning and immune simulation. <i>Computers in Biology and Medicine</i> , 2021, 133, 104420.	3.9	59
1330	Key Considerations for the Development of Safe and Effective SARS-CoV-2 Subunit Vaccine: A Peptide-Based Vaccine Alternative. <i>Advanced Science</i> , 2021, 8, e2100985.	5.6	16
1332	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <i>Viruses</i> , 2021, 13, 1055.	1.5	4
1333	Role of SARS-CoV-2 and ACE2 variations in COVID-19. <i>Biomedical Journal</i> , 2021, 44, 235-244.	1.4	20
1334	Addressing the Target Identification and Accelerating the Repositioning of Anti-Inflammatory/Anti-Cancer Organic Compounds by Computational Approaches. <i>European Journal of Organic Chemistry</i> , 2021, 2021, 2966-2981.	1.2	7
1335	Nucleic Acid Testing of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6150.	1.8	42
1336	COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2021, 9, 750-765.	1.6	18
1337	‘Just in Time’: The Role of Cryo-Electron Microscopy in Combating Recent Pandemics. <i>Biochemistry</i> , 2021, 60, 3449-3451.	1.2	4
1338	Natural products and phytochemicals as potential SARS-CoV-2 drugs. <i>Phytotherapy Research</i> , 2021, 35, 5384-5396.	2.8	39
1339	Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 648005.	1.2	25
1340	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
1341	An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies. <i>Gene Reports</i> , 2021, 23, 101122.	0.4	23
1342	The <i>Rhinolophus affinis</i> bat ACE2 and multiple animal orthologs are functional receptors for bat coronavirus RaTG13 and SARS-CoV-2. <i>Science Bulletin</i> , 2021, 66, 1215-1227.	4.3	24
1343	Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents. <i>Pharmaceuticals</i> , 2021, 14, 546.	1.7	18
1344	Identification of Severe Acute Respiratory Syndrome Coronavirus-2 inhibitors through in silico structure-based virtual screening and molecular interaction studies. <i>Journal of Molecular Recognition</i> , 2021, 34, e2918.	1.1	10
1345	The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. <i>PLoS ONE</i> , 2021, 16, e0253487.	1.1	76
1346	The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?. <i>Biomedicines</i> , 2021, 9, 710.	1.4	7



#	ARTICLE	IF	CITATIONS
1347	Identification of COVID-19 B-cell epitopes with phage-displayed peptide library. <i>Journal of Biomedical Science</i> , 2021, 28, 43.	2.6	17
1348	Hypothesis: Designation of Liposomal Scavenger System for Fighting against 2019-nCoV. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	0
1349	COVID-19 vaccine: Potential candidates, achievements, and challenges. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 15, 102-109.	0.1	0
1350	ABO phenotype and SARS-CoV-2 infection: Is there any correlation?. <i>Infection, Genetics and Evolution</i> , 2021, 90, 104751.	1.0	6
1351	Landscape-Based Mutational Sensitivity Cartography and Network Community Analysis of the SARS-CoV-2 Spike Protein Structures: Quantifying Functional Effects of the Circulating D614G Variant. <i>ACS Omega</i> , 2021, 6, 16216-16233.	1.6	10
1352	On-Site Detection of SARS-CoV-2 Antigen by Deep Learning-Based Surface-Enhanced Raman Spectroscopy and Its Biochemical Foundations. <i>Analytical Chemistry</i> , 2021, 93, 9174-9182.	3.2	58
1354	Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant. <i>MedComm</i> , 2021, 2, 442-452.	3.1	8
1355	Drug targets, mechanisms of drug action, and therapeutics against SARS-CoV-2. <i>Chemical Physics Impact</i> , 2021, 2, 100011.	1.7	18
1356	N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants. <i>Frontiers in Plant Science</i> , 2021, 12, 689104.	1.7	34
1357	Sphingolipids as Modulators of SARS-CoV-2 Infection. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 689854.	1.8	40
1358	Heparanase as a Potential Player in SARS-CoV-2 Infection and Induced-Coagulopathy. <i>Bioscience Reports</i> , 2021, 41, .	1.1	11
1359	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 697074.	2.2	18
1360	Governments and vaccination against COVID-19. <i>Vacunas (English Edition)</i> , 2021, 22, 125-125.	0.3	0
1361	IgA and IgG antibodies in SARS-CoV-2 vaccinated health workers by a homemade ELISA diagnostic test. <i>The EuroBiotech Journal</i> , 2021, 5, 13-19.	0.5	0
1362	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 642-648.	6.0	211
1363	In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. <i>Scientific Reports</i> , 2021, 11, 13063.	1.6	77
1366	Expression and functional identification of recombinant SARS-CoV-2 receptor binding domain (RBD) from <i>E. coli</i> system. <i>Preparative Biochemistry and Biotechnology</i> , 2022, 52, 318-324.	1.0	12
1367	Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies. <i>Viruses</i> , 2021, 13, 1145.	1.5	12

#	ARTICLE	IF	CITATIONS
1368	Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca <sup>2+</sup> -dependent membrane fusion. <i>Journal of Medical Virology</i> , 2021, 93, 5825-5832.	2.5	20
1369	COVID-19 convalescent plasma: mechanisms of action and rationale for use: a narrative review. <i>Annals of Blood</i> , 0, 6, 16-16.	0.4	1
1370	Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19. <i>Nature Nanotechnology</i> , 2021, 16, 942-951.	15.6	103
1371	Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 3262-3269.	1.8	12
1372	A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs. <i>Journal of Immunology</i> , 2021, 207, 344-351.	0.4	5
1373	Methods to Identify Immunogenic Peptides in SARS-CoV-2 Spike and Protective Monoclonal Antibodies in COVID-19 Patients. <i>Small Methods</i> , 2021, 5, 2100058.	4.6	6
1374	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
1375	Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics. <i>Nanomedicine</i> , 2021, 16, 1237-1254.	1.7	10
1376	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3802.	5.8	101
1377	SARS-CoV-2: Origin, Evolution, and Targeting Inhibition. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 676451.	1.8	21
1378	Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 691715.	2.2	76
1379	Binding of the SARS-CoV-2 spike protein to glycans. <i>Science Bulletin</i> , 2021, 66, 1205-1214.	4.3	69
1380	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. <i>Immunity</i> , 2021, 54, 1290-1303.e7.	6.6	101
1381	Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 15870-15878.	7.2	49
1382	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. <i>Immunity</i> , 2021, 54, 1304-1319.e9.	6.6	115
1384	AI-based spectroscopic monitoring of real-time interactions between SARS-CoV-2 and human ACE2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	7
1385	Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction. <i>International Dairy Journal</i> , 2021, 117, 105002.	1.5	7
1386	Susceptibility to SARS-CoV-2 infection in patients undergoing chemotherapy and radiation therapy. <i>Journal of Infection and Public Health</i> , 2021, 14, 766-771.	1.9	8

#	ARTICLE	IF	CITATIONS
1387	Biophysical properties of the isolated spike protein binding helix of human ACE2. <i>Biophysical Journal</i> , 2021, 120, 2785-2792.	0.2	5
1388	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. <i>Drug Metabolism Reviews</i> , 2021, 53, 508-541.	1.5	0
1390	Nanotraps for the containment and clearance of SARS-CoV-2. <i>Matter</i> , 2021, 4, 2059-2082.	5.0	38
1391	Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	18
1392	Does the SARS-CoV-2 Spike Protein Receptor Binding Domain Interact Effectively with the DPP4 (CD26) Receptor? A Molecular Docking Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7001.	1.8	24
1393	Sex and kidney ACE2 expression in primary focal segmental glomerulosclerosis: A NEPTUNE study. <i>PLoS ONE</i> , 2021, 16, e0252758.	1.1	5
1394	Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. <i>Cell</i> , 2021, 184, 3192-3204.e16.	13.5	68
1395	Impact of Expressing Cells on Glycosylation and Glycan of the SARS-CoV-2 Spike Glycoprotein. <i>ACS Omega</i> , 2021, 6, 15988-15999.	1.6	32
1396	Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species. <i>Cell</i> , 2021, 184, 3438-3451.e10.	13.5	100
1397	COVID-19: A Redox Disease—What a Stress Pandemic Can Teach Us About Resilience and What We May Learn from the Reactive Species Interactome About Its Treatment. <i>Antioxidants and Redox Signaling</i> , 2021, 35, 1226-1268.	2.5	28
1399	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021, 35, 109292.	2.9	375
1401	Enteroviruses and coronaviruses: similarities and therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 479-489.	1.5	7
1402	Computational analysis of protein stability and allosteric interaction networks in distinct conformational forms of the SARS-CoV-2 spike D614G mutant: reconciling functional mechanisms through allosteric model of spike regulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9724-9741.	2.0	11
1403	Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102435.	1.4	28
1404	Anchor-Locker Binding Mechanism of the Coronavirus Spike Protein to Human ACE2: Insights from Computational Analysis. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3529-3542.	2.5	26
1407	A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Vaccines</i> , 2021, 9, 641.	2.1	5
1408	Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. <i>Antioxidants</i> , 2021, 10, 971.	2.2	21
1409	Targeting SARS-CoV-2 Receptor Binding Domain with Stapled Peptides: An <i>In Silico</i> Study. <i>Journal of Physical Chemistry B</i> , 2021, 125, 6572-6586.	1.2	12

#	ARTICLE	IF	CITATIONS
1410	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
1411	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
1413	Plasmonic Biosensor Augmented by a Genetic Algorithm for Ultra-Rapid, Label-Free, and Multi-Functional Detection of COVID-19. <i>Analytical Chemistry</i> , 2021, 93, 9437-9444.	3.2	34
1414	Syntheses, crystal structures, antioxidant, in silico DNA and SARS-CoV-2 interaction studies of triorganotin(IV) carboxylates. <i>Journal of Molecular Structure</i> , 2021, 1234, 130190.	1.8	8
1416	Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India. <i>Virology</i> , 2021, 558, 13-21.	1.1	24
1417	The First Molecular Characterization of Serbian SARS-CoV-2 Isolates From a Unique Early Second Wave in Europe. <i>Frontiers in Microbiology</i> , 2021, 12, 691154.	1.5	11
1418	Machine Learning Reveals the Critical Interactions for SARS-CoV-2 Spike Protein Binding to ACE2. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 5494-5502.	2.1	44
1419	SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. <i>Cell Research</i> , 2021, 31, 847-860.	5.7	102
1420	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
1421	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	13.5	424
1422	Intestinal Abnormalities in Patients With SARS-CoV-2 Infection. <i>American Journal of Surgical Pathology</i> , 2022, 46, 89-96.	2.1	19
1424	Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. <i>Viruses</i> , 2021, 13, 1421.	1.5	6
1425	Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection. <i>Journal of Controlled Release</i> , 2021, 335, 584-595.	4.8	29
1426	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
1427	COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3313-3330.	2.0	9
1428	Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. <i>Frontiers in Microbiology</i> , 2021, 12, 701198.	1.5	27
1429	SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses. <i>Journal of Virology</i> , 2021, 95, e0020321.	1.5	35
1430	Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing Antibodies. <i>Frontiers in Microbiology</i> , 2021, 12, 698365.	1.5	16

#	ARTICLE	IF	CITATIONS
1432	The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7963.	1.8	19
1433	Susceptibility of Well-Differentiated Airway Epithelial Cell Cultures from Domestic and Wild Animals to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Emerging Infectious Diseases</i> , 2021, 27, 1811-1820.	2.0	11
1437	Is RAS the Link Between COVID-19 and Increased Stress in Head and Neck Cancer Patients?. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 714999.	1.8	4
1439	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. <i>Biologics</i> , 2021, 1, 111-128.	2.3	8
1440	The Post-COVID-19 Era: Interdisciplinary Demands of Contagion Surveillance Mass Spectrometry for Future Pandemics. <i>Sustainability</i> , 2021, 13, 7614.	1.6	2
1441	Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 678701.	1.6	22
1442	A computational study of the interface interaction between SARS-CoV-2 RBD and ACE2 from human, cat, dog, and ferret. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2287-2295.	1.3	4
1443	Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging Pathogens. <i>Diagnostics</i> , 2021, 11, 1259.	1.3	5
1444	Abrogation of SARS-CoV-2 interaction with host (NRP1) neuropilin-1 receptor through high-affinity marine natural compounds to curtail the infectivity: A structural-dynamics data. <i>Computers in Biology and Medicine</i> , 2022, 141, 104714.	3.9	14
1445	Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. <i>Euro-Mediterranean Journal for Environmental Integration</i> , 2021, 6, 61.	0.6	0
1446	Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2836-2847.	2.9	22
1447	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. <i>Cell Discovery</i> , 2021, 7, 57.	3.1	28
1448	Pulling-Force Spinning Top for Serum Separation Combined with Paper-Based Microfluidic Devices in COVID-19 ELISA Diagnosis. <i>ACS Sensors</i> , 2021, 6, 2709-2719.	4.0	44
1449	Molecular docking of secondary metabolites from Indonesian marine and terrestrial organisms targeting SARS-CoV-2 ACE-2, M pro, and PL pro receptors. <i>Pharmacia</i> , 2021, 68, 533-560.	0.4	5
1450	Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach. <i>Infection, Genetics and Evolution</i> , 2021, 91, 104815.	1.0	8
1451	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	1.8	69
1452	SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. <i>Journal of Medical Virology</i> , 2021, 93, 6551-6556.	2.5	79
1453	SARS-CoV-2 receptor-binding mutations and antibody contact sites. <i>Antibody Therapeutics</i> , 2021, 4, 149-158.	1.2	12

#	ARTICLE	IF	CITATIONS
1454	Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress. <i>Nature Communications</i> , 2021, 12, 4629.	5.8	108
1456	Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses. <i>Vaccines</i> , 2021, 9, 733.	2.1	4
1457	Lipid bilayer degradation induced by SARS-CoV-2 spike protein as revealed by neutron reflectometry. <i>Scientific Reports</i> , 2021, 11, 14867.	1.6	21
1458	Interaction of selected terpenoids with two SARS-CoV-2 key therapeutic targets: An in silico study through molecular docking and dynamics simulations. <i>Computers in Biology and Medicine</i> , 2021, 134, 104538.	3.9	25
1459	Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Frontiers in Medicine</i> , 2021, 8, 676554.	1.2	24
1460	Structural O-Glycoform Heterogeneity of the SARS-CoV-2 Spike Protein Receptor-Binding Domain Revealed by Top-Down Mass Spectrometry. <i>Journal of the American Chemical Society</i> , 2021, 143, 12014-12024.	6.6	48
1461	Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2. <i>Biomolecules</i> , 2021, 11, 1114.	1.8	13
1462	A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2). <i>International Journal of Biological Macromolecules</i> , 2021, 183, 2248-2261.	3.6	5
1463	Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak. <i>Biotechnology Progress</i> , 2021, 37, e3186.	1.3	20
1464	Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults. <i>Biomedicines</i> , 2021, 9, 868.	1.4	5
1465	A bird's eye view on the role of dendritic cells in SARS-CoV-2 infection: Perspectives for immune-based vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 100-110.	2.7	25
1466	V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. <i>Journal of Virology</i> , 2021, 95, e0061721.	1.5	90
1467	Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding. <i>Phytomedicine</i> , 2021, 87, 153591.	2.3	41
1468	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1591-1623.	5.7	57
1469	Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. <i>Structure</i> , 2021, 29, 655-663.e4.	1.6	52
1470	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421
1471	Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins. <i>Cell Reports</i> , 2021, 36, 109391.	2.9	32
1472	Anti-Viral and Immunomodulatory Properties of Propolis: Chemical Diversity, Pharmacological Properties, Preclinical and Clinical Applications, and In Silico Potential against SARS-CoV-2. <i>Foods</i> , 2021, 10, 1776.	1.9	42



#	ARTICLE	IF	CITATIONS
1473	The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. <i>Journal of Controlled Release</i> , 2021, 335, 449-456.	4.8	42
1474	The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study. <i>Computers in Biology and Medicine</i> , 2021, 134, 104464.	3.9	9
1475	Virus-receptor interactions of SARS-CoV-2 spike-receptor-binding domain and human neuropilin-1 b1 domain. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 3926-3928.	1.8	11
1477	Small molecule therapeutics to destabilize the ACE2-RBD complex: A molecular dynamics study. <i>Biophysical Journal</i> , 2021, 120, 2793-2804.	0.2	17
1479	Regulation Mechanism for the Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 6252-6261.	2.1	12
1480	Carbon Nanotube Mask Filters and Their Hydrophobic Barrier and Hyperthermic Antiviral Effects on SARS-CoV-2. <i>ACS Applied Nano Materials</i> , 2021, 4, 8135-8144.	2.4	25
1481	A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 41-53.	1.4	29
1482	Emetine, a potent alkaloid for the treatment of SARS-CoV-2 targeting papain-like protease and non-structural proteins: pharmacokinetics, molecular docking and dynamic studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 10122-10135.	2.0	16
1483	ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. <i>PLoS Pathogens</i> , 2021, 17, e1009723.	2.1	28
1484	Interplay between Neutrophils, NETs and T-Cells in SARS-CoV-2 Infection—A Missing Piece of the Puzzle in the COVID-19 Pathogenesis?. <i>Cells</i> , 2021, 10, 1817.	1.8	8
1485	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
1486	The Risk Factors and Clinical Outcomes Associated with Acute Kidney Injury in Patients with COVID-19: Data from a Large Cohort in Iran. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 620-628.	0.9	16
1487	Non-RBM Mutations Impaired SARS-CoV-2 Spike Protein Regulated to the ACE2 Receptor Based on Molecular Dynamic Simulation. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 614443.	1.6	5
1488	Human Coronaviruses: Counteracting the Damage by Storm. <i>Viruses</i> , 2021, 13, 1457.	1.5	5
1489	The molecular dynamics of possible inhibitors for SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-10.	2.0	5
1492	The Role of Alveolar Edema in COVID-19. <i>Cells</i> , 2021, 10, 1897.	1.8	18
1493	CyDisCo production of functional recombinant SARS-CoV-2 spike receptor binding domain. <i>Protein Science</i> , 2021, 30, 1983-1990.	3.1	16
1494	ARGOS: An adaptive refinement goal-oriented solver for the linearized Poisson-Boltzmann equation. <i>Journal of Computational Chemistry</i> , 2021, 42, 1832-1860.	1.5	2

#	ARTICLE	IF	CITATIONS
1495	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. <i>ACS Central Science</i> , 2021, 7, 1368-1380.	5.3	21
1496	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	3.2	113
1497	Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell-cell fusion. <i>Journal of Biological Chemistry</i> , 2021, 297, 100902.	1.6	17
1498	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
1499	COVID19 outbreak in Lombardy, Italy: An analysis on the short-term relationship between air pollution, climatic factors and the susceptibility to SARS-CoV-2 infection. <i>Environmental Research</i> , 2021, 198, 111197.	3.7	29
1500	SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies. <i>ACS Chemical Biology</i> , 2021, 16, 1223-1233.	1.6	57
1502	A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19. <i>Frontiers in Public Health</i> , 2021, 9, 695139.	1.3	32
1503	COVID-19 and the liver: A 2021 update. <i>Liver International</i> , 2021, 41, 1988-1998.	1.9	34
1504	The Spike of SARS-CoV-2: Uniqueness and Applications. <i>Frontiers in Immunology</i> , 2021, 12, 663912.	2.2	14
1505	SARS-CoV-2 Receptor Binding Domain as a Stable-Potential Target for SARS-CoV-2 Detection by Surface-Enhanced Raman Spectroscopy. <i>Sensors</i> , 2021, 21, 4617.	2.1	15
1507	The Characteristics of Spike Glycoprotein Gene of Swine Acute Diarrhea Syndrome Coronavirus Strain CH/FJWT/2018 Isolated in China. <i>Frontiers in Veterinary Science</i> , 2021, 8, 687079.	0.9	4
1508	Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers' Relevance to COVID-19. <i>Biomolecules</i> , 2021, 11, 979.	1.8	15
1509	Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during COVID-19 infection. <i>Biosensors and Bioelectronics</i> , 2021, 183, 113165.	5.3	20
1510	Overview of the pathogenesis of COVID-19 (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1011.	0.8	37
1511	Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. <i>PLoS Pathogens</i> , 2021, 17, e1009715.	2.1	24
1512	Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1349-1361.	2.5	3
1513	Computational optimization of the SARS-CoV-2 receptor-binding-motif affinity for human ACE2. <i>Biophysical Journal</i> , 2021, 120, 2859-2871.	0.2	10
1514	Electrostatic Interactions Explain the Higher Binding Affinity of the CR3022 Antibody for SARS-CoV-2 than the 4A8 Antibody. <i>Journal of Physical Chemistry B</i> , 2021, 125, 7368-7379.	1.2	25

#	ARTICLE	IF	CITATIONS
1516	Implications of inadequate water and sanitation infrastructure for community spread of COVID-19 in remote Alaskan communities. <i>Science of the Total Environment</i> , 2021, 776, 145842.	3.9	21
1517	Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7540.	1.8	12
1518	The molecular basis for SARS-CoV-2 binding to dog ACE2. <i>Nature Communications</i> , 2021, 12, 4195.	5.8	43
1519	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. <i>Journal of Clinical Medicine</i> , 2021, 10, 3276.	1.0	18
1520	Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography. <i>Frontiers in Immunology</i> , 2021, 12, 696370.	2.2	14
1521	Remdesivir analogs against SARS-CoV-2 RNA-dependent RNA polymerase. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11111-11124.	2.0	8
1522	Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. <i>Virologica Sinica</i> , 2021, 36, 934-947.	1.2	12
1523	Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study. <i>Frontiers in Immunology</i> , 2021, 12, 708184.	2.2	19
1524	Plant derived active compounds as potential anti SARS-CoV-2 agents: an <i>in-silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 10629-10650.	2.0	19
1525	Production of Proteins of the SARS-CoV-2 Proteome for Drug Discovery. <i>ACS Omega</i> , 2021, 6, 19983-19994.	1.6	6
1526	Rilpivirine inhibits SARS-CoV-2 protein targets: A potential multi-target drug. <i>Journal of Infection and Public Health</i> , 2021, 14, 1454-1460.	1.9	5
1527	Inhibitory and complementary therapeutic effect of sweet lime ( <i>Citrus limetta</i> ) against RNA-viruses. <i>Journal of Preventive Medicine and Holistic Health</i> , 2021, 7, 37-44.	0.2	6
1528	Luteolin: a blocker of SARS-CoV-2 cell entry based on relaxed complex scheme, molecular dynamics simulation, and metadynamics. <i>Journal of Molecular Modeling</i> , 2021, 27, 221.	0.8	17
1529	Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates. <i>European Journal of Medicinal Chemistry Reports</i> , 2021, 1, 100003.	0.6	8
1530	Sequence similarity in 3D for comparison of protein families. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 106, 107906.	1.3	3
1531	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3771-3788.	2.5	17
1533	Structural Decoding of a Small Molecular Inhibitor on the Binding of SARS-CoV-2 to the ACE 2 Receptor. <i>Journal of Physical Chemistry B</i> , 2021, 125, 8395-8405.	1.2	10
1534	SARS-CoV-2: is there neuroinvasion?. <i>Fluids and Barriers of the CNS</i> , 2021, 18, 32.	2.4	43

#	ARTICLE	IF	CITATIONS
1535	Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. <i>Cell Discovery</i> , 2021, 7, 53.	3.1	14
1539	Current status of traditional Chinese medicine for the treatment of COVID-19 in China. <i>Chinese Medicine</i> , 2021, 16, 63.	1.6	24
1540	Preliminary Structural Data Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor Stronger Than the Wild Type to Enhance the Infectivity. <i>ChemBioChem</i> , 2021, 22, 2641-2649.	1.3	46
1542	Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2. <i>Journal of Molecular Liquids</i> , 2021, 342, 116942.	2.3	28
1544	Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. <i>Drug Discovery Today</i> , 2021, 26, 2619-2636.	3.2	143
1545	Evaluation of kinetics and thermodynamics of interaction between immobilized SARS-CoV-2 nucleoprotein and specific antibodies by total internal reflection ellipsometry. <i>Journal of Colloid and Interface Science</i> , 2021, 594, 195-203.	5.0	36
1546	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. <i>Cell Reports</i> , 2021, 36, 109433.	2.9	75
1547	Free Energy Landscapes from SARS-CoV-2 Spike Glycoprotein Simulations Suggest that RBD Opening Can Be Modulated via Interactions in an Allosteric Pocket. <i>Journal of the American Chemical Society</i> , 2021, 143, 11349-11360.	6.6	54
1548	Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in waters via surface enhanced Raman scattering (SERS). <i>Water Research</i> , 2021, 200, 117243.	5.3	77
1549	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241
1550	Emerging SARS-CoV-2 variants of concern and potential intervention approaches. <i>Critical Care</i> , 2021, 25, 244.	2.5	186
1551	In search of lost time: attosecond physics, petahertz optoelectronics, and quantum speed limit. <i>Physics-Uspekhi</i> , 2021, 64, 370-385.	0.8	20
1553	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4210.	5.8	82
1559	CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro. <i>Frontiers in Immunology</i> , 2021, 12, 652223.	2.2	27
1560	A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 4635.	5.8	72
1561	Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2021, 18, 1281-1289.	1.9	3
1562	Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2. <i>Biophysical Journal</i> , 2021, 120, 2902-2913.	0.2	22
1563	S494 O-glycosylation site on the SARS-CoV-2 RBD affects the virus affinity to ACE2 and its infectivity; a molecular dynamics study. <i>Scientific Reports</i> , 2021, 11, 15162.	1.6	19

#	ARTICLE	IF	CITATIONS
1566	Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). <i>Frontiers in Medicine</i> , 2021, 8, 702066.	1.2	14
1567	A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. <i>Drugs in R and D</i> , 2021, 21, 273-283.	1.1	20
1568	The Potential for Transmission of Coronaviruses via Sports Equipment; A Cricket Case Study. <i>International Journal of Sports Medicine</i> , 2021, 42, 1058-1069.	0.8	0
1569	A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered <i>Pichia pastoris</i> Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses. <i>Engineering</i> , 2022, 13, 107-115.	3.2	13
1570	The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?. <i>Frontiers in Immunology</i> , 2021, 12, 693579.	2.2	2
1571	Rapid and Sensitive Inhibitor Screening Using Magnetically Modulated Biosensors. <i>Sensors</i> , 2021, 21, 4814.	2.1	7
1572	Age-dependent appearance of SARS-CoV-2 entry sites in mouse chemosensory systems reflects COVID-19 anosmia-ageusia symptoms. <i>Communications Biology</i> , 2021, 4, 880.	2.0	10
1573	COVID-19 vaccines: what do we know so far?. <i>FEBS Journal</i> , 2021, 288, 4996-5009.	2.2	7
1574	RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2. <i>Nano Letters</i> , 2021, 21, 5920-5930.	4.5	17
1575	Identification of HLA-A2 restricted CD8+ T cell epitopes in SARS-CoV-2 structural proteins. <i>Journal of Leukocyte Biology</i> , 2021, 110, 1171-1180.	1.5	11
1576	Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants. <i>Journal of Molecular Biology</i> , 2021, 433, 167058.	2.0	190
1577	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. <i>Immunity</i> , 2021, 54, 1611-1621.e5.	6.6	190
1578	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021, 597, 97-102.	13.7	385
1579	Binding of SARS-CoV-2 Fusion Peptide to Host Endosome and Plasma Membrane. <i>Journal of Physical Chemistry B</i> , 2021, 125, 7732-7741.	1.2	32
1580	Anticins from <i>Antrodia cinnamomea</i> and <i>Antrodia salmonea</i> Inhibit Angiotensin-Converting Enzyme 2 (ACE2) in Epithelial Cells: Can Be Potential Candidates for the Development of SARS-CoV-2 Prophylactic Agents. <i>Plants</i> , 2021, 10, 1736.	1.6	11
1581	The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R. <i>Vaccines</i> , 2021, 9, 937.	2.1	12
1582	Rapid and Efficient Detection of the SARS-CoV-2 Spike Protein Using an Electrochemical Aptamer-Based Sensor. <i>ACS Sensors</i> , 2021, 6, 3093-3101.	4.0	129
1583	Structure-Based Virtual Screening and Molecular Dynamics Simulation to Identify Potential SARS-CoV-2 Spike Receptor Inhibitors from Natural Compound Database. <i>Pharmaceutical Chemistry Journal</i> , 2021, 55, 441-453.	0.3	3

#	ARTICLE	IF	CITATIONS
1584	Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8604.	1.8	19
1586	A look at the C3 and C5 proteins in the Covid-19. <i>Actualidades Bioquímicas</i> , 2021, 43, 1-9.	0.1	0
1588	Spike protein mutational landscape in India during the complete lockdown phase: Could Muller's ratchet be a future game-changer for COVID-19?. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104874.	1.0	1
1589	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <i>Nature Microbiology</i> , 2021, 6, 1188-1198.	5.9	314
1590	Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. <i>Cell and Bioscience</i> , 2021, 11, 168.	2.1	69
1591	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. <i>Med</i> , 2021, 2, 979-992.e8.	2.2	127
1592	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. <i>Infection</i> , 2021, 49, 855-876.	2.3	61
1594	Rational optimization of a human neutralizing antibody of SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2021, 135, 104550.	3.9	7
1595	SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. <i>Microorganisms</i> , 2021, 9, 1744.	1.6	16
1596	Designing Self-Inhibitory fusion peptide analogous to viral spike protein against novel severe acute respiratory syndrome (SARS-CoV-2). <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-16.	2.0	0
1597	An unexpected biomaterial against SARS-CoV-2: Bio-polyphosphate blocks binding of the viral spike to the cell receptor. <i>Materials Today</i> , 2021, 51, 504-524.	8.3	8
1601	The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. <i>Tumor Biology</i> , 2021, 43, 177-196.	0.8	5
1602	Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks. <i>Journal of Infection</i> , 2021, 83, 197-206.	1.7	60
1603	Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies. <i>Biotechnology Journal</i> , 2021, 16, e2100207.	1.8	8
1604	Single-antigen multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry. <i>European Journal of Immunology</i> , 2021, 51, 2633-2640.	1.6	9
1605	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. <i>Cell Discovery</i> , 2021, 7, 67.	3.1	29
1606	Molecular modelling on SARS-CoV-2 papain-like protease: an integrated study with homology modelling, molecular docking, and molecular dynamics simulations. <i>SAR and QSAR in Environmental Research</i> , 2021, 32, 699-718.	1.0	7
1607	Deep learning for predicting COVID-19 malignant progression. <i>Medical Image Analysis</i> , 2021, 72, 102096.	7.0	55



#	ARTICLE	IF	CITATIONS
1608	Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19 – Mechanisms and Therapeutic Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	1.9	66
1609	Fragment molecular orbital based interaction analyses on complexes between SARS-CoV-2 RBD variants and ACE2. <i>Japanese Journal of Applied Physics</i> , 2021, 60, 090901.	0.8	8
1610	Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics. <i>Nature Communications</i> , 2021, 12, 4887.	5.8	14
1611	Unbiased interrogation of memory B cells from convalescent COVID-19 patients reveals a broad antiviral humoral response targeting SARS-CoV-2 antigens beyond the spike protein. <i>Vaccine: X</i> , 2021, 8, 100098.	0.9	9
1612	Liquid – liquid phase separation in human health and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 290.	7.1	231
1615	One year of the pandemic – how European endocrinologists responded to the crisis: a statement from the European Society of Endocrinology. <i>European Journal of Endocrinology</i> , 2021, 185, C1-C7.	1.9	10
1616	Host variations in SARS-CoV-2 infection. <i>Turkish Journal of Biology</i> , 2021, 45, 404-424.	2.1	2
1617	SARS-CoV-2 Unrevealed: Ultrastructural and Nanomechanical Analysis. <i>Langmuir</i> , 2021, 37, 10762-10769.	1.6	11
1619	Disparities in COVID-19 severities and casualties across ethnic groups around the globe and patterns of ACE2 and PIR variants. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104888.	1.0	8
1620	Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4425-4441.	2.5	100
1621	The Role of ACE2 Receptors of the Olfactory System in Anosmia in COVID-19: An Overview. <i>Neurology Research International</i> , 2021, 2021, 1-5.	0.5	1
1622	Probing the Allosteric Inhibition Mechanism of a Spike Protein Using Molecular Dynamics Simulations and Active Compound Identifications. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2827-2835.	2.9	15
1623	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 788-796.	2.8	40
1624	Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 679841.	2.2	28
1625	Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2021, 21, 23-29.	0.2	7
1626	Targeting CoV-2 spike RBD and ACE-2 interaction with flavonoids of Anatolian propolis by in silico and in vitro studies in terms of possible COVID-19 therapeutics. <i>Turkish Journal of Biology</i> , 2021, 45, 530-548.	2.1	17
1627	Designing Short Peptides to Block the Interaction of SARS-CoV-2 and Human ACE2 for COVID-19 Therapeutics. <i>Frontiers in Pharmacology</i> , 2021, 12, 731828.	1.6	11
1628	Biomolecular interactions with nanoparticles: applications for coronavirus disease 2019. <i>Current Opinion in Colloid and Interface Science</i> , 2021, 54, 101461.	3.4	7

#	ARTICLE	IF	CITATIONS
1629	Immunity, Sex Hormones, and Environmental Factors as Determinants of COVID-19 Disparity in Women. <i>Frontiers in Immunology</i> , 2021, 12, 680845.	2.2	18
1630	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. <i>JCI Insight</i> , 2021, 6, .	2.3	33
1633	Potential of CRISPR/Cas system in the diagnosis of COVID-19 infection. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1179-1189.	1.5	13
1634	Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19. <i>Vaccines</i> , 2021, 9, 928.	2.1	12
1636	Antisense Peptide Technology for Diagnostic Tests and Bioengineering Research. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9106.	1.8	5
1637	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
1638	Water-Borne Nanocoating for Rapid Inactivation of SARS-CoV-2 and Other Viruses. <i>ACS Nano</i> , 2021, 15, 14915-14927.	7.3	13
1639	Rapid Exclusion of COVID Infection With the Artificial Intelligence Electrocardiogram. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2081-2094.	1.4	15
1640	Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4656-4669.	2.5	24
1641	A decoy strategy to activate the immune system. <i>IUBMB Life</i> , 2021, 73, 1205-1209.	1.5	1
1643	Identification of Novel Gene Signatures using Next-Generation Sequencing Data from COVID-19 Infection Models: Focus on Neuro-COVID and Potential Therapeutics. <i>Frontiers in Pharmacology</i> , 2021, 12, 688227.	1.6	9
1644	Differentiation of immortalized human multi-lineage progenitor to alveolar type 2-like cells: angiotensin-converting enzyme 2 expression and binding of severe acute respiratory syndrome coronavirus 2 spike and spike 1 proteins. <i>Cytotherapy</i> , 2021, 23, 1064-1073.	0.3	2
1645	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
1646	Computational modeling of SARS-CoV-2 Nsp1 binding to human ribosomal 40S complex. , 2021, , .		0
1647	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
1649	SARS-CoV-2 infection: a global outbreak and its implication on public health. <i>Bulletin of the National Research Centre</i> , 2021, 45, 139.	0.7	4
1650	Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant. <i>Biomolecules</i> , 2021, 11, 1244.	1.8	17
1651	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33

#	ARTICLE	IF	CITATIONS
1652	An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. <i>Frontiers in Pharmacology</i> , 2021, 12, 717757.	1.6	28
1653	Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations. <i>Computers in Biology and Medicine</i> , 2021, 135, 104634.	3.9	20
1654	Computational and network pharmacology studies of <i>Phyllanthus emblica</i> to tackle SARS-CoV-2. <i>Phytomedicine Plus</i> , 2021, 1, 100095.	0.9	12
1655	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697035.	1.8	19
1656	A COVID-19 Overview and Potential Applications of Cell Therapy. <i>Biologics</i> , 2021, 1, 177-188.	2.3	2
1657	Analysis of the molecular mechanism of SARS-CoV-2 antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 45-52.	1.0	15
1659	Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19. <i>BioScience Trends</i> , 2021, 15, 205-210.	1.1	8
1660	SARS-CoV-2 NSP12 Protein Is Not an Interferon- $\beta$ Antagonist. <i>Journal of Virology</i> , 2021, 95, e0074721.	1.5	25
1661	An in silico scientific basis for $\alpha$ 37 as a therapeutic for Covid-19. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 1029-1043.	1.5	21
1662	Protocol for the Controlled evaluation of Angiotensin Receptor blockers for COVID-19 respiratory disease (CLARITY): a randomised controlled trial. <i>Trials</i> , 2021, 22, 573.	0.7	7
1664	Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. <i>EMBO Journal</i> , 2021, 40, e107985.	3.5	69
1665	Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	140
1666	Computational design of SARS-CoV-2 peptide binders with better predicted binding affinities than human ACE2 receptor. <i>Scientific Reports</i> , 2021, 11, 15650.	1.6	17
1668	Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV. <i>Advanced Therapeutics</i> , 2021, 4, 2100104.	1.6	11
1669	Medicinal plants as immune booster in the palliative management of viral diseases: A perspective on coronavirus. <i>Food Frontiers</i> , 2022, 3, 83-95.	3.7	6
1670	Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. <i>Biomolecules</i> , 2021, 11, 1273.	1.8	30
1671	MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12048-12061.	2.0	5
1672	Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?. <i>Methods</i> , 2022, 203, 564-574.	1.9	18

#	ARTICLE	IF	CITATIONS
1673	A Computational Approach to Evaluate the Combined Effect of SARS-CoV-2 RBD Mutations and ACE2 Receptor Genetic Variants on Infectivity: The COVID-19 Host-Pathogen Nexus. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 707194.	1.8	12
1674	Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. <i>PLoS Pathogens</i> , 2021, 17, e1009758.	2.1	17
1679	Sequence Analysis, Structure Prediction of Receptor Proteins and In Silico Study of Potential Inhibitors for Management of Life Threatening COVID-19. <i>Letters in Drug Design and Discovery</i> , 2022, 19, 108-122.	0.4	1
1680	Ebselen suitably interacts with the potential SARS-CoV-2 targets: an <i>in-silico</i> approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12286-12301.	2.0	7
1682	Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. <i>Clinical Proteomics</i> , 2021, 18, 19.	1.1	12
1683	ACE2 Variants Indicate Potential SARS-CoV-2 Susceptibility in Animals: A Molecular Dynamics Study. <i>Molecular Informatics</i> , 2021, 40, e2100031.	1.4	8
1684	Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. <i>Nature Communications</i> , 2021, 12, 5135.	5.8	107
1685	Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease. <i>Brain</i> , 2021, 144, 3576-3588.	3.7	101
1686	Cardiac biomarkers, cardiac injury, and comorbidities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1071-1100.	1.3	22
1687	Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. <i>Vaccines</i> , 2021, 9, 920.	2.1	16
1688	Mechanical activation of spike fosters SARS-CoV-2 viral infection. <i>Cell Research</i> , 2021, 31, 1047-1060.	5.7	33
1689	SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	251
1691	COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. <i>World Journal of Clinical Cases</i> , 2021, 9, 6178-6200.	0.3	24
1692	The Promise of Mutation Resistant Drugs for SARS-CoV-2 That Interdict in the Folding of the Spike Protein Receptor Binding Domain. <i>Covid</i> , 2021, 1, 288-302.	0.7	3
1693	Quantitative circular flow immunoassays with trained object recognition to detect antibodies to SARS-CoV-2 membrane glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2021, 565, 8-13.	1.0	3
1694	Expression pattern and function of SARS-CoV-2 receptor ACE2. <i>Biosafety and Health</i> , 2021, 3, 312-318.	1.2	16
1695	Molecular simulation studies of the interactions between the human/pangolin/cat/bat ACE2 and the receptor binding domain of the SARS-CoV-2 spike protein. <i>Biochimie</i> , 2021, 187, 1-13.	1.3	14
1696	Plant-Produced Glycosylated and In Vivo Deglycosylated Receptor Binding Domain Proteins of SARS-CoV-2 Induce Potent Neutralizing Responses in Mice. <i>Viruses</i> , 2021, 13, 1595.	1.5	23

#	ARTICLE	IF	CITATIONS
1697	DNA Aptamers Block the Receptor Binding Domain at the Spike Protein of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 713003.	1.6	11
1698	Structural Dissection of Viral Spike-Protein Binding of SARS-CoV-2 and SARS-CoV-1 to the Human Angiotensin-Converting Enzyme 2 (ACE2) as Cellular Receptor. <i>Biomedicines</i> , 2021, 9, 1038.	1.4	15
1701	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. <i>BMC Medicine</i> , 2021, 19, 208.	2.3	52
1702	“Molecular Masks” for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8963.	1.8	7
1703	Sterically confined rearrangements of SARS-CoV-2 Spike protein control cell invasion. <i>ELife</i> , 2021, 10, .	2.8	29
1704	Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations. <i>Chemical Physics Letters</i> , 2021, 777, 138745.	1.2	5
1705	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 581-599.	5.7	33
1706	N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2. <i>ELife</i> , 2021, 10, .	2.8	262
1707	Molecular Docking Analysis of the Phytochemicals from <i>Tinospora Cordifolia</i> as Potential Inhibitor Against Multi Targeted SARS-CoV-2 & Cytokine Storm. <i>Journal of Computational Biophysics and Chemistry</i> , 2021, 20, 559-580.	1.0	2
1709	Predicting hosts based on early SARS-CoV-2 samples and analyzing the 2020 pandemic. <i>Scientific Reports</i> , 2021, 11, 17422.	1.6	9
1710	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	2.1	74
1711	Ultrasensitive and Simultaneous Detection of Two Specific SARS-CoV-2 Antigens in Human Specimens Using Direct/Enrichment Dual-Mode Fluorescence Lateral Flow Immunoassay. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 40342-40353.	4.0	78
1712	Determination of the interaction between the receptor binding domain of 2019-nCoV spike protein, TMPRSS2, cathepsin B and cathepsin L, and glycosidic and aglycon forms of some flavonols. <i>Turkish Journal of Biology</i> , 2021, 45, 484-502.	2.1	5
1713	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6.	6.6	79
1714	Genome-wide CRISPR activation screen identifies candidate receptors for SARS-CoV-2 entry. <i>Science China Life Sciences</i> , 2022, 65, 701-717.	2.3	48
1715	Positive selection as a key player for SARS-CoV-2 pathogenicity: Insights into ORF1ab, S and E genes. <i>Virus Research</i> , 2021, 302, 198472.	1.1	27
1716	In Silico Analysis of Plant-Derived Medicinal Compounds Against Spike Protein of SARS-CoV-2 and Ace2. <i>Advances in Intelligent Systems and Computing</i> , 2022, , 299-313.	0.5	0
1717	Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain. <i>Biochemical Journal</i> , 2021, 478, 3671-3684.	1.7	12

#	ARTICLE	IF	CITATIONS
1718	Î±-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757691.	2.2	2
1719	Analysis of Intermediate Hosts and Susceptible Animals of SARS-CoV-2 by Computational Methods. <i>Zoonoses</i> , 2021, 1, .	0.5	4
1721	Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2021, 136, 104759.	3.9	35
1723	SARS-CoV-2 S glycoprotein binding to multiple host receptors enables cell entry and infection. <i>Glycoconjugate Journal</i> , 2021, 38, 611-623.	1.4	17
1724	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. <i>Frontiers in Immunology</i> , 2021, 12, 707977.	2.2	21
1726	Neutral evolution test of the spike protein of SARS-CoV-2 and its implications in the binding to ACE2. <i>Scientific Reports</i> , 2021, 11, 18847.	1.6	13
1727	Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	19
1728	Polyphenolic Natural Products Active In Silico Against SARS-CoV-2 Spike Receptor Binding Domains and Non-structural Proteins - A Review. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, 459-488.	0.6	7
1729	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 343.	7.1	24
1730	A highly potent antibody effective against SARS-CoV-2 variants of concern. <i>Cell Reports</i> , 2021, 37, 109814.	2.9	39
1731	Characterization of Phytochemicals in <i>Ulva intestinalis</i> L. and Their Action Against SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain. <i>Frontiers in Chemistry</i> , 2021, 9, 735768.	1.8	4
1732	Evolution of the <sc>SARSâ€CoV</sc>â€2 proteome in three dimensions (3D) during the first 6 months of the <sc>COVID</sc>â€19 pandemic. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 1054-1080.	1.5	31
1734	Identifying key determinants and dynamics of SARS-CoV-2/ACE2 tight interaction. <i>PLoS ONE</i> , 2021, 16, e0257905.	1.1	6
1735	In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108038.	1.3	9
1736	The use of negative oxygen ion clusters [O2âˆ“(H2O)n] and bicarbonate ions [HCO3âˆ“] as the supportive treatment of COVID-19 infections: A possibility. <i>Medical Hypotheses</i> , 2021, 154, 110658.	0.8	3
1737	The Antiviral Roles of Hydrogen Sulfide by Blocking the Interaction between SARS-CoV-2 and Its Potential Cell Surface Receptors. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-11.	1.9	14
1738	Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2. <i>Microbiology Spectrum</i> , 2021, 9, e0119921.	1.2	19
1739	Reappraisal of Dietary Phytochemicals for Coronavirus Infection: Focus on Hesperidin and Quercetin. , 0, , .		0



#	ARTICLE	IF	CITATIONS
1740	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	2.9	80
1741	IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases. <i>Viruses</i> , 2021, 13, 1945.	1.5	16
1742	A Novel Real-Time RT-PCR-Based Methodology for the Preliminary Typing of SARS-CoV-2 Variants, Employing Non-Extendable LNA Oligonucleotides and Three Signature Mutations at the Spike Protein Receptor-Binding Domain. <i>Life</i> , 2021, 11, 1015.	1.1	5
1743	The inhibitory effects of toothpaste and mouthwash ingredients on the interaction between the SARS-CoV-2 spike protein and ACE2, and the protease activity of TMPRSS2 in vitro. <i>PLoS ONE</i> , 2021, 16, e0257705.	1.1	15
1744	Evaluation of Inhibitory Activity In Silico of In-House Thiomorpholine Compounds between the ACE2 Receptor and S1 Subunit of SARS-CoV-2 Spike. <i>Pathogens</i> , 2021, 10, 1208.	1.2	0
1745	Zoonotic and Reverse Zoonotic Transmissibility of SARS-CoV-2. <i>Virus Research</i> , 2021, 302, 198473.	1.1	44
1746	Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 164, 3-18.	1.4	8
1747	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
1748	â€œSLC-omicsâ€• of the kidney: solute transporters along the nephron. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 321, C507-C518.	2.1	22
1749	The SARS-CoV-2 spike protein is vulnerable to moderate electric fields. <i>Nature Communications</i> , 2021, 12, 5407.	5.8	26
1750	Surface Engineering of Graphene through Heterobifunctional Supramolecular-Covalent Scaffolds for Rapid COVID-19 Biomarker Detection. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 43696-43707.	4.0	13
1751	Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 167, 106012.	1.9	8
1752	In Silico Evaluation of Iranian Medicinal Plant Phytoconstituents as Inhibitors against Main Protease and the Receptor-Binding Domain of SARS-CoV-2. <i>Molecules</i> , 2021, 26, 5724.	1.7	39
1753	Computational Study on the Function of Palmitoylation on the Envelope Protein in SARS-CoV-2. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 6483-6490.	2.3	15
1754	Potential natural products that target the SARS-CoV-2 spike protein identified by structure-based virtual screening, isothermal titration calorimetry and lentivirus particles pseudotyped (Vpp) infection assay. <i>Journal of Traditional and Complementary Medicine</i> , 2022, 12, 73-89.	1.5	16
1755	Analysing the impact of the two most common SARS-CoV-2 nucleocapsid protein variants on interactions with membrane protein in silico. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 138.	1.5	4
1756	Could live attenuated vaccines better control COVID-19?. <i>Vaccine</i> , 2021, 39, 5719-5726.	1.7	29
1757	Vitamin D and COVID-19: A review on the role of vitamin D in preventing and reducing the severity of COVID-19 infection. <i>Protein Science</i> , 2021, 30, 2206-2220.	3.1	20

#	ARTICLE	IF	CITATIONS
1758	Cellular host factors for SARS-CoV-2 infection. <i>Nature Microbiology</i> , 2021, 6, 1219-1232.	5.9	127
1759	Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. <i>Journal of Biological Chemistry</i> , 2021, 297, 101202.	1.6	28
1760	In silico study of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5455-5465.	1.9	11
1761	Synthetic Neutralizing Peptides Inhibit the Host Cell Binding of Spike Protein and Block Infection of SARS-CoV-2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14887-14894.	2.9	11
1762	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	13.9	734
1763	ACTIVITY OF ANGIOTENSIN-CONVERTING ENZYME-2 IN ACUTE PULMONARY INFLAMMATION. <i>Medical Science of Ukraine (MSU)</i> , 2021, 17, 3-14.	0.0	0
1766	Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2021, 186, 490-500.	3.6	28
1767	Ambulatory COVID-19 Patients Treated with Lactoferrin as a Supplementary Antiviral Agent: A Preliminary Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4276.	1.0	33
1768	Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. <i>Journal of Molecular Biology</i> , 2022, 434, 167265.	2.0	72
1769	An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research. <i>Journal of Virological Methods</i> , 2021, 295, 114221.	1.0	12
1770	Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2. <i>Journal of Pharmacological Sciences</i> , 2021, 147, 62-71.	1.1	24
1771	Structure, interface stability and hot-spots identification for RBD(SARS-CoV-2):hACE2 complex formation. <i>Molecular Simulation</i> , 2021, 47, 1443-1454.	0.9	3
1773	Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge. <i>Frontiers in Immunology</i> , 2021, 12, 729837.	2.2	18
1774	Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants. <i>Journal of Pharmaceutical Analysis</i> , 2022, 12, 58-64.	2.4	7
1775	Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. <i>MBio</i> , 2021, 12, e0239521.	1.8	13
1777	EVOLUTIONARY RELATIONSHIP AND REPURPOSING OF SARS INHIBITORS AGAINST SURFACE GLYCOPROTEIN OF SARS-COV-2. <i>International Journal of Applied Pharmaceutics</i> , 0, , 272-279.	0.3	0
1778	Exploring the Regulatory Function of the C-terminal Domain of SARS-CoV-2 Spike Protein through Molecular Dynamics Simulation. <i>Advanced Theory and Simulations</i> , 2021, 4, 2100152.	1.3	17
1779	Curious Binding Energy Increase between the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein and Angiotensin-Converting Enzyme 2 Adsorbed on a Silane Monolayer from Molecular Dynamics Simulations. <i>Journal of Physical Chemistry B</i> , 2021, 125, 11078-11090.	1.2	8

#	ARTICLE	IF	CITATIONS
1780	SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. <i>Frontiers in Immunology</i> , 2021, 12, 728021.	2.2	20
1781	Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms. , 2021, 225, 107843.		258
1782	Neutralizing antibodies for the prevention and treatment of COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2293-2306.	4.8	91
1783	Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications. <i>Diagnostics</i> , 2021, 11, 1808.	1.3	12
1784	Structural and kinetic analyses of holothurian sulfated glycans suggest potential treatment for SARS-CoV-2 infection. <i>Journal of Biological Chemistry</i> , 2021, 297, 101207.	1.6	31
1786	Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors. <i>Computers in Biology and Medicine</i> , 2021, 136, 104631.	3.9	75
1787	A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. <i>Science Advances</i> , 2021, 7, eabh1547.	4.7	44
1788	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2.0 19		
1789	Interactions of the Receptor Binding Domain of SARS-CoV-2 Variants with hACE2: Insights from Molecular Docking Analysis and Molecular Dynamic Simulation. <i>Biology</i> , 2021, 10, 880.	1.3	38
1790	Multi-Modal Biological Destruction by Cold Atmospheric Plasma: Capability and Mechanism. <i>Biomedicines</i> , 2021, 9, 1259.	1.4	20
1791	Spread of Mink SARS-CoV-2 Variants in Humans: A Model of Sarbecovirus Interspecies Evolution. <i>Frontiers in Microbiology</i> , 2021, 12, 675528.	1.5	35
1792	A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding. <i>Biochemical and Biophysical Research Communications</i> , 2021, 571, 152-158.	1.0	5
1793	Impact of COVID-19 on the Endocrine System: A Mini-review. <i>Endocrinology</i> , 2022, 163, .	1.4	63
1794	Development and Efficacy of Lateral Flow Point-of-Care Testing Devices for Rapid and Mass COVID-19 Diagnosis by the Detections of SARS-CoV-2 Antigen and Anti-SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2021, 11, 1760.	1.3	28
1795	Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 5654.	5.8	89
1796	Catching COVID: Engineering Peptide-Modified Surface-Enhanced Raman Spectroscopy Sensors for SARS-CoV-2. <i>ACS Sensors</i> , 2021, 6, 3436-3444.	4.0	32
1797	Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. <i>Journal of Proteins and Proteomics</i> , 2021, 12, 257-270.	1.0	8
1798	Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1514-1527.	2.5	17

#	ARTICLE	IF	CITATIONS
1799	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
1800	Chitosan derivatives: A suggestive evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus. <i>International Journal of Biological Macromolecules</i> , 2021, 187, 492-512.	3.6	17
1801	Will Auranofin Become a Golden New Treatment Against COVID-19?. <i>Frontiers in Immunology</i> , 2021, 12, 683694.	2.2	12
1802	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
1803	In silico study on the effect of SARS-CoV-2 RBD hotspot mutants' interaction with ACE2 to understand the binding affinity and stability. <i>Virology</i> , 2021, 561, 107-116.	1.1	44
1804	Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2022, 14, 55-63.	2.2	7
1807	A novel competition ELISA for the rapid quantification of SARS-CoV-2 neutralizing antibodies in convalescent plasma. <i>Transfusion</i> , 2021, 61, 2981-2990.	0.8	7
1808	The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants. <i>Environmental Chemistry Letters</i> , 2022, 20, 1539-1544.	8.3	6
1809	Novel ACE2 protein interactions relevant to COVID-19 predicted by evolutionary rate correlations. <i>PeerJ</i> , 2021, 9, e12159.	0.9	3
1810	Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants. <i>Journal of Biological Chemistry</i> , 2021, 297, 101208.	1.6	37
1812	SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19. <i>IScience</i> , 2021, 24, 103185.	1.9	13
1815	Structural characterization of $\gamma$ -irradiation inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles. <i>Microscopy Research and Technique</i> , 2022, 85, 562-569.	1.2	16
1816	Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action. <i>Patterns</i> , 2021, 2, 100325.	3.1	6
1817	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. <i>Cell Discovery</i> , 2021, 7, 82.	3.1	22
1819	In silico identification of RBD subdomain of spike protein from Pro322-Thr581 for applications in vaccine development against SARS-CoV2. <i>Journal of Molecular Structure</i> , 2021, 1240, 130534.	1.8	2
1820	Engineering of 2D nanomaterials to trap and kill SARS-CoV-2: a new insight from multi-microsecond atomistic simulations. <i>Drug Delivery and Translational Research</i> , 2021, 1, .	3.0	17
1821	Structural biology of SARS-CoV-2 and implications for therapeutic development. <i>Nature Reviews Microbiology</i> , 2021, 19, 685-700.	13.6	259
1822	Counter-Regulatory Renin-Angiotensin System: An Important Line of Research to Understand and Limit the Severity of COVID-19. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	9

#	ARTICLE	IF	CITATIONS
1824	Analysis of Effects of Surface Roughness on Sensing Performance of Surface Plasmon Resonance Detection for Refractive Index Sensing Application. <i>Sensors</i> , 2021, 21, 6164.	2.1	6
1825	Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. <i>Journal of Virology</i> , 2021, 95, e0143721.	1.5	24
1826	Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. <i>PLoS ONE</i> , 2021, 16, e0249254.	1.1	31
1829	Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1936.	1.5	9
1830	Teaching an old dog new tricks: a lipid membrane-based electric immunosensor for real-time probing of the spike S 1 protein subunit from SARS-CoV-2. <i>Proteomics</i> , 2021, , 2100047.	1.3	3
1831	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
1832	Coinfection and Interference Phenomena Are the Results of Multiple Thermodynamic Competitive Interactions. <i>Microorganisms</i> , 2021, 9, 2060.	1.6	23
1833	In silico investigation to identify potential small molecule inhibitors of the RNA-dependent RNA polymerase (RdRp) nidovirus RdRp-associated nucleotidyltransferase domain. <i>Chemical Physics Letters</i> , 2021, 779, 138889.	1.2	4
1834	Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104897.	1.0	18
1835	Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin. <i>Journal of Virology</i> , 2021, 95, e0139621.	1.5	52
1837	A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 243-257.	2.7	35
1838	A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry. <i>Journal of NeuroVirology</i> , 2021, 27, 691-701.	1.0	2
1839	Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 5152-5160.	2.5	11
1840	Effect of ORF7 of SARS-CoV-2 on the Chemotaxis of Monocytes and Neutrophils In Vitro. <i>Disease Markers</i> , 2021, 2021, 1-9.	0.6	1
1841	Pseudoephedrine and its derivatives antagonize wild and mutated severe acute respiratory syndrome-CoV-2 viruses through blocking virus invasion and antiinflammatory effect. <i>Phytotherapy Research</i> , 2021, 35, 5847-5860.	2.8	8
1842	Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro. <i>Pharmaceutics</i> , 2021, 13, 1400.	2.0	35
1844	Featuring ACE2 binding SARS-CoV and SARS-CoV-2 through a conserved evolutionary pattern of amino acid residues. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11719-11728.	2.0	5
1845	Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2021, 136, 104748.	3.9	45

#	ARTICLE	IF	CITATIONS
1846	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
1847	Impact of the Delta variant on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 1201-1209.	2.0	177
1848	Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. <i>Biomaterials</i> , 2021, 278, 121159.	5.7	23
1849	Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection. <i>International Immunopharmacology</i> , 2021, 99, 108013.	1.7	7
1850	Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. <i>Biochemical and Biophysical Research Communications</i> , 2021, 574, 14-19.	1.0	70
1851	Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target. <i>Antiviral Research</i> , 2021, 194, 105167.	1.9	19
1852	Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions. <i>Nature Communications</i> , 2021, 12, 5769.	5.8	51
1853	Cell entry by SARS-CoV-2. <i>Trends in Biochemical Sciences</i> , 2021, 46, 848-860.	3.7	118
1854	The importance of tears stability in SARS-CoV-2 transmission: COVID-19 prevalence in dry eye patients. <i>Journal Francais D'Ophtalmologie</i> , 2021, 44, 1115-1120.	0.2	3
1855	Mechanisms of instantaneous inactivation of SARS-CoV-2 by silicon nitride bioceramic. <i>Materials Today Bio</i> , 2021, 12, 100144.	2.6	18
1856	Antiviral nanoparticles for sanitizing surfaces: A roadmap to self-sterilizing against COVID-19. <i>Nano Today</i> , 2021, 40, 101267.	6.2	68
1857	Structure of SARS-CoV-2 spike protein. <i>Current Opinion in Virology</i> , 2021, 50, 173-182.	2.6	122
1858	Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112023.	2.5	21
1859	Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif. <i>Journal of Biological Chemistry</i> , 2021, 297, 101175.	1.6	3
1860	Active components in <i>Ephedra sinica</i> stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. <i>Journal of Ethnopharmacology</i> , 2021, 278, 114303.	2.0	27
1861	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <i>Journal of Biological Chemistry</i> , 2021, 297, 101151.	1.6	42
1862	From the environment to the cells: An overview on pivotal factors which affect spreading and infection in COVID-19 pandemic. <i>Environmental Research</i> , 2021, 201, 111555.	3.7	8
1863	Selection of a SARS-CoV-2 Surrogate for Use in Surface Disinfection Efficacy Studies with Chlorine and Antimicrobial Surfaces. <i>Environmental Science and Technology Letters</i> , 2021, 8, 995-1001.	3.9	26



#	ARTICLE	IF	CITATIONS
1864	The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation. <i>Journal of Molecular Biology</i> , 2022, 434, 167280.	2.0	92
1865	A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease. <i>Journal of Nanoscience and Nanotechnology</i> , 2021, 21, 5399-5407.	0.9	1
1866	Binding of SARS-COV-2 (COVID-19) and SARS-COV to human ACE2: Identifying binding sites and consequences on ACE2 stiffness. <i>Chemical Physics</i> , 2021, 551, 111353.	0.9	5
1867	In Vivo protection from SARS-CoV-2 infection by ATN-161 in k18-hACE2 transgenic mice. <i>Life Sciences</i> , 2021, 284, 119881.	2.0	22
1868	Evaluation of anti-cancer and anti-covid-19 properties of cationic pentapeptide Glu-Gln-Arg-Pro-Arg, from rice bran protein and its d-isomer analogs through molecular docking simulations. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 108, 107999.	1.3	10
1869	ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations. <i>Experimental Neurology</i> , 2021, 345, 113837.	2.0	50
1870	Track-etched membrane microplate and smartphone immunosensing for SARS-CoV-2 neutralizing antibody. <i>Biosensors and Bioelectronics</i> , 2021, 192, 113550.	5.3	14
1871	An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade. <i>Peptides</i> , 2021, 145, 170638.	1.2	10
1872	Computational modeling of protein conformational changes - Application to the opening SARS-CoV-2 spike. <i>Journal of Computational Physics</i> , 2021, 444, 110591.	1.9	6
1873	Molecular structure, tautomer's, reactivity and inhibition studies on 6-Methyl-2-thiouracil for mild steel corrosion in aqueous HCl (1.00 M): Experimental and Theoretical Studies. <i>Journal of Molecular Structure</i> , 2021, 1244, 130927.	1.8	31
1874	Resurgence of phosphotyrosine binding domains: Structural and functional properties essential for understanding disease pathogenesis. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129977.	1.1	3
1875	Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations. <i>Journal of Molecular Structure</i> , 2021, 1246, 131113.	1.8	11
1876	Immunological evaluation of an inactivated SARS-CoV-2 vaccine in rhesus macaques. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 108-118.	1.8	9
1877	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108035.	1.3	52
1878	SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166264.	1.8	5
1879	Structural behavior of monomer of SARS-CoV-2 spike protein during initial stage of adsorption on graphene. <i>Materials Today Chemistry</i> , 2021, 22, 100572.	1.7	11
1880	Gastrointestinal Tract and COVID-19. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2022, , 127-140.	0.1	1
1881	Molecular docking and dynamics studies of Nicotinamide Riboside as a potential multi-target nutraceutical against SARS-CoV-2 entry, replication, and transcription: A new insight. <i>Journal of Molecular Structure</i> , 2022, 1247, 131394.	1.8	20

#	ARTICLE	IF	CITATIONS
1882	Management of Coronavirus Disease 2019 (COVID-19) Pneumonia. , 2022, , 342-349.		4
1883	The Potency of Cinnamon as An Anti-Diabetic and Anti-Covid19 based on Its Mineral Content and Phenolic Compounds. Journal of Physics: Conference Series, 2021, 1751, 012105.	0.3	1
1884	Comparative genetic analyses of Korean bat coronaviruses with SARS-CoV and the newly emerged SARS-CoV-2. Journal of Veterinary Science, 2021, 22, e12.	0.5	2
1885	Computational insights into the membrane fusion mechanism of SARS-CoV-2 at the cellular level. Computational and Structural Biotechnology Journal, 2021, 19, 5019-5028.	1.9	10
1886	Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study. Molecular Diversity, 2022, 26, 157-169.	2.1	18
1887	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Membranes, 2021, 11, 64.	1.4	0
1888	An electrochemical SARS-CoV-2 biosensor inspired by glucose test strip manufacturing processes. Chemical Communications, 2021, 57, 3704-3707.	2.2	38
1889	Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. Computational and Structural Biotechnology Journal, 2021, 19, 4684-4701.	1.9	27
1890	Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management. Biomolecules, 2021, 11, 136.	1.8	20
1891	Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin. Molecules, 2021, 26, 406.	1.7	35
1893	Probing conformational hotspots for the recognition and intervention of protein complexes by lysine reactivity profiling. Chemical Science, 2021, 12, 1451-1457.	3.7	15
1894	Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors. Scientific Reports, 2021, 11, 1156.	1.6	6
1895	Structural assessment of SARS-CoV2 accessory protein ORF7a predicts LFA-1 and Mac-1 binding potential. Bioscience Reports, 2021, 41, .	1.1	20
1896	ACE2 glycans preferentially interact with SARS-CoV-2 over SARS-CoV. Chemical Communications, 2021, 57, 5949-5952.	2.2	26
1897	Modeling the interaction of SARS-CoV-2 binding to the ACE2 receptor <i>via</i> molecular theory of solvation. New Journal of Chemistry, 2021, 45, 15448-15457.	1.4	4
1898	COVID-19 and Cell Stress. Advances in Experimental Medicine and Biology, 2021, 1318, 169-178.	0.8	8
1899	Impact of Tobacco Smoking on the Risk of COVID-19: A Large Scale Retrospective Cohort Study. Nicotine and Tobacco Research, 2021, 23, 1398-1404.	1.4	94
1901	<i>De novo</i> design and synthesis of boomerang-shaped molecules and their <i>in silico</i> and SERS-based interactions with SARS-CoV-2 spike protein and ACE2. New Journal of Chemistry, 2021, 45, 17777-17781.	1.4	7

#	ARTICLE	IF	CITATIONS
1902	T cell epitopes of SARS-CoV-2 spike protein and conserved surface protein of <i>Plasmodium malariae</i> share sequence homology. <i>Open Life Sciences</i> , 2021, 16, 630-640.	0.6	4
1903	Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 897-910.	2.6	30
1904	Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1933-1943.	1.9	69
1905	No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. <i>Scientific Reports</i> , 2021, 11, 413.	1.6	156
1908	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. <i>Cell Research</i> , 2021, 31, 126-140.	5.7	356
1909	Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2806-2818.	1.9	33
1910	Analysis of Emerging Variants in Structured Regions of the SARS-CoV-2 Genome. <i>Evolutionary Bioinformatics</i> , 2021, 17, 117693432110141.	0.6	19
1911	Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2. <i>Informatics in Medicine Unlocked</i> , 2021, 24, 100578.	1.9	41
1912	Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. <i>PLoS ONE</i> , 2021, 16, e0245975.	1.1	11
1913	Mutations in the SARS CoV-2 spike protein may cause functional changes in the protein quaternary structure. <i>Turkish Journal of Biochemistry</i> , 2021, 46, 137-144.	0.3	4
1914	Laboratory-Based Resources for COVID-19 Diagnostics: Traditional Tools and Novel Technologies. A Perspective of Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2021, 11, 42.	1.1	6
1915	Genetic and epigenetic concept of SARS-CoV-2 targets in different renal cancer subtypes. <i>Turkish Journal of Biochemistry</i> , 2021, 46, 145-155.	0.3	0
1916	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. <i>Immune Network</i> , 2021, 21, e8.	1.6	3
1918	RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 47-53.	1.0	102
1919	Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 1043-1056.	0.9	8
1920	Smart and Sustainable Nanotechnological Solutions in a Battle against COVID-19 and Beyond: A Critical Review. <i>ACS Sustainable Chemistry and Engineering</i> , 2021, 9, 601-622.	3.2	14
1922	An update of coronavirus disease 2019 (COVID-19): an essential brief. <i>Modern Medical Laboratory Journal</i> , 2021, 4, 19-38.	0.2	0
1924	Development and application of therapeutic antibodies against COVID-19. <i>International Journal of Biological Sciences</i> , 2021, 17, 1486-1496.	2.6	47

#	ARTICLE	IF	CITATIONS
1925	Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2. Briefings in Bioinformatics, 2021, 22, 714-725.	3.2	17
1926	Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic. Immune Network, 2021, 21, e5.	1.6	21
1927	Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE, 2021, 16, e0245382.	1.1	14
1928	Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein. Quantitative Biology, 2021, 9, 61-72.	0.3	15
1929	<i>Scutellaria baicalensis</i> extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease <i>in vitro</i> . Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 497-503.	2.5	206
1930	An Account of Immune Senescence in the Clinical Pathophysiology of COVID-19 Infection in Aging. , 2021, 12, 662.		4
1931	Molecular optimization, docking, and dynamic simulation profiling of selective aromatic phytochemical ligands in blocking the SARS-CoV-2 S protein attachment to ACE2 receptor: an <i>in silico</i> approach of targeted drug designing. Journal of Advanced Veterinary and Animal Research, 2021, 8, 1.	0.5	27
1932	Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol. Frontiers in Cardiovascular Medicine, 2020, 7, 618651.	1.1	60
1933	501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab <i>in vitro</i> . MAbs, 2021, 13, 1919285.	2.6	65
1934	Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction—a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in Pharmacology, 2020, 11, 600372.	1.6	64
1935	Current understanding of the influence of environmental factors on SARS-CoV-2 transmission, persistence, and infectivity. Environmental Science and Pollution Research, 2021, 28, 6267-6288.	2.7	49
1936	Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nature Communications, 2021, 12, 250.	5.8	108
1937	Global pandemics interconnected — obesity, impaired metabolic health and COVID-19. Nature Reviews Endocrinology, 2021, 17, 135-149.	4.3	326
1938	SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection. FEBS Letters, 2020, 594, 1651-1660.	1.3	25
1939	Inactivation of SARS-CoV-2 and HCoV-229E <i>in vitro</i> by ColdZyme® a medical device mouth spray against the common cold. Journal of Medical Virology, 2021, 93, 1792-1795.	2.5	18
1940	Type I interferon: From innate response to treatment for COVID-19. Pediatric Investigation, 2020, 4, 275-280.	0.6	17
1941	An Overview of the Crystallized Structures of the SARS-CoV-2. Protein Journal, 2020, 39, 600-618.	0.7	32
1942	COVID-19 therapy: What weapons do we bring into battle?. Bioorganic and Medicinal Chemistry, 2020, 28, 115757.	1.4	22

#	ARTICLE	IF	CITATIONS
1943	IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine and Growth Factor Reviews, 2020, 53, 13-24.	3.2	237
1944	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resistance Updates, 2020, 53, 100721.	6.5	80
1945	Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Therapie, 2020, 75, 319-325.	0.6	7
1946	Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. Virus Research, 2020, 289, 198146.	1.1	37
1947	Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Bioconjugate Chemistry, 2021, 32, 215-223.	1.8	70
1948	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega, 2021, 6, 85-102.	1.6	54
1949	Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2. Nature Communications, 2020, 11, 2920.	5.8	35
1950	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. Scientific Reports, 2020, 10, 21894.	1.6	18
1951	Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19). RSC Advances, 2020, 10, 40867-40875.	1.7	17
1952	A pocket guide on how to structure SARS-CoV-2 drugs and therapies. Biochemical Society Transactions, 2020, 48, 2625-2641.	1.6	10
1953	Structure and regulation of coronavirus genomes: state-of-the-art and novel insights from SARS-CoV-2 studies. Biochemical Society Transactions, 2021, 49, 341-352.	1.6	32
1954	ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Clinical Science, 2020, 134, 2791-2805.	1.8	14
1955	ACE2 as therapeutic agent. Clinical Science, 2020, 134, 2581-2595.	1.8	7
1956	ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. Clinical Science, 2020, 134, 2851-2871.	1.8	47
1957	ACE2: from protection of liver disease to propagation of COVID-19. Clinical Science, 2020, 134, 3137-3158.	1.8	35
1958	How SARS-CoV-2 (COVID-19) spreads within infected hosts " what we know so far. Emerging Topics in Life Sciences, 2020, 4, 383-390.	1.1	28
1959	Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2. Gastroenterology, 2020, 159, 1145-1147.e4.	0.6	106
1960	Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin. Thrombosis and Haemostasis, 2020, 120, 1700-1715.	1.8	228

#	ARTICLE	IF	CITATIONS
1961	Cross-species recognition of SARS-CoV-2 to bat ACE2. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	73
1962	Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4015-4025.	2.0	65
1963	Design and in silico study of the novel coumarin derivatives against SARS-CoV-2 main enzymes. Journal of Biomolecular Structure and Dynamics, 2020, , 1-16.	2.0	13
1964	Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. Journal of Cell Biology, 2020, 219, .	2.3	20
1965	Key residues influencing binding affinities of 2019-nCoV with ACE2 in different species. Briefings in Bioinformatics, 2021, 22, 963-975.	3.2	14
1966	The impact of structural bioinformatics tools and resources on SARS-CoV-2 research and therapeutic strategies. Briefings in Bioinformatics, 2021, 22, 742-768.	3.2	29
1967	Conservation analysis of SARS-CoV-2 spike suggests complicated viral adaptation history from bat to human. Evolution, Medicine and Public Health, 2020, 2020, 290-303.	1.1	17
1968	COVID-19 in Chronic Liver Disease and Liver Transplantation. Journal of Clinical Gastroenterology, 2021, 55, 187-194.	1.1	39
1969	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	10
1970	Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.5	5
1971	Postoperative Onset and Detection of SARS-CoV-2 in Surgically Resected Specimens From Gastrointestinal Cancer Patients With Pre/Asymptomatic COVID-19. Annals of Surgery, 2020, 272, e321-e328.	2.1	9
1972	Development and Validation of a Multiplex, Bead-based Assay to Detect Antibodies Directed Against SARS-CoV-2 Proteins. Transplantation, 2021, 105, 79-89.	0.5	40
1973	ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study. Royal Society Open Science, 2020, 7, 200958.	1.1	12
1974	Identification of a SARS-like bat coronavirus that shares structural features with the spike glycoprotein receptor-binding domain of SARS-CoV-2. Access Microbiology, 2020, 2, acmi000166.	0.2	6
1975	Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus. Journal of General Virology, 2020, 101, 1251-1260.	1.3	12
2200	Chapter of Gastroenterologists professional guidance for management of patients with liver disease in Singapore during the COVID-19 pandemic. Singapore Medical Journal, 2020, 61, 619-623.	0.3	4
2201	COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight, 2020, 5, .	2.3	412
2202	Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. JCI Insight, 2020, 5, .	2.3	186



#	ARTICLE	IF	CITATIONS
2203	Convalescent plasma anti-“SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. <i>Journal of Clinical Investigation</i> , 2020, 130, 6728-6738.	3.9	172
2204	Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. <i>Journal of Translational Medicine</i> , 2020, 18, 494.	1.8	15
2205	Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. <i>Neurology</i> , 2020, 95, e910-e920.	1.5	194
2206	Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic. <i>Bulletin of the Chemical Society of Japan</i> , 2021, 94, 1478-1490.	2.0	24
2207	Understanding the immunopathogenesis of COVID-19: Its implication for therapeutic strategy. <i>World Journal of Clinical Cases</i> , 2020, 8, 5835-5843.	0.3	11
2208	Light and corona: guided-wave readout for coronavirus spike protein-“host-receptor binding. <i>Optics Letters</i> , 2020, 45, 5428.	1.7	2
2209	The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. <i>PLoS Biology</i> , 2020, 18, e3001016.	2.6	169
2210	Insights on cross-species transmission of SARS-CoV-2 from structural modeling. <i>PLoS Computational Biology</i> , 2020, 16, e1008449.	1.5	52
2211	In silico mutagenesis of human ACE2 with S protein and translational efficiency explain SARS-CoV-2 infectivity in different species. <i>PLoS Computational Biology</i> , 2020, 16, e1008450.	1.5	36
2212	Recombination events are concentrated in the spike protein region of Betacoronaviruses. <i>PLoS Genetics</i> , 2020, 16, e1009272.	1.5	52
2213	Bioinformatic characterization of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2. <i>PLoS ONE</i> , 2020, 15, e0240647.	1.1	24
2214	The hallmarks of COVID-19 disease. <i>PLoS Pathogens</i> , 2020, 16, e1008536.	2.1	342
2215	Coronavirus Disease-19 Presenting as Esophageal Ulceration. <i>American Journal of Gastroenterology</i> , 2021, 116, 421-424.	0.2	5
2216	Screening of preferential binding affinity of selected natural compounds to SARS-CoV-2 proteins using in silico methods. <i>Eurasian Journal of Medicine and Oncology</i> , 0, , .	1.0	5
2217	What hepatologists need to know about COVID-19?. <i>Hepatology Forum</i> , 2020, , .	0.3	3
2218	An original multiplex method to assess five different SARS-CoV-2 antibodies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 971-978.	1.4	15
2219	Modeling the incidence and death rates of COVID-19 pandemic in different regions of the world. <i>Epidemiologic Methods</i> , 2020, 9, .	0.8	7
2220	COVID-19 and women-“s health (literature review). <i>Russian Journal of Human Reproduction</i> , 2020, 26, 6.	0.1	13

#	ARTICLE	IF	CITATIONS
2222	Molecular Mechanisms of Proteins as Targets for SARS-CoV-2 (Review). <i>Sovremennye Tehnologii V Medicine</i> , 2020, 12, 98.	0.4	8
2223	De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2. <i>Aging</i> , 2020, 12, 11263-11276.	1.4	89
2224	Role of angiotensin-converting enzyme 2 in neurodegenerative diseases during the COVID-19 pandemic. <i>Aging</i> , 2020, 12, 24453-24461.	1.4	8
2225	Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19. <i>Aging</i> , 2020, 12, 23436-23449.	1.4	7
2226	Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer. <i>Aging</i> , 2020, 12, 22370-22389.	1.4	12
2227	Role of renin-angiotensin-aldosterone system in the interaction with coronavirus SARS-CoV-2 and in the development of strategies for prevention and treatment of new coronavirus infection (COVID-19). <i>Arterial Hypertension (Russian Federation)</i> , 2020, 26, 248-262.	0.1	12
2234	Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. <i>Future Microbiology</i> , 2020, 15, 1747-1758.	1.0	31
2235	Comparative Analysis of SARS-CoV2 with Special Emphasis on Genome Sequences. <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 1053-1064.	0.3	1
2236	Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?. <i>Zoological Research</i> , 2020, 41, 213-219.	0.9	76
2240	A Drug Repurposing Approach Towards Elucidating the Potential of Flavonoids as COVID-19 Spike Protein Inhibitors. <i>Biointerface Research in Applied Chemistry</i> , 2020, 11, 8482-8501.	1.0	7
2241	Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment. <i>Frontiers in Pediatrics</i> , 2020, 8, 626182.	0.9	120
2242	May SARS-CoV-2 Diffusion Be Favored by Alkaline Aerosols and Ammonia Emissions?. <i>Atmosphere</i> , 2020, 11, 995.	1.0	5
2243	Multiple Recombination Events and Strong Purifying Selection at the Origin of SARS-CoV-2 Spike Glycoprotein Increased Correlated Dynamic Movements. <i>International Journal of Molecular Sciences</i> , 2021, 22, 80.	1.8	21
2244	Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. <i>Molecules</i> , 2021, 26, 57.	1.7	27
2245	Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19. <i>Viruses</i> , 2021, 13, 29.	1.5	118
2246	Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. <i>Viruses</i> , 2021, 13, 54.	1.5	61
2247	Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy. <i>Journal of Lasers in Medical Sciences</i> , 2020, 11, 433-441.	0.4	8
2248	COVID-19 in China: From epidemiology to treatment (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	4

#	ARTICLE	IF	CITATIONS
2249	Lactoferrin for the treatment of COVID-19 (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	41
2250	An integrative look at SARS-CoV-2 (Review). <i>International Journal of Molecular Medicine</i> , 2020, 47, 415-434.	1.8	17
2251	COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 321-327.	0.6	43
2252	Update on the target structures of SARS-nCoV-2: A systematic review. <i>Indian Journal of Pharmacology</i> , 2020, 52, 142.	0.4	41
2253	Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19. <i>Endocrine Practice</i> , 2020, 26, 1166-1172.	1.1	31
2254	Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality. <i>Cardiology Journal</i> , 2020, 27, 616-624.	0.5	18
2255	SARS-CoV-2 (COVID-19) by the numbers. <i>ELife</i> , 2020, 9, .	2.8	826
2256	ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. <i>ELife</i> , 2020, 9, .	2.8	266
2257	Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. <i>ELife</i> , 2020, 9, .	2.8	165
2258	Single-cell multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of SARS-CoV2 host genes. <i>ELife</i> , 2020, 9, .	2.8	129
2259	Does Nicotine Prevent Cytokine Storms in COVID-19?. <i>Cureus</i> , 2020, 12, e11220.	0.2	4
2260	Is COVID-19 Similar in Pregnant and Non-Pregnant Women?. <i>Cureus</i> , 2020, 12, e8888.	0.2	15
2262	Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 22957-22971.	1.3	11
2263	Multimode participation of traditional Chinese medicine in the treatment of COVID-19. <i>Integrative Medicine Research</i> , 2021, 10, 100781.	0.7	10
2264	In silico antibody engineering for SARS-CoV-2 detection. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5525-5534.	1.9	2
2265	Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant. <i>RSC Advances</i> , 2021, 11, 33438-33446.	1.7	3
2266	Localized surface plasmon resonance aptasensor for selective detection of SARS-CoV-2 S1 protein. <i>Analyst</i> , The, 2021, 146, 7207-7217.	1.7	22
2267	The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100064.	1.7	4

#	ARTICLE	IF	CITATIONS
2268	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
2269	VÃrusellenes terÃpiÃs lehetÃsÃgek COVID-19 fertÃzÃs kezÃsÃre. <i>Scientia Et Securitas</i> , 2021, 2, 88-93.		1
2270	Exosomes: Emerging implementation of nanotechnology for detecting and managing novel corona virus- SARS-CoV-2. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 20-34.	4.3	10
2271	Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757197.	2.2	20
2272	The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19. <i>Topics in Current Chemistry</i> , 2021, 379, 40.	3.0	29
2273	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	3.6	42
2274	On the Selectivity of Heparan Sulfate Recognition by SARS-CoV-2 Spike Glycoprotein. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1710-1717.	1.3	22
2275	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. <i>Viruses</i> , 2021, 13, 2106.	1.5	7
2276	The challenges of COVID-19 Delta variant: Prevention and vaccine development. <i>MedComm</i> , 2021, 2, 846-854.	3.1	37
2277	The evaluation of potential global impact of the N501Y mutation in SARS-CoV-2 positive patients. <i>Journal of Medical Virology</i> , 2022, 94, 1009-1019.	2.5	12
2278	Evaluation of global evolutionary variations in the early stage of SARS-CoV-2 pandemic. <i>Heliyon</i> , 2021, 7, e08170.	1.4	0
2279	An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants. <i>Viruses</i> , 2021, 13, 2009.	1.5	9
2280	Lactoferrin as Antiviral Treatment in COVID-19 Management: Preliminary Evidence. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10985.	1.2	47
2281	High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors. <i>Journal of the Iranian Chemical Society</i> , 2022, 19, 1865-1876.	1.2	6
2282	The Rapid Assessment of Aggregated Wastewater Samples for Genomic Surveillance of SARS-CoV-2 on a City-Wide Scale. <i>Pathogens</i> , 2021, 10, 1271.	1.2	15
2283	Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 304-307.	0.8	4
2284	LigaÃo intracelular entre a toxina botulÃnica e covid-19. <i>CPAH Cientific Journal of Health</i> , 2021, 1, 133-138.	0.0	0
2286	Imaging and visualizing SARS-CoV-2 in a new era for structural biology. <i>Interface Focus</i> , 2021, 11, 20210019.	1.5	5

#	ARTICLE	IF	CITATIONS
2288	Expression and characterization of SARS-CoV-2 spike proteins. <i>Nature Protocols</i> , 2021, 16, 5339-5356.	5.5	31
2289	Intelligent health system for the investigation of consenting COVID-19 patients and precision medicine. <i>Personalized Medicine</i> , 2021, 18, 573-582.	0.8	8
2290	Screening Potential Drugs for COVID-19 Based on Bound Nuclear Norm Regularization. <i>Frontiers in Genetics</i> , 2021, 12, 749256.	1.1	5
2292	A Clinical Comparison of Imported or Locally Acquired COVID-19 Suggests Declining Severity after Viral Passages at the Early Stage of the Pandemic in China. <i>The Open Covid Journal</i> , 2021, 1, 101-107.	0.4	0
2293	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	1.6	33
2294	A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1759.	2.0	42
2295	The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 753721.	1.8	36
2296	Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure. <i>MSystems</i> , 2021, 6, e0009521.	1.7	26
2298	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
2300	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. <i>FASEB Journal</i> , 2021, 35, e21970.	0.2	22
2302	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80
2303	AI-driven prediction of SARS-CoV-2 variant binding trends from atomistic simulations. <i>European Physical Journal E</i> , 2021, 44, 123.	0.7	3
2304	Human Cell Receptors and Downstream Cascades: A Review of Molecular Aspects and Potential Therapeutic Targets in COVID-19. <i>Archives of Pediatric Infectious Diseases</i> , 2021, 10, .	0.1	0
2305	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
2306	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection. <i>Molecular Therapy</i> , 2022, 30, 1885-1896.	3.7	16
2307	Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. <i>EMBO Molecular Medicine</i> , 2021, 13, e14544.	3.3	17
2308	BCEPS: A Web Server to Predict Linear B Cell Epitopes with Enhanced Immunogenicity and Cross-Reactivity. <i>Cells</i> , 2021, 10, 2744.	1.8	21
2309	Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening. <i>Scientific Reports</i> , 2021, 11, 20738.	1.6	11

#	ARTICLE	IF	CITATIONS
2310	An ultrasensitive molecularly imprinted polymer-based electrochemical sensor for the determination of SARS-CoV-2-RBD by using macroporous gold screen-printed electrode. <i>Biosensors and Bioelectronics</i> , 2022, 196, 113729.	5.3	57
2311	Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0181321.	1.8	28
2312	The Misattributed and Silent Causes of Poor COVID-19 Outcomes Among Pregnant Women. <i>Frontiers in Medicine</i> , 2021, 8, 745797.	1.2	4
2313	Basophils and Mast Cells in COVID-19 Pathogenesis. <i>Cells</i> , 2021, 10, 2754.	1.8	40
2314	A Pair of ACE2. <i>Journal of Dental Research</i> , 2021, , 002203452110475.	2.5	10
2315	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17
2317	Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617. <i>Frontiers in Microbiology</i> , 2021, 12, 750725.	1.5	11
2318	Impact of COVID-19 on Patients with Inflammatory Bowel Disease. <i>Journal of Exploratory Research in Pharmacology</i> , 2022, 7, 37-44.	0.2	4
2320	The acid sphingomyelinase/ceramide system in COVID-19. <i>Molecular Psychiatry</i> , 2022, 27, 307-314.	4.1	71
2321	Peptides and peptidomimetics as therapeutic agents for Covid-19. <i>Peptide Science</i> , 2022, 114, e24245.	1.0	8
2322	Molecular Insights on the Possible Role of Annexin A2 in COVID-19 Pathogenesis and Post-Infection Complications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11028.	1.8	7
2323	Current treatment strategies for COVID-19 (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	19
2324	<i>Acmella oleracea</i> Is a Medicinal Plant That Decreases Chymase Activity, Oxidative Stress, and Inflammation: Possible Role in the Adjuvant Treatment of COVID-19. <i>Journal of Medicinal Food</i> , 2021, 24, 1243-1244.	0.8	2
2326	Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants. <i>Journal of the American Chemical Society</i> , 2021, 143, 17646-17654.	6.6	39
2327	Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies. <i>Biochimie</i> , 2022, 193, 90-102.	1.3	6
2328	Evaluation of SARS-CoV-2 main protease and inhibitor interactions using dihedral angle distributions and radial distribution function. <i>Heliyon</i> , 2021, 7, e08220.	1.4	6
2330	Global Diversification and Distribution of Coronaviruses With Furin Cleavage Sites. <i>Frontiers in Microbiology</i> , 2021, 12, 649314.	1.5	11
2331	SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10836.	1.8	25



#	ARTICLE	IF	CITATIONS
2332	Conformational variability of loops in the SARS-CoV-2 spike protein. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 691-703.	1.5	1
2333	Identification of Hotspot Residues in Binding of SARS-CoV-2 Spike and Human ACE2 Proteins. <i>Journal of Computational Biophysics and Chemistry</i> , 2021, 20, 729-739.	1.0	2
2334	Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective. <i>Scientific Reports</i> , 2021, 11, 19998.	1.6	6
2335	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6103.	5.8	117
2336	Transmission dynamics and susceptibility patterns of SARS-CoV-2 in domestic, farmed and wild animals: Sustainable One Health surveillance for conservation and public health to prevent future epidemics and pandemics. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2523-2543.	1.3	16
2338	Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach. <i>MBio</i> , 2021, 12, e0268721.	1.8	3
2339	SMOG 2 and OpenSMOG: Extending the limits of structure-based models. <i>Protein Science</i> , 2022, 31, 158-172.	3.1	11
2340	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	14
2342	Effective chimeric antigen receptor T cells against SARS-CoV-2. <i>IScience</i> , 2021, 24, 103295.	1.9	14
2343	A pathogen-like antigen based vaccine confers immune protection against SARS-CoV-2 in non-human primates. <i>Cell Reports Medicine</i> , 2021, 2, 100448.	3.3	11
2344	Accurate detection and quantification of SARS-CoV-2 genomic and subgenomic mRNAs by ddPCR and meta-transcriptomics analysis. <i>Communications Biology</i> , 2021, 4, 1215.	2.0	10
2345	DNA-Directed Patterning for Versatile Validation and Characterization of a Lipid-Based Nanoparticle Model of SARS-CoV-2. <i>Advanced Science</i> , 2021, 8, e2101166.	5.6	4
2347	An Update on Innate Immune Responses during SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2060.	1.5	10
2348	Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex. <i>In Silico Pharmacology</i> , 2021, 9, 55.	1.8	12
2351	Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A Comparative Genomics Approach. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 765039.	1.8	43
2352	Mutational profile confers increased stability of SARS-CoV-2 spike protein in Brazilian isolates. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13184-13189.	2.0	3
2353	Optical Detection of SARS-CoV-2 Utilizing Antigen-Antibody Binding Interactions. <i>Sensors</i> , 2021, 21, 6596.	2.1	5
2354	Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. <i>Lipids in Health and Disease</i> , 2021, 20, 126.	1.2	15

#	ARTICLE	IF	CITATIONS
2355	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021, 37, 109881.	2.9	14
2356	COVID-19 and metabolic disease: mechanisms and clinical management. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 786-798.	5.5	155
2357	Identification of nut protein-derived peptides against SARS-CoV-2 spike protein and main protease. <i>Computers in Biology and Medicine</i> , 2021, 138, 104937.	3.9	10
2358	Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects. <i>International Immunopharmacology</i> , 2021, 101, 108215.	1.7	20
2359	SARS-COV-2 AND BETACORONAVIRUS: WHAT HAVE WE LEARNED IN 8 MONTHS?. <i>Postepy Mikrobiologii</i> , 2020, 59, 197-206.	0.1	0
2365	El papel de la nanociencia y la nanotecnología en el marco de la pandemia de COVID-19. <i>Mundo Nano Revista Interdisciplinaria En Nanociencia Y Nanotecnología</i> , 2020, 14, 1e-29e.	0.1	0
2371	Lessons Learned from SARS-CoV and MERS-CoV: Preparation for SARS-CoV-2 induced COVID-19. <i>Journal of Bacteriology and Virology</i> , 2020, 50, 76-96.	0.0	1
2373	COVID-19: A Centennial Pandemic from Origin to Clinical Trials. <i>Acta Biologica Marisiensis</i> , 2020, 3, 30-52.	0.1	1
2390	A Review of Recent Trend of COVID-19 Infection and Correlation with Pulmonary Function. <i>Biomedical Science Letters</i> , 2020, 26, 127-135.	0.0	1
2391	Organoids: a new research model for SARS-CoV-2 infection and treatment. <i>Scientia Sinica Vitae</i> , 2023, 53, 238-249.	0.1	1
2392	Synthesis, cytotoxicity and docking studies (with SARS-CoV-2) of water-soluble binuclear Ru-p-cymene complex holding indole thiosemicarbazone ligand. <i>Inorganic Chemistry Communication</i> , 2021, 134, 109029.	1.8	18
2394	Phospholipids dock SARS-CoV-2 spike protein via hydrophobic interactions: a minimal in-silico study of lecithin nasal spray therapy. <i>European Physical Journal E</i> , 2021, 44, 132.	0.7	2
2395	Can a radioimmunoassay kit be developed for accurate detection of the S protein of severe acute respiratory syndrome coronavirus 2?. <i>World Journal of Clinical Infectious Diseases</i> , 2021, 11, 60-62.	0.5	0
2396	Synthesis, crystal structure, potential drug properties for Coronavirus of Co(II) and Zn(II) 2-chlorobenzoate with 3-cyanopyridine complexes. <i>Journal of Molecular Structure</i> , 2022, 1250, 131825.	1.8	11
2397	SARS-CoV-2 variant with mutations in N gene affecting detection by widely used PCR primers. <i>Journal of Medical Virology</i> , 2022, 94, 1227-1231.	2.5	18
2398	A Review of Human Coronaviruses' Receptors: The Host-Cell Targets for the Crown Bearing Viruses. <i>Molecules</i> , 2021, 26, 6455.	1.7	36
2399	Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. <i>Science</i> , 2021, 374, 1353-1360.	6.0	246
2400	Antibody-Free Rapid Detection of SARS-CoV-2 Proteins Using Corona Phase Molecular Recognition to Accelerate Development Time. <i>Analytical Chemistry</i> , 2021, 93, 14685-14693.	3.2	25

#	ARTICLE	IF	CITATIONS
2401	DNA Mutations via Chernâ€“Simons Currents. <i>European Physical Journal Plus</i> , 2021, 136, 1080.	1.2	2
2402	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
2403	Distinct Roles of Type I and Type III Interferons during a Native Murine Î² Coronavirus Lung Infection. <i>Journal of Virology</i> , 2022, 96, JM0124121.	1.5	10
2404	A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBDâ€“ACE2 Interaction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11627.	1.8	6
2405	Metallo drug Profiling against SARSâ€“CoVâ€“2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papainâ€“like Protease PL<sup>pro</sup>. <i>Chemistry - A European Journal</i> , 2021, 27, 17928-17940.	1.7	41
2406	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1249-1273.	3.6	19
2407	Celecoxib, Glipizide, Lapatinib, and Sitagliptin as potential suspects of aggravating SARS-CoV-2 (COVID-19) infection: a computational approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13747-13758.	2.0	5
2408	Neutralizing Antibodies to SARSâ€“CoVâ€“2 Selected from a Human Antibody Library Constructed Decades Ago. <i>Advanced Science</i> , 2022, 9, e2102181.	5.6	14
2409	Immunology and controlling of coronaviruses; the current enemy for humanity: A review. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	3
2410	The impact of the hypoxiaâ€“VEGFâ€“vascular permeability on COVIDâ€“19â€“infected patients. <i>Exploration</i> , 2021, 1, 20210051.	5.4	20
2411	Whey-Derived Peptides at the Heart of the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11662.	1.8	3
2413	SARS-CoV-2: Potential Drug Targets and Its Virtual Screening. <i>Studies in Systems, Decision and Control</i> , 2022, , 203-244.	0.8	2
2414	COVID-19 in Early Life: Infants and Children Are Affected Too. <i>Physiology</i> , 2021, 36, 359-366.	1.6	5
2415	The severity of SARS-CoV-2 infection is dictated by host factors? Epigenetic perspectives. <i>Current Research in Microbial Sciences</i> , 2021, 2, 100079.	1.4	2
2416	Bioinformatic evaluation of the potential animal models for studying SARS-Cov-2. <i>Heliyon</i> , 2020, 6, e05725.	1.4	3
2421	Coagulopathy: Another side effect of coronavirus infection. <i>Journal of Cardiovascular and Thoracic Research</i> , 2020, 13, 15-22.	0.3	1
2424	Initial study on SARS-CoV-2 main protease inhibition mechanism of some potential drugs using molecular docking simulation. <i>Science and Technology</i> , 2020, 58, 665-675.	0.1	0
2427	The CB index predicts prognosis of critically ill COVID-19 patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1654-1654.	0.7	1

#	ARTICLE	IF	CITATIONS
2428	Desafios em saúde mental durante a pandemia: relato de experiência. Revista Bioetica, 2020, 28, 647-654.	0.0	6
2431	Strategies for search of pharmacological drugs against SARS-CoV-2 on the base of studying the structural-genetic features of coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. Reviews on Clinical Pharmacology and Drug Therapy, 2020, 18, 269-296.	0.2	2
2432	Beta-Sitosterol: As Immunostimulant, Antioxidant and Inhibitor of SARS-CoV-2 Spike Glycoprotein. , 2020, 2, .		13
2435	Prediction of the Effects of Variants and Differential Expression of Key Host Genes ACE2, TMPRSS2, and FURIN in SARS-CoV-2 Pathogenesis: An In Silico Approach. Bioinformatics and Biology Insights, 2021, 15, 117793222110546.	1.0	6
2436	Protein-protein interactions at a glance: Protocols for the visualization of biomolecular interactions. Methods in Cell Biology, 2021, 166, 271-307.	0.5	2
2437	Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine Escape. SSRN Electronic Journal, 0, , .	0.4	0
2438	Mechanistic insights into the effects of key mutations on SARS-CoV-2 RBD-ACE2 binding. Physical Chemistry Chemical Physics, 2021, 23, 26451-26458.	1.3	19
2439	Cocktail polysaccharides isolated from Ecklonia kurome against the SARS-CoV-2 infection. Carbohydrate Polymers, 2022, 275, 118779.	5.1	9
2440	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. Immune Network, 2021, 21, e32.	1.6	51
2441	Natural Transmission and Experimental Models of SARS-CoV-2 Infection in Animals. Comparative Medicine, 2021, 71, 369-382.	0.4	2
2442	Unbiased Local Sequencing Similarity Analysis for SARS-CoV-2 Worldwide. SSRN Electronic Journal, 0, , .	0.4	0
2443	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. SSRN Electronic Journal, 2020, , 3639618.	0.4	3
2444	Application of Nanotechnology in Detection and Prevention of COVID-19. Disaster Resilience and Green Growth, 2020, , 361-395.	0.2	1
2447	Computational insights into differential interaction of mammalian angiotensin-converting enzyme 2 with the SARS-CoV-2 spike receptor binding domain. Computers in Biology and Medicine, 2022, 141, 105017.	3.9	11
2448	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400.	1.7	63
2449	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. ACS Central Science, 2021, 7, 1863-1873.	5.3	20
2450	Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method. Journal of Separation Science, 2022, 45, 456-467.	1.3	7
2451	Self and Nonself Short Constituent Sequences of Amino Acids in the SARS-CoV-2 Proteome for Vaccine Development. Covid, 2021, 1, 555-574.	0.7	4

#	ARTICLE	IF	CITATIONS
2452	IgG Study of Blood Sera of Patients with COVID-19. <i>Pathogens</i> , 2021, 10, 1421.	1.2	9
2453	Mutation profile of SARS-CoV-2 spike protein and identification of potential multiple epitopes within spike protein for vaccine development against SARS-CoV-2. <i>VirusDisease</i> , 2021, 32, 703-726.	1.0	15
2455	Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. <i>PLoS Pathogens</i> , 2021, 17, e1010053.	2.1	43
2456	An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 752739.	1.5	18
2457	Phylogenetic and Ancestral Sequence Reconstruction of SARS-CoV-2 Reveals Latent Capacity to Bind Human ACE2 Receptor. <i>Journal of Molecular Evolution</i> , 2021, 89, 656-664.	0.8	5
2458	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2214.	1.5	16
2459	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. <i>Translational Research</i> , 2022, 240, 1-16.	2.2	33
2460	The Usefulness of Rare Blood Group Systems in the Risk Determination for Severe COVID-19. <i>Pathophysiology</i> , 2021, 28, 496-500.	1.0	1
2461	Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7967-7989.	2.4	40
2462	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. <i>Nature Communications</i> , 2021, 12, 6304.	5.8	42
2463	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	0.7	8
2464	VTR: A Web Tool for Identifying Analogous Contacts on Protein Structures and Their Complexes. <i>Frontiers in Bioinformatics</i> , 2021, 1, .	1.0	4
2465	Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event. <i>Proceedings of the Indian National Science Academy</i> , 0, , .	0.5	0
2466	Development and Characterization of Magnetic SARS-CoV-2 Peptide-Imprinted Polymers. <i>Nanomaterials</i> , 2021, 11, 2985.	1.9	14
2467	Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations. <i>Scientific Reports</i> , 2021, 11, 21735.	1.6	11
2468	Genomic diversity and molecular dynamics interaction on mutational variances among RB domains of SARS-CoV-2 interplay drug inactivation. <i>Infection, Genetics and Evolution</i> , 2021, , 105128.	1.0	2
2469	Selection for constrained peptides that bind to a single target protein. <i>Nature Communications</i> , 2021, 12, 6343.	5.8	16
2470	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	7.1	26

#	ARTICLE	IF	CITATIONS
2471	Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom's first national lockdown. <i>Scientific Reports</i> , 2021, 11, 21484.	1.6	7
2472	ACE2's S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. <i>Advances in Pharmacological and Pharmaceutical Sciences</i> , 2021, 2021, 1-10.	0.7	5
2473	Folding Intermediates, Heterogeneous Native Ensembles and Protein Function. <i>Journal of Molecular Biology</i> , 2021, 433, 167325.	2.0	9
2474	SARS-CoV-2 spike protein: Site-specific breakpoints for the development of COVID-19 vaccines. <i>Journal of King Saud University - Science</i> , 2021, 33, 101648.	1.6	11
2484	Coronavirus and Homo Sapiens. <i>Journal of Cardiac Critical Care TSS</i> , 0, , .	0.0	0
2494	Binding Free Energy of the Novel Coronavirus Spike Protein and the Human ACE2 Receptor. , 2020, , .		1
2495	Activity of Some Novel Chalcone Substituted 9-anilinoacridines against Coronavirus (COVID-19): A Computational Approach. <i>Coronaviruses</i> , 2020, 1, 13-22.	0.2	6
2496	Complicações Neurológicas oriundas da infecção por SARS-CoV-2: uma revisão da literatura.. <i>Revista Neurociencias</i> , 0, 28, 1-14.	0.0	0
2500	Predictive Analysis of Susceptibility of Different Species to SARS-CoV-2 based on ACE2 Receptors. <i>Biomedical and Environmental Sciences</i> , 2020, 33, 877-881.	0.2	1
2501	The Pathogenesis and Treatment of COVID-19: A System Review. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 50-60.	0.2	4
2502	Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawai'i Reveals the Worldwide Emerging P681H Mutation. <i>Hawai'i Journal of Health &amp; Social Welfare</i> , 2021, 80, 52-61.	0.2	25
2504	Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail. <i>American Journal of Cancer Research</i> , 2021, 11, 2278-2290.	1.4	7
2505	Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An approach. <i>Indian Journal of Medical Research</i> , 2021, 153, 132-143.	0.4	0
2506	Rationally Designed Immunogens Enable Immune Focusing Following SARS-CoV-2 Spike Imprinting. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2507	Sulphated polysaccharides from seaweeds as potential entry inhibitors and vaccine adjuvants against SARS-CoV-2 RBD spike protein: a computational approach. <i>Journal of Taibah University for Science</i> , 2021, 15, 649-655.	1.1	3
2508	Single-cell RNA analysis reveals the potential risk of organ-specific cell types vulnerable to SARS-CoV-2 infections. <i>Computers in Biology and Medicine</i> , 2022, 140, 105092.	3.9	73
2509	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
2510	Innovative recombinant protein-based vaccines against SARS-CoV-2. , 2022, , 193-211.		1



#	ARTICLE	IF	CITATIONS
2511	Disulfide Bonds Play a Critical Role in the Structure and Function of the Receptor-binding Domain of the SARS-CoV-2 Spike Antigen. <i>Journal of Molecular Biology</i> , 2022, 434, 167357.	2.0	43
2512	Particulate vaccines against SARS-CoV-2. , 2022, , 153-171.		1
2513	Overview of the immune response against SARS-CoV-2. , 2022, , 95-113.		0
2514	Microsecond simulations and CD spectroscopy reveals the intrinsically disordered nature of SARS-CoV-2 spike-C-terminal cytoplasmic tail (residues 1242â€“1273) in isolation. <i>Virology</i> , 2022, 566, 42-55.	1.1	14
2515	Fundamental aspects of the structural biology of coronaviruses. , 2022, , 31-52.		0
2516	DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic. <i>Pharmacological Research</i> , 2022, 175, 105982.	3.1	18
2517	SARS-CoV-2 vaccines: current trends and prospects of developing plant-derived vaccines. , 2022, , 213-229.		5
2518	Anti-SARS-CoV-1 and â”2 nanobody engineering towards avidity-inspired therapeutics. <i>Nano Today</i> , 2022, 42, 101350.	6.2	16
2519	Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 164, 69-82.	0.9	34
2520	Designing a Multi-epitope Peptide Vaccine Against COVID-19 Variants Utilizing In-silico Tools. <i>Iranian Journal of Medical Microbiology</i> , 2021, 15, 592-605.	0.1	4
2521	Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection. <i>Journal of Virology</i> , 2022, 96, JVI0149221.	1.5	22
2522	The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis. <i>BiolImpacts</i> , 2021, 12, 139-146.	0.7	25
2523	Exposing structural variations in SARS-CoV-2 evolution. <i>Scientific Reports</i> , 2021, 11, 22042.	1.6	6
2525	A Multifunctional Neutralizing Antibodyâ€“Conjugated Nanoparticle Inhibits and Inactivates SARSâ€“CoVâ€“2. <i>Advanced Science</i> , 2022, 9, e2103240.	5.6	16
2526	In silico evaluation of the interaction between ACE2 and SARS-CoV-2 Spike protein in a hyperglycemic environment. <i>Scientific Reports</i> , 2021, 11, 22860.	1.6	13
2527	Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. <i>Journal of Virology</i> , 2022, 96, JVI0162621.	1.5	24
2528	Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6977.	5.8	55
2529	A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display. <i>Microorganisms</i> , 2021, 9, 2414.	1.6	6

#	ARTICLE	IF	CITATIONS
2530	Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 674074.	2.2	20
2531	Predicting the zoonotic capacity of mammals to transmit SARS-CoV-2. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2021, 288, 20211651.	1.2	53
2532	A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. <i>MBio</i> , 2021, , e0293621.	1.8	1
2533	Adaptation, spread and transmission of SARS-CoV-2 in farmed minks and associated humans in the Netherlands. <i>Nature Communications</i> , 2021, 12, 6802.	5.8	81
2534	SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells. <i>Cells</i> , 2021, 10, 3279.	1.8	16
2535	Current Trends in SPR Biosensing of SARS-CoV-2 Entry Inhibitors. <i>Chemosensors</i> , 2021, 9, 330.	1.8	6
2536	Metaviromic identification of discriminative genomic features in SARS-CoV-2 using machine learning. <i>Patterns</i> , 2022, 3, 100407.	3.1	4
2537	Interaction Analysis on the SARS-CoV-2 Spike Protein Receptor Binding Domain Using Visualization of the Interfacial Electrostatic Complementarity. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 11267-11272.	2.1	16
2538	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
2539	Elucidating important structural features for the binding affinity of spike $\hat{\epsilon}$ -SARS-CoV-2 neutralizing antibody complexes. <i>Proteins: Structure, Function and Bioinformatics</i> , 2022, 90, 824-834.	1.5	16
2540	SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12114.	1.8	22
2541	Affinity enhancement of CR3022 binding to RBD; <i>in silico</i> site directed mutagenesis using molecular dynamics simulation approaches. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 81-90.	2.0	3
2542	The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 751778.	2.2	142
2543	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. <i>Viruses</i> , 2021, 13, 2295.	1.5	13
2545	Traditional Uses, Pharmacological Effects, and Molecular Mechanisms of Licorice in Potential Therapy of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 719758.	1.6	14
2546	Fighting SARS-CoV-2 with green seaweed <i>Ulva</i> sp. extract: extraction protocol predetermines crude ulvan extract anti-SARS-CoV-2 inhibition properties in <i>in vitro</i> Vero-E6 cells assay. <i>PeerJ</i> , 2021, 9, e12398.	0.9	8
2547	The glycosylation in SARS-CoV-2 and its receptor ACE2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 396.	7.1	111
2548	Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2. <i>FEBS Open Bio</i> , 2022, 12, 285-294.	1.0	20

#	ARTICLE	IF	CITATIONS
2549	Pre-Existing Oxidative Stress Creates a Docking-Ready Conformation of the SARS-CoV-2 Receptor-Binding Domain. <i>ACS Bio &amp; Med Chem Au</i> , 2022, 2, 84-93.	1.7	11
2550	Treatment Effects of Integrated TCM and Western Medicine Treatment Scheme on COVID-19: A Single-armed Clinical Trial. <i>Clinical Complementary Medicine and Pharmacology</i> , 2021, 1, 100009.	0.9	2
2551	A Comparative Study between Spanish and British SARS-CoV-2 Variants. <i>Current Issues in Molecular Biology</i> , 2021, 43, 2036-2047.	1.0	2
2552	Robust Representation and Efficient Feature Selection Allows for Effective Clustering of SARS-CoV-2 Variants. <i>Algorithms</i> , 2021, 14, 348.	1.2	16
2553	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
2554	COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations. <i>Asia-Pacific Journal of Ophthalmology</i> , 2021, 10, 521-529.	1.3	23
2555	Insights into the conformation changes of SARS-CoV-2 spike receptor-binding domain on graphene. <i>Applied Surface Science</i> , 2021, , 151934.	3.1	11
2556	Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae <i>Chlamydomonas reinhardtii</i> . <i>PLoS ONE</i> , 2021, 16, e0257089.	1.1	20
2557	A colorimetric sandwich-type bioassay for SARS-CoV-2 using a hACE2-based affinity peptide pair. <i>Journal of Hazardous Materials</i> , 2022, 425, 127923.	6.5	19
2558	The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. <i>Clinical Science</i> , 2021, 135, 2667-2689.	1.8	97
2559	Pharmacological management of seizures in patients with COVID-19: a systematic review. <i>AAS Open Research</i> , 0, 4, 29.	1.5	0
2560	Structure-Based Epitope Design: Toward a Greater Antibodyâ€™SARS-CoV-2 RBD Affinity. <i>ACS Omega</i> , 2021, 6, 31469-31476.	1.6	3
2561	Why are some coronavirus variants more infectious?. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	18
2562	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
2565	Identification of potential inhibitors of SARS-CoV-2 S proteinâ€™ACE2 interaction by in silico drug repurposing. <i>F1000Research</i> , 0, 10, 358.	0.8	1
2566	Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection. <i>Journal of Advanced Research</i> , 2022, 36, 201-210.	4.4	57
2568	Understanding the role of nACE2 in neurogenic hypertension among COVID-19 patients. <i>Hypertension Research</i> , 2022, 45, 254-269.	1.5	10
2569	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 778829.	2.2	2

#	ARTICLE	IF	CITATIONS
2570	Comparative genomic analysis reveals varying levels of mammalian adaptation to coronavirus infections. <i>PLoS Computational Biology</i> , 2021, 17, e1009560.	1.5	5
2571	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. <i>MBio</i> , 2021, 12, e0297521.	1.8	24
2572	Comparative structural analyses of selected spike protein-RBD mutations in SARS-CoV-2 lineages. <i>Immunologic Research</i> , 2022, 70, 143-151.	1.3	13
2573	COVID-19 and oral lesions: A review. <i>Journal of Dental Panacea</i> , 2021, 3, 102-105.	0.2	0
2574	Computational identification of potential inhibitory compounds in Indian medicinal and aromatic plant species against major pathogenicity determinants of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 14096-14114.	2.0	4
2575	Common Inflammatory Mechanisms in COVID-19 and Parkinson's Diseases: The Role of Microbiome, Pharmabiotics and Postbiotics in Their Prevention. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6349-6381.	1.6	28
2576	SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. <i>Nature Communications</i> , 2021, 12, 6559.	5.8	75
2577	Site-Specific and Stable Conjugation of the SARS-CoV-2 Receptor-Binding Domain to Liposomes in the Absence of Any Other Adjuvants Elicits Potent Neutralizing Antibodies in BALB/c Mice. <i>Bioconjugate Chemistry</i> , 2021, 32, 2497-2506.	1.8	5
2579	Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. <i>PLoS ONE</i> , 2021, 16, e0260283.	1.1	1
2580	Dynamic, but Not Necessarily Disordered, Human-Virus Interactions Mediated through SLIMs in Viral Proteins. <i>Viruses</i> , 2021, 13, 2369.	1.5	10
2581	Nanodispersions of Polyelectrolytes Based on Humic Substances: Isolation, Physico-Chemical Characterization and Evaluation of Biological Activity. <i>Pharmaceutics</i> , 2021, 13, 1954.	2.0	6
2582	High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. <i>Microbiology Spectrum</i> , 2021, 9, e0096521.	1.2	17
2583	The Analyses of High Infectivity Mechanism of SARS-CoV-2 and Its Variants. <i>Covid</i> , 2021, 1, 666-673.	0.7	2
2584	Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection. <i>Journal of Human Hypertension</i> , 2022, 36, 488-492.	1.0	4
2585	Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 389.	7.1	21
2586	Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking. <i>Journal of Computer-Aided Molecular Design</i> , 2022, 36, 25-37.	1.3	5
2587	Nanometer-resolution in situ structure of the SARS-CoV-2 postfusion spike protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	30
2588	A rapid simple point-of-care assay for the detection of SARS-CoV-2 neutralizing antibodies. <i>Communications Medicine</i> , 2021, 1, .	1.9	23

#	ARTICLE	IF	CITATIONS
2589	Brief on Recent Application of Liposomal Vaccines for Lower Respiratory Tract Viral Infections: From Influenza to COVID-19 Vaccines. <i>Pharmaceuticals</i> , 2021, 14, 1173.	1.7	18
2590	Interaction between Spike Protein of SARS-CoV-2 and Human Virus Receptor ACE2 Using Two-Color Fluorescence Cross-Correlation Spectroscopy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 10697.	1.3	2
2591	Occurrence of a substitution or deletion of SARS-CoV-2 spike amino acid 677 in various lineages in Marseille, France. <i>Virus Genes</i> , 2022, 58, 53-58.	0.7	8
2592	Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421.	5.7	64
2593	Neuroinflammation and Its Impact on the Pathogenesis of COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 745789.	1.2	44
2594	COVID-19 pandemic: Insights into genetic susceptibility to SARS-CoV-2 and host genes implications on virus spread, disease severity and outcomes. <i>Human Antibodies</i> , 2022, 30, 1-14.	0.6	2
2597	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. <i>Translational Research</i> , 2022, 241, 25-40.	2.2	5
2598	E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody. <i>International Immunopharmacology</i> , 2022, 102, 108424.	1.7	31
2600	DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging. <i>EMBO Reports</i> , 2022, 23, e53658.	2.0	24
2601	Epigenetic glycosylation of SARS-CoV-2 impact viral infection through DC&L-SIGN receptors. <i>IScience</i> , 2021, 24, 103426.	1.9	8
2602	Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk. <i>Computational Biology and Chemistry</i> , 2022, 96, 107613.	1.1	7
2603	Analysis of BNT162b2 and CVnCoV elicited sera and of convalescent sera toward SARS-CoV-2 viruses. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, , .	2.7	9
2604	The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression. <i>Biomolecules</i> , 2021, 11, 1812.	1.8	22
2605	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
2606	Tracking the amino acid changes of spike proteins across diverse host species of severe acute respiratory syndrome coronavirus 2. <i>IScience</i> , 2022, 25, 103560.	1.9	5
2607	Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes. <i>Vaccines</i> , 2021, 9, 1419.	2.1	4
2608	Penta-peptide ATN-161 based neutralization mechanism of SARS-CoV-2 spike protein. <i>Biochemistry and Biophysics Reports</i> , 2021, 28, 101170.	0.7	7
2610	Computational screening and biochemical analysis of <i>Pistacia integerrima</i> and <i>Pandanus odorifer</i> plants to find effective inhibitors against Receptor-Binding domain (RBD) of the spike protein of SARS-Cov-2. <i>Arabian Journal of Chemistry</i> , 2022, 15, 103600.	2.3	11

#	ARTICLE	IF	CITATIONS
2611	COVID-19 variants that escape vaccine immunity: Global and Indian context—are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	2
2612	CD147-spike protein interaction in COVID-19: Get the ball rolling with a novel receptor and therapeutic target. <i>Science of the Total Environment</i> , 2022, 808, 152072.	3.9	66
2613	Temporal variations in country-specific mutational profiles of SARS-CoV-2: effect on vaccine efficacy. <i>Future Virology</i> , 2021, 16, 805-819.	0.9	2
2614	Physical activity and COVID-19. The basis for an efficient intervention in times of COVID-19 pandemic. <i>Physiology and Behavior</i> , 2022, 244, 113667.	1.0	62
2616	ACE2 Peptide Fragment Interaction with Different S1 Protein Sites. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 7.	0.9	7
2617	Detection of SARS-CoV-2 in COVID-19 Patient Nasal Swab Samples Using Signal Processing. <i>IEEE Journal on Selected Topics in Signal Processing</i> , 2022, 16, 164-174.	7.3	1
2618	Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach. <i>Indian Journal of Medical Research</i> , 2021, 153, 132.	0.4	10
2619	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0
2620	Targeting mechanism for SARS-CoV-2 <i>in silico</i> : interaction and key groups of TMPRSS2 toward four potential drugs. <i>Nanoscale</i> , 2021, 13, 19218-19237.	2.8	2
2621	Tear antibodies to SARS-CoV-2: implications for transmission. <i>Clinical and Translational Immunology</i> , 2021, 10, e1354.	1.7	15
2622	SARS-CoV-2: Genetic variability, mutations and variants of concern for the global world. <i>Medicinski Podmladak</i> , 2021, 72, 1-7.	0.2	0
2623	EXPRESSION OF ANGIOTENSIN-CONVERTING ENZYME-2 IN LUNG TISSUES IN EXPERIMENTAL BRONCHOPNEUMMONIA. <i>World of Medicine and Biology</i> , 2021, 17, 208.	0.1	1
2625	A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features. <i>Current Research in Structural Biology</i> , 2021, 3, 290-300.	1.1	17
2626	Study of gold nanoparticles™ preparation through ultrasonic spray pyrolysis and lyophilisation for possible use as markers in LFIA tests. <i>Nanotechnology Reviews</i> , 2021, 10, 1978-1992.	2.6	15
2627	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22
2628	Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0260897.	1.1	7
2629	Nicotinic receptors as SARS-CoV-2 spike co-receptors?. <i>Medical Hypotheses</i> , 2022, 158, 110741.	0.8	13
2630	A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and <i>Neisseria meningitidis</i> outer membrane vesicles. <i>RSC Chemical Biology</i> , 2022, 3, 242-249.	2.0	15



#	ARTICLE	IF	CITATIONS
2631	Molecular Aspects of Spike-ACE2 Interaction. Encyclopedia, 2022, 2, 96-108.	2.4	4
2632	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Reports, 2022, 38, 110210.	2.9	96
2633	Fruit Bromelain-Derived Peptide Potentially Restrains the Attachment of SARS-CoV-2 Variants to hACE2: A Pharmacoinformatics Approach. Molecules, 2022, 27, 260.	1.7	21
2634	Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein. Molecular Immunology, 2022, 141, 287-296.	1.0	6
2637	ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2. IScience, 2022, 25, 103670.	1.9	29
2638	Computational modelling of potentially emerging SARS-CoV-2 spike protein RBDs mutations with higher binding affinity towards ACE2: A structural modelling study. Computers in Biology and Medicine, 2022, 141, 105163.	3.9	17
2639	Development and validation of novel kit for quantification of SARS-CoV-2 antibodies on clinical samples. Journal of Virological Methods, 2022, 300, 114423.	1.0	1
2640	A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients. Medical Hypotheses, 2022, 159, 110754.	0.8	5
2641	A structural view of the SARS-CoV-2 virus and its assembly. Current Opinion in Virology, 2022, 52, 123-134.	2.6	42
2642	In silico evidence of beauvericin antiviral activity against SARS-CoV-2. Computers in Biology and Medicine, 2022, 141, 105171.	3.9	9
2643	Scanning the RBD-ACE2 molecular interactions in Omicron variant. Biochemical and Biophysical Research Communications, 2022, 592, 18-23.	1.0	47
2644	Postmortem findings in COVID-19 fatalities: A systematic review of current evidence. Legal Medicine, 2022, 54, 102001.	0.6	18
2645	Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein. Bioorganic Chemistry, 2022, 119, 105574.	2.0	10
2646	A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: Effects on proteolytic cleavage and ACE2 binding. Immunology Letters, 2022, 242, 1-7.	1.1	4
2647	Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor. Journal of King Saud University - Science, 2022, 34, 101773.	1.6	9
2648	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. Gene, 2022, 813, 146113.	1.0	8
2649	Computational investigation reveals that the mutant strains of SARS-CoV2 have differential structural and binding properties. Computer Methods and Programs in Biomedicine, 2022, 215, 106594.	2.6	5
2650	Graphene-based hybrid electrical-electrochemical point-of-care device for serologic COVID-19 diagnosis. Biosensors and Bioelectronics, 2022, 199, 113866.	5.3	18

#	ARTICLE	IF	CITATIONS
2651	Toxicity of spike fragments SARS-CoV-2 S protein for zebrafish: A tool to study its hazardous for human health?. <i>Science of the Total Environment</i> , 2022, 813, 152345.	3.9	19
2652	Potential SARS-CoV-2 Spike Protein-ACE2 Interface Inhibitors: Repurposing FDA-approved Drugs. <i>Journal of Exploratory Research in Pharmacology</i> , 2022, 7, 17-29.	0.2	5
2653	Liver disease in the Era of Coronavirus Disease 19 (COVID-19) pandemic. <i>Annals of Clinical Gastroenterology and Hepatology</i> , 2020, 4, .	0.1	1
2654	Deep learning-assisted pipeline for Virtual Screening of ligand compound databases: Application on inhibiting the entry of SARS-CoV-2 into human cells. , 2020, , .		1
2655	The Possible Protective Effect of Metformin in COVID-19 Infection. <i>Journal of Advances in Medical and Pharmaceutical Sciences</i> , 0, , 1-5.	0.2	0
2657	A SYSTEMATIC REVIEW ON ENHANCED TRANSMISSION AND EFFECTS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2: AN INDIAN SCENARIO. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 18-24.	0.3	1
2659	VII. Clinical Features of COVID-19 from the View Point of Respiratory Physician-point of Crossover between Infectious Diseases and Idiopathic Interstitial Pneumonia-. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 2290-2296.	0.0	0
2660	Active site-specific quantum tunneling of hACE2 receptor to assess its complexing poses with selective bioactive compounds in co-suppressing SARS-CoV-2 influx and subsequent cardiac injury. <i>Journal of Advanced Veterinary and Animal Research</i> , 2021, 8, 1.	0.5	13
2661	The Importance of Glycosylation in COVID-19 Infection. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1325, 239-264.	0.8	9
2662	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2663	SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues. <i>Immune Network</i> , 2021, 21, e38.	1.6	42
2664	Vaccination Management Process and Challenges: Case of Bangladesh. , 2021, 2, 65-78.		1
2665	Single-cell transcriptomics of lung organoids. <i>Organoid</i> , 0, 1, e9.	0.0	0
2666	Improvement of SARS-CoV-2 macromolecule conformation by algorithmic structural prediction. , 2021, , .		0
2667	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 602, 682-688.	13.7	395
2669	Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topicâ€”Experience and Outlines. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13173.	1.2	8
2671	Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 781843.	2.2	42
2672	The role of infectious agents in the development of neurodegenerative diseases. <i>IzvestiĀ Rossijskoj Voenno-medicinskoj Akademii</i> , 2021, 40, 25-32.	0.1	0

#	ARTICLE	IF	CITATIONS
2673	SARS-CoV-2â€™s host cell surface interactions and potential antiviral therapies. <i>Interface Focus</i> , 2022, 12, 20200081.	1.5	4
2674	Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2033-2045.	2.0	6
2675	BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. <i>Nature Cell Biology</i> , 2022, 24, 24-34.	4.6	47
2677	Comprehensive and Integrative Analysis of Two Novel SARS-CoV-2 Entry Associated Proteases CTSB and CTSL in Healthy Individuals and Cancer Patients. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 780751.	2.0	2
2680	Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	28
2681	Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	75
2682	Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	34
2683	Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses. <i>Nucleic Acids Research</i> , 2022, 50, e47-e47.	6.5	8
2684	Epistatic models predict mutable sites in SARS-CoV-2 proteins and epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	54
2685	Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 351-367.	3.0	19
2686	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. <i>RSC Medicinal Chemistry</i> , 2022, 13, 647-675.	1.7	3
2687	SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders. <i>Cell Biology and Toxicology</i> , 2022, 38, 667-678.	2.4	10
2688	Insights Into the Changing Landscape of Coronavirus Disease 2019. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 761521.	1.8	11
2689	Photodynamic Inactivation of Human Coronaviruses. <i>Viruses</i> , 2022, 14, 110.	1.5	18
2690	Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. <i>MBio</i> , 2022, 13, e0290621.	1.8	17
2691	An Updated Review on the Role of Single Nucleotide Polymorphisms in COVID-19 Disease Severity: A Global Aspect. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, 1596-1611.	0.9	2
2692	Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2. <i>Applied and Environmental Microbiology</i> , 2022, 88, aem0230321.	1.4	7
2693	Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo. <i>Nature Microbiology</i> , 2022, 7, 213-223.	5.9	45

#	ARTICLE	IF	CITATIONS
2696	Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 147-172.	2.7	6
2697	Immobilization of the SARS-CoV-2-receptor binding domain onto methacrylate-based monoliths for nano LC at 30 nL min <sup>-1</sup> and application for research of its ligands. <i>Analytical Methods</i> , 2022, 14, 156-164.	1.3	4
2698	SARS-like Coronaviruses in Horseshoe Bats ( <i>Rhinolophus</i> spp.) in Russia, 2020. <i>Viruses</i> , 2022, 14, 113.	1.5	41
2699	Structure- and Interaction- Based Design of Anti-SARS-CoV-2 Aptamers. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	9
2700	The impact of calcitriol and estradiol on the SARS-CoV-2 biological activity: a molecular modeling approach. <i>Scientific Reports</i> , 2022, 12, 717.	1.6	10
2701	Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 3021-3033.	2.8	65
2702	Identification of potent small molecule inhibitors of SARS-CoV-2 entry. <i>SLAS Discovery</i> , 2022, 27, 8-19.	1.4	20
2703	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110368.	2.9	82
2704	Potential Genes Associated with COVID-19 and Comorbidity. <i>International Journal of Medical Sciences</i> , 2022, 19, 402-415.	1.1	26
2705	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
2706	The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 139-147.	1.9	19
2707	The puzzling mutational landscape of the SARS-CoV-2 variant Omicron. <i>Journal of Medical Virology</i> , 2022, 94, 2019-2025.	2.5	63
2710	A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of <i>Thermothelomyces heterothallica</i> induces a functional immune response in mice. <i>Vaccine</i> , 2022, 40, 1162-1169.	1.7	11
2711	Prion-like Domains in Spike Protein of SARS-CoV-2 Differ across Its Variants and Enable Changes in Affinity to ACE2. <i>Microorganisms</i> , 2022, 10, 280.	1.6	25
2713	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 8-19.	2.5	5
2714	Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context. <i>EPMA Journal</i> , 2022, 13, 149-175.	3.3	28
2716	Tracking structural changes of protein residues by two-dimensional correlation surface-enhanced Raman spectroscopy. <i>Food Chemistry</i> , 2022, 382, 132237.	4.2	8
2717	Emergence of SARS-CoV-2 Variants in the World: How Could This Happen?. <i>Life</i> , 2022, 12, 194.	1.1	25

#	ARTICLE	IF	CITATIONS
2718	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. <i>Science</i> , 2022, 375, 449-454.	6.0	108
2720	Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 838.	1.8	15
2723	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
2724	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. <i>Cell Host and Microbe</i> , 2022, 30, 373-387.e7.	5.1	138
2725	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2022, 375, .	6.0	68
2726	Lower Rate of Daily Smokers With Symptomatic COVID-19: A Monocentric Self-Report of Smoking Habit Study. <i>Frontiers in Medicine</i> , 2021, 8, 668995.	1.2	23
2727	Risk of coronavirus disease 2019 (COVID-19) infection on leukemia patients: basic science to clinical aspect â€ž. <i>Journal of Advanced Pharmacy Education and Research</i> , 2022, 12, 38-45.	0.2	7
2729	Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19. <i>Viruses</i> , 2022, 14, 94.	1.5	7
2730	Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2. <i>Tropical Medicine and Health</i> , 2022, 50, 6.	1.0	8
2732	Binding behavior of spike protein and receptor binding domain of the SARS-CoV-2 virus at different environmental conditions. <i>Scientific Reports</i> , 2022, 12, 789.	1.6	5
2733	Allele $\Delta_i$ (rs5186) of <i>at1r</i> is associated with the severity of COVID-19 in the Ukrainian population. <i>Infection, Genetics and Evolution</i> , 2022, 98, 105227.	1.0	10
2734	Structure Based Affinity Maturation and Characterizing of SARS-CoV Antibody CR3022 against SARS-CoV-2 by Computational and Experimental Approaches. <i>Viruses</i> , 2022, 14, 186.	1.5	6
2735	Spatio-temporal dynamics of intra-host variability in SARS-CoV-2 genomes. <i>Nucleic Acids Research</i> , 2022, 50, 1551-1561.	6.5	18
2736	Prospectus of advanced nanomaterials for antiviral properties. <i>Materials Advances</i> , 2022, 3, 2960-2970.	2.6	12
2737	Site Density Functional Theory and Structural Bioinformatics Analysis of the SARS-CoV Spike Protein and hACE2 Complex. <i>Molecules</i> , 2022, 27, 799.	1.7	5
2738	Structural Insights into the Cofactor Role of Heparin/Heparan Sulfate in Binding between the SARS-CoV-2 Spike Protein and Host Angiotensin-Converting Enzyme II. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 656-667.	2.5	8
2739	Peptide epitope-imprinted polymer microarrays for selective protein recognition. Application for SARS-CoV-2 RBD protein. <i>Chemical Science</i> , 2022, 13, 1263-1269.	3.7	28
2741	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788

#	ARTICLE	IF	CITATIONS
2742	Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. <i>Cell</i> , 2022, 185, 860-871.e13.	13.5	310
2743	Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 412-422.	2.5	507
2744	Plastic Antibodies Mimicking the ACE2 Receptor for Selective Binding of SARS-CoV-2 Spike. <i>Advanced Materials Interfaces</i> , 2022, 9, 2101925.	1.9	12
2745	Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. <i>BMC Molecular and Cell Biology</i> , 2022, 23, 2.	1.0	10
2746	Central hubs prediction for bio networks by directed hypergraph - GA with validation to COVID-19 PPI. <i>Pattern Recognition Letters</i> , 2022, 153, 246-253.	2.6	6
2748	Characterization of SARS-CoV-2 isolated from a patient in Iran compared to SARS-CoV-2 different variants. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 1217-1232.	2.0	0
2750	Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115636.	0.8	2
2751	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 835.	1.8	15
2752	Assessing the therapeutic potential of agomelatine, ramelteon, and melatonin against SARS-CoV-2. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 3140-3150.	1.8	8
2753	Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. <i>Frontiers in Medicine</i> , 2021, 8, 793437.	1.2	4
2754	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	2.6	144
2755	Rapid de novo discovery of peptidomimetic affinity reagents for human angiotensin converting enzyme 2. <i>Communications Chemistry</i> , 2022, 5, .	2.0	7
2756	IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity. <i>Journal of Infectious Diseases</i> , 2022, 226, 474-484.	1.9	11
2757	Aptamers as Diagnostic and Therapeutic Solution in SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1412.	1.8	18
2759	Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift. <i>Journal of Medical Virology</i> , 2022, , .	2.5	5
2760	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 230.	1.5	1
2762	SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. <i>Frontiers in Immunology</i> , 2022, 13, 825256.	2.2	54
2763	Structural biology of SARS-CoV-2: open the door for novel therapies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 26.	7.1	139



#	ARTICLE	IF	CITATIONS
2764	Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. <i>Biochemical and Biophysical Research Communications</i> , 2022, 590, 34-41.	1.0	178
2765	Molecular Docking and Dynamics Studies to Explore Effective Inhibitory Peptides Against the Spike Receptor Binding Domain of SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 791642.	1.6	14
2766	Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 799-811.	1.9	10
2767	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
2768	A Multi-Disulfide Receptor-Binding Domain (RBD) of the SARS-CoV-2 Spike Protein Expressed in <i>E. coli</i> Using a SEP-Tag Produces Antisera Interacting with the Mammalian Cell Expressed Spike (S1) Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1703.	1.8	15
2769	Development and Evaluation of Peptidomimetic Compounds against SARS-CoV-2 Spike Protein: An <i>in silico</i> and <i>in vitro</i> Study. <i>Molecular Informatics</i> , 2022, 41, .	1.4	1
2771	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. <i>Angewandte Chemie</i> , 2022, 134, 1797-1802.	1.6	0
2772	Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID-19 and response to treatment. <i>Pharmacology Research and Perspectives</i> , 2022, 10, e00922.	1.1	20
2773	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 221-230.	5.5	78
2774	CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	3.1	12
2775	The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms. <i>Journal of Biological Chemistry</i> , 2022, 298, 101507.	1.6	57
2776	Of mice and human-specific long noncoding RNAs. <i>Mammalian Genome</i> , 2022, 33, 281-292.	1.0	6
2777	Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	19
2778	SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. <i>FEBS Journal</i> , 2022, 289, 4240-4250.	2.2	25
2779	HBD-2 binds SARS-CoV-2 RBD and blocks viral entry: Strategy to combat COVID-19. <i>IScience</i> , 2022, 25, 103856.	1.9	23
2780	Human Milk Oligosaccharides: Potential Applications in COVID-19. <i>Biomedicines</i> , 2022, 10, 346.	1.4	15
2781	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. <i>EBioMedicine</i> , 2022, 76, 103818.	2.7	14
2782	Designed SARS-CoV-2 receptor binding domain variants form stable monomers. <i>Biotechnology Journal</i> , 2022, 17, e2100422.	1.8	8

#	ARTICLE	IF	CITATIONS
2784	Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay. ACS Central Science, 2022, 8, 192-204.	5.3	30
2785	Mutations in the receptor-binding domain of human SARS CoV-2 spike protein increases its affinity to bind human ACE-2 receptor. Journal of Biomolecular Structure and Dynamics, 2023, 41, 2368-2381.	2.0	7
2786	Effect of COVID 19 pneumonia on hyperglycemia: Is it different from non COVID pneumonia?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102407.	1.8	0
2787	Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. Infection, 2022, , 1.	2.3	15
2788	Alzheimer's-like signaling in brains of COVID-19 patients. Alzheimer's and Dementia, 2022, 18, 955-965.	0.4	106
2789	Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics. Gene Reports, 2022, 26, 101537.	0.4	3
2790	The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione. Biochemical and Biophysical Research Communications, 2022, 597, 30-36.	1.0	20
2791	Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. International Immunopharmacology, 2022, 104, 108502.	1.7	30
2792	Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition. European Journal of Medicinal Chemistry, 2022, 231, 114121.	2.6	30
2793	A vaccine built from potential immunogenic pieces derived from the SARS-CoV-2 spike glycoprotein: A computational approximation. Journal of Immunological Methods, 2022, 502, 113216.	0.6	1
2794	Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes. Arabian Journal of Chemistry, 2022, 15, 103631.	2.3	1
2795	501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations. Computational Biology and Chemistry, 2022, 97, 107636.	1.1	1
2796	Zinc associated nanomaterials and their intervention in emerging respiratory viruses: Journey to the field of biomedicine and biomaterials. Coordination Chemistry Reviews, 2022, 457, 214402.	9.5	28
2797	Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. International Immunopharmacology, 2022, 105, 108531.	1.7	1
2798	Detection and discrimination of SARS-CoV-2 spike protein-derived peptides using THz metamaterials. Biosensors and Bioelectronics, 2022, 202, 113981.	5.3	27
2799	ACE2-based capacitance sensor for rapid native SARS-CoV-2 detection in biological fluids and its correlation with real-time PCR. Biosensors and Bioelectronics, 2022, 202, 114021.	5.3	18
2800	Synthetic nanobody-functionalized nanoparticles for accelerated development of rapid, accessible detection of viral antigens. Biosensors and Bioelectronics, 2022, 202, 113971.	5.3	13
2801	'All In One' SARS-CoV-2 variant recognition platform: Machine learning-enabled point of care diagnostics. Biosensors and Bioelectronics: X, 2022, 10, 100105.	0.9	17

#	ARTICLE	IF	CITATIONS
2802	Systems pharmacology-based drug discovery and active mechanism of natural products for coronavirus pneumonia (COVID-19): An example using flavonoids. <i>Computers in Biology and Medicine</i> , 2022, 143, 105241.	3.9	15
2803	Versatile role of ACE2-based biosensors for detection of SARS-CoV-2 variants and neutralizing antibodies. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114034.	5.3	30
2804	Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. <i>Journal of Biosafety and Biosecurity</i> , 2022, 4, 33-37.	1.4	75
2805	Evaluation of Commercial Anti-SARS-CoV-2 Neutralizing Antibody Assays in Seropositive Subjects. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2806	Aspects of the physiochemical properties of SARS-CoV-2 to prevent S-protein receptor binding using Arabic gum. <i>Green Processing and Synthesis</i> , 2022, 11, 150-163.	1.3	1
2807	SARS-CoV-2 Infection Is Associated with Vitamin D Deficiency in Côte d'Ivoire. <i>Advances in Microbiology</i> , 2022, 12, 43-52.	0.3	0
2811	Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. <i>Molecular Diversity</i> , 2022, 26, 3309-3324.	2.1	17
2812	The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate. <i>PLoS ONE</i> , 2022, 17, e0263684.	1.1	6
2813	In Silico Molecular Characterization of Human TMPRSS2 Protease Polymorphic Variants and Associated SARS-CoV-2 Susceptibility. <i>Life</i> , 2022, 12, 231.	1.1	5
2814	The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. <i>Journal of Medical Virology</i> , 2022, 94, 2376-2383.	2.5	322
2816	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 789882.	1.5	20
2817	Electron microscopy overview of SARS-COV2 and its clinical impact. <i>Ultrastructural Pathology</i> , 2022, 46, 1-17.	0.4	3
2818	True or false: what are the factors that influence COVID-19 diagnosis by RT-qPCR?. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 157-167.	1.5	10
2819	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. <i>Viruses</i> , 2022, 14, 370.	1.5	5
2821	Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101710.	1.6	38
2824	Are There Hidden Genes in DNA/RNA Vaccines?. <i>Frontiers in Immunology</i> , 2022, 13, 801915.	2.2	9
2826	Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approach. <i>Molecular Diversity</i> , 2022, 26, 3205-3224.	2.1	11
2827	Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations. <i>Methods</i> , 2022, 203, 498-510.	1.9	16

#	ARTICLE	IF	CITATIONS
2828	Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody. <i>Science</i> , 2022, 375, 1048-1053.	6.0	216
2829	Indigo plant leaf extract inhibits the binding of SARS-CoV-2 spike protein to angiotensin-converting enzyme 2. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 274.	0.8	8
2831	Identification of Potential Antiviral Inhibitors from Hydroxychloroquine and 1,2,4,5-Tetraoxanes Analogues and Investigation of the Mechanism of Action in SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1781.	1.8	11
2833	<i>Escherichia coli</i> recombinant expression of SARS-CoV-2 protein fragments. <i>Microbial Cell Factories</i> , 2022, 21, 21.	1.9	7
2834	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
2835	Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6574-6585.	2.5	9
2836	Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. <i>Molecular Therapy</i> , 2022, 30, 1913-1925.	3.7	21
2837	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
2838	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
2839	A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle. <i>Microbiology Spectrum</i> , 2022, , e0236421.	1.2	0
2840	Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intensive, phase 2 clinical trial. <i>Gut</i> , 2022, 71, 879-888.	6.1	24
2841	From Free Binding Energy Calculations of SARS-CoV-2 Receptor Interactions to Cellular Immune Responses. <i>Medicina (Lithuania)</i> , 2022, 58, 226.	0.8	6
2842	Antioxidant, anti-inflammatory and immunomodulatory roles of vitamins in COVID-19 therapy. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114175.	2.6	41
2843	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 766821.	2.2	15
2848	Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. <i>Journal of Medical Virology</i> , 2022, 94, 1641-1649.	2.5	421
2849	SARS-CoV-2 Omicron variant: Characteristics and prevention. <i>MedComm</i> , 2021, 2, 838-845.	3.1	364
2850	Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. <i>Antiviral Research</i> , 2021, 196, 105197.	1.9	15
2851	Potential of X-ray free-electron lasers for challenging targets in structure-based drug discovery. <i>Drug Discovery Today: Technologies</i> , 2021, 39, 101-110.	4.0	6

#	ARTICLE	IF	CITATIONS
2852	Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. <i>Journal of Genetics and Genomics</i> , 2021, 48, 1111-1121.	1.7	206
2853	Discovery of Bile Acid Derivatives as Potent ACE2 Activators by Virtual Screening and Essential Dynamics. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 196-209.	2.5	15
2854	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 0, , .	13.7	56
2855	Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM. <i>Nature Communications</i> , 2021, 12, 7345.	5.8	58
2856	SARS-CoV-2 spreads through cell-to-cell transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	145
2857	Elucidating the role of N440K mutation in SARS-CoV-2 spike " ACE-2 binding affinity and COVID-19 severity by virtual screening, molecular docking and dynamics approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-18.	2.0	11
2858	The effect of Covid-19 mRNA vaccine on serum anti-M $\beta$ 1/4lllerian hormone levels. <i>Human Reproduction</i> , 2022, 37, 534-541.	0.4	37
2873	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. <i>Science</i> , 2022, 375, 864-868.	6.0	394
2875	Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry. <i>Frontiers in Immunology</i> , 2021, 12, 796855.	2.2	63
2876	Structural Analysis of the SARS-CoV-2 Omicron Variant Proteins. <i>Research</i> , 2021, 2021, 9769586.	2.8	27
2877	Collective residue interactions in trimer complexes of SARS-CoV-2 spike proteins analyzed by fragment molecular orbital method. <i>Applied Physics Express</i> , 2022, 15, 017001.	1.1	7
2878	Host cell entry mediators implicated in the cellular tropism of SARS-CoV-2, the pathophysiology of COVID-19 and the identification of microRNAs that can modulate the expression of these mediators (Review). <i>International Journal of Molecular Medicine</i> , 2021, 49, .	1.8	14
2879	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	2.8	36
2880	Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. <i>ELife</i> , 2021, 10, .	2.8	29
2882	Why are some coronavirus variants more infectious?. <i>Journal of Biosciences</i> , 2021, 46, .	0.5	2
2883	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2021, , eabl6251.	6.0	12
2884	COVID-19 variants that escape vaccine immunity: Global and Indian context-are more vaccines needed?. <i>Journal of Biosciences</i> , 2021, 46, .	0.5	0
2885	Human Challenge Studies with Coronaviruses Old and New. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	0.7	0

#	ARTICLE	IF	CITATIONS
2886	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN) Tj ETQq0 0 0,rgBT /Overlock 10 T	0.1	0
2887	Procuring Covid-19 Vaccine and the Contemporary Geopolitical Paradigm for Bangladesh. <i>Business Ethics and Leadership</i> , 2021, 5, 118-126.	0.5	2
2888	Possible Therapeutic Intervention Strategies for COVID-19 by Manipulating the Cellular Proteostasis Network. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 125-147.	0.8	4
2889	B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies. <i>International Journal of Biological Sciences</i> , 2022, 18, 1844-1851.	2.6	34
2890	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. <i>American Heart Journal Plus</i> , 2022, 13, 100112.	0.3	3
2891	Significance of the RBD mutations in the SARS-CoV-2 omicron: from spike opening to antibody escape and cell attachment. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 9123-9129.	1.3	24
2892	RT-Lamp Assay Combining Multi-Fluorescent Probes for SARS-CoV-2 RNA Detection and Variant Differentiation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2893	Bioinformatic Analysis of SARS-CoV-2 S Protein. <i>Lecture Notes in Electrical Engineering</i> , 2022, , 425-434.	0.3	0
2894	Insights from computational analysis: how does the SARS-CoV-2 Delta (B.1.617.2) variant hijack ACE2 more effectively?. <i>Physical Chemistry Chemical Physics</i> , 2022, , .	1.3	7
2895	Stabilization of the SARS-CoV-2 receptor binding domain by protein core redesign and deep mutational scanning. <i>Protein Engineering, Design and Selection</i> , 2022, 35, .	1.0	8
2896	Silver-Based Bimetallic Metal-Organic Frameworks Nanomaterials for Rapid and Collaborative Sterilization. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2897	Daphnoretin from <i>Carthamus tinctorius</i> as a Potential Inflammatory Inhibitor in COVID-19 by Binding to Toll-like Receptor-4: An in silico Molecular Docking Study. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 220-227.	0.1	1
2898	A Paper-Based Optical Sensor for the Screening of Viruses Through the Cysteine Residues of Their Surface Proteins: The Detection of Coronavirus Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2899	Evaluation of Peppermint Leaf Flavonoids as SARS-CoV-2 Spike Receptor-Binding Domain Attachment Inhibitors to the Human ACE2 Receptor: A Molecular Docking Study. <i>Open Journal of Biophysics</i> , 2022, 12, 132-152.	0.7	3
2901	Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers. <i>Infection and Chemotherapy</i> , 2022, 54, 140.	1.0	4
2902	Energy landscape of the SARS-CoV-2 reveals extensive conformational heterogeneity. <i>Current Research in Structural Biology</i> , 2022, 4, 68-77.	1.1	8
2903	Computer-aided discovery, design, and investigation of COVID-19 therapeutics. <i>Tzu Chi Medical Journal</i> , 2022, .	0.4	3
2904	Origin of the tight binding mode to ACE2 triggered by multi-point mutations in the omicron variant: a dynamic insight. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 8724-8737.	1.3	11



#	ARTICLE	IF	CITATIONS
2905	COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymes. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1254-1263.	1.9	13
2906	SARS-CoV-2 2 <sup>nd</sup> ACE2 binding site. <i>Scientia Sinica Chimica</i> , 2022, , .	0.2	0
2907	Blocking viral infections with lysine-based polymeric nanostructures: a critical review. <i>Biomaterials Science</i> , 2022, 10, 1904-1919.	2.6	6
2909	Effect of SARS-CoV-2 Entry Factors on Myeloid Cancers. <i>Journal of Nippon Medical School</i> , 2022, 89, 95-101.	0.3	1
2910	Intrinsically Disordered Proteins: Perspective on COVID-19 Infection and Drug Discovery. <i>ACS Infectious Diseases</i> , 2022, 8, 422-432.	1.8	13
2911	Stapled peptides as potential inhibitors of SARS-CoV-2 binding to the hACE2 receptor. <i>Journal of Peptide Science</i> , 2022, 28, e3409.	0.8	4
2913	Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. <i>Cell Discovery</i> , 2022, 8, 17.	3.1	23
2914	Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2911-2925.	2.0	0
2915	Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac093.	0.4	3
2917	Factores genéticos del hospedero involucrados en la susceptibilidad y gravedad de la COVID-19.., 2022, 25, 32-38.		0
2918	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. <i>MBio</i> , 2022, 13, e0322721.	1.8	48
2919	Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors. <i>Viruses</i> , 2022, 14, 384.	1.5	10
2920	COVID-19 infection in pregnancy: a review of existing knowledge. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2022, .	0.3	3
2923	Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2022, 13, 796682.	2.2	8
2924	Structural Bases of Zoonotic and Zooanthroponotic Transmission of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 418.	1.5	8
2925	Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts. <i>Frontiers in Immunology</i> , 2022, 13, 820131.	2.2	29
2926	Bat coronaviruses related to SARS-CoV-2 and infectious for human cells. <i>Nature</i> , 2022, 604, 330-336.	13.7	238
2927	<i>In silico</i> and <i>in vitro</i> evaluation of imatinib as an inhibitor for SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3052-3061.	2.0	5

#	ARTICLE	IF	CITATIONS
2928	Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP). <i>Viruses</i> , 2022, 14, 481.	1.5	9
2929	Molecular basis of receptor binding and antibody neutralization of Omicron. <i>Nature</i> , 2022, 604, 546-552.	13.7	135
2930	Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies. <i>Frontiers in Pharmacology</i> , 2022, 13, 835136.	1.6	17
2931	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
2932	The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies. <i>Molecular Therapy</i> , 2022, 30, 1869-1884.	3.7	36
2933	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 57.	7.1	34
2934	SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	2
2935	Investigation of the Role of Healthy and Sick Equids in the COVID-19 Pandemic through Serological and Molecular Testing. <i>Animals</i> , 2022, 12, 614.	1.0	12
2936	A Portable Screening Device for SARS-CoV-2 with Smartphone Readout. , 2022, 16, .		1
2937	Hypertension and COVID-19: Current Evidence and Perspectives. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 115-123.	1.0	44
2939	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. <i>Frontiers in Neurology</i> , 2022, 13, 828616.	1.1	4
2940	Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein. <i>Biomedicines</i> , 2022, 10, 441.	1.4	4
2941	The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. <i>Environmental Science and Pollution Research</i> , 2023, 30, 61430-61454.	2.7	6
2942	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. <i>Nature Communications</i> , 2022, 13, 871.	5.8	107
2943	A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19. <i>Medical Science Monitor</i> , 2022, 28, e936292.	0.5	11
2944	Genomic Diversity of SARS-CoV-2 in Algeria and North African Countries: What We Know So Far and What We Expect?. <i>Microorganisms</i> , 2022, 10, 467.	1.6	7
2945	The pH Effects on SARS-CoV and SARS-CoV-2 Spike Proteins in the Process of Binding to hACE2. <i>Pathogens</i> , 2022, 11, 238.	1.2	20
2946	Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera. <i>Viruses</i> , 2022, 14, 410.	1.5	3

#	ARTICLE	IF	CITATIONS
2947	Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan. <i>Vaccines</i> , 2022, 10, 312.	2.1	3
2950	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
2951	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
2952	Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. <i>Biomolecules</i> , 2022, 12, 298.	1.8	13
2953	mRNA expression of the severe acute respiratory syndrome-coronavirus 2 angiotensin-converting enzyme 2 receptor in the lung tissue of Wistar rats according to age. <i>Veterinary World</i> , 2022, 15, 427-434.	0.7	0
2954	Replication is the key barrier during the dual-host adaptation of mosquito-borne flaviviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2110491119.	3.3	7
2955	Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. <i>Covid</i> , 2022, 2, 407-418.	0.7	3
2956	Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain. <i>Nature Communications</i> , 2022, 13, 1214.	5.8	93
2957	One Health and Cattle Genetic Resources: Mining More than 500 Cattle Genomes to Identify Variants in Candidate Genes Potentially Affecting Coronavirus Infections. <i>Animals</i> , 2022, 12, 838.	1.0	1
2958	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
2959	Structure/Function Analysis of Truncated Amino-Terminal ACE2 Peptide Analogs That Bind to SARS-CoV-2 Spike Glycoprotein. <i>Molecules</i> , 2022, 27, 2070.	1.7	3
2960	Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1. <i>Journal of Virology</i> , 2022, 96, e0024922.	1.5	36
2962	Gender differences in COVID-19. <i>Maturitas</i> , 2022, 161, 72-73.	1.0	2
2964	Safety and Pharmacokinetics of Intranasally Administered Heparin. <i>Pharmaceutical Research</i> , 2022, 39, 541-551.	1.7	3
2965	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16
2966	COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond. <i>Biology</i> , 2022, 11, 520.	1.3	8
2967	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	2.3	23
2968	Cytoplasmic domain and enzymatic activity of ACE2 are not required for PI4KB dependent endocytosis entry of SARS-CoV-2 into host cells. <i>Virologica Sinica</i> , 2022, 37, 380-389.	1.2	10

#	ARTICLE	IF	CITATIONS
2969	Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. <i>Scientific Reports</i> , 2022, 12, 4150.	1.6	9
2971	Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2. <i>Archiv Der Pharmazie</i> , 2022, 355, e2100360.	2.1	5
2972	Hidden Relationships between N-Glycosylation and Disulfide Bonds in Individual Proteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3742.	1.8	2
2974	The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines. <i>Health Policy and Technology</i> , 2022, 11, 100619.	1.3	7
2976	Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain. <i>Journal of Virology</i> , 2022, 96, e0025022.	1.5	10
2980	Recombinant subunits of SARS-CoV-2 spike protein as vaccine candidates to elicit neutralizing antibodies. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24328.	0.9	2
2982	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2122954119.	3.3	57
2983	Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape. <i>MBio</i> , 2022, 13, e0013522.	1.8	35
2984	Computational studies suggest compounds restoring function of p53 cancer mutants can bind SARS-CoV-2 spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, , 1-14.	2.0	0
2985	Identification of inhibitors for the S1-ACE2 interaction of the SARS-CoV-2 using magnetically modulated biosensors. , 2022, , .		0
2988	Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms. <i>Journal of Clinical Medicine</i> , 2022, 11, 1564.	1.0	13
2989	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. <i>EBioMedicine</i> , 2022, 77, 103893.	2.7	48
2990	Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell entry process, and cytokine storm in COVID-19. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 964-986.	1.2	8
2991	Exploring the Potentials of Phytochemicals for Targeting Coronavirus. <i>Natural Products Journal</i> , 2022, 12, .	0.1	0
2992	Evaluation of Spike Protein Epitopes by Assessing the Dynamics of Humoral Immune Responses in Moderate COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 770982.	2.2	4
2993	Is strain echocardiography a more sensitive indicator of myocardial involvement in patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2?. <i>Cardiology in the Young</i> , 2022, 32, 1657-1667.	0.4	7
2995	A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114397119.	3.3	38
2996	Fractionation of sulfated galactan from the red alga <i>Botryocladia occidentalis</i> separates its anticoagulant and anti-SARS-CoV-2 properties. <i>Journal of Biological Chemistry</i> , 2022, 298, 101856.	1.6	13

#	ARTICLE	IF	CITATIONS
2997	Numerical approach to design the graphene-based multilayered surface plasmon resonance biosensor for the rapid detection of the novel coronavirus. , 2022, 1, 494.		10
2998	HIV and SARS-CoV-2 biochemical interactions may not explain clinical outcomes among adults hospitalized with COVID-19 co-infected with HIV: authorsâ€™ reply. Aids, 2022, 36, 616-617.	1.0	0
2999	Antibody escape and global spread of SARS-CoV-2 lineage A.27. Nature Communications, 2022, 13, 1152.	5.8	20
3000	Structures of a deltacoronavirus spike protein bound to porcine and human receptors. Nature Communications, 2022, 13, 1467.	5.8	24
3001	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nature Communications, 2022, 13, 1638.	5.8	11
3002	Cannabidiol and SARS-CoV-2 Infection. Frontiers in Immunology, 2022, 13, 870787.	2.2	6
3004	Reduced levels of pulmonary surfactant in COVID-19 ARDS. Scientific Reports, 2022, 12, 4040.	1.6	20
3005	Use of Circular Dichroism in the characterization of the fusion protein SARS-CoV-2â€™s protein (RBD)-hFc. Pure and Applied Chemistry, 2022, 94, 829-838.	0.9	0
3006	CEBIT screening for inhibitors of the interaction between SARS-CoV-2 spike and ACE2. Fundamental Research, 2022, 2, 562-569.	1.6	2
3007	Omicron Variant of SARS-CoV-2 Virus: In Silico Evaluation of the Possible Impact on People Affected by Diabetes Mellitus. Frontiers in Endocrinology, 2022, 13, 847993.	1.5	8
3008	The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines. Mini-Reviews in Medicinal Chemistry, 2022, 22, 2166-2185.	1.1	3
3009	Antigenâ€™Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. Frontiers in Molecular Biosciences, 2022, 9, 797132.	1.6	3
3010	Host Cell Glycocalyx Remodeling Reveals SARS-CoV-2 Spike Protein Glycomic Binding Sites. Frontiers in Molecular Biosciences, 2022, 9, 799703.	1.6	11
3011	SARS-CoV-2 Spike Glycoprotein and ACE2 Interaction Reveals Modulation of Viral Entry in Wild and Domestic Animals. Frontiers in Medicine, 2021, 8, 775572.	1.2	9
3012	Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q. 3 Biotech, 2022, 12, 87.	1.1	5
3013	COVID-19 Outcomes and Liver Disease. , 0, , .		0
3014	Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions. Pharmaceuticals, 2022, 15, 377.	1.7	7
3015	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science, 2022, 376, eabn8897.	6.0	119

#	ARTICLE	IF	CITATIONS
3016	Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. <i>PLoS ONE</i> , 2022, 17, e0261045.	1.1	70
3017	Tuftsins: A Natural Molecule Against SARS-CoV-2 Infection. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 859162.	1.6	5
3018	Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike. <i>ELife</i> , 2022, 11, .	2.8	45
3020	Graphene-metasurface-based biosensor for SARS-CoV-2 detection. , 2022, , .		0
3021	A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1293-1307.	3.0	26
3022	Interaction Analysis of the Spike Protein of Delta and Omicron Variants of SARS-CoV-2 with hACE2 and Eight Monoclonal Antibodies Using the Fragment Molecular Orbital Method. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1771-1782.	2.5	15
3023	The Finding of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) in a Wild Eurasian River Otter ( <i>Lutra lutra</i> ) Highlights the Need for Viral Surveillance in Wild Mustelids. <i>Frontiers in Veterinary Science</i> , 2022, 9, 826991.	0.9	29
3024	Experimental and natural infections of severe acute respiratory syndrome-related coronavirus 2 in pets and wild and farm animals. <i>Veterinary World</i> , 2022, 15, 565-589.	0.7	12
3025	Mild COVID-19 imprints a long-term inflammatory eicosanoid- and chemokine memory in monocyte-derived macrophages. <i>Mucosal Immunology</i> , 2022, 15, 515-524.	2.7	37
3026	Metal-based complexes against SARS-CoV-2. <i>BioMetals</i> , 2022, 35, 639-652.	1.8	8
3027	COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	7
3028	A 336-nucleotide in-frame deletion in ORF7a gene of SARS-CoV-2 identified in genomic surveillance by next-generation sequencing. <i>Journal of Clinical Virology</i> , 2022, 148, 105105.	1.6	1
3029	Evaluation of Natural Peptides to Prevent and Reduce the Novel SARS-CoV-2 Infection. <i>Journal of Food Quality</i> , 2022, 2022, 1-13.	1.4	3
3030	The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research. <i>Frontiers in Pharmacology</i> , 2022, 13, 744439.	1.6	12
3032	Investigating underlying human immunity genes, implicated diseases and their relationship to COVID-19. <i>Personalized Medicine</i> , 2022, , .	0.8	2
3033	Mutations of Omicron Variant at the Interface of the Receptor Domain Motif and Human Angiotensin-Converting Enzyme-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2870.	1.8	18
3034	Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity. <i>Journal of Virology</i> , 2022, 96, e0012822.	1.5	64
3036	Histones released by NETosis enhance the infectivity of SARS-CoV-2 by bridging the spike protein subunit 2 and sialic acid on host cells. , 2022, 19, 577-587.		22



#	ARTICLE	IF	CITATIONS
3037	Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. <i>Future Microbiology</i> , 2022, 17, 377-391.	1.0	14
3038	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	1.5	15
3039	Unbinding of hACE2 and inhibitors from the receptor binding domain of SARS-CoV-2 spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 3245-3264.	2.0	2
3040	Transmission of SARS-CoV-2 delta variant (AY.127) from pet hamsters to humans, leading to onward human-to-human transmission: a case study. <i>Lancet, The</i> , 2022, 399, 1070-1078.	6.3	140
3041	Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern. <i>Life Science Alliance</i> , 2022, 5, e202101322.	1.3	3
3042	Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4590-4599.	2.9	15
3043	Molecular Virology of SARS-CoV-2 and Related Coronaviruses. <i>Microbiology and Molecular Biology Reviews</i> , 2022, 86, e0002621.	2.9	22
3044	Epicardial adipose tissue in contemporary cardiology. <i>Nature Reviews Cardiology</i> , 2022, 19, 593-606.	6.1	160
3045	Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. <i>Microbiology Spectrum</i> , 2022, 10, e0181421.	1.2	9
3046	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 516.	2.1	2
3047	Improved Binding Affinity of Omicron's Spike Protein for the Human Angiotensin-Converting Enzyme 2 Receptor Is the Key behind Its Increased Virulence. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3409.	1.8	34
3048	<i>In silico</i> design of ACE2 mutants for competitive binding of SARS-CoV-2 receptor binding domain with hACE2. <i>ChemistrySelect</i> , 2022, .	0.7	0
3050	Prolonged shedding of infectious viruses with haplotype switches of SARS-CoV-2 in an immunocompromised patient. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1001-1004.	0.8	6
3052	Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization. <i>Biochemistry (Moscow)</i> , 2022, 87, 319-330.	0.7	2
3053	EK1 with dual Q1004E/N1006I mutation: a promising fusion inhibitor for the HR1 domain of SARS-CoV-2. <i>Journal of Infection</i> , 2022, 84, 579-613.	1.7	2
3054	Mutational scanning of spike RBD protein for enhanced ACE2 affinity emerging Southeast Asia in the late transmission phase. <i>Scientific Reports</i> , 2022, 12, 5896.	1.6	3
3055	Fighting SARS-CoV-2 with structural biology methods. <i>Nature Methods</i> , 2022, 19, 381-383.	9.0	3
3056	<i>In silico</i> investigations of heparin binding to SARS-CoV-2 variants with a focus at the RBD/ACE2 interface. <i>Process Biochemistry</i> , 2022, 115, 70-79.	1.8	4

#	ARTICLE	IF	CITATIONS
3057	The use of standardized Brazilian green propolis extract (EPP-AF) as an adjunct treatment for hospitalized COVID-19 patients (BeeCovid2): a structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, 255.	0.7	3
3058	Online Hydrophilic Interaction Chromatography (HILIC) Enhanced Top-Down Mass Spectrometry Characterization of the SARS-CoV-2 Spike Receptor-Binding Domain. <i>Analytical Chemistry</i> , 2022, 94, 5909-5917.	3.2	15
3059	Isotyping and quantitation of the humoral immune response to SARS-CoV-2. <i>Experimental Biology and Medicine</i> , 2022, 247, 1055-1060.	1.1	0
3060	A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 114.	7.1	17
3061	A novel plant lectin, NTL-125, interferes with SARS-CoV-2 interaction with hACE2. <i>Virus Research</i> , 2022, 315, 198768.	1.1	5
3062	Factors affecting the content of Ig G-antibodies to S-protein SARS-CoV-2 in the blood of convalescents after new coronaviral infection (COVID-19). <i>Meditinskiy Sovet</i> , 2022, , 51-65.	0.1	5
3063	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design. <i>Reviews in Medical Virology</i> , 2022, 32, e2347.	3.9	7
3064	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
3065	Molecular Dynamics and MM-PBSA Analysis of the SARS-CoV-2 Gamma Variant in Complex with the hACE-2 Receptor. <i>Molecules</i> , 2022, 27, 2370.	1.7	10
3066	Kappa-RBD produced by glycoengineered <i>Pichia pastoris</i> elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants. <i>Virology</i> , 2022, 569, 56-63.	1.1	6
3067	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. <i>Antiviral Research</i> , 2022, 200, 105290.	1.9	3
3068	Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4050.	1.8	17
3069	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	1.0	21
3070	Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 1067-1082.	2.0	23
3072	Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern. <i>MedComm</i> , 2022, 3, e129.	3.1	3
3073	Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2091-2111.	1.9	18
3075	ABO blood groups and the risk of SARS-CoV-2 infection. <i>Protoplasma</i> , 2022, 259, 1381-1395.	1.0	5
3076	Vitamin D and its Possible Relationship to Neuroprotection in COVID-19: Evidence in the Literature. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 1346-1368.	1.0	4

#	ARTICLE	IF	CITATIONS
3077	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. <i>MAbs</i> , 2022, 14, 2057832.	2.6	7
3078	Interaction of surface glycoprotein of SARS-CoV-2 variants of concern with potential drug candidates: A molecular docking study. <i>F1000Research</i> , 0, 11, 400.	0.8	1
3079	Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein. <i>Biological Chemistry</i> , 2022, 403, 615-624.	1.2	2
3080	Mechanistic Origin of Different Binding Affinities of SARS-CoV and SARS-CoV-2 Spike RBDs to Human ACE2. <i>Cells</i> , 2022, 11, 1274.	1.8	8
3081	Contribution of CD4+ T cell mediated inflammation to diarrhoea in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, , .	1.5	4
3082	Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic. <i>Antibiotics</i> , 2022, 11, 475.	1.5	10
3083	Synthesis, vibrational spectroscopic investigation, molecular docking, antibacterial and antimicrobial studies of a new anthraquinone derivative compound. <i>Spectroscopy Letters</i> , 2022, 55, 259-277.	0.5	4
3084	Is heparan sulfate a target for inhibition of RNA virus infection?. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C605-C613.	2.1	9
3085	COVID-19-related Conjunctivitis Review: Clinical Features and Management. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 778-784.	1.0	7
3086	The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMIRNATY vaccine (Pfizer/BioNTech). <i>Scientific Reports</i> , 2022, 12, 5999.	1.6	3
3087	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
3088	Mind the feline coronavirus: Comparison with SARS-CoV-2. <i>Gene</i> , 2022, 825, 146443.	1.0	7
3089	Application of the SARS-CoV-2-S1 ACE-2 receptor interaction as the basis of the fully automated assay to detect neutralizing SARS-CoV-2-S1 antibodies in blood samples. <i>Journal of Immunological Methods</i> , 2022, 504, 113258.	0.6	2
3090	Can pulmonary RNA delivery improve our pandemic preparedness?. <i>Journal of Controlled Release</i> , 2022, 345, 549-556.	4.8	5
3091	Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid. <i>Computers in Biology and Medicine</i> , 2022, 144, 105367.	3.9	21
3092	Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 341-359.	2.0	27
3093	Sequence determinants of human-cell entry identified in ACE2-independent bat sarbecoviruses: A combined laboratory and computational network science approach. <i>EBioMedicine</i> , 2022, 79, 103990.	2.7	16
3094	Structural insights revealed by crystal structure of B38-CAP, an isoenzyme of carboxypeptidase ACE2, the receptor of SARS-CoV-2. <i>Biochemical and Biophysical Research Communications</i> , 2022, 606, 17-22.	1.0	0

#	ARTICLE	IF	CITATIONS
3095	Vibrational spectroscopic characterization and structural investigations of Cepharanthine, a natural alkaloid. <i>Journal of Molecular Structure</i> , 2022, 1258, 132693.	1.8	25
3096	Addition of arginine hydrochloride and proline to the culture medium enhances recombinant protein expression in <i>Brevibacillus choshinensis</i> : The case of RBD of SARS-CoV-2 spike protein and its antibody. <i>Protein Expression and Purification</i> , 2022, 194, 106075.	0.6	5
3097	Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19. <i>Computers in Biology and Medicine</i> , 2022, 145, 105468.	3.9	34
3098	A computational protein design protocol for optimization of the SARS-CoV-2 receptor-binding-motif affinity for human ACE2. <i>STAR Protocols</i> , 2022, 3, 101254.	0.5	0
3099	Design and various in silico studies of the novel curcumin derivatives as potential candidates against COVID-19-associated main enzymes. <i>Computational Biology and Chemistry</i> , 2022, 98, 107657.	1.1	9
3100	Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection. <i>Talanta</i> , 2022, 243, 123393.	2.9	19
3101	Prospects of NIR fluorescent nanosensors for green detection of SARS-CoV-2. <i>Sensors and Actuators B: Chemical</i> , 2022, 362, 131764.	4.0	11
3102	Flavonoids of <i>Zinnia elegans</i> : Chemical profile and, in vitro antioxidant and in silico anti-COVID-19 activities. <i>South African Journal of Botany</i> , 2022, 147, 576-585.	1.2	4
3103	Synthesis, spectroscopic characterization of novel phthalimides derivatives bearing a 1,2,3-triazole unit and examination as potential SARS-CoV-2 inhibitors via in silico studies. <i>Journal of Molecular Structure</i> , 2022, 1261, 132915.	1.8	8
3104	SARS-CoV-2 gained a novel spike protein S1 N-Terminal Domain (S1-NTD). <i>Environmental Research</i> , 2022, 211, 113047.	3.7	7
3105	FRET-based hACE2 receptor mimic peptide conjugated nanoprobe for simple detection of SARS-CoV-2. <i>Chemical Engineering Journal</i> , 2022, 442, 136143.	6.6	12
3106	GlycoGrip: Cell Surface-Inspired Universal Sensor for Betacoronaviruses. <i>ACS Central Science</i> , 2022, 8, 22-42.	5.3	31
3107	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <i>The Open Covid Journal</i> , 2021, 1, 216-234.	0.4	1
3108	Computational Electrostatics Predict Variations in SARS-CoV-2 Spike and Human ACE2 Interactions. , 2021, , .		0
3110	Detection and Quantification of SARS-CoV-2 Receptor Binding Domain Neutralization by a Sensitive Competitive ELISA Assay. <i>Vaccines</i> , 2021, 9, 1493.	2.1	5
3111	Nonmuscle myosin heavy chain IIA facilitates SARS-CoV-2 infection in human pulmonary cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	25
3113	Histologic pulmonary lesions of SARS-CoV-2 in 4 nonhuman primate species: An institutional comparative review. <i>Veterinary Pathology</i> , 2022, 59, 673-680.	0.8	19
3115	A proposed workflow for proactive virus surveillance and prediction of variants for vaccine design. <i>PLoS Computational Biology</i> , 2021, 17, e1009624.	1.5	2

#	ARTICLE	IF	CITATIONS
3116	Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	9
3118	COMPARATIVE ANALYSIS OF HUMAN AND LIVESTOCK SARS-CoV-2 RECEPTORS FOR SARS-COV-2. <i>Animal Breeding and Genetics</i> , 0, 62, 120-129.	0.0	0
3121	RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor. <i>Viruses</i> , 2022, 14, 1.	1.5	23
3122	Antigenic characterization of influenza and SARS-CoV-2 viruses. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2841-2881.	1.9	11
3124	Potential COVID-19 therapeutic approaches targeting angiotensin-converting enzyme 2; An updated review. <i>Reviews in Medical Virology</i> , 2022, 32, e2321.	3.9	16
3126	Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2. <i>Covid</i> , 2021, 1, 757-774.	0.7	7
3128	How Distinct Structural Flexibility within SARS-CoV-2 Spike Protein Reveals Potential Therapeutic Targets. , 2021, , .		3
3129	Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen. <i>ACS Omega</i> , 2021, 6, 35657-35666.	1.6	27
3130	Angiotensin-Converting Enzyme 2 (ACE2) As a Novel Biorecognition Element in A Cell-Based Biosensor for the Ultra-Rapid, Ultra-Sensitive Detection of the SARS-CoV-2 S1 Spike Protein Antigen. <i>Chemosensors</i> , 2021, 9, 341.	1.8	6
3132	$\text{I}^{\text{2}}$ -Catalyzed Carbonylation of $\alpha$ -Methylene Ketones to Synthesize 1,2-Diaryl Diketones and Antiviral Quinoxalines in One Pot. <i>ACS Omega</i> , 2022, 7, 1380-1394.	1.6	7
3133	In Silico Study for Similar FDA Approved Drugs as Inhibitors of SARS-CoV-2 Spike and the Host Receptor Proteins. <i>Journal of Molecular Docking</i> , 2021, 1, 49-58.	0.0	1
3135	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
3136	Insights into the Binding of Receptor-Binding Domain (RBD) of SARS-CoV-2 Wild Type and B.1.620 Variant with hACE2 Using Molecular Docking and Simulation Approaches. <i>Biology</i> , 2021, 10, 1310.	1.3	5
3137	Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2. <i>ACS Omega</i> , 2022, 7, 3203-3211.	1.6	21
3140	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020–March 2021) Using a Statistical Learning Strategy. <i>Viruses</i> , 2022, 14, 9.	1.5	10
3141	SARS-CoV-2 spike engagement of ACE2 primes S2' site cleavage and fusion initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	60
3142	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	1.6	44
3143	In Silico Anti-Inflammation Prediction of Glycyrrhiza Extracts Against Covid-19. <i>Journal of Molecular Docking</i> , 2021, 1, 84-90.	0.0	0

#	ARTICLE	IF	CITATIONS
3144	Assessing Differential Binding of Aggregation-Induced Emission-Based Luminogens to Host Interacting Surface Proteins of SARS-CoV-2 and Influenza Virus – An in silico Approach. <i>Frontiers in Microbiology</i> , 2021, 12, 766351.	1.5	2
3145	SARS-CoV-2 Infection and Pancreatic Î² Cell Failure. <i>Biology</i> , 2022, 11, 22.	1.3	15
3149	Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design. <i>Pathogens</i> , 2021, 10, 1599.	1.2	14
3150	Biosensor-Enabled Deconvolution of the Avidity-Induced Affinity Enhancement for the SARS-CoV-2 Spike Protein and ACE2 Interaction. <i>Analytical Chemistry</i> , 2022, 94, 1187-1194.	3.2	9
3152	Rescuing the Host Immune System by Targeting the Immune Evasion Complex ORF8-IRF3 in SARS-CoV-2 Infection with Natural Products Using Molecular Modeling Approaches. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 112.	1.2	5
3153	Kobalt(II) 4-Floro- ve 4-Bromobenzoat Nikotinamid Komplekslerinin Hirshfeld Yâ¼zey Analizi, EtkileÅŸim Enerjisi HesaplamalarÅ± ve KoronavirÅ¼s Spike Proteinini ile EtkileÅŸimlerinin MolekÅ¼ler Docking ÅŸalÅ±ÅŸmalarÅ± ile Å°ncelenmesi. <i>Caucasian Journal of Science</i> , 0, , .		0
3154	Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. <i>Frontiers in Immunology</i> , 2021, 12, 793191.	2.2	16
3155	Protein-Based Nanoparticle Vaccines for SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13445.	1.8	12
3156	High-Yield Production of Receptor Binding Domain of SARS-CoV-2 Linked to Bacterial Flagellin in Plants Using Self-Replicating Viral Vector pEff. <i>Plants</i> , 2021, 10, 2682.	1.6	10
3158	Cardiac manifestation of corona virus disease 2019: a preliminary report. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 11-14.	0.2	1
3159	An Integrated Platform for Serological Detection and Vaccination of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 771011.	2.2	6
3161	Effect of Cysteine Oxidation in SARS-CoV-2 Receptor-Binding Domain on Its Interaction with Two Cell Receptors: Insights from Atomistic Simulations. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 129-141.	2.5	9
3162	Epidemiology of COVID-19: An updated review. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 82.	0.4	12
3164	A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues. , 2022, 19, 647-649.		4
3165	Molecular binding studies of anthocyanins with multiple antiviral activities against SARS-CoV-2. <i>Bulletin of the National Research Centre</i> , 2022, 46, 102.	0.7	13
3167	Mutational Effect of Some Major COVID-19 Variants on Binding of the S Protein to ACE2. <i>Biomolecules</i> , 2022, 12, 572.	1.8	8
3168	Immunoinformatics approach of epitope prediction for SARS-CoV-2. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 60.	1.5	3
3169	Glycosylation of viral proteins: Implication in virus – host interaction and virulence. <i>Virulence</i> , 2022, 13, 670-683.	1.8	30



#	ARTICLE	IF	CITATIONS
3171	Amomum tsao-ko essential oil, a novel anti-COVID-19 Omicron spike protein natural products: A computational study. <i>Arabian Journal of Chemistry</i> , 2022, 15, 103916.	2.3	4
3173	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 797918.	2.2	1
3174	Docking Analysis of Some Bioactive Compounds from Traditional Plants against SARS-CoV-2 Target Proteins. <i>Molecules</i> , 2022, 27, 2662.	1.7	6
3175	Outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 B.1.620 Lineage in the General Hospital of Jeju Island, Republic of Korea. <i>Frontiers in Microbiology</i> , 2022, 13, 860535.	1.5	1
3176	Bayesian Context Trees: Modelling and Exact Inference for Discrete Time Series. <i>Journal of the Royal Statistical Society Series B: Statistical Methodology</i> , 2022, 84, 1287-1323.	1.1	12
3177	COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response. <i>Biochem</i> , 2022, 2, 115-144.	0.5	1
3178	Peptide-Based Vaccines and Therapeutics for COVID-19. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 94.	0.9	15
3179	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
3180	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
3181	Computational design of stapled peptide inhibitor against SARS-CoV-2 receptor binding domain. <i>Peptide Science</i> , 2022, 114, e24267.	1.0	8
3183	Pathology of COVID-19. <i>Russian Journal of Forensic Medicine</i> , 2022, 8, 41-50.	0.0	0
3184	Advances in the Development of SARS-CoV-2 Mpro Inhibitors. <i>Molecules</i> , 2022, 27, 2523.	1.7	27
3185	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. <i>Trends in Molecular Medicine</i> , 2022, 28, 542-554.	3.5	104
3186	Nanoplasmonic biosensor for rapid detection of multiple viral variants in human serum. <i>Sensors and Actuators B: Chemical</i> , 2022, 365, 131906.	4.0	32
3187	A magnetic bead immunoassay to detect high affinity human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in <i>Escherichia coli</i> . <i>Brazilian Journal of Microbiology</i> , 2022, , 1.	0.8	3
3188	Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination. <i>Circulation Research</i> , 2022, 130, 1187-1203.	2.0	20
3189	Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems. <i>Pharmaceutics</i> , 2022, 14, 856.	2.0	4
3191	Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2022, 209, 1379-1388.	3.6	3

#	ARTICLE	IF	CITATIONS
3192	Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction. <i>Cell Research</i> , 2022, 32, 593-595.	5.7	55
3193	SARS-CoV-2 Employ BSG/CD147 and ACE2 Receptors to Directly Infect Human Induced Pluripotent Stem Cell-Derived Kidney Podocytes. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 855340.	1.8	23
3194	ACE2, BOAT1, and SARS-CoV-2 spike protein: Structural and functional implications. <i>Current Opinion in Structural Biology</i> , 2022, 74, 102388.	2.6	10
3195	COVID-19 Vaccines: Current and Future Perspectives. <i>Vaccines</i> , 2022, 10, 608.	2.1	26
3196	Chromatographic characterization of the fusion protein SARS-CoV-2 S protein (RBD)-hFc. <i>ChemistrySelect</i> , 2022, .	0.7	0
3197	Insect cell expression and purification of recombinant SARS-CoV-2 spike proteins that demonstrate ACE2 binding. <i>Protein Science</i> , 2022, 31, e4300.	3.1	5
3199	Repurposing of Four Drugs as Anti-SARS-CoV-2 Agents and Their Interactions with Protein Targets. <i>Scientia Pharmaceutica</i> , 2022, 90, 24.	0.7	7
3200	Rapid evolution of SARS-CoV-2 challenges human defenses. <i>Scientific Reports</i> , 2022, 12, 6457.	1.6	18
3201	Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4341.	1.8	11
3202	Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA. <i>Human Antibodies</i> , 2022, 30, 105-115.	0.6	5
3203	A novel structure-based approach for identification of vertebrate susceptibility to SARS-CoV-2: Implications for future surveillance programmes. <i>Environmental Research</i> , 2022, 212, 113303.	3.7	6
3204	The Impact of COVID-19 in Bone Metabolism: Basic and Clinical Aspects. <i>Hormone and Metabolic Research</i> , 2022, 54, 540-548.	0.7	4
3205	SARS-CoV-2 aerosol transmission and detection. , 2022, 1, 3-10.		11
3207	SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response. <i>Science Signaling</i> , 2022, 15, eabg8744.	1.6	54
3208	Molecular insights into the differential dynamics of SARS-CoV-2 variants of concern. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 114, 108194.	1.3	21
3235	Prevalence of oral lesions in COVID-19 Egyptian patients. <i>Journal of International Society of Preventive and Community Dentistry</i> , 2021, 11, 712.	0.4	4
3236	Probing the competitive inhibitor efficacy of frog-skin alpha helical AMPs identified against ACE2 binding to SARS-CoV-2 S1 spike protein as therapeutic scaffold to prevent COVID-19. <i>Journal of Molecular Modeling</i> , 2022, 28, 128.	0.8	4
3237	Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. <i>International Journal of Biological Macromolecules</i> , 2022, 209, 1359-1367.	3.6	3

#	ARTICLE	IF	CITATIONS
3238	Pose Classification Using Three-Dimensional Atomic Structure-Based Neural Networks Applied to Ion Channel Ligand Docking. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2301-2315.	2.5	5
3239	Smart Mushroom-Inspired Imprintable and Lightly Detachable (MILD) Microneedle Patterns for Effective COVID-19 Vaccination and Decentralized Information Storage. <i>ACS Nano</i> , 2022, 16, 7512-7524.	7.3	19
3240	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern. <i>Science Immunology</i> , 2022, 7, eabp9312.	5.6	35
3243	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
3244	Anti-Fungal Drug Anidulafungin Inhibits SARS-CoV-2 Spike-Induced Syncytia Formation by Targeting ACE2-Spike Protein Interaction. <i>Frontiers in Genetics</i> , 2022, 13, 866474.	1.1	13
3247	Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF.. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 529-536.	1.0	0
3248	Potential effects of COVID-19 on reproductive health: a mini review.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13321-13327.	0.0	0
3249	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2042-2056.	1.9	8
3250	Autophagy and evasion of the immune system by SARS-CoV-2. Structural features of the non-structural protein 6 from wild type and Omicron viral strains interacting with a model lipid bilayer. <i>Chemical Science</i> , 2022, 13, 6098-6105.	3.7	11
3251	Antibody Persistence after Primary Sars-Cov-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3252	Broadly neutralizing antibodies against SARS-CoV-2 variants. , 2022, 1, 20220005.		3
3253	Presence of SARS-CoV-2 in peritoneal fluid and its significance in clinical course: A review analysis. <i>Ankara EÄŸitim Ve AraÄŸtÄ±rma Hastanesi TÄ±p Dergisi</i> , 0, , .	0.1	0
3254	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
3255	The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice. <i>Viruses</i> , 2022, 14, 854.	1.5	5
3257	Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 387-394.	1.5	29
3258	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
3259	Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. <i>Frontiers in Immunology</i> , 2022, 13, 856033.	2.2	5
3260	Neutralization heterogeneity of circulating SARS-CoV-2 variants to sera elicited by a vaccinee or convalescent. <i>Future Virology</i> , 2022, 17, 403-413.	0.9	6

#	ARTICLE	IF	CITATIONS
3261	Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 143.	7.1	83
3262	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. <i>Microorganisms</i> , 2022, 10, 857.	1.6	8
3263	Pilot Investigation of SARS-CoV-2 Variants in the Island of Sicily Prior to and in the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 869559.	1.5	2
3264	The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. <i>Vaccines</i> , 2022, 10, 696.	2.1	11
3265	Controlled evaluation of Angiotensin Receptor Blockers for COVID-19 respiratory disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial. <i>Trials</i> , 2022, 23, 361.	0.7	2
3266	SARS-CoV-2 Susceptibility and ACE2 Gene Variations Within Diverse Ethnic Backgrounds. <i>Frontiers in Genetics</i> , 2022, 13, 888025.	1.1	14
3267	Jiedu Huoxue Decoction for Cytokine Storm and Thrombosis in Severe COVID-19: A Combined Bioinformatics and Computational Chemistry Approach. <i>Natural Product Communications</i> , 2022, 17, 1934578X2210969.	0.2	0
3268	Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Vitamin D3 and COVID-19 as Potential Therapeutic Targets. <i>Frontiers in Pharmacology</i> , 2022, 13, 874637.	1.6	3
3269	Cold atmospheric plasma for addressing the COVID-19 pandemic. <i>Plasma Processes and Polymers</i> , 2022, 19, e2200012.	1.6	9
3270	ABO Blood System and COVID-19 Susceptibility: Anti-A and Anti-B Antibodies Are the Key Points. <i>Frontiers in Medicine</i> , 2022, 9, 882477.	1.2	12
3271	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	5
3272	Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. <i>Vaccine</i> , 2022, 40, 3380-3388.	1.7	13
3273	Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 3915-3921.	2.1	49
3274	Structure and Orientation of the SARS-Coronavirus-2 Spike Protein at Air-Water Interfaces. <i>Journal of Physical Chemistry B</i> , 2022, 126, 3425-3430.	1.2	3
3276	Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	6
3277	Advances in Research on Antiviral Activities of Sulfated Polysaccharides from Seaweeds. <i>Pharmaceuticals</i> , 2022, 15, 581.	1.7	22
3278	Identification of FDA-approved Bifonazole as SARS-CoV-2 blocking agent following a bioreporter drug screen. <i>Molecular Therapy</i> , 2022, , .	3.7	5
3279	Label-Free Detection of the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein at Physiologically Relevant Concentrations Using Surface-Enhanced Raman Spectroscopy. <i>Biosensors</i> , 2022, 12, 300.	2.3	9

#	ARTICLE	IF	CITATIONS
3280	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
3281	Immunouniverse of SARS-CoV-2. <i>Immunological Medicine</i> , 2022, 45, 186-224.	1.4	8
3282	Bioinformatic Screening of Compounds from Iranian Lamiaceae Family Members against SARS-CoV-2 Spike Protein. <i>Letters in Drug Design and Discovery</i> , 2023, 20, 684-698.	0.4	1
3283	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12
3284	Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. <i>MAbs</i> , 2022, 14, 2072455.	2.6	9
3285	Mechanisms of Cardiovascular System Injury Induced by COVID-19 in Elderly Patients With Cardiovascular History. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	1
3286	In silico mutational analysis of ACE2 to check the susceptibility of lung cancer patients towards COVID-19. <i>Scientific Reports</i> , 2022, 12, 7798.	1.6	2
3287	Assessing of Humoral Immunity to SARS-COV-2 in Residents of Orenburg During the Epidemic Period. <i>Epidemiologiya i Vaktsinoprofilaktika</i> , 2022, 21, 17-22.	0.2	0
3288	Antiviral Drug Discovery for the Treatment of COVID-19 Infections. <i>Viruses</i> , 2022, 14, 961.	1.5	44
3289	Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C. <i>Frontiers in Pediatrics</i> , 2022, 10, .	0.9	6
3290	Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. <i>Cell Reports</i> , 2022, 39, 110862.	2.9	9
3291	A high-affinity aptamer with base-appended base-modified DNA bound to isolated authentic SARS-CoV-2 strains wild-type and B.1.617.2 (delta variant). <i>Biochemical and Biophysical Research Communications</i> , 2022, 614, 207-212.	1.0	6
3292	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
3293	Human-to-dog transmission of SARS-CoV-2, Colombia. <i>Scientific Reports</i> , 2022, 12, 7880.	1.6	9
3294	Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
3295	SARS-CoV-2 Delta Variant Decreases Nanobody Binding and ACE2 Blocking Effectivity. <i>Journal of Chemical Information and Modeling</i> , 2022, , .	2.5	5
3296	The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects. <i>Biophysical Chemistry</i> , 2022, 288, 106824.	1.5	5
3297	A Multi-dimensional Review on Severe Acute Respiratory Syndrome CoronaVirus-2. <i>Current Pharmaceutical Biotechnology</i> , 2022, 23, .	0.9	1

#	ARTICLE	IF	CITATIONS
3298	SARS-CoV-2 Infection and Taste Alteration: An Overview. <i>Life</i> , 2022, 12, 690.	1.1	15
3300	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
3301	Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. <i>Viruses</i> , 2022, 14, 1029.	1.5	17
3302	A multilevel approach for screening natural compounds as an antiviral agent for COVID-19. <i>Computational Biology and Chemistry</i> , 2022, 98, 107694.	1.1	7
3303	Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins. <i>Antiviral Research</i> , 2022, 203, 105332.	1.9	2
3304	Evaluation of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. <i>Journal of Clinical Virology</i> , 2022, 152, 105169.	1.6	10
3305	Virtual and biochemical screening to identify the inhibitors of binding between SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 114, 108206.	1.3	2
3306	COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113089.	2.5	36
3307	Evolution and Epidemiology of SARS-CoV-2 Virus. <i>Methods in Molecular Biology</i> , 2022, 2452, 3-18.	0.4	0
3308	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
3309	Anisodamine potently inhibits SARS-CoV-2 infection <i>in vitro</i> and targets its main protease. <i>Biochemical and Biophysical Research Communications</i> , 2022, 616, 8-13.	1.0	5
3310	Computational studies evidenced the potential of steroidal lactone to disrupt surface interaction of SARS-CoV-2 spike protein and hACE2. <i>Computers in Biology and Medicine</i> , 2022, 146, 105598.	3.9	3
3311	Gestational diabetes mellitus and COVID-19: results from the COVID-19-Related Obstetric and Neonatal Outcome Study (CRONOS). <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 631.e1-631.e19.	0.7	34
3312	Development of DNA Vaccine Candidate against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1049.	1.5	7
3313	SARS-CoV-2 variant trends in Ireland: Wastewater-based epidemiology and clinical surveillance. <i>Science of the Total Environment</i> , 2022, 838, 155828.	3.9	25
3314	Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region. <i>Computers in Biology and Medicine</i> , 2022, 146, 105625.	3.9	5
3315	Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5534.	1.8	10
3316	A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection. <i>European Journal of Human Genetics</i> , 2022, 30, 889-898.	1.4	30



#	ARTICLE	IF	CITATIONS
3317	Changes in smell and taste perception related to COVID-19 infection: a caseâ€‘control study. <i>Scientific Reports</i> , 2022, 12, 8192.	1.6	14
3318	Structure-Based Development of SARS-CoV-2 Spike Interactors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5601.	1.8	3
3319	An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. <i>Journal of Molecular Biology</i> , 2022, 434, 167637.	2.0	1
3320	Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants. <i>Cell and Bioscience</i> , 2022, 12, 63.	2.1	4
3321	A Class of Sharkâ€‘Derived Singleâ€‘Domain Antibodies can Broadly Neutralize SARSâ€‘Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape. <i>Small Methods</i> , 2022, 6, e2200387.	4.6	14
3322	Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 301.	2.4	9
3323	Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine. <i>Journal of Controlled Release</i> , 2022, 347, 476-488.	4.8	15
3324	Detecting Intact Virus Using Exogenous Oligonucleotide Labels. <i>Analytical Chemistry</i> , 2022, 94, 7619-7627.	3.2	0
3325	Hijacking of Cellular Functions by Severe Acute Respiratory Syndrome Coronavirus-2. Permeabilization and Polarization of the Host Lipid Membrane by Vioporins. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 4642-4649.	2.1	3
3326	ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 1488-1499.	3.0	40
3327	Feasibility analysis and mechanism exploration of Rhei Radix et Rhizomeâ€‘Schisandrae Sphenantherae Fructus (RS) against COVID-19. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	11
3328	Serological screening in wild ruminants in Germany, 2021/2022: No evidence of SARSâ€‘CoVâ€‘2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virus. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	9
3329	Recent Progress on Rapid Lateral Flow Assay-Based Early Diagnosis of COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 866368.	2.0	21
3330	A Bacterially Expressed SARS-CoV-2 Receptor Binding Domain Fused With Cross-Reacting Material 197 A-Domain Elicits High Level of Neutralizing Antibodies in Mice. <i>Frontiers in Microbiology</i> , 2022, 13, 854630.	1.5	3
3331	The Impact of Some Natural Phenolic Compounds on Î±-Glucosidase and Sorbitol Dehydrogenase Enzymes, and Anti-leukemia Cancer Potential, Spin Density Distributions, and <i>in silico</i> Studies. <i>Journal of Oleo Science</i> , 2022, . .	0.6	3
3333	A Broadband Biosensor Using Graphene-Metasurface Based Cross-Polarization Converter. <i>IEEE Sensors Journal</i> , 2022, 22, 12820-12828.	2.4	11
3334	Pyrazolone-type compounds: synthesis and <i>in silico</i> assessment of antiviral potential against key viral proteins of SARS-CoV-2. <i>RSC Advances</i> , 2022, 12, 16054-16070.	1.7	3
3338	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3

#	ARTICLE	IF	CITATIONS
3339	Discovery of Natural Lead Compound from <i>Dendrobium</i> sp. against SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2022, 15, 620.	1.7	4
3340	Post-Proline Cleaving Enzymes (PPCEs): Classification, Structure, Molecular Properties, and Applications. <i>Plants</i> , 2022, 11, 1330.	1.6	5
3342	An Aptamer-Functionalised Schottky-Field Effect Transistor for the Detection of Proteins. <i>Biosensors</i> , 2022, 12, 347.	2.3	7
3343	SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress. <i>International Journal of Cardiology</i> , 2022, 362, 196-205.	0.8	9
3344	Aerosol capture and coronavirus spike protein deactivation by enzyme functionalized antiviral membranes. <i>Communications Materials</i> , 2022, 3, .	2.9	6
3345	Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern. <i>Journal of Virological Methods</i> , 2022, 307, 114553.	1.0	9
3348	A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. <i>Journal of Medical Virology</i> , 2022, 94, 4287-4293.	2.5	13
3349	SARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5. <i>Nature Communications</i> , 2022, 13, .	5.8	32
3350	Exploring the Spike-hACE 2 Residue Residue Interaction in Human Coronaviruses SARS-CoV-2, SARS-CoV, and HCoV-NL63. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2857-2868.	2.5	6
3351	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
3354	Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	53
3355	Omicron variant receptor-binding domain phylogenetics and molecular dynamics. <i>Computers in Biology and Medicine</i> , 2022, 146, 105633.	3.9	4
3356	Label free detection of SARS CoV-2 Receptor Binding Domain (RBD) protein by fabrication of gold nanorods deposited on electrochemical immunosensor (GDEI). <i>Biosensors and Bioelectronics</i> , 2022, 212, 114406.	5.3	38
3357	Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. <i>Biotechnology Advances</i> , 2022, 59, 107986.	6.0	4
3359	Interaction of Sars-Cov-2 Delta Variant B.1.617.2 with Antibody Cr3022: Homology Modelling and Molecular Dynamics Studies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3360	Longitudinal Neutralization Activities on Authentic Omicron Variant Provided by 3 Doses of BBIBP-CorV Vaccination During One Year. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3361	Using Multiple Computational Platforms to Validate Suitable Therapeutic Candidates that Interfere with the Viral S-Glycoprotein and Host ACE2 Receptor Protein Interaction. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3362	Evidence of SARS-CoV-2 infection in pets, captive non-human primates and farm animals in Central Africa. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022, 15, 232.	0.4	0

#	ARTICLE	IF	CITATIONS
3363	An $\alpha$ -IGHG1 Variant Introgressed From Vindija Neanderthal Archaic Hominin Confers Enhanced Antibody Immunity Against SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	0
3364	Rela�o entre os nveis de ferritina e o prognstico da COVID-19. , 2022, 101, .	0.0	0
3365	Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies. Pharmaceuticals, 2022, 15, 676.	1.7	1
3366	The role of angiotensin-converting enzyme 2 (ACE2) genetic variations in COVID-19 infection: a literature review. Egyptian Journal of Medical Human Genetics, 2022, 23, .	0.5	6
3367	Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	9
3369	Design, synthesis, inhibitory activity, and SAR studies of hydrophobic phenylacetic acid derivatives as neuraminidase inhibitors. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
3370	Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers: A case series of 20 patients. Journal of Cosmetic Dermatology, 2022, 21, 3181-3187.	0.8	11
3371	Human Cell Organelles in SARS-CoV-2 Infection: An Up-to-Date Overview. Viruses, 2022, 14, 1092.	1.5	3
3372	Transmission of SARS-CoV-2 from humans to animals and potential host adaptation. Nature Communications, 2022, 13, .	5.8	67
3373	Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes. Nature Communications, 2022, 13, .	5.8	12
3375	Isolation and Characterization of Werneria Chromene and Dihydroxyacidissimol from Burkillanthus Amalaccensis (Ridl.) Swingle. Plants, 2022, 11, 1388.	1.6	2
3376	Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. Journal of Cellular Biochemistry, 2022, 123, 1207-1221.	1.2	3
3377	Healthy humans can be a source of antibodies countering COVID-19. Bioengineered, 2022, 13, 12598-12624.	1.4	0
3378	An Insight Based on Computational Analysis of the Interaction between the Receptor-Binding Domain of the Omicron Variants and Human Angiotensin-Converting Enzyme 2. Biology, 2022, 11, 797.	1.3	10
3379	Protective neutralizing epitopes in SARS-CoV-2. Immunological Reviews, 2022, 310, 76-92.	2.8	23
3380	COVID-19 therapies: do we see substantial progress?. Cellular and Molecular Biology Letters, 2022, 27, .	2.7	4
3381	Engineering defensin $\alpha$ -helix to produce high-affinity SARS-CoV-2 spike protein binding ligands. Protein Science, 2022, 31, .	3.1	3
3383	Graphs of Hydrogen-Bond Networks to Dissect Protein Conformational Dynamics. Journal of Physical Chemistry B, 2022, 126, 3973-3984.	1.2	8

#	ARTICLE	IF	CITATIONS
3385	Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	3
3386	Principles of SARS-CoV-2 glycosylation. <i>Current Opinion in Structural Biology</i> , 2022, 75, 102402.	2.6	27
3387	Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins. <i>Cell Research</i> , 2022, 32, 609-620.	5.7	63
3388	GMI, a protein from <i>Ganoderma microsporum</i> , induces ACE2 degradation to alleviate infection of SARS-CoV-2 Spike-pseudotyped virus. <i>Phytomedicine</i> , 2022, 103, 154215.	2.3	11
3389	<scp>Preâ€œexascale HPC</scp> approaches for molecular dynamics simulations. Covidâ€œ19 research: A use case. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2023, 13, .	6.2	6
3390	Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	5
3391	SARSâ€œCoVâ€œ2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
3392	MIL-101 (Fe) @Ag Rapid Synergistic Antimicrobial and Biosafety Evaluation of Nanomaterials. <i>Molecules</i> , 2022, 27, 3497.	1.7	13
3393	Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats. <i>Cell Reports</i> , 2022, 39, 110969.	2.9	29
3395	Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. <i>Vaccines</i> , 2022, 10, 897.	2.1	5
3397	Rise of the SARS-CoV-2 Variants: can proteomics be the silver bullet?. <i>Expert Review of Proteomics</i> , 2022, 19, 197-212.	1.3	2
3398	Functionalized SPION immobilized on graphene-oxide: Anticancer and antiviral study. <i>Diamond and Related Materials</i> , 2022, 127, 109149.	1.8	10
3399	Smaller, Stronger, More Stable: Peptide Variants of a SARS-CoV-2 Neutralizing Miniprotein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6309.	1.8	10
3400	Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19. <i>PLoS ONE</i> , 2022, 17, e0268919.	1.1	2
3401	Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2. <i>IScience</i> , 2022, 25, 104500.	1.9	2
3402	Genome-Wide Analysis of the Indispensable Role of Non-structural Proteins in the Replication of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	7
3403	A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein. <i>Nature Chemical Biology</i> , 2022, 18, 1046-1055.	3.9	9
3404	Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein. <i>Structure</i> , 2022, 30, 1062-1074.e4.	1.6	21

#	ARTICLE	IF	CITATIONS
3405	VE607 stabilizes SARS-CoV-2 Spike in the RBD-up-conformation and inhibits viral entry. <i>IScience</i> , 2022, 25, 104528.	1.9	8
3406	Rapid screening of SARS-CoV-2 inhibitors via ratiometric fluorescence of RBD-ACE2 complexes in living cells by competitive binding. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3739-3742.	5.7	6
3407	Development of Nested PCR for SARS-CoV-2 Detection and Its Application for Diagnosis of Active Infection in Cats. <i>Veterinary Sciences</i> , 2022, 9, 272.	0.6	4
3408	The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	14
3409	Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	5
3410	Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
3411	A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies. <i>Antiviral Research</i> , 2022, 203, 105349.	1.9	3
3412	Natural compounds may contribute in preventing SARS-CoV-2 infection: a narrative review. <i>Food Science and Human Wellness</i> , 2022, 11, 1134-1142.	2.2	8
3413	RT-LAMP assay combining multi-fluorescent probes for SARS-CoV-2 RNA detection and variant differentiation. <i>Talanta</i> , 2022, 248, 123644.	2.9	10
3414	A paper-based optical sensor for the screening of viruses through the cysteine residues of their surface proteins: A proof of concept on the detection of coronavirus infection. <i>Talanta</i> , 2022, 248, 123630.	2.9	4
3416	Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
3417	Effect of the Graphene Nanosheet on Bio-Functions of the Spike Protein at Open and Closed States: The Comparison Between SARS-CoV-2 WT and Omicron Variant. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3418	Polyphosphate in Antiviral Protection: A Polyanionic Inorganic Polymer in the Fight Against Coronavirus SARS-CoV-2 Infection. <i>Progress in Molecular and Subcellular Biology</i> , 2022, , 145-189.	0.9	4
3420	Graphene BioFET sensors for SARS-CoV-2 detection: a multiscale simulation approach. <i>Nanoscale Advances</i> , 0, , .	2.2	5
3421	Metal-based strategies for the fight against COVID-19. <i>Chemical Communications</i> , 2022, 58, 7466-7482.	2.2	14
3422	Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. <i>Chemical Reviews</i> , 2022, 122, 11287-11368.	23.0	38
3423	Xâ°,çº;âfç'æZÇæµ«â™™ç”ç©¶è;â±+. <i>Chinese Science Bulletin</i> , 2022, , .	0.4	0
3424	Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design. <i>Vaccines</i> , 2022, 10, 841.	2.1	0

#	ARTICLE	IF	CITATIONS
3425	Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. <i>PLoS Computational Biology</i> , 2022, 18, e1010160.	1.5	14
3426	Allosteric Binders of ACE2 Are Promising Anti-SARS-CoV-2 Agents. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 468-478.	2.5	3
3427	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	4
3428	Peptide Binder with High-Affinity for the SARS-CoV-2 Spike Receptor-Binding Domain. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 28527-28536.	4.0	6
3429	Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	7
3430	Deciphering the conformational landscape of few selected aromatic noncoded amino acids (NCAAs) for applications in rational design of peptide therapeutics. <i>Amino Acids</i> , 2022, 54, 1183-1202.	1.2	6
3431	Peptide mediated colorimetric detection of SARS-CoV-2 using gold nanoparticles: a molecular dynamics simulation study. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	2
3432	Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
3433	Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. <i>Vaccines</i> , 2022, 10, 944.	2.1	5
3434	Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	53
3435	Detection of SARS-CoV-2 in tissue: the comparative roles of RT-qPCR, in situ RNA hybridization, and immunohistochemistry. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 559-574.	1.5	5
3436	Alchemical Free Energy Calculations to Investigate Protein-Protein Interactions: the Case of the CDC42/PAK1 Complex. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3023-3033.	2.5	8
3437	In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6MO). <i>Molecular Diversity</i> , 2023, 27, 1087-1099.	2.1	1
3440	SARS-CoV-2 Spike Glikoproteinlerinin Farklı Hücrelerde Karşılaştıkları Biyoinformatik Analizleri. <i>Commagene Journal of Biology</i> , 0, , 68-73.	0.1	0
3441	An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variants. <i>Heliyon</i> , 2022, 8, e09660.	1.4	1
3442	Singular Interface Dynamics of the SARS-CoV-2 Delta Variant Explained with Contact Perturbation Analysis. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3107-3122.	2.5	5
3443	Different Binding Modes of SARS-CoV-1 and SARS-CoV-2 Fusion Peptides to Cell Membranes: The Influence of Peptide Helix Length. <i>Journal of Physical Chemistry B</i> , 2022, 126, 4261-4271.	1.2	6
3444	In silico study to identify novel potential thiazazole-based molecules as anti-Covid-19 candidates by hierarchical virtual screening and molecular dynamics simulations. <i>Structural Chemistry</i> , 2022, 33, 1727-1739.	1.0	9



#	ARTICLE	IF	CITATIONS
3445	Polymerized porin as a novel delivery platform for coronavirus vaccine. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	1
3446	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
3447	Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 Omicron variant. <i>Computers in Biology and Medicine</i> , 2022, 147, 105735.	3.9	13
3448	The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3449	Detection of SARS-CoV-2 infection in thyroid follicular cells from a COVID-19 autopsy series. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	8
3450	Exploring the Potential Role of Theaflavin-3,3â€²-Digallate in Inhibiting Various Stages of SARS-CoV-2 Life Cycle: An In-Silico Approach. <i>Chemistry Africa</i> , 2022, 5, 883-898.	1.2	2
3451	Potent human broadly SARS-CoV-2â€™neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	34
3452	Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3453	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
3454	Lessons from SARSâ€™CoVâ€™2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	1.1	5
3455	Confirmatory Virucidal Activity of Ionised Active Water S-100Â® on the SARS-CoV-2 Virus. <i>Advances in Virology</i> , 2022, 2022, 1-7.	0.5	2
3456	The Candidate Molecules, RBD-ACE2 Binding Inhibitors to Prevent SARS-CoV-2 Infection. <i>Journal of Computational Biophysics and Chemistry</i> , 0, , .	1.0	0
3457	Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454.	1.5	2
3458	Severe Acute Respiratory Syndrome Coronavirus 2 Epitope Mapping for Antibodies. <i>ImmunoHorizons</i> , 2022, 6, 344-355.	0.8	1
3459	SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation. <i>Journal of Physical Chemistry B</i> , 2022, 126, 4669-4678.	1.2	25
3460	Methodology of Purification of Inactivated Cell-Culture-Grown SARS-CoV-2 Using Size-Exclusion Chromatography. <i>Vaccines</i> , 2022, 10, 949.	2.1	0
3461	Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like Î²-Coronaviruses. <i>ACS Chemical Biology</i> , 2022, 17, 1937-1950.	1.6	16
3462	In Silico Molecular Dynamics of Griseofulvin and Its Derivatives Revealed Potential Therapeutic Applications for COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6889.	1.8	6

#	ARTICLE	IF	CITATIONS
3463	Broad Cross-Reactive IgA and IgG against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection. <i>Vaccines</i> , 2022, 10, 980.	2.1	9
3464	RelCoVax <sup>®</sup> , a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice. <i>Vaccine</i> , 2022, 40, 4522-4530.	1.7	6
3465	Rapid and accurate identification of SARS-CoV-2 Omicron variants using droplet digital PCR (RT-ddPCR). <i>Journal of Clinical Virology</i> , 2022, 154, 105218.	1.6	12
3466	Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein. <i>MBio</i> , 2022, 13, .	1.8	23
3467	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
3468	Superimmunity by pan-sarbecovirus nanobodies. <i>Cell Reports</i> , 2022, 39, 111004.	2.9	13
3469	Binding and structural basis of equine ACE2 to RBDs from SARS-CoV, SARS-CoV-2 and related coronaviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	16
3470	Emergence and widespread circulation of a recombinant SARS-CoV-2 lineage in North America. <i>Cell Host and Microbe</i> , 2022, 30, 1112-1123.e3.	5.1	20
3471	High generation of reactive oxygen species from neutrophils in patients with severe COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	26
3472	Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune escape. , 2022, 19, 848-851.		9
3473	SARS-CoV-2 couples evasion of inflammatory response to activated nucleotide synthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
3475	From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1704-1714.	2.5	15
3476	Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2. <i>PLoS Pathogens</i> , 2022, 18, e1010590.	2.1	18
3477	Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3478	Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758.	3.9	6
3479	Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters. <i>Antiviral Research</i> , 2022, 204, 105365.	1.9	7
3480	Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 176, 106234.	1.9	14
3481	SARS, MERS, nSARS-CoV-2 infections and diseases: Emerging threats to public health. , 2022, , 235-252.		0

#	ARTICLE	IF	CITATIONS
3482	Genomic, proteomic and metabolomic profiling of severe acute respiratory syndrome-Coronavirus-2. , 2022, , 49-76.		0
3483	Experimental Models of SARS-COV-2 Infection in the Central Nervous System. Journal of Central Nervous System Disease, 2022, 14, 117957352211022.	0.7	0
3485	Technical performance of a lateral flow immunoassay for detection of anti-SARS-CoV-2 IgG in the outpatient follow-up of non-severe cases and at different times after vaccination: comparison with enzyme and chemiluminescent immunoassays. Revista Do Instituto De Medicina Tropical De Sao Paulo, 0, 64, .	0.5	0
3486	CARs-DB: A Database of Cryptic Amyloidogenic Regions in Intrinsically Disordered Proteins. Frontiers in Molecular Biosciences, 0, 9, .	1.6	4
3487	Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes. Journal of Virology, 2022, 96, .	1.5	10
3488	An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry. Emerging Microbes and Infections, 2022, 11, 1920-1935.	3.0	7
3489	Deciphering the Impact of Mutations on the Binding Efficacy of SARS-CoV-2 Omicron and Delta Variants With Human ACE2 Receptor. Frontiers in Chemistry, 0, 10, .	1.8	12
3490	The nervous system during <sc>COVID</sc>â€9: Caught in the crossfire. Immunological Reviews, 2022, 311, 90-111.	2.8	9
3491	Genomic Comparisons of Alphacoronaviruses and Betacoronaviruses from Korean Bats. Viruses, 2022, 14, 1389.	1.5	0
3492	Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis. , 2022, 1, 103-112.		3
3493	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. FEBS Open Bio, 2022, 12, 1602-1622.	1.0	6
3494	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nature Medicine, 2022, 28, 1785-1790.	15.2	456
3495	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	59
3496	Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. Cell and Bioscience, 2022, 12, .	2.1	7
3497	On the Concept of â€œComplexityâ€in Radiation Physics. Journal of Surface Investigation, 2022, 16, 364-373.	0.1	3
3498	The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant. Current Issues in Molecular Biology, 2022, 44, 2842-2855.	1.0	1
3499	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS Pathogens, 2022, 18, e1010592.	2.1	13
3500	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. Science, 2022, 377, 420-424.	6.0	140

#	ARTICLE	IF	CITATIONS
3501	SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly. <i>Nature Communications</i> , 2022, 13, .	5.8	12
3502	PROSPECTS FOR IMMUNOTHERAPY TREATMENT AGAINST COVID-19 INFECTION. <i>Ek'sperimentuli Da Klinikuri Medic'ina</i> , 0, , .	0.0	0
3503	Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review. <i>Medicine (United States)</i> , 2022, 101, e29660.	0.4	4
3504	Analysis of Interaction Between Odorant Receptors and Flexible Spike of SARS CoV-2- Key to Loss of Smell. <i>Current Neuropharmacology</i> , 2023, 21, 151-159.	1.4	1
3505	Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 6064-6073.	2.1	14
3506	A broad and potent neutralization epitope in SARS-related coronaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	34
3507	Hazardous Shortcuts in Standard Binding Free Energy Calculations. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 6250-6258.	2.1	10
3508	Antibodyâ€“nanobody combination increases their neutralizing activity against SARS-CoV-2 and nanobody H11-H4 is effective against Alpha, Kappa and Delta variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
3509	Zinc Nanomaterials: A Double-Edged Sword in Detection and Prevention against SARS-CoV-2 Spread (A) Tj ETQq0 0.0,rgBT /Oylock 10 0.1	0.1	0
3510	An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population. <i>Diagnostics</i> , 2022, 12, 1629.	1.3	5
3511	Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng. <i>Journal of Ginseng Research</i> , 2023, 47, 123-132.	3.0	5
3512	Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2. <i>PeerJ</i> , 0, 10, e13680.	0.9	1
3513	Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination. <i>Endocrine</i> , 2022, 78, 42-46.	1.1	18
3514	Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection. <i>Journal of Infection</i> , 2022, 85, 418-427.	1.7	20
3515	The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. <i>PLoS Pathogens</i> , 2022, 18, e1010631.	2.1	11
3516	Analysis of the docking property of host variants of hACE2 for SARS-CoV-2 in a large cohort. <i>PLoS Computational Biology</i> , 2022, 18, e1009834.	1.5	1
3517	In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding. <i>PLoS Pathogens</i> , 2022, 18, e1010733.	2.1	28
3518	Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	9

#	ARTICLE	IF	CITATIONS
3519	A new strategy: identification of specific antibodies for neutralizing epitope on SARS-CoV-2 S protein by LC-MS/MS combined with immune repertoire. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	1
3520	Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies. <i>Nature Communications</i> , 2022, 13, .	5.8	14
3521	In silico screening of some compounds derived from the desert medicinal plant <i>Rhazya stricta</i> for the potential treatment of COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3522	Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7704.	1.8	5
3523	Creation of transgenic mice susceptible to coronaviruses: a platform for studying viral pathogenesis and testing vaccines. <i>Vavilovskii Zhurnal Genetiki i Seleksii</i> , 2022, 26, 402-408.	0.4	0
3524	A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action. <i>Proteomics</i> , 0, , 2200118.	1.3	3
3525	Screened $\alpha$ -Helix Peptide Inhibitor toward SARS-CoV-2 by Blocking a Prion-like Domain in the Receptor Binding Domain. <i>Analytical Chemistry</i> , 2022, 94, 11464-11469.	3.2	1
3526	Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry. <i>IScience</i> , 2022, 25, 104716.	1.9	6
3527	NMR Experiments Provide Insights into Ligand-Binding to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. <i>Journal of the American Chemical Society</i> , 2022, 144, 13060-13065.	6.6	7
3528	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. <i>Nature Microbiology</i> , 2022, 7, 1161-1179.	5.9	352
3529	Development of a Biosensor Based on Angiotensin-Converting Enzyme II for Severe Acute Respiratory Syndrome Coronavirus 2 Detection in Human Saliva. <i>Frontiers in Sensors</i> , 0, 3, .	1.7	5
3530	Omicron Binding Mode: Contact Analysis and Dynamics of the Omicron Receptor-Binding Domain in Complex with ACE2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 3844-3853.	2.5	11
3531	Neurological Effects of COVID-19 and Its Treatment/Management. , 0, , .		0
3532	Identification of Surface Glycoprotein Mutations of SARS-CoV-2 in Isolated Strains from Iraq. <i>Medical Immunology (Russia)</i> , 2022, 24, 729-740.	0.1	2
3533	A Biosensor Platform for Point-of-Care SARS-CoV-2 Screening. <i>Biosensors</i> , 2022, 12, 487.	2.3	5
3534	Effects of Plant Metabolites on the Growth of COVID-19 (Coronavirus Disease-19) Including Omicron Strain. <i>Cureus</i> , 2022, , .	0.2	1
3535	Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System. <i>Viruses</i> , 2022, 14, 1461.	1.5	3
3536	Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. <i>BioEssays</i> , 2022, 44, .	1.2	9

#	ARTICLE	IF	CITATIONS
3537	ACE2 and SARS-CoV-2-Main Protease Capillary Columns for Affinity Chromatography: Testimony of the Binding of Dexamethasone and its Carbon Nanotube Nanovector. <i>Chromatographia</i> , 0, , .	0.7	1
3538	A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. <i>Journal of Virology</i> , 2022, 96, .	1.5	7
3539	A So-Far Overlooked Secondary Conformation State in the Binding Mode of SARS-CoV-2 Spike Protein to Human ACE2 and Its Conversion Rate Are Crucial for Estimating Infectivity Efficacy of the Underlying Virus Variant. <i>Journal of Virology</i> , 2022, 96, .	1.5	2
3540	All-Atom Simulations of Human ACE2-Spike Protein RBD Complexes for SARS-CoV-2 and Some of its Variants: Nature of Interactions and Free Energy Diagrams for Dissociation of the Protein Complexes. <i>Journal of Physical Chemistry B</i> , 2022, 126, 5375-5389.	1.2	14
3541	SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 960-971.	0.9	20
3542	Vascular Endothelial Growth Factor Receptor, fms-Like Tyrosine Kinase-1 (Flt-1), as a Novel Binding Partner for SARS-CoV-2 Spike Receptor-Binding Domain. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3543	Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and Î±-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine. <i>Pharmaceutics</i> , 2022, 14, 1455.	2.0	3
3544	Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2. <i>PLoS ONE</i> , 2022, 17, e0271112.	1.1	23
3545	Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein. <i>Drug Discovery Today</i> , 2022, 27, 103312.	3.2	13
3546	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	5.8	93
3547	Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. <i>Nature Biomedical Engineering</i> , 2022, 6, 791-805.	11.6	100
3548	Iron and iron-related proteins in COVID-19. <i>Clinical and Experimental Medicine</i> , 2023, 23, 969-991.	1.9	20
3549	Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	6
3550	Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. <i>Science Advances</i> , 2022, 8, .	4.7	27
3551	Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking. <i>IScience</i> , 2022, 25, 104709.	1.9	16
3552	Kidney organoid research: current status and applications. <i>Current Opinion in Genetics and Development</i> , 2022, 75, 101944.	1.5	10
3553	In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2022, 147, 105788.	3.9	10
3554	Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19. <i>IScience</i> , 2022, 25, 104719.	1.9	0



#	ARTICLE	IF	CITATIONS
3555	Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113368.	2.5	6
3556	Allosteric inhibitors of the main protease of SARS-CoV-2. <i>Antiviral Research</i> , 2022, 205, 105381.	1.9	23
3557	A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114570.	2.6	23
3558	In silico analysis of SARS-CoV-2 spike protein N501Y and N501T mutation effects on human ACE2 binding. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 116, 108260.	1.3	4
3559	Neuroprotective Drug Discovery From Phytochemicals and Metabolites for CNS Viral Infection: A Systems Biology Approach With Clinical and Imaging Validation. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	3
3560	<i>S</i>-Palmitoylation and Sterol Interactions Mediate Antiviral Specificity of IFITMs. <i>ACS Chemical Biology</i> , 2022, 17, 2109-2120.	1.6	18
3561	Predictive Models of within- and between-Species SARS-CoV-2 Transmissibility. <i>Viruses</i> , 2022, 14, 1565.	1.5	1
3562	A SARS-CoV-2 oral vaccine development strategy based on the attenuated Salmonella type III secretion system. <i>Journal of Applied Microbiology</i> , 2022, 133, 2484-2500.	1.4	3
3564	Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice. <i>Research</i> , 2022, 2022, .	2.8	4
3565	Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Biomedicines</i> , 2022, 10, 1731.	1.4	8
3566	G6PD deficiency: imbalance of functional dichotomy contributing to the severity of COVID-19. <i>Future Microbiology</i> , 0, , .	1.0	5
3567	Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern. <i>PLoS Pathogens</i> , 2022, 18, e1010686.	2.1	2
3568	Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	7
3569	Decreased Interfacial Dynamics Caused by the N501Y Mutation in the SARS-CoV-2 S1 Spike:ACE2 Complex. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	9
3570	Three-Dimensional Visualization of Viral Structure, Entry, and Replication Underlying the Spread of SARS-CoV-2. <i>Chemical Reviews</i> , 2022, 122, 14066-14084.	23.0	11
3571	Human IgG antibody responses to severe acute respiratory syndrome coronavirus 2 viral antigens receptor-binding domain, spike, and nucleocapsid, in vaccinated adults from Merida, Mexico. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
3572	Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants. <i>CheM</i> , 2022, 8, 2766-2783.	5.8	18
3573	Engineering ACE2 decoy receptors to combat viral escapability. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 838-851.	4.0	22

#	ARTICLE	IF	CITATIONS
3574	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
3576	A strategy to optimize the peptide-based inhibitors against different mutants of the spike protein of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6191-6202.	2.0	2
3577	Bis(thio)carbohydrazone Luminogens with AIEE and ACQ Features and Their <i>in Silico</i> Investigations with SARSâ€™CoVâ€™2. <i>ChemistrySelect</i> , 2022, 7, .	0.7	6
3578	Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
3579	Activated Platelets and Platelet-Derived Extracellular Vesicles Mediate COVID-19-Associated Immunothrombosis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	16
3580	Docking Based Identification of Bioactive Diosmin as Potential Multi-Targeted Anti SARS-Cov-2 Agent. <i>Journal of the Mexican Chemical Society</i> , 2022, 66, .	0.2	1
3581	Optical Biosensor for the Detection of Infectious Diseases Using the Copolymer F8T2 with Application to COVID-19. <i>Sensors</i> , 2022, 22, 5673.	2.1	3
3582	Peimine inhibits variants of <i>SARSâ€™CoV</i> cell entry via blocking the interaction between viral spike protein and <i>ACE2</i> . <i>Journal of Food Biochemistry</i> , 2022, 46, .	1.2	8
3583	Host Cell Proteases Mediating SARS-CoV-2 Entry: An Overview.. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, .	1.0	7
3584	Exceptional diversity and selection pressure on coronavirus host receptors in bats compared to other mammals. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2022, 289, .	1.2	13
3585	Progress in Electrochemical Biosensing of SARS-CoV-2 Virus for COVID-19 Management. <i>Chemosensors</i> , 2022, 10, 287.	1.8	21
3586	In Silico Analysis of the Effects of Omicron Spike Amino Acid Changes on the Interactions with Human Proteins. <i>Molecules</i> , 2022, 27, 4827.	1.7	2
3587	Large-scale application of free energy perturbation calculations for antibody design. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
3588	Molecular adaptations during viral epidemics. <i>EMBO Reports</i> , 2022, 23, .	2.0	18
3589	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10
3590	A Closed-Form, Analytical Approximation for Apparent Surface Charge and Electric Field of Molecules. <i>ACS Omega</i> , 2022, 7, 26123-26136.	1.6	2
3592	Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8895.	1.2	4
3593	A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	3

#	ARTICLE	IF	CITATIONS
3594	Covariance predicts conserved protein residue interactions important for the emergence and continued evolution of SARS-CoV-2 as a human pathogen. <i>PLoS ONE</i> , 2022, 17, e0270276.	1.1	1
3595	Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. <i>Virus Evolution</i> , 2022, 8, .	2.2	10
3596	Encoding protein dynamic information in graph representation for functional residue identification. <i>Cell Reports Physical Science</i> , 2022, 3, 100975.	2.8	1
3597	Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Nephilysin in the Renin Angiotensin System. <i>Molecules</i> , 2022, 27, 4854.	1.7	4
3598	Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs. <i>Biomolecules</i> , 2022, 12, 1060.	1.8	2
3600	Early Isolates of SARS-CoV-2 Result in Different Pathogenesis in the Transduced Mouse Model of COVID-19. <i>Viruses</i> , 2022, 14, 1769.	1.5	1
3601	Coagulopathy in COVID-19 and anticoagulation clinical trials. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101377.	0.7	3
3603	Identification of antiviral peptide inhibitors for Receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach. <i>3 Biotech</i> , 2022, 12, .	1.1	16
3604	Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
3605	Density functional theory computation of the binding free energies between various mutations of SARS-CoV-2 RBD and human ACE2: molecular level roots of the contagiousness. <i>Heliyon</i> , 2022, 8, e10128.	1.4	2
3606	Intermediates in SARS-CoV-2 spike-mediated cell entry. <i>Science Advances</i> , 2022, 8, .	4.7	24
3607	Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, .	1.0	7
3608	Coronavirus Disease-2019 and Implications on the Liver. <i>Clinics in Liver Disease</i> , 2023, 27, 27-45.	1.0	7
3609	Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients. <i>Cells</i> , 2022, 11, 2480.	1.8	15
3610	Evolutionary progression of collective mutations in Omicron sub-lineages towards efficient RBD-hACE2: Allosteric communications between and within viral and human proteins. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4562-4578.	1.9	3
3612	SARS-CoV-2 in a Mink Farm in Italy: Case Description, Molecular and Serological Diagnosis by Comparing Different Tests. <i>Viruses</i> , 2022, 14, 1738.	1.5	5
3613	Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models. <i>PLoS ONE</i> , 2022, 17, e0269823.	1.1	5
3614	Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD. <i>Biochemical Engineering Journal</i> , 2022, 187, 108596.	1.8	2

#	ARTICLE	IF	CITATIONS
3615	Physical-Chemical Regulation of Membrane Receptors Dynamics in Viral Invasion and Immune Defense. <i>Journal of Molecular Biology</i> , 2023, 435, 167800.	2.0	2
3616	An engineered SARS-CoV-2 receptor-binding domain produced in <i>Pichia pastoris</i> as a candidate vaccine antigen. <i>New Biotechnology</i> , 2022, 72, 11-21.	2.4	15
3617	Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	12
3619	SARS-CoV-2 Variability in Patients and Wastewatersâ€™ Potential Immuno-Modulation during the Shift from Delta to Omicron. <i>Biomedicines</i> , 2022, 10, 2080.	1.4	0
3620	Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. <i>Acta Crystallographica Section D: Structural Biology</i> , 2022, 78, 1156-1170.	1.1	2
3621	Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
3623	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	0.7	5
3624	COVIDâ€™19 metabolism: Mechanisms and therapeutic targets. <i>MedComm</i> , 2022, 3, .	3.1	15
3626	Molecular interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 protein complex. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
3627	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2211-2233.	0.9	1
3628	Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. <i>Pharmaceuticals</i> , 2022, 15, 1002.	1.7	3
3629	Multi Epitope-Based Vaccine Design for Protection Against <i>Mycobacterium tuberculosis</i> and SARS-CoV-2 Coinfection. <i>Advances and Applications in Bioinformatics and Chemistry</i> , 0, Volume 15, 43-57.	1.6	5
3630	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3631	Impact of SARS-CoV-2 RBD Mutations on the Production of a Recombinant RBD Fusion Protein in Mammalian Cells. <i>Biomolecules</i> , 2022, 12, 1170.	1.8	2
3632	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	1.6	6
3634	Screening of cellâ€™virus, cellâ€™cell, geneâ€™gene crosstalk among animal kingdom at single cell resolution. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	3
3635	Evolution of Stronger SARS-CoV-2 Variants as Revealed Through the Lens of Molecular Dynamics Simulations. <i>Protein Journal</i> , 2022, 41, 444-456.	0.7	4
3636	APOE interacts with ACE2 inhibiting SARS-CoV-2 cellular entry and inflammation in COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	26

#	ARTICLE	IF	CITATIONS
3637	A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. PLoS ONE, 2022, 17, e0272364.	1.1	6
3638	PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. Communications Biology, 2022, 5, .	2.0	7
3639	İşık Tobacco smokers as target group for complicated coronavirus infection. Pharmacia, 2022, 69, 791-800.	0.4	0
3640	Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display. Journal of the American Chemical Society, 2022, 144, 15885-15893.	6.6	21
3641	Two Years into the COVID-19 Pandemic: Lessons Learned. ACS Infectious Diseases, 2022, 8, 1758-1814.	1.8	47
3643	The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: A comparative analysis of the early and current strains. Journal of Medical Virology, 0, , .	2.5	1
3646	A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor. Cell Reports, 2022, 40, 111335.	2.9	2
3647	SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors. Environmental Science and Pollution Research, 2022, 29, 69117-69136.	2.7	7
3648	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. Polymers, 2022, 14, 3263.	2.0	3
3649	Impact of high-dose vitamin C on the mortality, severity, and duration of hospital stay in COVID-19 patients: A meta-analysis. Health Science Reports, 2022, 5, .	0.6	5
3650	A Study on the Relationship between the 3-D Structure of Spike Proteins and Infectiousness of SARS-CoV-2 Delta Variant. , 0, 8, 169-177.		0
3651	A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination. Cell Reports, 2022, 40, 111276.	2.9	29
3652	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19. Glycobiology, 0, , .	1.3	1
3653	Computational Design of Miniprotein Inhibitors Targeting SARS-CoV-2 Spike Protein. Langmuir, 0, , .	1.6	6
3654	Variations in Cell Surface ACE2 Levels Alter Direct Binding of SARS-CoV-2 Spike Protein and Viral Infectivity: Implications for Measuring Spike Protein Interactions with Animal ACE2 Orthologs. Journal of Virology, 2022, 96, .	1.5	3
3655	Modular Label-Free Electrochemical Biosensor Loading Nature-Inspired Peptide toward the Widespread Use of COVID-19 Antibody Tests. ACS Nano, 2022, 16, 14239-14253.	7.3	17
3656	Identification of three conserved linear B cell epitopes on the SARS-CoV-2 spike protein. Emerging Microbes and Infections, 2022, 11, 2120-2131.	3.0	4
3657	Genome Similarities between Human-Derived and Mink-Derived SARS-CoV-2 Make Mink a Potential Reservoir of the Virus. Vaccines, 2022, 10, 1352.	2.1	3

#	ARTICLE	IF	CITATIONS
3658	Development and Evaluation of Enzyme-Linked Viral Immune Capture Assay for Detection of SARS-CoV-2. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	1
3659	Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
3660	Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2. <i>Structure</i> , 2022, 30, 1432-1442.e4.	1.6	18
3661	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination. <i>Nature Nanotechnology</i> , 2022, 17, 993-1003.	15.6	58
3662	CoVM2: Molecular Biological Data Integration of SARS-CoV-2 Proteins in a Macro-to-Micro Method. <i>Biomolecules</i> , 2022, 12, 1067.	1.8	1
3663	Clinical and Diagnostic Significance of Sialic Acids Determination in Biological Material. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2022, 16, 165-174.	0.2	0
3664	Assessment of hypertension and other factors associated with the severity of disease in COVID-19 pneumonia, Addis Ababa, Ethiopia: A case-control study. <i>PLoS ONE</i> , 2022, 17, e0273012.	1.1	1
3665	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
3666	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
3668	Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3670	Nanotechnology-based strategies against SARS-CoV-2 variants. <i>Nature Nanotechnology</i> , 2022, 17, 1027-1037.	15.6	63
3671	Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection. <i>3 Biotech</i> , 2022, 12, .	1.1	4
3672	Cell-based receptor discovery identifies host factors specifically targeted by the SARS CoV-2 spike. <i>Communications Biology</i> , 2022, 5, .	2.0	1
3673	Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. <i>EBioMedicine</i> , 2022, 83, 104232.	2.7	48
3674	Immunogenicity and safety of a RBD vaccine against SARS-CoV-2 in a murine model. <i>Travel Medicine and Infectious Disease</i> , 2022, 49, 102427.	1.5	0
3675	Potential of targeting host cell calcium dynamics to curtail SARS-CoV-2 infection and COVID-19 pathogenesis. <i>Cell Calcium</i> , 2022, 106, 102637.	1.1	6
3676	Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2. <i>Microbial Pathogenesis</i> , 2022, 170, 105687.	1.3	4
3677	Multivalent ACE2 engineeringâ€”A promising pathway for advanced coronavirus nanomedicine development. <i>Nano Today</i> , 2022, 46, 101580.	6.2	7



#	ARTICLE	IF	CITATIONS
3678	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
3679	Potential of antibody pair targeting conserved antigenic sites in diagnosis of SARS-CoV-2 variants infection. <i>Journal of Virological Methods</i> , 2022, 309, 114597.	1.0	1
3680	Decoding molecular factors shaping human angiotensin converting enzyme 2 receptor usage by spike glycoprotein in lineage B beta-coronaviruses. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166514.	1.8	2
3681	Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 117, 108286.	1.3	20
3682	Large interfacial relocation in RBD-ACE2 complex may explain fast-spreading property of Omicron. <i>Journal of Molecular Structure</i> , 2022, 1270, 133842.	1.8	0
3683	Structural aspects of SARS-CoV-2 mutations: Implications to plausible infectivity with ACE-2 using computational modeling approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6518-6533.	2.0	9
3684	Afecciones, manifestaciones y repercusiones neurológicas del COVID-19.. <i>Revista Médica De Risaralda</i> , 2022, 28, .	0.1	0
3685	A Sulfated Abalone Polysaccharide Inhibited SARS-CoV-2 Infection of Vero E6 Cells In Vitro. <i>Foods</i> , 2022, 11, 2865.	1.9	2
3686	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
3687	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
3689	Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. <i>Nature Chemical Biology</i> , 2022, 18, 1270-1276.	3.9	8
3690	Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1502.	2.1	1
3691	A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT. <i>International Journal of Applied Pharmaceutics</i> , 0, , 22-31.	0.3	1
3692	Tailored lipopeptide surfactants as potentially effective drugs to treat SARS-CoV-2 infection. <i>Medical Hypotheses</i> , 2022, 167, 110948.	0.8	1
3693	Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain. <i>Computers in Biology and Medicine</i> , 2022, 149, 106035.	3.9	14
3694	Oral inhalation of cannabidiol delivered from a metered dose inhaler to alleviate cytokine production induced by SARS-CoV-2 and pollutants. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103805.	1.4	2
3695	Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening. <i>Virus Research</i> , 2022, 321, 198915.	1.1	2
3696	Unfolding of the SARS-CoV-2 spike protein through infrared and ultraviolet-C radiation based disinfection. <i>International Journal of Biological Macromolecules</i> , 2022, 221, 71-82.	3.6	5

#	ARTICLE	IF	CITATIONS
3697	Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection. <i>Chemico-Biological Interactions</i> , 2022, 367, 110179.	1.7	2
3698	Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive tools. <i>International Journal of Biological Macromolecules</i> , 2022, 220, 1415-1428.	3.6	5
3699	Omicron variant: Current insights and future directions. <i>Microbiological Research</i> , 2022, 265, 127204.	2.5	32
3700	A six-month study of anti-SARS-CoV-2 BNT162b2 mRNA vaccination: A comparative analysis of essential trace elements and anti-RBD IgG sera levels. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 74, 127079.	1.5	1
3701	Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. <i>Biomedical Engineering Advances</i> , 2022, 4, 100054.	2.2	3
3702	Role of spike compensatory mutations in the interspecies transmission of SARS-CoV-2. <i>One Health</i> , 2022, 15, 100429.	1.5	7
3703	Selection and characterisation of bioreceptors to develop nanoparticle-based lateral-flow immunoassays in the context of the SARS-CoV-2 outbreak. <i>Lab on A Chip</i> , 2022, 22, 2938-2943.	3.1	5
3704	Overview and applications of map and model validation tools in the CCP-EM software suite. <i>Faraday Discussions</i> , 0, , .	1.6	0
3705	Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies. <i>Communications in Information and Systems</i> , 2022, 22, 339-361.	0.3	2
3706	Fluorescence detection of the human angiotensinogen protein by the G-quadruplex aptamer. <i>Analyst</i> , 2022, 147, 4040-4048.	1.7	3
3707	RBD spatial orientation of the spike protein and its binding to ACE2: insight into the high infectivity of the SARS-CoV-2 Delta variant from MD simulations. <i>Physical Chemistry Chemical Physics</i> , 0, , .	1.3	2
3708	Genetics and Biological Characteristics of SARS-CoV-2. , 2022, , 49-66.		0
3709	Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. <i>Infection and Chemotherapy</i> , 2022, 54, 504.	1.0	2
3710	Design of high-avidity multivalent ligand structures that target cells with high ligand economy. <i>Chemical Communications</i> , 2022, 58, 9802-9805.	2.2	1
3711	Natural drugs for the treatment of severe acute respiratory syndrome coronaviruses infections (SARS-CoV and COVID-19). , 2022, , 73-153.		0
3712	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
3713	Computationally Repurposed Natural Products Targeting SARS-CoV-2 Attachment and Entry Mechanisms. , 2022, , 505-537.		3
3714	Development and application of ribonucleic acid therapy strategies against COVID-19. <i>International Journal of Biological Sciences</i> , 2022, 18, 5070-5085.	2.6	18

#	ARTICLE	IF	CITATIONS
3715	Pathogenetic connection of chronic sinusitis with polyps and new coronavirus infection. Rossiiskaya Rinologiya, 2022, 30, 192.	0.1	0
3716	Prospects of Coffee Leaf against SARS-CoV-2 Infection. International Journal of Biological Sciences, 2022, 18, 4677-4689.	2.6	7
3717	Omicron Coronavirus Variant: pH-Dependent Electrostatic Potentials and Energy of Association of S-Protein to ACE2 Receptor. SSRN Electronic Journal, 0, , .	0.4	1
3718	Antibody-mediated immunity to SARS-CoV-2 spike. Advances in Immunology, 2022, , 1-69.	1.1	12
3719	The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. Carbohydrate Polymers, 2023, 299, 120167.	5.1	8
3720	Structural modeling of protein ensembles between E3 RING ligases and SARS-CoV-2: The role of zinc binding domains. Journal of Trace Elements in Medicine and Biology, 2023, 75, 127089.	1.5	2
3721	In Silico Evaluation of Sesquiterpenes and Benzoxazinoids Phytotoxins against Mpro, RNA Replicase and Spike Protein of SARS-CoV-2 by Molecular Dynamics. Inspired by Nature. Toxins, 2022, 14, 599.	1.5	1
3722	Long-term Lung Abnormalities Associated with COVID-19 Pneumonia. Radiology, 2023, 306, .	3.6	35
3723	A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	10
3725	Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments. Drug Discoveries and Therapeutics, 2022, 16, 196-197.	0.6	2
3726	Simultaneous measurement of the antibody responses against SARS-CoV-2 and its multiple variants by a phage display mediated immuno-multiplex quantitative PCR-based assay. Frontiers in Microbiology, 0, 13, .	1.5	3
3727	Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. International Journal of Molecular Sciences, 2022, 23, 9763.	1.8	17
3728	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spikeâ€”ACE2 Proteinâ€”Protein Interaction from a Chemical Space of Privileged Protein Binders. Pharmaceuticals, 2022, 15, 1084.	1.7	5
3729	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. Cell, 2022, 185, 4008-4022.e14.	13.5	55
3730	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. Frontiers in Immunology, 0, 13, .	2.2	2
3731	Molecular insights into the interaction of apo-lactoferrin with the receptor binding domain of the SARS-CoV-2 spike protein: a molecular dynamics simulation study. Journal of Biomolecular Structure and Dynamics, 2023, 41, 7372-7385.	2.0	0
3733	Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach. International Journal of Molecular Sciences, 2022, 23, 10716.	1.8	5
3735	Structural Reshaping of the Zinc-Finger Domain of the SARS-CoV-2 nsp13 Protein Using Bismuth(III) Ions: A Multilevel Computational Study. Inorganic Chemistry, 2022, 61, 15664-15677.	1.9	9

#	ARTICLE	IF	CITATIONS
3736	Improvement of native structure-based peptides as efficient inhibitors of protein-protein interactions of SARS-CoV-2 spike protein and human ACE2. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
3737	Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2. <i>Bioprocess and Biosystems Engineering</i> , 2022, 45, 1753-1769.	1.7	3
3738	Expression analysis of <i>miRNA</i> hsa-let-7b-5p in nasopharyngeal swabs of COVID-19 patients supports its role in regulating <i>ACE2</i> and <i>DPP4</i> receptors. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4940-4948.	1.6	15
3739	An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines. <i>PLoS Pathogens</i> , 2022, 18, e1010828.	2.1	25
3740	When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy. <i>Journal of Chemical Theory and Computation</i> , 2022, 18, 5890-5900.	2.3	15
3741	A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. <i>Nature Communications</i> , 2022, 13, .	5.8	37
3742	Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	2
3743	Integrated network pharmacology analysis, molecular docking, LC-MS analysis and bioassays revealed the potential active ingredients and underlying mechanism of <i>Scutellariae radix</i> for COVID-19. <i>Frontiers in Plant Science</i> , 0, 13, .	1.7	5
3744	Drug repurposing and sequence analysis in S-glycoprotein variants reveals critical signature patterns and destabilization of receptor-binding domain in omicron variant. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 7931-7948.	2.0	0
3745	Molecular Mechanism of the Non-Covalent Orally Targeted SARS-CoV-2 M <sup>pro</sup> Inhibitor S-217622 and Computational Assessment of Its Effectiveness against Mainstream Variants. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 8893-8901.	2.1	7
3746	Memory CD8 <sup>+</sup> T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. <i>Nature Immunology</i> , 2022, 23, 1445-1456.	7.0	27
3748	From COVID-19 to the Central Dogma. <i>American Biology Teacher</i> , 2022, 84, 410-414.	0.1	0
3749	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. <i>ACS Infectious Diseases</i> , 2022, 8, 2119-2132.	1.8	1
3750	SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows. <i>Biomedicines</i> , 2022, 10, 2242.	1.4	6
3752	Dok3 restrains neutrophil production of calprotectin during TLR4 sensing of SARS-CoV-2 spike protein. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3753	Applications of Functional DNA Materials in Immunomodulatory Therapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 45079-45095.	4.0	9
3754	A study protocol to prepare an RBD protein for vaccine against COVID-19. <i>F1000Research</i> , 0, 10, 943.	0.8	0
3755	Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10315.	1.8	7

#	ARTICLE	IF	CITATIONS
3756	Evidence for Multiple Binding Modes in the Initial Contact Between SARS-CoV-2 Spike S1 Protein and Cell Surface Glycans**. Chemistry - A European Journal, 2023, 29, .	1.7	2
3757	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	4
3758	Tracking mutational semantics of SARS-CoV-2 genomes. Scientific Reports, 2022, 12, .	1.6	2
3759	Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors. Scientific Reports, 2022, 12, .	1.6	6
3760	A comparative study of receptor interactions between SARS-CoV and SARS-CoV-2 from molecular modeling. Journal of Molecular Modeling, 2022, 28, .	0.8	3
3761	Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies. Frontiers in Medicine, 0, 9, .	1.2	5
3762	MVsim is a toolset for quantifying and designing multivalent interactions. Nature Communications, 2022, 13, .	5.8	1
3764	Biophysical and Biochemical Characterization of the Receptor Binding Domain of SARS-CoV-2 Variants. Protein Journal, 2022, 41, 457-467.	0.7	0
3765	Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Science Advances, 2022, 8, .	4.7	22
3766	Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2. Viruses, 2022, 14, 2020.	1.5	1
3767	Computation of the Binding Energies between Human ACE2 and Spike RBDs of the Original Strain, Delta and Omicron Variants of the SARS-CoV-2: A DFT Simulation Approach. Advanced Theory and Simulations, 2022, 5, .	1.3	6
3768	Engineering recombinantly expressed lectin-based antiviral agents. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2
3769	Modeling of the thermal properties of SARS-CoV-2 S-protein. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
3770	Utility of in silico-identified-peptides in spike-S1 domain and nucleocapsid of SARS-CoV-2 for antibody detection in COVID-19 patients and antibody production. Scientific Reports, 2022, 12, .	1.6	2
3771	Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection. Nature Chemical Biology, 2023, 19, 275-283.	3.9	12
3772	The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity. International Journal of Molecular Sciences, 2022, 23, 11325.	1.8	6
3773	Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing. Frontiers in Immunology, 0, 13, .	2.2	6
3774	Receptor-binding domain-anchored peptides block binding of severe acute respiratory syndrome coronavirus 2 spike proteins with cell surface angiotensin-converting enzyme 2. Frontiers in Microbiology, 0, 13, .	1.5	1

#	ARTICLE	IF	CITATIONS
3775	Immune Evasion of SARS-CoV-2 Omicron Subvariants. <i>Vaccines</i> , 2022, 10, 1545.	2.1	19
3776	Genomic surveillance unfolds the SARS-CoV-2 transmission and divergence dynamics in Bangladesh. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
3777	Association of Male Hypogonadism With Risk of Hospitalization for COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2229747.	2.8	11
3778	SP-A binding to the SARS-CoV-2 spike protein using hybrid quantum and classical in silico modeling and molecular pruning by Quantum Approximate Optimization Algorithm (QAOA) Based MaxCut with ZDOCK. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3779	Thermoresponsive and antibacterial two-dimensional polyglycerol-interlocked-polynipam for targeted drug delivery. <i>Journal of Nanostructure in Chemistry</i> , 0, , .	5.3	3
3780	Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. <i>Communications Biology</i> , 2022, 5, .	2.0	13
3781	Delta variant: Partially sensitive to vaccination, but still worth global attention. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 227-235.	1.0	2
3783	SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope. <i>Nature Microbiology</i> , 2022, 7, 1635-1649.	5.9	25
3784	Recent advances in small-molecular therapeutics for COVID-19. <i>Precision Clinical Medicine</i> , 2022, 5, .	1.3	9
3785	Metalloprotease-Dependent S2â€²-Activation Promotes Cellâ€²Cell Fusion and Syncytiation of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 2094.	1.5	6
3786	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. <i>IScience</i> , 2022, 25, 105193.	1.9	7
3787	Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. <i>Cell</i> , 2022, 185, 3992-4007.e16.	13.5	167
3788	Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10091.	1.8	8
3789	Sequence difference of angiotensin-converting enzyme 2 between nonhuman primates affects its binding-affinity with SARS-CoV-2 S receptor binding domain. <i>Biosafety and Health</i> , 2022, , .	1.2	0
3790	A comparative overview of SARSâ€²CoVâ€²2 and its variants of concern. <i>Infezioni in Medicina</i> , 2022, 30, .	0.7	6
3791	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
3792	Longitudinal neutralization activities on authentic Omicron variant provided by 3 doses of BBIBPâ€²CorV vaccination during one year. <i>Proteomics</i> , 0, , 2200306.	1.3	2
3793	Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naÃve individuals. <i>Scientific Reports</i> , 2022, 12, .	1.6	8



#	ARTICLE	IF	CITATIONS
3794	Tea as a natural gift for discovering antiviral candidates. , 2022, 2, 211-220.		4
3795	Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2. <i>IScience</i> , 2022, 25, 105259.	1.9	4
3796	SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	6
3798	Apple polyphenols attenuate the binding ability of angiotensin converting enzyme 2 to viral proteins: Computer simulation and in vitro experiments. <i>Food Bioscience</i> , 2022, , 102090.	2.0	1
3799	Newly-onset Autoimmune Diabetes Mellitus Triggered by COVID 19 Infection: A Case-based Review. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, 887-893.	0.6	4
3800	The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0267423.	1.1	12
3801	Plasmonic photonic biosensor: in situ detection and quantification of SARS-CoV-2 particles. <i>Optics Express</i> , 2022, 30, 40277.	1.7	9
3802	Effect of Disulfide Bridge on the Binding of SARS-CoV-2 Fusion Peptide to Cell Membrane: A Coarse-Grained Study. <i>ACS Omega</i> , 0, , .	1.6	2
3803	Genomic and structural mechanistic insight to reveal the differential infectivity of omicron and other variants of concern. <i>Computers in Biology and Medicine</i> , 2022, 150, 106129.	3.9	6
3804	Non-uniform aspects of the SARS-CoV-2 intraspecies evolution reopen question of its origin. <i>International Journal of Biological Macromolecules</i> , 2022, 222, 972-993.	3.6	2
3805	Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 30, 184-197.	2.3	19
3806	Computational Modeling of ACE2 Inhibitors for Development of Drugs Against Coronaviruses. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 615-629.	0.1	0
3807	Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic. <i>Environmental Health Insights</i> , 2022, 16, 117863022211293.	0.6	17
3808	Biological effect of black phosphorus nanosheets on the interaction between SARS-CoV-2 S protein and ACE2. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 27388-27393.	1.3	1
3809	MoS <sub>2</sub> nanosheets effectively bind to the receptor binding domain of the SARS-CoV-2 spike protein and destabilize the spike–human ACE2 receptor interactions. <i>Soft Matter</i> , 2022, 18, 8961-8973.	1.2	4
3810	Osteosarcopenia and Long-COVID: a dangerous combination. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211304.	1.2	5
3811	Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2. <i>Viruses</i> , 2022, 14, 2178.	1.5	5
3812	ML-DTD: Machine Learning-Based Drug Target Discovery for the Potential Treatment of COVID-19. <i>Vaccines</i> , 2022, 10, 1643.	2.1	5

#	ARTICLE	IF	CITATIONS
3813	Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Immunology</i> , 2022, 209, 1499-1512.	0.4	1
3814	Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations. <i>Viruses</i> , 2022, 14, 2259.	1.5	12
3815	Continued Complexity of Mutations in Omicron Sublineages. <i>Biomedicines</i> , 2022, 10, 2593.	1.4	5
3816	Quantitative proteomics and biological activity of extracellular vesicles engineered to express SARS-CoV-2 spike protein. , 2022, 1, .		2
3818	A snapshot of protein trafficking in SARS-CoV-2 infection. <i>Biology of the Cell</i> , 2023, 115, .	0.7	8
3819	Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein. <i>Cells</i> , 2022, 11, 3355.	1.8	3
3820	Cell Entry and Unusual Replication of SARS-CoV-2. <i>Current Drug Targets</i> , 2022, 23, 1539-1554.	1.0	1
3821	Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3822	Angiotensin converting enzyme 2 level and its significance in COVID-19 and other diseases patients. <i>European Journal of Clinical Investigation</i> , 0, , .	1.7	2
3823	The SARS-CoV-2 S1 Spike Protein Promotes MAPK and NF- $\kappa$ B Activation in Human Lung Cells and Inflammatory Cytokine Production in Human Lung and Intestinal Epithelial Cells. <i>Microorganisms</i> , 2022, 10, 1996.	1.6	11
3824	Spike protein mediated membrane fusion during SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	15
3825	Dissecting Naturally Arising Amino Acid Substitutions at Position L452 of SARS-CoV-2 Spike. <i>Journal of Virology</i> , 2022, 96, .	1.5	5
3826	The pathogenesis of coronavirus-19 disease. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	34
3827	Prevalence and coagulation correlation of anticardiolipin antibodies in patients with COVID-19. <i>Medicine (United States)</i> , 2022, 101, e31040.	0.4	0
3828	PATHOGENESIS OF COVID-19. <i>TavriĚskij Mediko-biologiĚskij Vestnik</i> , 2022, 23, 113-132.	0.1	3
3829	Isolation of SARS-CoV-2-blocking recombinant antibody fragments and characterisation of their binding to variant spike proteins. <i>Frontiers in Nanotechnology</i> , 0, 4, .	2.4	0
3830	Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
3831	Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor. <i>Nutrients</i> , 2022, 14, 4170.	1.7	8

#	ARTICLE	IF	CITATIONS
3832	A core epitope targeting antibody of SARS-CoV-2. <i>Protein and Cell</i> , 0, , .	4.8	0
3833	Adaptive immunity to SARS-CoV-2 infection: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	18
3834	Syntheses and Structural Characterization of Divalent Metal Complexes (Co, Ni, Pd and Zn) of Sterically Hindered Thiourea Ligand and A Theoretical Insight of their Interaction with SARS-CoV-2 Enzyme. <i>Journal of Molecular Structure</i> , 2022, , 134442.	1.8	1
3835	Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. <i>Biophysical Reviews</i> , 2022, 14, 1109-1140.	1.5	15
3836	SARS-CoV-2 down-regulates ACE2 through lysosomal degradation. <i>Molecular Biology of the Cell</i> , 2022, 33, .	0.9	19
3837	SARS-CoV-2 Spike Protein (RBD) Subunit Adsorption at Abiotic Surfaces and Corona Formation at Polymer Particles. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12374.	1.8	1
3838	Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3839	Antiviral drug design based on structural insights into the N-terminal domain and C-terminal domain of the SARS-CoV-2 nucleocapsid protein. <i>Science Bulletin</i> , 2022, 67, 2327-2335.	4.3	7
3841	Detection of SARS-CoV-2 in a dog with hemorrhagic diarrhea. <i>BMC Veterinary Research</i> , 2022, 18, .	0.7	10
3842	Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines. <i>Polymers</i> , 2022, 14, 4195.	2.0	13
3843	Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12516.	1.8	4
3844	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. <i>Science</i> , 2022, 378, 619-627.	6.0	117
3845	Proteomic Approach for Comparative Analysis of the Spike Protein of SARS-CoV-2 Omicron (B.1.1.529) Variant and Other Pango Lineages. <i>Proteomes</i> , 2022, 10, 34.	1.7	1
3846	Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2. <i>Cell Reports</i> , 2022, 41, 111650.	2.9	12
3847	Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	26
3848	Effects of a Shift of the Signal Peptide Cleavage Site in Signal Peptide Variant on the Synthesis and Secretion of SARS-CoV-2 Spike Protein. <i>Molecules</i> , 2022, 27, 6688.	1.7	3
3849	Elucidation of Binding Features and Dissociation Pathways of Inhibitors and Modulators in SARS-CoV-2 Main Protease by Multiple Molecular Dynamics Simulations. <i>Molecules</i> , 2022, 27, 6823.	1.7	3
3850	LRR15 inhibits SARS-CoV-2 cellular entry in trans. <i>PLoS Biology</i> , 2022, 20, e3001805.	2.6	10

#	ARTICLE	IF	CITATIONS
3852	Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. <i>Advanced Science</i> , 2022, 9, .	5.6	17
3853	Virtual screening and molecular dynamics simulation study of abyssomicins as potential inhibitors of COVID-19 virus main protease and spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 8961-8977.	2.0	1
3854	Cyclophilin A-mediated mitigation of coronavirus <sc>SARS-CoV</sc>. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	8
3855	In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19. <i>Chemical Papers</i> , 2023, 77, 1129-1148.	1.0	1
3856	Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of <sc>SARS-CoV</sc>. <i>Protein Science</i> , 2022, 31, .	3.1	1
3858	Glycosylation in SARS-CoV-2 variants: A path to infection and recovery. <i>Biochemical Pharmacology</i> , 2022, 206, 115335.	2.0	7
3859	Screening of Selected Stingless Bee Honey Varieties for ACE2-Spike Protein-Binding Inhibition Activity: A Potential Preventive Medicine Against SARS-Cov-2 Infection. <i>The Malaysian Journal of Medical Sciences</i> , 2022, 29, 146-153.	0.3	2
3860	Antiviral Disaccharide Lead Compounds against SARS-CoV-2 through Computer-Aided High-Throughput Screen. <i>ChemBioChem</i> , 2022, 23, .	1.3	2
3861	Genetic diversity and evolutionary convergence of cryptic SARS-CoV-2 lineages detected via wastewater sequencing. <i>PLoS Pathogens</i> , 2022, 18, e1010636.	2.1	32
3862	Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. <i>Cell Host and Microbe</i> , 2022, 30, 1540-1555.e15.	5.1	96
3863	Immunoglobulin Y Specific for SARS-CoV-2 Spike Protein Subunits Effectively Neutralizes SARS-CoV-2 Infectivity and Ameliorates Disease Manifestations In Vivo. <i>Biomedicines</i> , 2022, 10, 2774.	1.4	0
3864	SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. <i>Communications Biology</i> , 2022, 5, .	2.0	37
3865	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
3866	Effect of the Graphene Nanosheet on Functions of the Spike Protein in Open and Closed States: Comparison between SARS-CoV-2 Wild Type and the Omicron Variant. <i>Langmuir</i> , 2022, 38, 13972-13982.	1.6	3
3867	Recent approaches to mRNA vaccine delivery by lipid-based vectors prepared by continuous-flow microfluidic devices. <i>Future Medicinal Chemistry</i> , 2022, 14, 1561-1581.	1.1	7
3868	High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 2779.	1.4	2
3869	Inhalation of Low Molecular Weight Heparins as Prophylaxis against SARS-CoV-2. <i>MBio</i> , 2022, 13, .	1.8	4
3870	Polymer-based microneedle composites for enhanced non-transdermal drug delivery. <i>Applied Materials Today</i> , 2022, 29, 101659.	2.3	4

#	ARTICLE	IF	CITATIONS
3871	Multiplexed rapid antigen tests developed using multicolored nanoparticles and cross-reactive antibody pairs: Implications for pandemic preparedness. <i>Nano Today</i> , 2022, 47, 101669.	6.2	6
3872	A peptide array pipeline for the development of Spike-ACE2 interaction inhibitors. <i>Peptides</i> , 2022, 158, 170898.	1.2	2
3873	The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2 infection. <i>Annals of Diagnostic Pathology</i> , 2022, 61, 152057.	0.6	9
3874	Intranasal SARS-CoV-2 spike-based immunisation adjuvanted with polyethyleneimine elicits mucosal and systemic humoral responses in mice. <i>Journal of Immunological Methods</i> , 2022, 511, 113380.	0.6	0
3875	Integrated computational approach towards identification of HSPG and ACE2 mimicking moieties for SARS-CoV-2 inhibition. <i>Journal of Molecular Liquids</i> , 2022, 367, 120566.	2.3	0
3876	<i>In silico</i> study identifies peptide inhibitors that negate the effect of non-synonymous mutations in major drug targets of SARS-CoV-2 variants. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9551-9561.	2.0	1
3877	Evaluation of STANDARDTM M10 SARS-CoV-2, a Novel Cartridge-Based Real-Time PCR Assay for the Rapid Identification of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Applied Microbiology</i> , 2022, 2, 873-881.	0.7	2
3878	Molecular Docking and Dynamics Simulation Studies of Ginsenosides with SARS-CoV-2 Host and Viral Entry Protein Targets. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211343.	0.2	3
3879	Infrared spectra of the SARS-CoV-2 spike receptor-binding domain: Molecular dynamics simulations. <i>Chemical Physics Letters</i> , 2023, 810, 140176.	1.2	4
3881	Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. <i>BMJ</i> , The, 0, , e072175.	3.0	16
3882	Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
3883	Molecular dynamics simulations of the spike trimeric ectodomain of the SARS-CoV-2 Omicron variant: structural relationships with infectivity, evasion to immune system and transmissibility. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9326-9343.	2.0	4
3884	Structural and energetic analyses of SARS-CoV-2 N-terminal domain characterise sugar binding pockets and suggest putative impacts of variants on COVID-19 transmission. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 6302-6316.	1.9	0
3885	A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13716.	1.8	3
3886	Multivalent Pattern Recognition through Control of Nano-Spacing in Low-Valency Super-Selective Materials. <i>Journal of the American Chemical Society</i> , 2022, 144, 21576-21586.	6.6	13
3887	Proteolysis and Deficiency of $\hat{1}$ -Proteinase Inhibitor in SARS-CoV-2 Infection. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2022, 16, 271-291.	0.2	1
3888	Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of <i>Escherichia coli</i> . <i>Bioengineering</i> , 2022, 9, 670.	1.6	2
3889	In Silico Protein Folding Prediction of COVID-19 Mutations and Variants. <i>Biomolecules</i> , 2022, 12, 1665.	1.8	4

#	ARTICLE	IF	CITATIONS
3890	A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies. <i>Analytica Chimica Acta</i> , 2023, 1238, 340633.	2.6	2
3891	Combined effect of traditional Chinese herbal-based formulations Jing Si herbal tea and Jing Si nasal drop inhibits adhesion and transmission of SARS-CoV2 in diabetic SKH-1 mice. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3892	Role of milk glycome in prevention, treatment, and recovery of COVID-19. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	6
3893	A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. <i>Immunobiology</i> , 2023, 228, 152302.	0.8	14
3894	Seroprevalence of SARS-CoV-2 in 1186 Equids Presented to a Veterinary Medical Teaching Hospital in California from 2020 to 2022. <i>Viruses</i> , 2022, 14, 2497.	1.5	3
3895	Virtual screening based on the structure of more than 105 compounds against four key proteins of SARS-CoV-2: MPro, SRBD, RdRp, and PLpro. <i>Informatics in Medicine Unlocked</i> , 2022, 35, 101134.	1.9	3
3896	A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3897	Review of Developments in Combating COVID-19 by Vaccines, Inhibitors, Radiations, and Nonthermal Plasma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5666-5690.	1.0	4
3898	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	1.9	10
3900	Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3901	Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS. <i>Journal of Proteome Research</i> , 0, , .	1.8	2
3902	Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
3903	The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13502.	1.8	6
3904	The Expression Levels of SARS-CoV-2 Infection-Mediating Molecules Promoted by Interferon- $\beta$ and Tumor Necrosis Factor- $\alpha$ Are Downregulated by Hydrogen Sulfide. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13624.	1.8	1
3905	The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. <i>Vaccines</i> , 2022, 10, 1926.	2.1	29
3906	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3908	Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor-binding affinity. <i>Glycobiology</i> , 2023, 33, 126-137.	1.3	11
3909	Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19. <i>Journal of Molecular Modeling</i> , 2022, 28, .	0.8	2



#	ARTICLE	IF	CITATIONS
3910	The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
3911	Structural analysis of a simplified model reproducing SARS-CoV-2 S RBD/ACE2 binding site. <i>Heliyon</i> , 2022, 8, e11568.	1.4	4
3912	Stochastic Lag Time Parameterization for Markov State Models of Protein Dynamics. <i>Journal of Physical Chemistry B</i> , 2022, 126, 9465-9475.	1.2	0
3913	Involvement of sialoglycans in <scp>SARSâ€COV</scp>â€2 infection: Opportunities and challenges for glycoâ€based inhibitors. <i>IUBMB Life</i> , 2022, 74, 1253-1263.	1.5	3
3914	Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis. <i>Molecular Immunology</i> , 2022, 152, 172-182.	1.0	10
3915	Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases. <i>Experimental Biology and Medicine</i> , 2022, 247, 1923-1936.	1.1	1
3916	Alcohol use disorder as a potential risk factor for<scp>COVID</scp>â€19 severity: A narrative review. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1930-1943.	1.4	2
3917	Green and Regioselective Approach for the Synthesis of 3-Substituted Indole Based 1,2-Dihydropyridine and Azaxanthone Derivatives as a Potential Lead for SARS-CoV-2 and Delta Plus Mutant Virus: DFT and Docking Studies. <i>ACS Omega</i> , 0, , .	1.6	3
3918	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <i>PLoS ONE</i> , 2022, 17, e0277745.	1.1	4
3919	A novel plantâ€made monoclonal antibody enhances the synergetic potency of an antibody cocktail against the <scp>SARSâ€CoV</scp>â€2 Omicron variant. <i>Plant Biotechnology Journal</i> , 2023, 21, 549-559.	4.1	8
3920	Conformational stability of SARS-CoV-2 glycoprotein spike variants. <i>IScience</i> , 2023, 26, 105696.	1.9	5
3921	Effect of N343 glycosylation and N501Y mutation on the SARS-CoV-2 spike protein: Modeling and MD Simulations. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	2
3922	Modified intelligent magnetic nanoparticles as a treatment for severe acute respiratory syndrome coronavirus type 2 In Silico. <i>Biomedical and Biotechnology Research Journal</i> , 2022, 6, 510.	0.3	0
3923	Deep Recurrent Neural Networks for the Generation of Synthetic Coronavirus Spike Protein Sequences. <i>Lecture Notes in Computer Science</i> , 2022, , 217-226.	1.0	0
3924	Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. <i>IScience</i> , 2023, 26, 105783.	1.9	4
3925	Nanobody derived using a peptide epitope from the spike protein receptor-binding motif inhibits entry of SARS-CoV-2 variants. <i>Journal of Biological Chemistry</i> , 2023, 299, 102732.	1.6	3
3926	A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. <i>Virus Research</i> , 2023, 324, 199024.	1.1	5
3927	Circulating microRNAs as emerging regulators of COVID-19. <i>Theranostics</i> , 2023, 13, 125-147.	4.6	11

#	ARTICLE	IF	CITATIONS
3928	Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. <i>International Journal of Biological Macromolecules</i> , 2023, 226, 780-792.	3.6	4
3929	Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic. <i>Biochemical Pharmacology</i> , 2023, 208, 115370.	2.0	7
3930	Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2023, 227, 896-902.	3.6	2
3931	SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor. <i>Nano Today</i> , 2023, 48, 101729.	6.2	14
3932	Inhibitory activities of alginate phosphate and sulfate derivatives against SARS-CoV-2 in vitro. <i>International Journal of Biological Macromolecules</i> , 2023, 227, 316-328.	3.6	2
3933	Polymer modification of SARS-CoV-2 spike protein impacts its ability to bind key receptor. <i>European Polymer Journal</i> , 2023, 184, 111767.	2.6	0
3934	Molecular Evolution of the Novel Coronavirus SARS-CoV-2. <i>Journal of Evolutionary Science</i> , 2020, 1, 53-64.	0.4	1
3935	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. <i>Journal of Biomedical Research</i> , 2023, 37, 166.	0.7	1
3936	SARS-CoV-2 Infection after Effects: Multi-Organ Damage through Oxygen Radicals. <i>Apollo Medicine</i> , 2022, .	0.0	0
3937	Biochemical Laboratory Findings on COVID-19 Patients: Pathogen-Disease Relationship. <i>Eurasian Journal of Biological and Chemical Sciences</i> , 0, , .	0.0	0
3938	Investigating RNA-protein recognition mechanisms through supervised molecular dynamics (SuMD) simulations. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	6
3940	Spike protein of SARS-CoV-2 Omicron variant: An in-silico study evaluating spike interactions and immune evasion. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
3941	An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	11
3942	A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3943	Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14796.	1.8	14
3944	Antiviral activity of amiodarone in SARS-CoV-2 disease. <i>Physiological Research</i> , 2022, 71, 869-875.	0.4	1
3945	Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review. <i>Medicina (Lithuania)</i> , 2022, 58, 1733.	0.8	2
3946	Structural Profiles of SARS-CoV-2 Variants in India. <i>Current Microbiology</i> , 2023, 80, .	1.0	4

#	ARTICLE	IF	CITATIONS
3947	The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case. <i>Advanced Science</i> , 2023, 10, .	5.6	4
3948	Is SARS-CoV-2 viral load a predictor of mortality in COVID-19 acute respiratory distress syndrome patients?. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211374.	0.4	1
3950	Pea eggplant ( <i>Solanum torvum</i> Swartz) is a source of plant food polyphenols with SARS-CoV inhibiting potential. <i>PeerJ</i> , 0, 10, e14168.	0.9	1
3951	Electrochemical immunosensor nanoarchitectonics with the Ag-rGO nanocomposites for the detection of receptor-binding domain of SARS-CoV-2 spike protein. <i>Journal of Solid State Electrochemistry</i> , 2023, 27, 489-499.	1.2	3
3952	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3953	Cross-species binding spectrum of ACE2 to SARS-CoV-2 RBD. <i>Science China Life Sciences</i> , 0, , .	2.3	1
3954	CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	15
3955	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. <i>Vaccines</i> , 2022, 10, 2035.	2.1	3
3957	Severe acute respiratory disease in American mink experimentally infected with SARS-CoV-2. <i>JCI Insight</i> , 2022, 7, .	2.3	10
3959	Investigation of Protein-Protein Interactions Utilizing a Nano-Gold Colloid Surface Plasmon Resonance: Application to SARS CoV-2 Spike Protein Coated Gold Colloids. <i>ACS Symposium Series</i> , 0, , 145-164.	0.5	0
3960	Azole derivatives inhibit the binding of the RBD domain of SARS-Cov-2 against host ACE2 in in vitro assays. <i>Journal of Human Virology &amp; Retrovirology</i> , 2022, 9, 58-63.	0.1	0
3961	A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPinS. <i>Nature Chemical Biology</i> , 2023, 19, 284-291.	3.9	7
3962	Prediction of Recurrent Mutations in SARS-CoV-2 Using Artificial Neural Networks. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14683.	1.8	4
3963	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
3964	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
3965	Effects of Mangiferin on LPS-Induced Inflammation and SARS-CoV-2 Viral Adsorption in Human Lung Cells. <i>Pharmaceutics</i> , 2022, 14, 2845.	2.0	2
3966	QSAR of SARS-CoV-2 Main Protease Inhibitors Utilizing Theoretical Molecular Descriptors. <i>Letters in Drug Design and Discovery</i> , 2022, 20, .	0.4	2
3967	Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid. <i>International Journal of Molecular Sciences</i> , 2023, 24, 20.	1.8	3

#	ARTICLE	IF	CITATIONS
3968	Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. <i>ACS Applied Bio Materials</i> , 2023, 6, 182-190.	2.3	1
3969	Development of Electrochemical Biosensor Platforms for Determination of Environmental Viral Structures. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 12971.	1.3	2
3970	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
3971	Insight into the mechanisms of olfactory dysfunction by COVID-19. <i>Auris Nasus Larynx</i> , 2022, , .	0.5	0
3972	De-erosion of X chromosome dosage compensation by the editing of XIST regulatory regions restores the differentiation potential in hPSCs. <i>Cell Reports Methods</i> , 2022, 2, 100352.	1.4	4
3973	Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. <i>Molecules</i> , 2022, 27, 9044.	1.7	6
3974	Supramolecular filaments for concurrent ACE2 docking and enzymatic activity silencing enable coronavirus capture and infection prevention. <i>Matter</i> , 2023, 6, 583-604.	5.0	6
3975	Developing Biosensors for SARS-CoV-2 Wastewater-Based Epidemiology: A Systematic Review of Trends, Limitations and Future Perspectives. <i>Sustainability</i> , 2022, 14, 16761.	1.6	2
3976	Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge. <i>Vaccines</i> , 2022, 10, 2119.	2.1	4
3977	An In-Silico Multi-Targeted Approach in Search of Potential Drug Candidate(s) Against SARS-CoV-2 Lung Infection. <i>Coronaviruses</i> , 2022, 04, .	0.2	0
3978	The Effect of COVID-19 Vaccines on Stroke Outcomes: A Single-Center Study. <i>World Neurosurgery</i> , 2023, 170, e834-e839.	0.7	2
3980	In Vitro and In Silico Studies for the Identification of Potent Metabolites of Some High-Altitude Medicinal Plants from Nepal Inhibiting SARS-CoV-2 Spike Protein. <i>Molecules</i> , 2022, 27, 8957.	1.7	3
3981	HBD-2 variants and SARS-CoV-2: New insights into inter-individual susceptibility. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3982	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	42
3983	Pharmacoinformatic approach to identify potential phytochemicals against SARS-CoV-2 spike receptor-binding domain in native and variants of concern. <i>Molecular Diversity</i> , 0, , .	2.1	0
3984	Soluble ACE2 as a Risk or Prognostic Factor in COVID-19 Patients: A Cross-sectional Study. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	1
3985	A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern. <i>PLoS Pathogens</i> , 2022, 18, e1010994.	2.1	7
3986	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17

#	ARTICLE	IF	CITATIONS
3987	High-Yield Production of Chimeric Hepatitis E Virus-Like Particles Bearing the M2e Influenza Epitope and Receptor Binding Domain of SARS-CoV-2 in Plants Using Viral Vectors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15684.	1.8	8
3988	Development of Fluorescence-Tagged SARS-CoV-2 Virus-like Particles by a Tri-Cistronic Vector Expression System for Investigating the Cellular Entry of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 2825.	1.5	4
3989	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. <i>Science Advances</i> , 2022, 8, .	4.7	9
3990	<sc>IRAA</sc> : A statistical tool for investigating a proteinâ€“protein interaction interface from multiple structures. <i>Protein Science</i> , 2023, 32, .	3.1	1
3991	Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. <i>Nature Communications</i> , 2022, 13, .	5.8	8
3992	Network analysis uncovers the communication structure of SARS-CoV-2 spike protein identifying sites for immunogen design. <i>IScience</i> , 2023, 26, 105855.	1.9	7
3993	Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective. <i>Molecular Biology Reports</i> , 2023, 50, 2713-2721.	1.0	13
3994	Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. <i>Microorganisms</i> , 2023, 11, 30.	1.6	11
3995	Scalable agroinfiltration-based production of SARS-CoV-2 antigens for use in diagnostic assays and subunit vaccines. <i>PLoS ONE</i> , 2022, 17, e0277668.	1.1	5
3996	A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3997	A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2. <i>3 Biotech</i> , 2023, 13, .	1.1	2
3999	Absolute binding free energies of the antiviral peptide ATN-161 with protein targets of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 10546-10557.	2.0	2
4000	Potential antiviral peptides targeting the SARS-CoV-2 spike protein. <i>BMC Pharmacology &amp; Toxicology</i> , 2022, 23, .	1.0	3
4002	An <i>Escherichia coli</i> Expressed Multi-Disulfide Bonded SARS-CoV-2 RBD Shows Native-like Biophysical Properties and Elicits Neutralizing Antisera in a Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15744.	1.8	3
4003	Near-Native Visualization of SARS-CoV-2 Induced Membrane Remodeling and Virion Morphogenesis. <i>Viruses</i> , 2022, 14, 2786.	1.5	3
4004	Molecular screening of SARSâ€“CoVâ€“2 in dogs and cats from households with infected owners diagnosed with COVIDâ€“19 during Delta and Omicron variant waves in Iran. <i>Veterinary Medicine and Science</i> , 2023, 9, 82-90.	0.6	9
4005	Rapid Transient Expression of Receptor-Binding Domain of SARS-CoV-2 and the Conserved M2e Peptide of Influenza A Virus Linked to Flagellin in <i>Nicotiana benthamiana</i> Plants Using Self-Replicating Viral Vector. <i>Plants</i> , 2022, 11, 3425.	1.6	4
4006	Improved Expression of SARS-CoV-2 Spike RBD Using the Insect Cell-Baculovirus System. <i>Viruses</i> , 2022, 14, 2794.	1.5	1

#	ARTICLE	IF	CITATIONS
4007	Evaluation of S- and M-Proteins Expressed in Escherichia coli and HEK Cells for Serological Detection of Antibodies in Response to SARS-CoV-2 Infections and mRNA-Based Vaccinations. Pathogens, 2022, 11, 1515.	1.2	1
4008	Identification of anti-SARS-CoV-2 agents based on flavor/fragrance compositions that inhibit the interaction between the virus receptor binding domain and human angiotensin converting enzyme 2. PLoS ONE, 2022, 17, e0279182.	1.1	0
4009	Corona virus disease 2019-associated liver injury in cold regions. Frigid Zone Medicine, 2022, 2, 193-199.	0.2	0
4010	Prophylaxis and Remediation for Future Pandemic Pathogensâ€”(Lessons from a Post-COVID World). Microorganisms, 2022, 10, 2407.	1.6	0
4011	An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2. Cell Host and Microbe, 2023, 31, 243-259.e6.	5.1	20
4012	Synthesis and In Silico Investigation of Isatinâ€”Based Schiff Bases as Potential Inhibitors for Promising Targets against SARSâ€”CoVâ€”2. ChemistrySelect, 2022, 7, .	0.7	3
4013	Molecular Complementarity of Proteomimetic Materials for Targetâ€”Specific Recognition and Recognitionâ€”Mediated Complex Functions. Advanced Materials, 2023, 35, .	11.1	1
4015	<i>In Vitro</i> Screening and MD Simulations of Thiourea Derivatives against SARS-CoV-2 in Association with Multidrug Resistance ABCB1 Transporter. ACS Omega, 2022, 7, 47671-47679.	1.6	2
4016	Thermodynamic analysis of the interactions between human <sc>ACE2</sc> and spike <sc>RBD</sc> of Betacoronaviruses ( <sc>SARSâ€”CoV</sc> â€”1 and <sc>SARSâ€”CoV</sc> â€”2). FEBS Open Bio, 0, , .		2
4017	Potential targets of severe acute respiratory syndrome coronavirus 2 of clinical drug fluvoxamine: Docking and molecular dynamics studies to elucidate viral action. Cell Biochemistry and Function, 2023, 41, 98-111.	1.4	5
4018	Dendrimer-Peptide Conjugates for Effective Blockade of the Interactions between SARS-CoV-2 Spike Protein and Human ACE2 Receptor. Biomacromolecules, 2023, 24, 141-149.	2.6	5
4019	Molecular mechanisms implicated in SARS-CoV-2 liver tropism. World Journal of Gastroenterology, 0, 28, 6875-6887.	1.4	3
4020	Targeting SARS-CoV-2 and host cell receptor interactions. Antiviral Research, 2023, 210, 105514.	1.9	9
4021	Current and Emerging Knowledge in COVID-19. Radiology, 2023, 306, .	3.6	30
4023	Biology of SARS-CoV-2 Coronavirus; Origin, Structure, and Variants. Contemporary Cardiology, 2022, , 3-18.	0.0	0
4024	Clinical Symptoms and Course of COVID-19. Contemporary Cardiology, 2022, , 31-48.	0.0	0
4025	Receptor-binding domain of SARS-CoV-2 is a functional Î±v-integrin agonist. Journal of Biological Chemistry, 2023, 299, 102922.	1.6	11
4026	A bivalent subunit vaccine efficiently produced in Pichia pastoris against SARS-CoV-2 and emerging variants. Frontiers in Microbiology, 0, 13, .	1.5	2



#	ARTICLE	IF	CITATIONS
4027	Engineered soluble ACE2 receptor: Responding to change with change. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4028	SARS-CoV-2 N protein mediates intercellular nucleic acid dispersion, a feature reduced in Omicron. <i>IScience</i> , 2023, 26, 105995.	1.9	2
4029	DGCddG: Deep Graph Convolution for Predicting Protein-Protein Binding Affinity Changes Upon Mutations. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, 20, 2089-2100.	1.9	4
4030	S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review. <i>Vaccines</i> , 2023, 11, 204.	2.1	5
4031	Functionalized Fullerene for Inhibition of SARS-CoV-2 Variants. <i>Small</i> , 2023, 19, .	5.2	8
4032	Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 1467-1483.	2.9	3
4033	Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. <i>Nature</i> , 2023, 615, 143-150.	13.7	52
4034	Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. <i>Heliyon</i> , 2023, 9, e12667.	1.4	0
4035	The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. <i>Virology Journal</i> , 2023, 20, .	1.4	41
4036	Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
4037	Evaluating the transmission feasibility of SARS-CoV-2 Omicron (B.1.1.529) variant to 143 mammalian hosts: insights from S protein RBD and host ACE2 interaction studies. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	5
4038	Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
4039	Affinity Exploration of SARS-CoV-2 RBD Variants to mAb-Functionalized Plasmonic Metasurfaces for Label-Free Immunoassay Boosting. <i>ACS Nano</i> , 2023, 17, 3383-3393.	7.3	12
4040	Fetal demise and SARS-CoV-2 infection during pregnancy: Histopathological and immunohistochemical findings of three cases referred to the Colombian National Institute of Health. <i>Clinical Infection in Practice</i> , 2023, 17, 100219.	0.2	1
4041	Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots. <i>ACS Omega</i> , 2023, 8, 3319-3328.	1.6	3
4042	Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. <i>Nature Microbiology</i> , 2023, 8, 121-134.	5.9	6
4043	Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	11
4046	Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. <i>EBioMedicine</i> , 2023, 87, 104390.	2.7	3

#	ARTICLE	IF	CITATIONS
4047	Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2023, 25, 2304-2319.	1.3	3
4049	Humoral immunity for durable control of SARS-CoV-2 and its variants. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	6
4050	Interactions of SARS-CoV-2 and MERS-CoV fusion peptides measured using single-molecule force methods. <i>Biophysical Journal</i> , 2023, 122, 646-660.	0.2	1
4051	<i>α</i> -GalNAc glycosylation affects the immunogenicity of the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. <i>Chemical Communications</i> , 2023, 59, 1797-1800.	2.2	3
4052	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
4053	Molecularly Imprinted Polymers as Synthetic Antibodies for Protein Recognition: The Next Generation. <i>Small</i> , 2023, 19, .	5.2	30
4054	Identification of a short ACE2-derived stapled peptide targeting the SARS-CoV-2 spike protein. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115118.	2.6	6
4055	A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
4057	Evolutionary rate of SARS-CoV-2 increases during zoonotic infection of farmed mink. <i>Virus Evolution</i> , 2023, 9, .	2.2	16
4058	SARS-CoV-2 infection predicts larger infarct volume in patients with acute ischemic stroke. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
4059	The role of S477N mutation in the molecular behavior of SARS-CoV-2 spike protein: An <i>in silico</i> perspective. <i>Journal of Cellular Biochemistry</i> , 2023, 124, 308-319.	1.2	7
4060	A perspective on SARS-CoV-2 virus-like particles vaccines. <i>International Immunopharmacology</i> , 2023, 115, 109650.	1.7	6
4061	Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions. <i>Heliyon</i> , 2023, 9, e12890.	1.4	1
4062	Anti-inflammatory and antiviral activities of flavone C-glycosides of <i>Lophatherum gracile</i> for COVID-19. <i>Journal of Functional Foods</i> , 2023, 101, 105407.	1.6	4
4063	QM/MM study of N501 involved intermolecular interaction between SARS-CoV-2 receptor binding domain and antibody of human origin. <i>Computational Biology and Chemistry</i> , 2023, 102, 107810.	1.1	0
4064	Spatiotemporal changes of tissue glycans depending on localization in cardiac aging. <i>Regenerative Therapy</i> , 2023, 22, 68-78.	1.4	1
4065	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 37, e00780.	2.1	3
4066	Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants. <i>Vaccine</i> , 2022, , .	1.7	1

#	ARTICLE	IF	CITATIONS
4067	Computational Analysis of Receptor-Binding Domains of SARS-CoV-2 to Reveal the Mechanism of Immune Escape. , 2022, , .		0
4068	S-PDB: Analysis and Classification of SARS-CoV-2 Spike Protein Structures. , 2022, , .		4
4069	Asafetida ( <i>Ferula asafoetida</i> ) and its Potential Risks on Respiratory Disorders. <i>Current Traditional Medicine</i> , 2023, 9, .	0.1	0
4071	Targeting <sc>SARSâ€CoV</sc>â€2 by synthetic dualâ€acting thiol compounds that inhibit Spike/<sc>ACE2</sc> interaction and viral protein production. <i>FASEB Journal</i> , 2023, 37, .	0.2	6
4072	Revisiting the South Indian Traditional Plants against Several Targets of SARS-CoV-2 - An in silico Approach. <i>Current Computer-Aided Drug Design</i> , 2023, 19, 202-233.	0.8	1
4073	mRNA COVID-19 Vaccinesâ€Facts and Hypotheses on Fragmentation and Encapsulation. <i>Vaccines</i> , 2023, 11, 40.	2.1	1
4075	Association of hypernatremia with outcomes of COVID-19 patients: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e32535.	0.4	9
4076	Molecular insights into the <i>in silico</i> discovery of corilagin from <i>Terminalia chebula</i> as a potential dual inhibitor of SARS-CoV-2 structural proteins. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 10869-10884.	2.0	6
4077	High-Affinity Antibodies Designing of SARS-CoV-2 Based on Molecular Dynamics Simulations. <i>International Journal of Molecular Sciences</i> , 2023, 24, 481.	1.8	1
4078	Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo. <i>Virologica Sinica</i> , 2023, 38, 257-267.	1.2	2
4079	Rapid Detection of SARS-CoV-2 Spike RBD Protein in Body Fluid: Based on Special Calcium Ion-Mediated Gold Nanoparticles Modified by Bromide Ions. <i>Journal of Physical Chemistry Letters</i> , 2023, 14, 88-94.	2.1	3
4082	Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in <i>E. coli</i> Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants. <i>Vaccines</i> , 2023, 11, 42.	2.1	5
4083	Emerging Dominant SARS-CoV-2 Variants. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 335-342.	2.5	12
4084	History of vaccine: from centuries to present. , 2022, , 3-16.		0
4086	SKI-1/S1P Facilitates SARS-CoV-2 Spike Induced Cell-to-Cell Fusion via Activation of SREBP-2 and Metalloproteases, Whereas PCSK9 Enhances the Degradation of ACE2. <i>Viruses</i> , 2023, 15, 360.	1.5	3
4087	Numerical Analysis of Coronavirus Detection Using Photonic Crystal Fibreâ€Based SPR Sensor. <i>Plasmonics</i> , 2023, 18, 577-585.	1.8	6
4088	Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity. <i>Viruses</i> , 2023, 15, 309.	1.5	6
4090	Utilizing the codon adaptation index to evaluate the susceptibility to HIV-1 and SARS-CoV-2 related coronaviruses in possible target cells in humans. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	4

#	ARTICLE	IF	CITATIONS
4091	Tracking of Mutational Signature of SARS-CoV-2 Omicron on Distinct Continents and Little Difference was Found. <i>Viruses</i> , 2023, 15, 321.	1.5	0
4092	Navigating with chemometrics and machine learning in chemistry. <i>Artificial Intelligence Review</i> , 2023, 56, 9089-9114.	9.7	3
4093	Characterization of two linear epitopes SARS CoV-2 spike protein formulated in tandem repeat. <i>PLoS ONE</i> , 2023, 18, e0280627.	1.1	2
4095	Revealing the Molecular Interactions between Human ACE2 and the Receptor Binding Domain of the SARS-CoV-2 Wild-Type, Alpha and Delta Variants. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2517.	1.8	1
4096	Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. <i>Nature Communications</i> , 2023, 14, .	5.8	8
4097	Systematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker. <i>Annals of Translational Medicine</i> , 2023, 11, 121-121.	0.7	2
4100	Computational approaches to define poncirin from <i>Magnolia champaka</i> leaves as a novel multi-target inhibitor of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13078-13097.	2.0	7
4101	Bromhexine: Into the spotlight. , 2023, , 719-731.		0
4103	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. <i>Bioengineering</i> , 2023, 10, 148.	1.6	3
4104	Effect of polymorphism in <i>Rhinolophus affinis</i> ACE2 on entry of SARS-CoV-2 related bat coronaviruses. <i>PLoS Pathogens</i> , 2023, 19, e1011116.	2.1	7
4106	Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1923.	1.8	11
4107	Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals. <i>ISME Journal</i> , 2023, 17, 549-560.	4.4	5
4108	Compact surface plasmon resonance sensor using the digital versatile disc grating as a coupler and a disperser. <i>Optical Engineering</i> , 2023, 62, .	0.5	3
4109	Plant Extracts and SARS-CoV-2: Research and Applications. <i>Life</i> , 2023, 13, 386.	1.1	3
4111	Biopolymer Coating Imparts Sustainable Self-Disinfecting and Antimicrobial Properties to Fabric: Translated to Protective Gears for the Pandemic and Beyond. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 1116-1131.	2.6	4
4112	Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: Pharmacophore-based virtual screening, molecular docking, molecular dynamics and binding free energy studies. <i>Journal of Molecular Liquids</i> , 2023, 375, 121345.	2.3	3
4113	Efficient capture of recombinant SARS-CoV-2 receptor-binding domain (RBD) with citrate-coated magnetic iron oxide nanoparticles. <i>Nanoscale</i> , 2023, 15, 7854-7869.	2.8	1
4114	SARS-CoV-2 infection and immune responses. <i>AIMS Microbiology</i> , 2023, 9, 245-276.	1.0	2

#	ARTICLE	IF	CITATIONS
4115	Angiotensin and COVID-19. , 2023, , 473-489.		0
4116	Scalable Inhibitors of the Nsp3â€“Nsp4 Coupling in SARS-CoV-2. ACS Omega, 2023, 8, 5349-5360.	1.6	4
4118	PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application. Npj Vaccines, 2023, 8, .	2.9	0
4119	A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19. , 2023, 20, 351-364.		5
4120	Molecular recognition of SARS-CoV-2 spike protein with three essential partners: exploring possible immune escape mechanisms of viral mutants. Journal of Molecular Modeling, 2023, 29, .	0.8	4
4121	19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. IScience, 2023, 26, 106562.	1.9	1
4122	Adaptive Evolution of the Spike Protein in Coronaviruses. Molecular Biology and Evolution, 2023, 40, .	3.5	6
4123	In silico targeting of SARS-CoV-2 spike receptor-binding domain from different variants with chaga mushroom terpenoids. Journal of Biomolecular Structure and Dynamics, 2024, 42, 1079-1087.	2.0	2
4124	SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research. Current Topics in Medicinal Chemistry, 2023, 23, .	1.0	1
4125	Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RABD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus. Heliyon, 2023, 9, e15032.	1.4	0
4127	Is BF.7 more infectious than other Omicron subtypes: Insights from structural and simulation studies of BF.7 spike RBD variant. International Journal of Biological Macromolecules, 2023, 238, 124154.	3.6	4
4128	Molecular insights into the inhibition mechanism of harringtonine against essential proteins associated with SARS-CoV-2 entry. International Journal of Biological Macromolecules, 2023, 240, 124352.	3.6	3
4129	Aptamer-based nanointerferometer enables amplification-free ultrasensitive detection and differentiation of SARS-CoV-2 variants. Analytica Chimica Acta, 2023, 1260, 341207.	2.6	2
4130	Potential differentiation of successive SARS-CoV-2 mutations by RNA: DNA hybrid analyses. Biophysical Chemistry, 2023, 297, 107013.	1.5	0
4131	Analysis of protein-protein interface with incorporating low-frequency molecular interactions in molecular dynamics simulation. Journal of Molecular Graphics and Modelling, 2023, 122, 108461.	1.3	0
4132	New Short RNA Motifs Potentially Relevant in the SARS-CoV-2 Genome. Current Genomics, 2022, 23, 424-440.	0.7	0
4133	Viruses as biomaterials. Materials Science and Engineering Reports, 2023, 153, 100715.	14.8	4
4135	Electrical biosensing system utilizing ion-producing enzymes conjugated with aptamers for the sensing of severe acute respiratory syndrome coronavirus 2. Sensing and Bio-Sensing Research, 2023, 39, 100549.	2.2	2

#	ARTICLE	IF	CITATIONS
4137	Omicron mutations increase interdomain interactions and reduce epitope exposure in the SARS-CoV-2 spike. <i>IScience</i> , 2023, 26, 105981.	1.9	4
4138	Broadly neutralizing aptamers to SARS-CoV-2: A diverse panel of modified DNA antiviral agents. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 370-382.	2.3	4
4139	New emerging pandemic: head and neck manifestations. <i>Minerva Medica</i> , 2023, 113, .	0.3	1
4140	Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
4141	SARS-CoV-2 Spike Protein Post-Translational Modification Landscape and Its Impact on Protein Structure and Function via Computational Prediction. <i>Research</i> , 2023, 6, .	2.8	2
4142	Investigation of the effects of N-Acetylglucosamine on the stability of the spike protein in SARS-CoV-2 by molecular dynamics simulations. <i>Computational and Theoretical Chemistry</i> , 2023, 1222, 114049.	1.1	1
4143	Implications of SARS-CoV-2 spike protein interactions with Zn-bound form of ACE2: a computational structural study. <i>BioMetals</i> , 0, , .	1.8	1
4145	Targeting viral proteins for restraining SARS-CoV-2: focusing lens on viral proteins beyond spike for discovering new drug targets. <i>Expert Opinion on Drug Discovery</i> , 2023, 18, 247-268.	2.5	1
4146	Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. <i>Glycobiology</i> , 2023, 33, 188-202.	1.3	7
4147	The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution. <i>Viruses</i> , 2023, 15, 408.	1.5	6
4148	On the Sensitivity and Affinity of Gold, Silver, and Platinum Surfaces against the SARS-CoV-2 Virus: A Comparative Computational Study. <i>Journal of Chemical Information and Modeling</i> , 2023, 63, 1276-1292.	2.5	0
4149	Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0281281.	1.1	4
4150	Identification of natural compounds as SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
4151	LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein. <i>PLoS Biology</i> , 2023, 21, e3001959.	2.6	8
4152	Comparison of truncated human angiotensin-converting enzyme 2 (hACE2) expression in pET28a(+) versus pET-SUMO vector and two <i>Escherichia coli</i> strains. <i>Advances in Medical Sciences</i> , 2023, 68, 61-70.	0.9	0
4153	Use of the particle agglutination/particle agglutination inhibition test for antigenic analysis of SARS-CoV-2. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	0
4155	Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	1
4156	In Silico Discovery of Small Molecule Modulators Targeting the Achilles™ Heel of SARS-CoV-2 Spike Protein. <i>ACS Central Science</i> , 2023, 9, 252-265.	5.3	11



#	ARTICLE	IF	CITATIONS
4157	SARS-CoV-2 infection of kidney tissues from severe COVID-19 patients. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
4158	Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding. <i>Journal of Infection</i> , 2023, 86, 513-515.	1.7	4
4159	Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
4160	Performance Evaluation of RapiSure (EDGC) COVID-19 S1 RBD IgG/Neutralizing Ab Test for the Rapid Detection of SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2023, 13, 643.	1.3	0
4161	Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs. <i>PLoS Biology</i> , 2023, 21, e3001967.	2.6	14
4162	Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. <i>Biomedicines</i> , 2023, 11, 517.	1.4	4
4163	PREHOST: Host prediction of coronaviridae family using machine learning. <i>Heliyon</i> , 2023, 9, e13646.	1.4	0
4164	A Potential Role of the Spike Protein in Neurodegenerative Diseases: A Narrative Review. <i>Cureus</i> , 2023, .	0.2	4
4165	Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508.	1.5	15
4166	Reversal of the unique Q493R mutation increases the affinity of Omicron S1-RBD for ACE2. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 1966-1977.	1.9	16
4167	Identification of Potential Anti-COVID-19 Drug Leads from Medicinal Plants through Virtual High-Throughput Screening. <i>ChemistrySelect</i> , 2023, 8, .	0.7	1
4168	Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	3
4169	Surface-Functionalized Metal-Organic Frameworks for Binding Coronavirus Proteins. <i>ACS Applied Materials &amp; Interfaces</i> , 2023, 15, 9058-9065.	4.0	9
4170	Novel Inhibitory Role of Fenofibric Acid by Targeting Cryptic Site on the RBD of SARS-CoV-2. <i>Biomolecules</i> , 2023, 13, 359.	1.8	2
4171	Thrombosis and Anticoagulation Strategies in Patients with COVID-19 Including Japanese Perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2023, 30, 311-320.	0.9	0
4173	How the Competition for Cysteine May Promote Infection of SARS-CoV-2 by Triggering Oxidative Stress. <i>Antioxidants</i> , 2023, 12, 483.	2.2	0
4175	Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology. <i>Vaccines</i> , 2023, 11, 442.	2.1	0
4176	Biophysical Correlates of Enhanced Immunogenicity of a Stabilized Variant of the Receptor Binding Domain of SARS-CoV-2. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1704-1714.	1.2	0

#	ARTICLE	IF	CITATIONS
4177	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2)., 2023, , 1-15.		0
4179	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.2	0
4180	Single Crystal Investigations, Hirshfeld Surface Analysis, DFT Studies, Molecular Docking, Physico-Chemical Characterization, and Biological Activity of a Novel Non-Centrosymmetric Compound with a Copper Transition Metal Precursor. <i>ACS Omega</i> , 2023, 8, 7738-7748.	1.6	3
4181	SARS-CoV-2 spike proteins react with Au and Si, are electrically conductive and denature at $3 \text{ \AA} - 10 \text{ \AA}$ V m <sup>-1</sup> : a surface bonding and a single-protein circuit study. <i>Chemical Science</i> , 2023, 14, 3428-3440.	3.7	0
4182	Integrative network pharmacology and in silico analyses identify the anti-omicron SARS-CoV-2 potential of eugenol. <i>Heliyon</i> , 2023, 9, e13853.	1.4	4
4183	CDK4/6 inhibitor palbociclib promotes SARS-CoV-2 cell entry by down-regulating SKP2 dependent ACE2 degradation. <i>Antiviral Research</i> , 2023, 212, 105558.	1.9	4
4184	Protein nanopore reveals the renin-angiotensin system crosstalk with single-amino-acid resolution. <i>Nature Chemistry</i> , 2023, 15, 578-586.	6.6	15
4185	SARS-CoV-2 S Glycoprotein Stabilization Strategies. <i>Viruses</i> , 2023, 15, 558.	1.5	1
4186	<i>In silico</i> analysis of dietary polyphenols and their gut microbial metabolites suggest inhibition of SARS-CoV-2 infection, replication, and host inflammatory mediators. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-19.	2.0	0
4187	Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
4188	Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	2
4190	Oral manifestations of COVID-19: A review. <i>Journal of Cellular Biotechnology</i> , 2023, , 1-11.	0.1	0
4191	Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19. <i>Life</i> , 2023, 13, 617.	1.1	5
4192	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
4193	Computational investigation of honeybee venom proteins as potential Omicron SARS-CoV-2 inhibitors. <i>Ukrainian Biochemical Journal</i> , 2023, 94, 3-10.	0.1	0
4194	Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation. <i>International Immunopharmacology</i> , 2023, 117, 109929.	1.7	2
4195	Design of an artificial transcriptional system for production of high levels of recombinant proteins in tobacco ( <i>Nicotiana benthamiana</i> ). <i>Frontiers in Plant Science</i> , 0, 14, .	1.7	0
4196	Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants. <i>Viruses</i> , 2023, 15, 611.	1.5	1

#	ARTICLE	IF	CITATIONS
4197	Trends in Electroanalytical Assays for COVID-19 Diagnosis. , 2023, , 1-20.		0
4198	ZF2001, A Protein Subunit Vaccines against SARS-CoV-2. , 0, , .		0
4199	Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022. Journal of Medical Virology, 2023, 95, .	2.5	0
4200	Establishment of angiotensin-converting enzyme 2 and cluster of differentiation 147 dual target cell membrane chromatography based on SNAP-tag technology for screening anti severe acute respiratory syndrome coronavirus 2 active components. Journal of Chromatography A, 2023, 1693, 463903.	1.8	6
4201	Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	1
4202	Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. Vaccines, 2023, 11, 545.	2.1	3
4203	COVID-19 Biogenesis and Intracellular Transport. International Journal of Molecular Sciences, 2023, 24, 4523.	1.8	7
4204	A structural perspective on the evolution of viral/cellular macromolecular complexes within the arenaviridae family of viruses. Current Opinion in Structural Biology, 2023, 79, 102561.	2.6	2
4205	Nasal sprays for treating COVID-19: a scientific note. Pharmacological Reports, 2023, 75, 249-265.	1.5	10
4206	No indication for SARS-CoV-2 transmission to pet ferrets, in five cities in Poland, 2021 - antibody testing among ferrets living with owners infected with SARS-CoV-2 or free of infection. Acta Veterinaria Scandinavica, 2023, 65, .	0.5	1
4207	Can Probiotics, Particularly Limosilactobacillus fermentum UCO-979C and Lacticaseibacillus rhamnosus UCO-25A, Be Preventive Alternatives against SARS-CoV-2?. Biology, 2023, 12, 384.	1.3	2
4208	SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity. Viruses, 2023, 15, 639.	1.5	1
4209	A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA. PLoS ONE, 2023, 18, e0281907.	1.1	2
4210	Effects of PM2.5 Exposure on the ACE/ACE2 Pathway: Possible Implication in COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2023, 20, 4393.	1.2	3
4211	Discriminating promiscuous from target-specific autoantibodies in COVID-19. European Journal of Immunology, 2023, 53, .	1.6	6
4212	Development of a screening platform to discover natural products active against SARS-CoV-2 infection using lung organoid models. Biomaterials Research, 2023, 27, .	3.2	9
4213	Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants. Antiviral Research, 2023, 212, 105576.	1.9	5
4214	PROT-ON: A structure-based detection of designer PROTEin interface MutatiONs. Frontiers in Molecular Biosciences, 0, 10, .	1.6	1

#	ARTICLE	IF	CITATIONS
4215	SARS-CoV-2 S Mutations: A Lesson from the Viral World to Understand How Human Furin Works. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4791.	1.8	2
4216	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	5.8	11
4217	Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach. <i>Molecules</i> , 2023, 28, 2333.	1.7	4
4218	Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain. <i>Cell Reports</i> , 2023, 42, 112256.	2.9	13
4219	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
4220	Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells. <i>Biomolecules</i> , 2023, 13, 472.	1.8	1
4221	Understanding COVID-19 in children: immune determinants and post-infection conditions. <i>Pediatric Research</i> , 2023, 94, 434-442.	1.1	11
4223	SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells. <i>Cell Chemical Biology</i> , 2023, 30, 248-260.e4.	2.5	8
4224	SARS-CoV-2 infection of kidney tissues in some severe and fatal cases of COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
4225	Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. <i>Cell Reports</i> , 2023, 42, 112271.	2.9	12
4227	Virus-like Plasmonic Nanoprobes for Quick Analysis of Antiviral Efficacy and Mutation-Induced Drug Resistance. <i>Analytical Chemistry</i> , 2023, 95, 5009-5017.	3.2	2
4228	COVID-19, the Gut, and Nutritional Implications. <i>Current Nutrition Reports</i> , 2023, 12, 263-269.	2.1	2
4229	Cigarette smoke preferentially induces full length ACE2 expression in differentiated primary human airway cultures but does not alter the efficiency of cellular SARS-CoV-2 infection. <i>Heliyon</i> , 2023, 9, e14383.	1.4	1
4230	Functional evolution of SARS-CoV-2 spike protein: Maintaining wide host spectrum and enhancing infectivity via surface charge of spike protein. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2068-2074.	1.9	2
4231	Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential. <i>European Journal of Medicinal Chemistry</i> , 2023, 252, 115272.	2.6	4
4232	COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5374.	1.8	6
4233	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. <i>Nature Communications</i> , 2023, 14, .	5.8	21
4234	SARS-CoV-2 receptor-binding domain deep mutational AlphaFold2 structures. <i>Scientific Data</i> , 2023, 10, .	2.4	1

#	ARTICLE	IF	CITATIONS
4235	Antibody Persistence After Primary SARS-CoV-2 Infection and Protection Against Future Variants Including Omicron in Adolescents: National, Prospective Cohort Study. <i>Pediatric Infectious Disease Journal</i> , 2023, 42, 496-502.	1.1	2
4236	Genetic analysis of ACE2 peptidase domain in SARS-CoV-2-positive and SARS-CoV-2-negative individuals from Pakistan. <i>Molecular Biology Reports</i> , 2023, 50, 4309-4316.	1.0	1
4237	Biodegradation of 2,4,6-trinitrotoluene and hexahydro-1,3,5-trinitro-1,3,5-triazine by Actinomycetes species, first time isolated and characterized from water, wastewater, and sludge. <i>Water and Environment Journal</i> , 2023, 37, 538-548.	1.0	3
4239	Surface enhanced Raman spectroscopy based analysis of SARS-CoV-2 spike protein binding to ACE2 receptor. , 2023, , .		0
4240	Advances in developing ACE2 derivatives against SARS-CoV-2. <i>Lancet Microbe</i> , The, 2023, 4, e369-e378.	3.4	14
4241	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
4242	A Small Molecule That In Vitro Neutralizes Infection of SARS-CoV-2 and Its Most Infectious Variants, Delta, and Omicron. <i>Biomedicines</i> , 2023, 11, 916.	1.4	0
4243	Production of neutralizing antibody fragment variants in the cytoplasm of E. coli for rapid screening: SARS-CoV-2 a case study. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
4244	Intraduodenal Delivery of Exosome-Loaded SARS-CoV-2 RBD mRNA Induces a Neutralizing Antibody Response in Mice. <i>Vaccines</i> , 2023, 11, 673.	2.1	10
4245	Surface-modified biomaterials as disinfectants to combat viral infections: a SARS-COV-2 case study. , 2023, , 147-169.		0
4246	Timeline of changes in spike conformational dynamics in emergent SARS-CoV-2 variants reveal progressive stabilization of trimer stalk with altered NTD dynamics. <i>ELife</i> , 0, 12, .	2.8	16
4247	Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2. <i>Cell Biochemistry and Function</i> , 2023, 41, 284-295.	1.4	2
4248	Minimal purification method enables developability assessment of recombinant proteins. <i>Biotechnology and Bioengineering</i> , 0, , .	1.7	0
4249	Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2339-2351.	1.9	5
4251	Highly Selective Aptamer-Molecularly Imprinted Polymer Hybrids for Recognition of SARS-CoV-2 Spike Protein Variants. <i>Global Challenges</i> , 2023, 7, .	1.8	0
4252	Challenges and Recent Advancements in COVID-19 Vaccines. <i>Microorganisms</i> , 2023, 11, 787.	1.6	1
4253	Exploiting Modeling Studies for Evaluating the Potential Antiviral Activities of some Clinically Approved Drugs and Herbal Materials against SARS-CoV-2: Theoretical Studies toward Hindering the Virus and Blocking the Human Cellular Receptor. <i>Polycyclic Aromatic Compounds</i> , 0, , 1-12.	1.4	2
4254	Insights on the interaction of SARS-CoV-2 variant B.1.617.2 with antibody CR3022 and analysis of antibody resistance. <i>Journal of Genetic Engineering and Biotechnology</i> , 2023, 21, 35.	1.5	0

#	ARTICLE	IF	CITATIONS
4255	Structure, anti-SARS-CoV-2, and anticoagulant effects of two sulfated galactans from the red alga <i>Botryocladia occidentalis</i> . <i>International Journal of Biological Macromolecules</i> , 2023, 238, 124168.	3.6	7
4256	The role of dendritic cells in COVID-19 infection. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	11
4257	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944.	1.8	12
4258	Reviews of drug candidates for COVID-19. , 0, 36, 219-226.		0
4259	A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System. <i>Bioengineering</i> , 2023, 10, 389.	1.6	2
4260	COVID-19 as a Trigger for Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 2176-2183.	1.8	8
4261	Modeling of SARS-CoV-2 Virus Proteins: Implications on Its Proteome. <i>Methods in Molecular Biology</i> , 2023, , 265-299.	0.4	0
4262	Genome surveillance of SARS-CoV-2 variants and their role in pathogenesis focusing on second wave of COVID-19 in India. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
4263	DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response. <i>Communications Biology</i> , 2023, 6, .	2.0	14
4264	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	1.1	2
4265	Computational study of 2D photonic crystal based biosensor for SARS-COV-2 detection. <i>Measurement Science and Technology</i> , 2023, 34, 074004.	1.4	8
4266	Proteomic characteristics and diagnostic potential of exhaled breath particles in patients with COVID-19. <i>Clinical Proteomics</i> , 2023, 20, .	1.1	0
4267	Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants. <i>ACS Nano</i> , 2023, 17, 7017-7034.	7.3	1
4268	A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
4269	SARS-CoV2 billion-compound docking. <i>Scientific Data</i> , 2023, 10, .	2.4	4
4270	Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine. <i>Applied Microbiology and Biotechnology</i> , 2023, 107, 2983-2995.	1.7	1
4271	Different Variants of SARS-CoV-2: A Comprehensive Review on Mutation Patterns and Pathogenicity. <i>Coronaviruses</i> , 2023, 4, .	0.2	1
4272	Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery. <i>ACS Nanoscience Au</i> , 2023, 3, 192-203.	2.0	8



#	ARTICLE	IF	CITATIONS
4273	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15207-15218.	2.0	1
4274	Molecular Modeling of Viral Type I Fusion Proteins: Inhibitors of Influenza Virus Hemagglutinin and the Spike Protein of Coronavirus. <i>Viruses</i> , 2023, 15, 902.	1.5	1
4275	Biomimetic SARS-CoV-2 Spike Protein Nanoparticles. <i>Biomacromolecules</i> , 2023, 24, 2030-2041.	2.6	1
4276	<sc>All</sc> atom simulations of the trimeric spike protein of <sc>SARS-CoV</sc> in aqueous medium: Nature of interactions, conformational stability and free energy diagrams for conformational transition of the protein. <i>Journal of Computational Chemistry</i> , 2023, 44, 1560-1577.	1.5	2
4277	Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses. <i>IScience</i> , 2023, 26, 106540.	1.9	2
4278	Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 705-717.	1.5	6
4279	The role of the endothelium in severe acute respiratory syndrome coronavirus 2 infection and pathogenesis. <i>Current Opinion in Physiology</i> , 2023, 34, 100670.	0.9	3
4280	Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. <i>MBio</i> , 2023, 14, .	1.8	9
4281	Anti-SARS-CoV-2 Activity of <i>Ampelozizyphus amazonicus</i> (Saracura-Mirã): Focus on the Modulation of the Spike-ACE2 Interaction by Chemically Characterized Bark Extracts by LC-DAD-APCI-MS/MS. <i>Molecules</i> , 2023, 28, 3159.	1.7	3
4282	A review of metal nanoparticle-based surface-enhanced Raman scattering substrates for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. <i>Aggregate</i> , 2023, 4, .	5.2	4
4283	Single Nucleotide Variants (SNVs) of Angiotensin-Converting Enzymes (ACE1 and ACE2): A Plausible Explanation for the Global Variation in COVID-19 Prevalence. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2023, 2023, .	1.0	2
4284	A Single Multiomics Transistor for Electronic Detection of SARS-CoV2 Variants Antigen and Viral RNA Without Amplification. <i>Advanced Materials Technologies</i> , 2023, 8, .	3.0	2
4285	Lung Expression of Macrophage Markers CD68 and CD163, Angiotensin Converting Enzyme 2 (ACE2), and Caspase-3 in COVID-19. <i>Medicina (Lithuania)</i> , 2023, 59, 714.	0.8	3
4286	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
4287	Oral Cavity and COVID-19: Clinical Manifestations, Pathology, and Dental Profession. , 2024, , 173-190.		0
4288	SARS-CoV-2 evolved variants optimize binding to cellular glycocalyx. <i>Cell Reports Physical Science</i> , 2023, 4, 101346.	2.8	12
4289	Spatial Distribution of SARS-CoV-2 Receptors and Proteases in Testicular Cells. <i>Journal of Histochemistry and Cytochemistry</i> , 0, , 002215542311689.	1.3	1
4290	Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. <i>Communications Biology</i> , 2023, 6, .	2.0	4

#	ARTICLE	IF	CITATIONS
4291	COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies. <i>MedComm</i> , 2023, 4, .	3.1	19
4292	High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. <i>Nature Communications</i> , 2023, 14, .	5.8	12
4293	Copper-based nanoparticles against microbial infections. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	6
4294	Persistent Topological Laplacian Analysis of SARS-CoV-2 Variants. <i>Journal of Computational Biophysics and Chemistry</i> , 2023, 22, 569-587.	1.0	1
4295	<i>In silico</i> analysis of ACE2 from different animal species provides new insights into SARS-CoV-2 species spillover. <i>Future Virology</i> , 2023, 18, 359-371.	0.9	1
4296	Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1183.	3.8	19
4297	High-throughput screening of spike variants uncovers the key residues that alter the affinity and antigenicity of SARS-CoV-2. <i>Cell Discovery</i> , 2023, 9, .	3.1	2
4298	Portable Surface Plasmon Resonance Detector for COVID-19 Infection. <i>Sensors</i> , 2023, 23, 3946.	2.1	3
4299	Unpolarized laser method for infrared spectrum calculation of amide I C O bonds in proteins using molecular dynamics simulation. <i>Computers in Biology and Medicine</i> , 2023, 159, 106902.	3.9	1
4300	Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7292.	1.8	2
4301	Interactions between carbon nanotubes and external structures of SARS-CoV-2 using molecular docking and molecular dynamics. <i>Journal of Molecular Structure</i> , 2023, 1286, 135604.	1.8	1
4302	Electrostatic interaction between sulfated polysaccharides and oligopeptides from viral envelope glycoproteins using surface plasmon resonance. <i>Carbohydrate Research</i> , 2023, , 108815.	1.1	0
4303	In-Silico Approaches for the Screening and Discovery of Broad-Spectrum Marine Natural Product Antiviral Agents Against Coronaviruses. <i>Infection and Drug Resistance</i> , 0, Volume 16, 2321-2338.	1.1	5
4304	Repurposed Drugs/Potential Pharmacological Agents Targeting Cytokine Release and Induction of Coagulation in COVID-19. , 2023, , 100-136.		0
4306	Specific Activation of T Cells by an ACE2-Based CAR-Like Receptor upon Recognition of SARS-CoV-2 Spike Protein. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7641.	1.8	4
4307	Dietary intervention with functional foods modulating gut microbiota for improving the efficacy of COVID-19 vaccines. <i>Heliyon</i> , 2023, 9, e15668.	1.4	5
4308	DNA-scaffolded multivalent vaccine against SARS-CoV-2. <i>Acta Biomaterialia</i> , 2023, 164, 387-396.	4.1	2
4309	Crystallographic and biophysical analysis of the fusion core from SARS-CoV-2 spike protein. <i>Journal of the Chinese Chemical Society</i> , 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
4337	A review of current effective COVID-19 testing methods and quality control. Archives of Microbiology, 2023, 205, .	1.0	3
4348	Zoonoses and anthroponoses: Reverse transmission of pathogens. , 2023, , 1-49.		0
4380	De Novo Drug Design of Potential Inhibitors of the Receptor-Binding Domain of SARS-CoV-2 Variants. , 0, , .		0
4412	An analysis of S-RBD quantitative antibody levels in post-vaccination of health workers at Jemursari Islamic hospital and Menur Mental Hospital Surabaya. AIP Conference Proceedings, 2023, , .	0.3	0
4446	COVID Diagnostics: From Molecules to Omics. Advances in Experimental Medicine and Biology, 2023, , 141-158.	0.8	0
4459	Advanced fluorescence microscopy in respiratory virus cell biology. Advances in Virus Research, 2023, , .	0.9	0
4476	Conducting polymer-based electrochemical biosensors for biomedical application. , 2023, , 411-453.		0
4499	The use of moist oxygen anion from PUVICO3 technology for air purification and supportive treatment of COVID-19 infection: Synergistic potential and possibilities. AIP Conference Proceedings, 2023, , .	0.3	0
4512	Adopting Autodock Koto for Virtual Screening of COVID-19. Lecture Notes in Computer Science, 2023, , 752-763.	1.0	0
4532	Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Clinical and Experimental Medicine, 0, , .	1.9	0
4534	Steroid hormone receptors and regulation of ACE2 and COVID-19 disease outcomes. , 2024, , 129-145.		0
4542	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. Chemical Society Reviews, 2023, 52, 6497-6553.	18.7	1
4546	The role of cell death in SARS-CoV-2 infection. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	4
4568	Phenome-wide association study and precision medicine of cardiovascular diseases in the post-COVID-19 era. Acta Pharmacologica Sinica, 0, , .	2.8	0
4605	Investigation on SARS-Cov-2 immune escape-related spike mutations. , 2023, , .		0
4606	Techniques for Developing Reliable Machine Learning Classifiers Applied to Understanding and Predicting Protein:Protein Interaction Hot Spots. Methods in Molecular Biology, 2024, , 235-268.	0.4	0
4618	In Silico Identification of Potential Antivirals Against SARS-CoV-2 Main Protease and RBD of Spike Protein: A Drug Repurposing Approach. , 2023, , 399-410.		0
4634	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1529-1543.		0

#	ARTICLE	IF	CITATIONS
4655	In silico study of the interaction of taurocholic acid from eel ( <i>Anguilla bicolor bicolor</i> ) with angiotensin-converting enzyme 2. AIP Conference Proceedings, 2023, , .	0.3	0
4672	Immune imprinting and next-generation coronavirus vaccines. <i>Nature Microbiology</i> , 2023, 8, 1971-1985.	5.9	4
4715	Research on Variation of Sars-Cov-2 and Rapid Detection. , 2023, , .		0
4737	Virus-Induced Cell Fusion and Syncytia Formation. <i>Results and Problems in Cell Differentiation</i> , 2024, , 283-318.	0.2	1
4752	Assessing the Effectiveness of COVID-19/SARS-CoV-2 Vaccinations in Terms of Mortality Rates. , 2023, , .		0
4758	Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. <i>RSC Advances</i> , 2023, 13, 35500-35524.	1.7	0
4775	Bio-analysis of Saliva Using Paper Devices and Colorimetric Assays. <i>Journal of Analysis and Testing</i> , 2024, 8, 114-132.	2.5	0
4781	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	1.5	0
4782	Coagulation and Thrombotic Considerations in Covid-19: Implications for Disease Severity, and Its Vaccines. , 2023, , .		0
4795	KIO <sub>3</sub> -catalyzed selective oxidation of thiols to disulfides in water under ambient conditions. <i>Organic and Biomolecular Chemistry</i> , 0, , .	1.5	0
4813	Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions. , 2024, , 209-241.		0
4822	Structure-Based Screening of Potential Drugs against SARS-CoV-2 Variants. , 0, , .		0
4848	Clinical investigation of COVID-19 prevention and treatment. , 2024, , 127-137.		0
4861	A human antibody derived from original SARS-CoV-2 infection effectively neutralizes omicron. , 2024, 2, .		0
4878	Pneumonia Including COVID-19. <i>Radiology Illustrated</i> , 2023, , 323-335.	0.0	0